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Abstract 
Fabry disease is an X-linked lysosomal storage disorder caused by a deficiency 
of the enzyme alpha-galactosidase A. The resultant progressive intracellular 
accumulation of the glycosphingolipids globotriaosylceramide (Gb3) and 
globotriaosylsphingosine (lyso-Gb3) are the source of a variety of clinical 
consequences. Biomarkers capable of detecting Fabry disease at an early 
stage of disease progression and that enable monitoring of response to 
treatment are required urgently. 
 
Using a label-free quantitative proteomic methodology two potential biomarkers, 
proactivator polypeptide and ganglioside GM2 activator protein, were identified 
in the urine of paediatric Fabry disease patients. An ultra-performance liquid 
chromatography-tandem mass spectrometry (UPLC-MS/MS) assay was then 
developed for verification and validation purposes. Subsequently a second, 
larger multiplexed assay was developed to identify biomarkers capable of 
detecting and monitoring pre-symptomatic kidney disease in those patients 
most at risk. 
 
A complementary metabolomic approach was also used to identify and evaluate 
new Gb3-related biomarkers in the plasma of Fabry disease patients. This 
aspect of the study revealed five novel Gb3-related biomarkers as well as 
existing Gb3-related analogues and isoforms providing a metabolic profile in 
these patients.         
 
Potential disease mechanisms involved in Fabry disease were investigated by 
studying the interactions between proteins and those molecules involved in the 
glycosphingolipid pathway, with particular interest to Gb3. A number of 
mitochondrial proteins were found to interact with Gb3 resulting in the 
investigation of the effect of glycosphingolipids and their deacylated 
counterparts on ATP synthase activity. Increasing concentrations of Gb3 and 
lyso-Gb3 were shown to increase ATP synthase activity. Subsequently the 
activities of the enzymes preceding ATP synthase, the mitochondrial respiratory 
chain enzymes, were investigated in a Fabry mouse model. In this aspect of the 
study complex II/III activity was found to be significantly decreased in kidney 
tissues. Finally, the assessment of pain thresholds in mice has demonstrated a 
significant increase in sensitivity to applied mechanical stimuli following 
exposure to Gb3 and lyso-Gb3. 
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1.0 Introduction 
 
1.1 The lysosome and lysosomal network 
 
Following the first description of the lysosome in 1949 by Christian De Duve and 
colleagues as ‘a saclike structure containing a variety of acid hydrolases, 
surrounded by a membrane’ our understanding of the lysosome has evolved 
significantly. Far from been the ‘suicide bags’ of the cell as first thought 
lysosomes are now recognised as dynamic organelles characterised by the 
presence of a limiting external membrane, a low internal pH (4.5-5.0) 
maintained by proton-pumping vacuolar ATPases and vesicles containing many 
acid hydrolases (e.g. proteases, glycosidase, nuclease, lipases and 
phosphatases) responsible for receiving and degrading macromolecules from 
the phagocytic, autophagic and endocytic pathways (Saftig 2005; Walkley 
2009). As a greater understanding of the lysosomes role in cellular biology 
develops it is becoming clear that lysosomes have a more complex role than 
simply as organelles dedicated to catabolism (Jeyakumar et al., 2005).  
 
1.1.1 The lysosomal system 
 
The lysosomal system (Figure 1.1) is a major metabolic regulatory network 
requiring not only the transport of newly synthesised proteins to the lysosome 
but also the effective operation of the endosomal, autophagic and salvage 
pathways which are necessary to maintain this highly efficient and co-ordinated 
network. In addition, the ubiquitin-proteasome system operates in coordination 
with the lysosomal system ensuring efficient protein turnover. Ultimately at the 
centre of this intracellular network is the lysosome itself, demonstrating that 
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lysosomal function is essential, in order to maintain the operation and function 
of this complex system (Mehta and Winchester 2013; Walkley 2009).  
 
 
Figure 1.1  The lysosomal system and associated endocytic and 
autophagic pathways. Reproduced from Jeyakumar et al., 2005. 
 
1.1.2 Endocytosis and lysosome formation 
 
A major function of the lysosome is the degradation of both extracellular and 
cell surface material delivered by endocytosis, a process which also plays a 
vital role in the formation of the lysosome (Figure 1.1) (Walkley 2009). The 
diverse nature of molecules at the cell surface requires a variety of endocytic 
pathways in order to mediate their internalisation. In addition to the classical 
clathrin-mediated endocytosis, clathrin-independent endocytic pathways such 
as macropinocytosis and phagocytosis have recently been described (Mayor 
and Pagano 2007). Following internalisation and delivery of material by 
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endocytic vesicles these compartments fuse with early endosomes, which go on 
to mature into late endosomes. An increasingly acidic gradient during 
endosome maturation is required to ensure that on fusion of late endosomes 
with transport vesicles from the Golgi apparatus the acid hydrolases which they 
are carrying are delivered effectively. Late endosomes mature into lysosomes 
as they acquire this full complement of lysosomal enzymes. Endosomes can 
also diverge from this pathway enabling this complex system to recycle and 
reorganise within the cell (Walkley 2009; Mayor and Pagano 2007; Saftig and 
Klumperman 2009).  
 
1.1.3 The autophagic pathway for the degradation of intracellular 
materials  
 
The autophagic pathway targets intracellular materials for degradation though 
sequestration of cellular materials in double-layered membrane structures 
termed phagophores (Hung et al., 2013). Depending on how substrates are 
delivered to the lysosome autophagy can be divided into three subtypes - 
microautophagy, macroautophagy and chaperone-mediated autophagy (CMA). 
In microautophagy cytosolic components are sequestered to the lysosome by 
direct invagination of the lysosomal membrane and subsequent budding of 
vesicles into the lysosomal lumen (Marzella, Ahlberg and Glaumann 1981; 
Kunz, Schwarz and Mayer 2004). In macroautophagy, double membrane 
vesicles, known as autophagosomes, engulf cytosolic material and deliver it to 
the lysosome for degradation. Although once considered as a vesicle mediated 
bulk degradation mechanism, macroautophagy has recently been shown to be 
constitutively active and selective (Lemasters et al., 2002 Klionsky and 
Schulman 2014). CMA is characterised by its selectivity for soluble monomeric 
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proteins with a specific peptide signalling motif recognised by heat shock 
cognate 70 protein which together with its co-chaperones promote protein 
unfolding and translocation across the lysosomal membrane via the lysosome-
associated membrane protein type 2A (LAMP2A) (Kaushik and Cuervo 2012). 
Impairment of the autophagic pathway has been demonstrated in several 
lysosomal storage disorders however, the extent to which this impacts on 
downstream consequences for disease progression remains unclear 
(Settembre et al., 2008; Fukuda et al., 2006).   
 
1.1.4 The salvage pathway for reutilisation of simple molecular products 
within a cell 
 
Following degradation of molecules in the lysosome into simple molecular 
products they must be trafficked out of the lysosome in order to be transported 
to other organelles throughout the cell for reutilisation. This salvage process 
involves numerous lysosomal membrane proteins which act as transporters, 
defects in any such transporter can result in downstream shortages of enzymes 
essential for multiple metabolic processes within the cell (Ruivo et al., 2009). 
Compromises in the salvage pathway can also lead to inadequate reutilisation 
of degradation products in synthetic pathways in the Golgi and in other 
organelles within the cell (Xie et al., 1999). The cost of this to the cell in terms of 
energy consumption and altered regulatory processing is currently been 
investigated. However, needless to say reutilisation of simple molecular 
components would be favourable energetically over full de novo synthesis 
(Mehta and Winchester 2013).                    
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1.1.5 The ubiquitin-proteasome system and degradation of protein within 
a cell  
 
The ubiquitin-proteasome system (UPS) works in association with the 
autosomal/lysosomal system to maintain proteolytic quality control. In the first 
instance, it is the pathway responsible for the degradation of short-lived proteins 
within the cell and plays a vital role in cellular regulatory processes (Cook, 
Stetler, and Petrucelli 2012). In addition, the UPS is capable of coordinating 
proteolysis with the autosomal/lysosomal system under certain conditions, for 
example, if the UPS is inhibited, macroautophagy is upregulated in an attempt 
to maintain efficient protein degradation through the lysosome. The UPS and 
autophagic/lysosomal systems also rely on several vital molecules, most 
notably ubiquitin, to selectively target substrates for degradation. However, 
differences in the degradative capacity of these pathways mean that this 
complementation is limited. In circumstances where the lysosome is 
compromised and therefore unable to perform its role in cellular degradation, for 
example in a lysosomal storage disorder, it has been suggested that the UPS 
may be engaged to take care of some of the proteolytic load. It is as yet 
unknown if there is a limit where the burden on the UPS becomes so great that 
complete proteolytic failure results (Mehta and Winchester 2013).       
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1.2 Lysosomal storage disorders 
 
The lysosomal storage disorders (LSDs) are a group of over 50 distinct 
metabolic diseases caused by defects in proteins essential for lysosomal 
function (Fuller, Meikle, and Hopwood 2006). These include lysosomal 
enzymes, lysosomal integral membrane proteins and proteins involved in the 
post-translational modification and trafficking of lysosomal proteins (Saftig and 
Klumperman 2009). The resultant consequence of a defect in any of these 
proteins is primarily a disruption in the catabolism and/or transport of by-
products of cellular turnover. A secondary consequence is the accumulation of 
the undegraded substrate within the lysosome and other cell types (Parkinson-
Lawrence et al., 2010).  
 
1.2.1 Clinical aspects and diagnosis of lysosomal storage disorders 
 
The lysosomal storage disorders show extensive clinical heterogeneity (Beck 
2001). Age at onset, organ involvement, disease severity and disease course 
differ significantly between each LSD (Beck 2001; Bekri 2006). There are some 
acute and severe LSD subtypes with clinical features such as 
hepatosplenomegaly, coarse facial features and skeletal dysplasia, that may be 
strongly suggestive of a LSD resulting in a rapid diagnosis (Pastores 2009). For 
many however, disease progression occurs over weeks, months and even 
years and the variable and non-specific nature of the presenting clinical 
symptoms can make diagnosis challenging (Wang et al., 2011; Bekri 2006; 
Pastores 2009).  
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1.2.2 Laboratory diagnosis of lysosomal storage disorders 
 
A universal diagnostic test for all LSDs is not currently available. Measurement 
of the structure and content of the accumulated substrate is often used in 
screening techniques performed as part of the primary assessment. However, 
the definitive diagnosis is based both upon clinical suspicion and the 
appropriate biochemical and/or genetic laboratory based test(s).  
 
1.2.3 Genetic basis of lysosomal storage disorders 
 
All LSDs are monogenic and whilst most are inherited in an autosomal 
recessive manner (Fuller, Meikle, and Hopwood 2006), there are three 
exceptions, these are; Fabry disease which follows X-linked inheritance 
(Germain 2006; Germain et al., 2007), mucopolysaccharidosis type II (Hunter 
syndrome) which is inherited in an X-linked recessive manner and Danon 
disease which shows X-linked dominant inheritance (Fuller, Meikle, and 
Hopwood 2006).  
 
1.2.4 Incidence and prevalence of lysosomal storage disorders 
 
Although individually rare, when combined the LSDs occur with a high 
incidence. A number of countries have completed retrospective studies to 
establish the incidence of the LSDs calculated from the total number of patients 
identified divided by the total number of births during the same time period. In 
studies from Australia, The Netherlands and the Czech Republic similar 
incidences of 1 in 7,700 births (Meikle et al., 1999), 1 in 7,100 births (Poorthuis 
et al., 1999) and 1 in 8,000 births (Poupetová et al., 2010), respectively were 
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reported. The highest incidence was reported in Northern Portugal where the 
occurrence of a LSD was 1 in 2,500 births (Pinto et al., 2004).  
More recently, newborn screening (NBS) studies performed in dried blood spots 
to assess the incidence of LSDs have been completed. This has been made 
possible largely due to advances in the capacity of mass spectrometers to 
rapidly, sensitively and selectively detect a large number of disorders in a single 
assay. One study, performed in an Austrian cohort consisting of samples from 
34,736 newborn babies was designed to detect four LSDs, Gaucher, Fabry, 
Pompe and Niemann-Pick A/B. The study found a higher than expected 
combined incidence of these four LSDs occurring 1 in 2,315 births. The most 
prevalent was Fabry disease with an incidence of 1 in 3,589 births (Mechtler et 
al., 2012). Another study performed on 40,024 samples from the Hungarian 
NBS program identified three cases of Gaucher disease, three cases of Fabry 
disease, and two cases of Niemann-Pick A/B (Wittmann et al., 2012). An 
inherent flaw when using studies such as these to determine the incidence of a 
LSD is that information is provided on a finite number of diseases from this 
large group of disorders. However, the increased incidence detected from data 
on the few disorders studied suggests that data from retrospective studies show 
that LSDs are substantially under-diagnosed in the general population. Studies 
such as this are not without problems and raise numerous ethical issues not 
least the fact that a large proportion of patients detected in these studies will not 
require treatment due to the mild nature of their disease and some patients may 
never develop clinical manifestations of a LSD.        
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1.2.5  Classification of lysosomal storage disorders 
 
The lysosomal storage disorders have historically been classified according to 
the nature of the substrate that accumulates and can broadly be grouped as 
lipidoses, mucopolysaccharidoses, glycoproteinoses, mucolipidoses and 
glycogen storage diseases. By classification in this way diseases are grouped 
according to disturbances in common catabolic pathways for a particular group 
of metabolites. This provides informative classifications for those diseases that 
result from a block in a single enzymatic step in a common catabolic pathway 
such as defects in the catabolism of the glycosphingolipids including those due 
to a defect in a sphingolipid activator protein (Figure 1.2) (Mehta and 
Winchester 2013). 
 
 
 
Figure 1.2  The glycosphingolipid biosynthetic pathway. Enzymes and 
sphingolipid activator proteins are shown in blue and the disease(s) associated 
with defects in the indicated enzyme are shown in red. Adapted from Platt and 
Walkley (2004).   
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1.3  Anderson-Fabry disease 
 
Anderson-Fabry disease, now known simply as Fabry disease, was first 
described in 1898. Independently, William Anderson and Johannes Fabry 
described patients with ‘angiokeratoma corporis diffusum’ which is now 
recognised as one of the first visible signs of the disease. Other clinical 
symptoms were subsequently described before the lysosome was identified as 
the organelle responsible for this disease (Anderson 1898; Fabry 1898; Fabry 
1916; Fabry 1930).  
 
1.3.1  Genetics of Fabry disease  
 
1.3.1.1 The GLA gene encodes α-galactosidase A 
 
Fabry disease results from a deficiency of the enzyme α-galactosidase A 
caused by mutations in the GLA gene. The locus of the GLA gene is situated on 
the long arm of chromosome X, in position Xq22. The GLA gene is comprised of 
seven exons distributed over 12,436 base pairs (Kornreich, Desnick, and 
Bishop 1989).  
 
1.3.1.2 GLA mutations in Fabry disease 
 
To date over six-hundred mutations that result in Fabry disease have been 
described. The majority of mutations (~75 %) are point mutations, including an 
assortment of polymorphisms, missense, nonsense and splice site mutations. 
To a lesser extent short length rearrangements, mainly deletions and 
duplications are seen with large rearrangements involving one or more exons 
occurring infrequently (Blaydon, Hill, and Winchester 2001; Davies et al., 1996; 
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Shabbeer et al., 2006; Eng et al., 1997; Germain et al., 2002b; Ashley et al., 
2001; Ashton-Prolla et al., 2000; Altarescu et al., 2001; Sakuraba et al., 1990; 
Topaloglu et al., 1999). The majority of these mutations result in the production 
of non-functioning enzyme. Most families have unique (‘private’) GLA mutations 
which provides some explanation as to the vast phenotypic presentation of the 
disease. However, a high degree of variability is also observed both between 
members of the same family and unrelated patients carrying the same mutation 
(Germain 2010; Altarescu 2010).   
 
1.3.1.3 Inheritance of Fabry disease 
 
Inheritance of Fabry disease is X-linked (Germain 2006). Although disease 
symptoms present earlier and are generally more clinically severe in affected 
males, a large proportion of heterozygous females are also affected 
(MacDermot, Holmes, and Miners 2001; Whybra et al., 2001; Wilcox et al., 
2008). The reason for this is attributed to random X-chromosome inactivation 
(Lyon 1961). In a process called lyonization, one of the two X chromosomes is 
randomly inactivated during the early stages of embryonic development. As the 
cells multiply each keeps the same pattern of inactivation. This results in a 
heterozygote for an X-linked disorder having 2 cell populations, one which will 
express the normal chromosome and the other which will express the abnormal 
chromosome. Variability in X-chromosome inactivation is thought to be 
responsible for the range of clinical and biochemical phenotypes experienced 
by females with the disease (Happle 1985; Germain 2006).     
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1.3.2  The structure of human α-galactosidase A 
 
In 1967, Brady and colleagues showed that the defective protein responsible for 
Fabry disease was α-galactosidase A (α-gal A, also known as GLA and α-GAL) 
(E.C. 3.2.1.22). α-GAL is required for the removal of the terminal α-galactose 
groups from substrates such as glycoproteins and glycolipids. In Fabry disease 
a deficiency of functional α-GAL results in the progressive accumulation of 
neutral glycosphingolipids, primarily globotriaosylceramide (Gb3) and 
globotriaosylsphingosine (lyso-Gb3; Figure 1.3), in organs, tissues and 
biological fluids (Eng, Ioannou, and Desnick 2001).      
   
 
 
Figure 1.3  Molecular structures of a.) globotriaosylceramide (Gb3) with 
palmitic acid (C16) as fatty acid and b.) globotriaosylsphingosine (lyso-
Gb3). Glu: glucose, Gal: galactose. 
 
The structure of human α-GAL was determined by X-ray crystallography in 
2004. It was shown to be a homodimeric glycoprotein with each monomer 
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composed of two domains, a (β/α)8 domain containing the active site, and a C-
terminal domain containing 8 antiparallel β-strands on two sheets in a β-
sandwich (Figure 1.4) (Garman and Garboczi 2004). Three N-linked 
carbohydrates are located on the surface of the molecule, away from the 
location of the active sites and the dimer interface. These N-linked 
carbohydrates are essential for the correct folding and trafficking of this 
molecule to the lysosome via the mannose-6-phosphate receptor pathway. The 
dimer has a pronounced negative charge, consistent with a molecule that is 
most stable in the low pH of the lysosome (Ioannou et al., 2001; Garman and 
Garboczi 2004).  
 
 
Figure 1.4  The structure of human α-galactosidase A in ribbon 
presentation. Reproduced from Garman 2007. The ribbon is coloured from 
blue to red as the polypeptide goes from N- to C-terminus. The active site is 
identified by the catalytic product galactose, shown in sphere Corey-Pauling-
Koltun (CPK) format. Each monomer in the homodimer contains two-domains, a 
(β/α)8 barrel containing the active site (blue to yellow) plus a C-terminal 
antiparallel β-domain (yellow to red).    
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Garman and Garboczi (2004) also elucidated the structure of α-GAL in complex 
with its catalytic product, the α-galactose monosaccharide, in order to determine 
how the enzyme cleaves galactose from glycoproteins and glycolipids. As a 
result, the location of two aspartic acid residues at D170 and D231, which act 
as a nucleophile and an acid/base respectively, have shown that the enzyme 
uses a double displacement reaction mechanism in order to cleave terminal α-
galactose residues off the substrate and therefore are responsible for the 
catalytic mechanism of this enzyme (Garman and Garboczi 2004; Garman 
2007). 
Determination of the structure of α-GAL provides a step toward answering vital 
questions regarding the structure and function of this enzyme and its 
relationship to disease processes. Mapping the mutations that result in Fabry 
disease onto the structure of α-GAL has revealed three groups of mutations: 
those that compromise the active site leading to loss of enzyme activity, those 
that perturb the hydrophobic core resulting in folding defects in the protein and 
those that result in other alterations to the structure such as broken disulphide 
bonds. The class of mutations that most lead to Fabry disease have been 
shown to result from perturbation of the hydrophobic core of the protein and as 
such Fabry disease is primarily caused as a result of protein misfolding. The 
structure of α-GAL can therefore, to some extent, enable treatment to be 
tailored to the nature of the mutation. For example, patients with a defect in the 
hydrophobic core may benefit more from pharmacological chaperone therapy 
(section 1.3.9.2) which can assist in the correct folding of the enzyme from the 
endoplasmic reticulum. Whereas for patients with a defect in the active site 
where the folded protein does not have catalytic capacity, the use of a 
pharmacological chaperone that assists in the correct folding of the protein is 
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not likely to show efficacy and enzyme replacement therapy (section 1.3.9.1) 
may be a more appropriate treatment option (Garman and Garboczi 2004; 
Garman 2007).  
     
1.3.3  Incidence of Fabry disease 
 
The classic Fabry disease phenotype has an estimated incidence of ~1 in 
40,000 – 60 000 males (Desnick, Ioannou, and Eng 2001; Meikle et al., 1999). 
Recently, the recognition of later-onset variants in males with renal (Choi et al., 
2012; Nakao et al., 2003; Ichinose et al., 2005), cardiac (Nakao et al., 1995; von 
Scheidt et al., 1991; Beer et al., 2002) and cerebrovascular (Brouns et al., 2010; 
Baptista et al., 2010; Rolfs et al., 2005) disease has suggested that the 
occurrence of this lysosomal storage disorder is more frequent than historically 
documented. As a result a number of newborn screening studies, assaying α-
GAL activity in dried blood spots have been performed to determine the disease 
incidence. The frequency of later-onset variants was found to be ~1 in 3100 
males in an Italian cohort (Spada et al., 2006), ~1 in 1250 males in a Taiwanese 
cohort (Hwu et al., 2009) and ~1 in 3859 in an Austrian cohort (Mechtler et al., 
2012). Identification of these patients would be beneficial in enabling early 
therapeutic intervention, genetic counselling and familial screening. However, it 
raises significant ethical issues for consideration as to the appropriate timing of 
screening and therefore treatment (i.e. in the neonatal period or at early 
maturity) for these late onset variants (Müller et al., 2012).  
 
1.3.4  Clinical manifestations of Fabry disease  
 
Fabry disease begins primarily in infancy, or even as early as the fetal stage of 
development (Bouwman et al., 2010; Popli et al., 1990; Vedder et al., 2006). 
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However, most patients remain asymptomatic during the first years of life. The 
average age of onset of the first clinical symptoms is reported to be between 3 
and 10 years in boys and a few years later in girls (Hopkin et al., 2008; Wilcox 
et al., 2008). Lysosomal storage of glycosphingolipids resulting in cellular 
dysfunction is believed, in part, to be responsible for the multisystemic nature of 
this disease which progresses with advancing age. 
 
1.3.5  Early signs of Fabry disease 
 
There are a number physical signs associated with Fabry disease that are often 
apparent during childhood and adolescence. These include neuropathic pain,   
angiokeratomas, dyshidrosis, gastrointestinal disturbances, ophthalmological, 
auditory and vestibular abnormalities. Identification of these symptoms is vital in 
obtaining an early diagnosis and for monitoring of disease progression to 
ensure the appropriate timing for therapeutic intervention.  
 
1.3.5.1 Neuropathic pain  
 
The neuropathic pain in Fabry disease may be chronic or experienced as 
episodic Fabry ‘crises’ or acroparaesthesiae. The pain is described as a 
numbness, tingling or burning sensation in one of more of the extremities. 
Acroparathesia is believed to result from ischemia of the peripheral nerves or 
lysosomal accumulation of glycosphingolipids in neurons, dorsal root ganglia 
and the spinal cord (Lidove, Jaussaud, and Aractingi 2006; Zarate and Hopkin 
2008). It occurs most often in males (MacDermot, Holmes, and Miners 2001; 
Mehta et al., 2004) but also affects a significant number of females with Fabry 
disease (Whybra et al., 2001; Deegan et al., 2006; Larralde et al., 2004). Painful 
crises lasting from a few minutes to several days may develop, these can occur 
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suddenly or be exacerbated by heat, illness, stress or exercise (Lidove, 
Jaussaud and Aractingi 2006).  
 
1.3.5.2  Angiokeratoma  
 
Angiokeratomas are benign vascular skin lesions characterised by proliferation 
of dilated blood vessels in the upper dermis and are considered a hallmark of 
Fabry disease (Figure 1.5) (Lidove, Jaussaud and Aractingi 2006). They are 
reported to be present in 83 % of male and 80 % of female patients with Fabry 
disease (Larralde et al., 2004). They may often be the first physical sign of 
disease presenting during childhood on the knees, elbows and flanks, and 
increase in both size and number with age becoming visible on the lips, hands 
and feet (Zampetti et al., 2012; Lidove, Jaussaud and Aractingi 2006).  
 
 
Figure 1.5  Typical angiokeratomas observed in Fabry disease. 
Reproduced from (Pastores 2009).   
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1.3.5.3  Dyshidrosis 
 
Disrupted sweating is a common clinical manifestation of Fabry disease 
attributed to both a direct effect on the sweat glands as well as to autonomic 
neuropathy (Zarate and Hopkin 2008). Hypohidrosis (inability to correctly 
perspire) is reported to have a higher prevalence in males (> 50 %) than 
females (> 25 %) often manifesting during childhood (Ries et al., 2003). 
Hypohidrosis results in decreased tolerance to heat and exercise and can have 
a significant impact on quality of life (Lidove, Jaussaud and Aractingi 2006). 
Hyperhidrosis (increased sweating) is less common in Fabry disease however, 
it is reported to be more prevalent in females (14.5 %) than males (4.1 %) 
(Ramaswami et al., 2006; Lidove et al., 2006).   
 
1.3.5.4 Gastrointestinal disturbances 
 
Gastrointestinal involvement is a frequent and early manifestation in Fabry 
disease (Hopkin et al., 2008; Ramaswami et al., 2006; Hoffmann et al., 2007a). 
The most common gastrointestinal symptoms reported are abdominal pain 
(often after eating) and diarrhoea but constipation, nausea and vomiting have 
also been reported (Hoffmann et al., 2007a; Hoffmann et al., 2007b). It has 
been suggested that these symptoms could be as a result of the deposition of 
Gb3 in the autonomic ganglia of the bowel and mesenteric blood vessels (Eng 
et al., 2006).   
 
1.3.5.5 Ophthalmological abnormalities 
 
Whorled corneal opacities (cornea verticillata) that do not affect vision are the 
most common ocular abnormality in Fabry disease (Figure 1.6), often reported 
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in childhood (Ramaswami et al., 2006) and frequently observed in adults with 
disease (Orssaud, Dufier and Germain 2003; Nguyen et al., 2005; Sodi et al., 
2007). Vessel tortuosity, cataracts and enlargement of the blind spot have also 
been noted in Fabry disease but in fewer cases (Orssaud, Dufier and Germain 
2003; Cox-Brinkman et al., 2007). 
 
 
 
Figure 1.6 Cornea verticillata characteristic of Fabry disease (indicated by 
arrows). Reproduced from Sodi, Ioannidis and Pitz 2006. 
 
1.3.5.6 Auditory and vestibular abnormalities 
 
A number of auditory and vestibular deficits have been reported in Fabry 
disease including high frequency sensorineural hearing loss (Sergi et al., 2010; 
Germain et al., 2002a; Sakurai et al., 2009), tinnitus and vertigo (Conti and 
Sergi 2003; Germain et al., 2002a). Progressive hearing loss (Palla et al., 2007; 
Germain et al., 2002a) and sudden deafness (Germain et al., 2002a) has also 
been reported in a number of cases.   
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1.3.6  Major organ involvement in Fabry disease  
 
With advancing age the myriad of symptoms experienced by Fabry disease 
patients develop. This includes worsening of the clinical manifestations that 
develop in childhood as well as the progression to major organ dysfunction with 
cardiac, renal and cerebrovascular disease developing in many patients.   
 
1.3.6.1  The heart and cardiovascular dysfunction in Fabry disease 
 
Cardiac involvement is the major cause of morbidity in Fabry disease and 
cardiac symptoms are reported in approximately 40-60% of both male and 
female patients with the disease (Kampmann et al., 2002; Senechal and 
Germain 2003; Schiffmann et al., 2009; Linhart et al., 2000; Shah et al., 2005). 
These include dyspnoea, angina, chest pain, palpitations and syncope which 
occur as a result of the development of progressive cardiac hypertrophy, 
conduction abnormalities and arrhythmias (Linhart 2006). Accumulation of Gb3 
has been shown in cardiomyocytes, conduction system cells, valvular 
fibroblasts, endothelial cells within all types of vessels and vascular smooth 
muscle cells (Hůlková et al., 1999). However, it is believed that the amount of 
stored Gb3 alone is insufficient to explain the observed level of cardiac 
involvement in this disease (Linhart 2006).  
Left ventricular structural changes are the predominant finding in patients with 
Fabry disease (Weidemann et al., 2005; Linhart et al., 2000; Kampmann et al., 
2002; Senechal and Germain 2003). The hypertrophy, as with other aspects of 
the disease, is progressive and occurs earlier in males than females. However, 
despite concentric remodelling and other less common structural changes, 
systolic function appears to be largely preserved when assessed using 
conventional techniques such as ejection fraction or fractional shortening 
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(Weidemann et al., 2005; Linhart et al., 2007; Kampmann et al., 2002; Senechal 
and Germain 2003; Linhart et al., 2000; Linhart and Elliott 2007). Tissue 
Doppler imaging has shown that the cardiomyopathy in Fabry disease is 
characterised by a substantial decrease in myocardial contractile performance 
and relaxation tissue Doppler velocities. This technique can also be used to 
provide a pre-clinical diagnosis of Fabry cardiomyopathy (Weidemann et al., 
2005; Pieroni et al., 2003; Pieroni et al., 2004). Recently, advances in non-
contrast T1 mapping by cardiovascular magnetic resonance imaging (MRI) 
have been shown to provide a useful measure of left ventricular hypertrophy 
(LVH) in Fabry disease. This technique has the potential to detect not only early 
cardiac involvement but also the ability to distinguish LVH due to Fabry disease 
with LVH attributable to other causes (Sado et al., 2013).    
Right ventricular hypertrophy has also been reported in Fabry disease. In two 
thirds of patients this occurred in addition to LVH and has been shown to have a 
similar prevalence in both males and females with the disease (Palecek et al., 
2008). In addition, a recent study has shown that the degree of right ventricular 
involvement was directly related to the left ventricular cardiomyopathy stage 
(Niemann et al., 2010). Ultimately, right ventricular involvement progresses to 
severe diastolic right ventricular dysfunction (Germain 2010).    
A number of other cardiac manifestations have been described in patients with 
Fabry disease. These include abnormal coronary microvascular function (Elliott 
et al., 2006), bradycardia resulting in the requirement of a pacemaker 
(O’Mahony et al., 2011), reduced exercise capacity (Bierer et al., 2005; Lobo et 
al., 2008), autonomic dysfunction (Hilz et al., 2010), aortic root dilation (Germain 
2010) and sudden cardiac death (Linhart et al., 2007).  
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1.3.6.2 The development of kidney disease and renal involvement in 
Fabry disease 
 
Renal impairment is reported in approximately 50 % of patients with Fabry 
disease and often begins with proteinuria in the second to third decade of life 
(Schiffmann et al., 2009; Branton et al., 2002; Mehta et al., 2004). Proteinuria 
has also been reported in a number of children and adolescents with Fabry 
disease (Ramaswami et al., 2006; Hopkin et al., 2008). However, biopsy studies 
have demonstrated that changes in glomerular and vascular architecture are 
evident before detectable proteinuria and suggest that at present biopsy may be 
required for the early detection of renal disease (Tøndel et al., 2008).  
As in diabetic nephropathy, the degree of proteinuria is thought to directly 
contribute to the progression of renal involvement in Fabry disease and 
worsens with advancing age (Fervenza, Torra, and Lager 2008; Schiffmann et 
al., 2009). Resultant decline in renal function by the fourth to fifth decade of life 
is evident by the presence of fibrosis, sclerosis and tubular atrophy which 
indicates development to end stage renal disease (Ortiz et al., 2008; 
Schiffmann et al., 2009; Branton et al., 2002). The cause of death of a large 
proportion of both treated (Mehta, et al., 2009b; Waldek et al., 2009) and 
untreated (Schiffmann et al., 2009) Fabry patients is attributable to renal 
disease. However, data from the Fabry Outcome Survey and the Fabry Registry 
indicates that this is improving, most likely as a result of the improved 
management of renal disease in these patients (Waldek et al., 2009; Mehta et 
al., 2009b).  
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1.3.6.3  Cerebrovascular involvement in Fabry disease   
 
Fabry patients may experience a variety of cerebrovascular manifestations 
ranging from mild to severe which can include headache, vertigo/dizziness, 
transient ischaemic attacks (TIAs) and strokes (Sims et al., 2009; Mitsias and 
Levine 1996; Clavelou et al., 2006; Mehta et al., 2004; Buechner et al., 2008). 
As with other symptoms associated with Fabry disease these neurological 
features generally occur earlier in males than females, typically during the third 
and fourth decade of life respectively (Sims et al., 2009; Mehta et al., 2004). 
Renal and cardiac disease may already be present at the onset of neurological 
involvement (Mehta et al., 2005; Sims et al., 2009). However, data from the 
Fabry Registry shows that in over 70 % of both males and females with the 
disease, stroke occurred in the absence of other major organ participation 
(Sims et al., 2009).  
A number of imaging techniques can be used to assess cerebrovascular 
involvement in Fabry disease including MRI (Fellgiebel et al., 2009), trans-
cranial Doppler (TCD) (Hilz et al., 2004) and positron emission tomography 
(PET) (Fellgiebel et al., 2007). These neuroimaging techniques can depict white 
matter lesions, dolichoectasia, territorial or lacunar strokes and increased 
tortuosity of the basilar artery (Viana-Baptista 2012; Germain 2010). A highly 
specific finding, visible by T1 weighted MRI, which is distinctly characteristic of 
Fabry disease, is the so called “pulvinar sign”, and has been described in both 
males (Moore et al., 2003; Viana-Baptista 2012; Burlina et al., 2008) and more 
recently females (Burlina et al., 2012) with the disease. In addition, the 
presence of the pulvinar sign is more frequently observed in males with 
cardiomyopathy and severe kidney disease suggesting that there may be a 
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correlation with the presence of this neurological finding and disease severity 
(Germain 2010; Burlina et al., 2008). 
 
1.3.7  Other symptoms associated with Fabry disease         
 
1.3.7.1 Depression and quality of life 
 
Depression is a frequent but under-recognised finding in Fabry disease 
(Germain 2010). In the limited number of studies that have been completed a 
high proportion of both male and female Fabry patients suffer from acute and 
often lifelong depression (Cole et al., 2007; Sadek et al., 2004; Crosbie, 
Packman and Packman 2009; Müller et al., 2006). This can have a serious 
impact on quality of life in patients with Fabry disease which has been 
demonstrated using a variety of different assessment criteria (Miners et al., 
2002; Street et al., 2006; Gold et al., 2002).     
 
1.3.7.2 Dysmorphology 
 
Dysmorphism, whilst not as prominent in Fabry disease as some of the other 
lysosomal storage disorders has been reported (Cox-Brinkman et al., 2007; 
Ries et al., 2006b). Fabry patients share common morphological characteristics 
of the face, trunk and extremities (Ries et al., 2006b). However, although these 
differences have been shown to be significant discrimination between affected 
patients and healthy controls is very small (Cox-Brinkman et al., 2007). 
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1.3.7.3  Skeletal involvement 
 
In a study of 23 males affected with classic Fabry disease, bone mineral density 
of the lumbar spine and femoral neck was assessed, osteopenia or 
osteoporosis was detected at one or both sites in 88% of cases (Germain et al., 
2005a; Germain et al., 2005b). Further studies have subsequently been 
performed confirming the presence of skeletal involvement in Fabry disease 
(Mersebach et al., 2007; Sacre et al., 2010).         
 
1.3.7.4 Respiratory involvement   
 
Airway obstruction, most likely as a result of glycosphingolipid accumulation, 
has been reported in 26 % of females and 61 % of males with Fabry disease 
(Magage et al., 2005; Magage et al., 2007). Other recognised aspects of 
respiratory involvement in Fabry disease include dyspnea, wheezing and a 
chronic cough (Rosenberg et al., 1980; Brown et al., 1997). These symptoms 
are progressive with advancing disease (Wang et al., 2008; Brown et al., 1997; 
Magage et al., 2007) in an age and gender dependent manner (Magage et al., 
2007). 
 
1.3.7.5 Anaemia 
 
Mild peripheral blood cytopenias, particularly anaemia, have been shown to be 
present in a large number of patients with Fabry disease as shown by data 
obtained from the Fabry Outcome Survey and the Fabry registry (Kleinert et al., 
2005; Oliveira et al., 2008).  
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1.3.7.6 Telangiectasiae  
 
Telangiectasiae are the second most common dermatological manifestation 
reported in Fabry disease and are small widened blood vessels on the skin. 
They occur on photodamaged areas such as the face and the ‘V’ of the neck 
(Zampetti et al., 2012; Giuseppe, Daniele and Rita 2013).    
 
1.3.7.7 Lymphoedema  
 
Lymphoedema has been reported in Fabry disease and is caused by a 
blockage of the lymphatic system resulting in swelling of the arms and/or legs. 
In Fabry disease this blockage is most likely related to the accumulation of 
glycosphingolipids in the lymph vessels (Lidove, Jaussaud and Aractingi 2006).  
 
1.3.7.8 Miscellaneous  
 
Other less common manifestations reported in Fabry disease include arterial 
remodelling and intima media thickening (Boutouyrie et al., 2002; Boutouyrie et 
al., 2001; Barbey et al., 2006). In a small study hypothyroidism was found in 
36% of patients (Hauser et al., 2005). In addition, priapism has also been 
reported in a small number of patients with Fabry disease (Backenroth et al., 
2010; Foda et al., 1996; Labarthe et al., 2010).   
 
1.3.8  Diagnosis of Fabry disease 
 
Although most patients with Fabry disease present with symptoms in early 
childhood, these symptoms are not necessarily specific to the disease. Hence, 
there is often a significant delay between the onset of symptoms before a 
diagnosis is confirmed and treatment can be initiated. Like all LSDs, Fabry 
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disease is progressive in nature and once suspected a diagnosis can be 
obtained relatively quickly using the appropriate biochemical and/or genetic 
laboratory based test(s).   
 
1.3.8.1 Enzymatic assay 
 
The gold standard laboratory method for confirming the diagnosis of Fabry 
disease in males, is the demonstration of decreased α-GAL activity in 
leukocytes (Mayes et al., 1981). A plasma assay may also be used although 
there have been reports of false positive results been obtained (Hoffmann et al., 
2005). Enzyme activity for determination of Fabry disease in females is not a 
reliable indicator of disease as many females demonstrate α-GAL activity that 
falls within the normal range (Linthorst et al., 2005). Therefore, all females 
suspected of having Fabry disease should have a diagnosis confirmed by 
mutation analysis (Germain 2010).    
 
1.3.8.2 Globotriaosylceramide (Gb3) measurement  
 
Gb3, the major metabolite that accumulates in Fabry disease (Figure 1.3), is 
routinely used to assess disease burden and monitor response to therapy. It 
has also been proposed and is currently used, as a first line screen, in the 
biochemical diagnosis of Fabry disease, enabling the identification of the 
majority of males and females with the disease (Mills et al., 2005; Auray-Blais et 
al., 2007; Auray-Blais et al., 2008) However, whilst Gb3 levels in urine have 
been shown to be more reliable than those in plasma, Gb3 is not elevated in 
patients with certain mutations raising some concerns about the use of this 
biomarker in the diagnosis of Fabry disease (Young et al., 2005; Mills et al., 
2005).   
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1.3.8.3 DNA analysis in the diagnosis of Fabry disease  
 
Confirmatory diagnosis of Fabry disease in males can be obtained by mutation 
analysis (Froissart, Piraud and Maire 2010). In addition, a definitive diagnosis of 
Fabry disease by genetic analysis is required in heterozygous females, due to 
the often normal α-GAL activity (Caudron et al., 2005; Linthorst et al., 2005). 
Many advances have been made since genotyping became available, including 
developments in the technologies capable of genetic analysis as well as 
publication of both the complementary (Bishop et al., 1986) and genomic DNA 
(Kornreich, Desnick and Bishop 1989) sequences of the GLA gene. These 
advances combined with the small size of the GLA gene has made molecular 
analysis to characterise mutations in Fabry disease relatively simple. 
Furthermore, a method that allows genotyping on DNA extracted from a dried 
blood spot on filter paper has recently been published. This method allows both 
enzymatic and confirmatory mutation analysis to be performed on a single 
sample (Hagège et al., 2011). 
 
1.3.9   Treatment of Fabry disease 
 
Since the first enzyme replacement therapy (ERT) became available for 
Gaucher disease (Barton et al., 1991) much progress has been made in the 
development of not only ERT for the LSDs but also in the development of novel 
therapies such as chaperone therapy and substrate reduction therapy.  
 
1.3.9.1 Enzyme replacement therapy  
 
Enzyme replacement therapy is a therapeutic approach for LSDs based on the 
intravenous administration of the deficient enzyme. Currently two products, 
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agalsidase alfa (Replagal, Shire, HGT) and agalsidase beta (Fabrazyme, 
Genzyme Corporation) are licensed for use as enzyme replacement therapies 
in Fabry disease. Agalsidase alfa is produced in a human cell line and is infused 
at 0.2 mg/kg over a period of forty minutes, every two weeks. Agalsidase beta is 
produced in a Chinese hamster ovary (CHO) cell line and is infused at a dose of 
1.0 mg/kg over a period of up to four hours every two weeks. Although both 
glycoprotein products have the same amino acid sequences the difference in 
production between a human or CHO cell line results in different glycosylation 
at the N-linked carbohydrate attachment sites. Agalsidase alfa contains a larger 
proportion of complex carbohydrate compared to agalsidase beta which has a 
larger fraction of sialylated and phosphorylated carbohydrate. As the 
polypeptide sequence of the two glycoproteins is identical these differences in 
carbohydrate composition are thought to be solely responsible for the 
differences in tissue distribution and dose response of the two ERTs (Garman 
and Garboczi 2004).  
Efficacy data from the initial randomised controlled clinical trial of agalsidase 
alfa after six months showed improved renal structure and function, improved 
cardiac conduction and decreased levels of pain and plasma Gb3 
concentrations (Schiffmann et al., 2001). Likewise the initial randomised 
controlled clinical trial of agalsidase beta showed that after twenty weeks of 
treatment plasma and tissue Gb3 levels were reduced and pain scores had 
improved (Eng et al., 2001). Following the initial randomised controlled clinical 
trials a vast array of studies have been completed to assess the efficacy of both 
enzyme preparations. In general, these studies have demonstrated 
normalisation of Gb3 levels in a variety of tissue types and biological fluids for 
the majority of Fabry patients. In addition, overall measures of disease burden 
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have been shown to be reduced (Motwani et al., 2012) and occurrence of major 
organ involvement has been shown to be delayed (Banikazemi et al., 2007). 
However, a recent study suggests that the long term outcome with ERT is one 
of limited effectiveness (Rombach et al., 2013).   
 
1.3.9.1.1 Effect of ERT on cardiac function      
 
A progressive decrease in intraventricular septum thickness and a decrease or 
stabilisation in left ventricular mass has been shown following up to 24 months 
of ERT (Spinelli et al., 2004; Hughes et al., 2008). One study reported the 
greatest response was observed in patients who display a degree of 
hypertrophy at baseline (Beck et al., 2004). However, Kalliokoski et al., (2006) 
found that after 12 months of ERT patients who displayed hypertrophy at 
baseline showed a poorer response than those that did not. Improvements in 
LVH and regional myocardial function have also been observed following 12 
months of therapy (Weidemann et al., 2003). More recently, a long-term report 
following 3 years of ERT (Weidemann et al., 2009) has shown significant 
cardiac benefits by demonstrating improved myocardial function, reduced left 
ventricular mass, and increased exercise capacity. In addition, long-term data 
from the Fabry Outcome Survey has demonstrated a sustained reduction of left 
ventricular mass following 5 years of ERT and a significant increase in mid-wall 
fractional shortening after 3 years of therapy (Mehta et al., 2009a).  
 
1.3.9.1.2 Effect of ERT on renal function        
 
In a number of studies creatinine clearance and estimated glomerular filtration 
rate (eGFR) have been shown to remain stable following treatment with 
agalsidase alfa following up to 2 years of ERT (Beck et al., 2004; Schwarting et 
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al., 2006; Choi et al., 2008; Dehout et al., 2003) and in another study after up to 
36 months of treatment (Wilcox et al., 2004). Similar findings have been 
reported in patients treated with agalsidase beta after 54 months of treatment 
(Germain et al., 2007). In those patients where there is a mild to moderate 
degree of Fabry nephropathy ERT has been shown to slow the decline in eGFR 
in some patients (West et al., 2009). However, for those patients with more 
advanced nephropathy and/or overt proteinuria (> 1 g per day) ERT has little, if 
any, effect (Germain et al., 2007; West et al., 2009). Therefore the initiation of 
treatment before substantial renal involvement occurs may be required in order 
to prevent or, at the very least delay, renal disease in patients with Fabry 
disease (Schiffmann et al., 2009).   
 
1.3.9.1.3 Effect of ERT on cerebrovascular events 
 
A limited number of studies performed in small patient cohorts have resulted in 
conflicting evidence regarding the effect of ERT on cerebrovascular events. An 
initial report showed progression of white matter lesions in 2 out of 7 patients 
following one year of therapy (Jardim et al., 2004). In contrast, Yamadera et al., 
(2009) report amelioration of white matter lesions in a single patient with Fabry 
disease following ERT. In a larger study, long-term data following 25 males with 
Fabry disease over 4.5 years of treatment with agalsidase alfa has shown that 
during the time period studied 16 % of patients suffered a cerebrovascular 
accident or a transient ischaemic attack (Schiffmann et al., 2006). Ideally, a 
study of patients not receiving ERT is required to establish the progression of 
cerebrovascular involvement in Fabry patients, only then will conclusions be 
able to be drawn as to the effectiveness of ERT on this clinical parameter.     
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1.3.9.1.4 ERT in females with Fabry disease 
 
A number of studies looking at the effectiveness of ERT in relatively small 
numbers of female patients have been completed. In general, a more 
favourable clinical course is observed for female patients with a degree of 
stabilisation in renal function and a stabilisation or reduction in left ventricular 
mass. An overall reduction in the prevalence of body pain in females has also 
been documented and ERT has been shown to be well tolerated (Whybra et al., 
2009; Hughes et al., 2011; Rombach et al., 2013).  
 
1.3.9.1.5 ERT in children with Fabry disease 
 
Several studies have specifically documented the effects of ERT in paediatric 
populations. ERT has been shown to reduce pain scores, improve pain-related 
quality of life, increase sweat volume and reduce gastrointestinal symptoms and 
acroparathesia (Ries et al., 2006a; Ramaswami et al., 2007; Wraith et al., 2008; 
Mills et al., 2005). More recently, a study looking at the effects of ERT over a 4-
year period (Schiffmann et al., 2010) and the largest observational study to date 
(Ramaswami et al., 2012) have shown similar results to those published 
previously. Further follow-up studies are required in order to understand fully 
and assess any long-term benefits of initiating treatment when there is little 
disease burden.   
 
1.3.9.2 Pharmacological chaperone therapy 
 
The aim of chaperone therapy is to use small molecules to selectively bind and 
stabilise target proteins in order to help normal folding. This ‘tricks’ the ER 
quality control system into allowing the protein to reach its final destination, the 
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lysosome. This results in improved intracellular trafficking and increased 
lysosomal enzyme activity, instead of the mis-folded but potentially catalytically 
active protein being exported and degraded by the proteasome. Chaperone 
therapy is suitable for use where small conformational changes are present but 
is not expected to restore the effect of mutations that cause major structural 
changes (van Gelder et al., 2012; Valenzano et al., 2011). As large gene 
rearrangements represent less than 10% of mutations occurring in Fabry 
disease pharmacological chaperone therapy could provide an attractive 
alternative treatment option (Ishii 2012). In addition, small molecule drugs are 
beneficial as they can be administered orally, they have the potential to access 
most cell types, they are able to cross the blood brain barrier (BBB) and access 
the central nervous system (CNS), and the cost of treatment is significantly 
lower than ERT.  
A number of in vitro studies have demonstrated the benefits of chaperone 
therapy (Valenzano et al., 2011) and Fabry disease became the first LSD to 
benefit from a clinical trial using intravenously administered galactose as the 
pharmacological chaperone (Frustaci et al., 2001). More recently, the 
investigation of a small molecule drug which is a competitive inhibitor of α-GAL, 
1-deoxygalactonojirimycin (DGJ, migalastat HCl, Amigal™), for use in Fabry 
disease both as an oral monotherapy and in combination with ERT has begun. 
Two phase III global studies for migalastat HCl monotherapy are currently 
underway following promising outcomes in preliminary studies. The first phase 
III trial will assess the efficacy, safety and pharmacodynamics of the oral 
administration of migalastat HCl in over 60 male and female Fabry patients. The 
second phase III clinical trial is to compare the safety and efficacy of migalastat 
HCl compared to ERT in over 50 patients with Fabry disease.  
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Preclinical studies using migalastat HCl in combination with ERT have 
demonstrated that the chaperone may improve the function of the α-GAL 
infused enzyme and be able to address some of the underlying limitations 
currently experienced when ERT is used alone (Benjamin et al., 2012). In 
addition, a phase II drug-drug interaction study evaluating the co-administration 
of migalastat HCl and ERT has been completed and plans are currently 
underway for a repeat dose clinical study to be performed. 
 
1.3.9.3 Substrate reduction therapy        
 
Substrate reduction therapy (SRT) involves the use of drugs, often small 
molecules, in order to inhibit substrate synthesis thereby, reducing substrate 
levels and decreasing storage burden (Beck 2010; Pastores 2009; Schultz et 
al., 2011; van Gelder et al., 2012). For the glycosphingolipidoses this can be 
achieved by inhibiting the enzyme glucosylceramide synthase which catalyses 
the first step in the synthesis of glycosphingolipids and therefore subsequent 
molecules, including Gb3 (Marshall et al., 2010). SRT reduces the level of 
substrate to a point where residual enzyme activity is sufficient to prevent 
substrate accumulation. Ultimately, the action of these small molecules is 
therefore dependent on the presence of residual endogenous enzyme and as 
such this therapeutic option is only suitable for those patients having mutations 
which result in some conserved enzyme activity (Pastores 2009). 
The use of N-butyldeoxynojirimycin (NB-DNJ), an imino sugar analog and 
glucosylceramide synthase inhibitor has been approved for use in Type I 
Gaucher disease. The investigation of the use of NB-DNJ in a mouse model of 
Fabry disease has produced promising results, including reduction of Gb3 (Abe 
et al., 2000; Heare et al., 2007). However, NB-DNJ is associated with adverse 
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side effects that may compound Fabry disease symptoms, for example 
gastrointestinal disturbances and peripheral neuropathies, and has therefore 
not been approved for use (Hollak et al., 2009). 
The use of eliglustat tartrate (Genzyme Corporation), another inhibitor of 
glucosylceramide synthase, has been shown to be effective as both a 
monotherapy and in combination with ERT in a mouse model of Gaucher 
disease. This success prompted investigations of eliglustat tartrate in a mouse 
model of Fabry disease following which reductions in tissue Gb3 levels were 
reported. The greatest effects were seen when eliglustat tartrate was used in 
combination with ERT (Marshall et al., 2010).  
Substrate reduction therapy has the potential to be used as a complementary or 
additive therapy to ERT, thereby improving the therapeutic management of 
Fabry disease. However, as the majority of male Fabry patients have very little 
residual enzyme activity substrate reduction therapy as a monotherapy will only 
be an appropriate and effective therapeutic option in a small proportion of 
patients (Marshall et al., 2010). 
 
1.3.10  Biomarkers in Fabry disease 
 
The definition of a biomarker is “a characteristic that is objectively measured 
and evaluated as an indicator of normal biological processes, pathogenic 
processes or pharmacological responses to a therapeutic intervention” (Hulka 
1990; Naylor 2003). In lysosomal storage disorders accumulating primary and 
secondary metabolites or proteins make good candidates for biomarkers (Aerts 
et al., 2011). Currently two biomarkers globotriaosylceramide (Gb3) (Mills et al., 
2005; Auray-Blais et al., 2008) and globotriaosylsphingosine (lyso-Gb3) (Aerts 
et al., 2008) (Figure 1.3) are routinely used to assess disease burden and 
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monitor response to therapy in Fabry disease. Gb3 levels can be reliably 
determined in urine and plasma by tandem mass spectrometry (Young et al., 
2005; Mills et al., 2005; Mills et al., 2004; Auray-Blais et al., 2007). Urinary Gb3 
levels have been shown to be more useful than Gb3 levels in plasma (Young et 
al., 2005) however, Gb3 has not proven to be an ideal biomarker. As Gb3 is not 
significantly elevated in a large proportion of female heterozygotes this 
biomarker cannot be used to monitor response to treatment in patients who 
initially have Gb3 levels within the normal range. In addition, falls in urinary Gb3 
in patients receiving ERT are not sustained in all cases despite clinical 
improvement (Mills et al., 2005). A more recent study has identified a number of 
novel Gb3 isoforms in the urine of Fabry patients (Auray-Blais and Boutin 2012). 
In the small number of untreated patients that were studied variable levels of 
excretion of the biomarkers was observed (Auray-Blais and Boutin 2012). 
Further studies are required on a larger cohort of patients to establish if 
measurement of these analogs will provide a better degree of correlation with 
disease severity, progression and response to treatment.    
Lyso-Gb3, a deacylated form of Gb3, has also been proposed as a potentially 
useful diagnostic marker of Fabry disease (Aerts et al., 2008). As with Gb3, this 
cationic amphiphile, possesses a large polar sugar moiety making it relatively 
hydrophilic and water-soluble. Various hypotheses have been suggested as to 
the origin of lyso-Gb3 including, its spontaneous formation from stored Gb3, 
active formation by the action of a specific enzyme and formation by sequential 
glycosylation of sphingoid bases (Aerts et al., 2008). However, as yet the origin 
of lyso-Gb3 remains unknown. Following the identification of lyso-Gb3 a number 
of studies have been completed to assess the level of this biomarker in both the 
plasma and urine of Fabry patients (Aerts et al., 2008; Rombach et al., 2010; 
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Auray-Blais et al., 2010; van Breemen et al., 2011). This analyte has been 
found to be elevated in both males and to a lesser extent in females with the 
disease. In addition, it appears to show a good degree of correlation with 
severity of disease manifestation and response to ERT (Aerts et al., 2008; 
Auray-Blais et al., 2010; Togawa et al., 2010; van Breemen et al., 2011; 
Rombach et al., 2010). More recently newly defined lyso-Gb3 analogs in plasma 
and urine from Fabry patients have been described (Dupont et al., 2013; Auray-
Blais et al., 2012). Interestingly, the excretion of the majority of these analogs in 
urine was shown to be significantly elevated above the excretion of lyso-Gb3 
itself (Dupont et al., 2013; Auray-Blais et al., 2012).  
Another potential biomarker having a structural resemblance to lyso-Gb3 has 
been proposed recently. Sphingosine-1-phosphate (S1P) is a biologically active 
growth-promoting factor involved in cardiovascular remodelling in both males 
and females with Fabry disease (Brakch et al., 2010). S1P levels in males were 
shown to be significantly higher than those of controls and levels in both males 
and females showed a good degree of correlation with left ventricular mass 
index and increased carotid intima media thickening (Brakch et al., 2010).  
The recent identification of S1P and a number of novel isoforms of both Gb3 
and lyso-Gb3 suggests that the use of only Gb3 and/or lyso-Gb3 as biomarkers 
in Fabry disease provides a limited view of this complex disease (Auray-Blais 
and Boutin 2012, Auray-Blais et al., 2012). This could provide an explanation as 
to why discrepancies in levels of these metabolites and clinical outcome have 
been observed. It remains to be seen if these recently identified biomarkers will 
indeed prove to be ideal biomarkers that provide a better correlation with 
disease severity, progression and response to treatment. It may be that no 
single biomarker is available for Fabry disease and in order to have the most 
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comprehensive understanding of this complex disease a panel of appropriate 
biomarkers is required. 
Following the identification of potential biomarkers their extensive validation is 
required prior to use in clinical practice. The first stage of validation requires the 
selection of the most appropriate candidate assay, for example, the use of an 
ELISA based method or a mass spectrometry based assay. The next stage of 
validation requires both the development of the assay and subsequent 
experimentation to ascertain performance parameters of the method including 
evaluation of accuracy, precision, reproducibility, sensitivity, specificity and 
evaluation of the assay range (LLOQ-ULOQ). Folowing the development of an 
assay fitness-for-purpose testing is performed to assess the robustness of the 
assay and to identify any potential problems with patient sampling such as 
collection, storage and stability issues. Only when these parameters have been 
ascertained can the verification of biomarkers identified during the biomarker 
discovery experiments be performed. Larger cohorts of patients can now be 
analysed in order to confirm the validity of the biomarker/s and demonstrate 
links to pertinent clinical endpoints or processes. Once the validity of a 
biomarker/s has been proven the final stage of biomarker validation requires the 
assay to enter routine use, where quality control (QC) monitoring, proficiency 
testing and batch-to-batch QC performance parameters are required to be 
continually assessed to ensure the performance of the assay is maintained 
(Cummings et al., 2010).   
       
1.4 Mass spectrometry and biomarker discovery 
 
Numerous advances in biological and analytical applications in recent years 
have led to an increasing interest in the identification and quantitation of 
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candidate biomarkers. Mass spectrometry (MS), when coupled with liquid 
chromatography (LC), is a powerful analytical technique capable of sensitive 
and selective detection, multi-analyte analysis and an ability to provide 
structural information. Owing to these attributes mass spectrometry has become 
increasingly important in the detection, validation and quantitation of biomarkers 
using both proteomic and metabolomic rationales (Ackermann, Hale, and Duffin 
2006; Cravatt, Simon, and Yates 2007; Griffiths and Wang 2009).   
A number of fundamental steps are required for all types of proteomic and 
metabolomic methodologies, these include: (i) sample preparation; (ii) sample 
separation by liquid chromatography; (iii) mass spectrometry analysis and; (iv) 
data acquisition and analysis.    
 
1.4.1 Sample preparation 
 
Sample preparation is a key step in proteomic and metabolomic analyses and 
has a direct impact on the quality of the final data obtained. By using the most 
appropriate preparation procedures both ion suppression and adduct formation 
can be minimised and the best instrument performance can be maintained 
(Issaq and Veenstra 2013). 
 
1.4.2 Proteomics 
 
Proteomics encompasses the identification and quantitation of all the expressed 
gene products of a cell, i.e. the proteins. The identification, structure and 
function of a protein is defined by a specific amino acid sequence. However, in 
order to sequence a protein it must first be converted into peptides, which fall 
within an appropriate mass range for MS analysis. This can be achieved with 
the use of a protease, a number of which are available. Trypsin, a sequence-
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specific protease, is one of the most specific and robust proteolytic enzymes 
and acts by hydrolysing peptide bonds at the carboxylic groups of arginine and 
lysine. This protease creates positive charges at the cleavage site which is 
beneficial for analyses using MS. As a result, trypsin is often the protease of 
choice for the digestion of proteins prior to sample separation and MS analysis 
(Swaney, Wenger, and Coon 2010).  
 
1.4.3 Metabolomics 
 
Metabolomics is the characterisation of the small molecule metabolites found in 
an organism. Prior to analysis metabolites need to be effectively extracted from 
the matrix in which they are contained. For biological samples, such as urine 
and plasma, this is most often achieved with liquid-liquid extraction (Álvarez-
Sánchez, Priego-Capote, and Castro 2010). In general, a polar aqueous 
solution, for example methanol, is paired with a non-polar organic solvent, such 
as chloroform, to create a two-phase system. When this immiscible solution is 
added to the biological sample compounds within the matrix distribute between 
the two layers based on their relative solubility. Thus permitting the separation 
of polar and non-polar metabolites, this chemical separation step also reduces 
the complexity of the analogues and reduces ion suppresion prior to 
subsequent chromatographic separation and analysis (Issaq and Veenstra 
2013).  
 
1.4.4 Sample separation by liquid chromatography 
 
Prior to MS analysis the peptides and metabolites in a biological sample are 
required to be separated by liquid chromatography. This process also allows 
simultaneous desalting of the sample, which can reduce the effects of ion 
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suppression by salts and other co-eluting molecules. In effect, greater 
separation of peptides or metabolites before they enter the mass spectrometer 
will enable better, more robust detection and identification of both proteins and 
metabolites (Aebersold and Mann 2003).   
 
1.4.5 High performance liquid chromatography 
 
High performance liquid chromatography (HPLC) is an analytical technique 
used to separate components of a mixture through the mass-transfer of 
analytes between stationary and mobile phases. The liquid mobile phase, 
carrying the analytes of interest, is pumped at a high pressure (500 – 2000 psi) 
through the stationary phase, in the form of a HPLC column packed with 
particles > 2µm. Individual components of the mixture separate based on their 
affinity for the solid and mobile phase, with each emerging from the column at 
separate time points. This separation may be manipulated through different 
choices of stationary phase and by changing the physico-chemical properties of 
the mobile phase (Prichard 2003). HPLC enables the simultaneous desalting 
and separation of analytes, including the separation of isomers, thereby 
reducing ion suppression.   
 
1.4.6 Ultra performance liquid chromatography™  
 
Ultra performance liquid chromatography™ (UPLC™) is based on the same 
chromatographic principles as HPLC but uses columns packed with smaller 
particles (< 2µm) and which are able to withstand ultra-high pressures (up to 
15,000 psi). This enables UPLC™ to separate compounds at increased speeds 
with superior resolution and sensitivity (Swartz 2013).  
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1.4.7 Reverse phase chromatography 
 
In HPLC and UPLC™, reverse phase chromatography (RPC) is commonly used 
and separates compounds according to their polarity. In RPC the use of a 
chromatography column composed of hydrophobic alkyl chains which retain 
hydrophobic compounds over hydrophilic ones is employed. A solvent gradient 
of increasing organic content (often either acetonitrile or methanol) is used to 
elute the compounds in order of their hydrophobicity. The more polar a 
compound, the greater its affinity for the polar mobile phase, the less it will 
interact with the non-polar stationary phase and will thus be eluted from the 
column more quickly than less polar compounds. RPC allows compounds with a 
wide range of polarities to be separated achievable by manipulating the polarity 
of the mobile phase (Westermeier, Naven and Höpker 2008).  
 
1.4.8 Liquid chromatography mass spectrometry 
 
When HPLC or UPLC™ is coupled with mass spectrometry the separating 
power of liquid chromatography and the mass analysing capabilities of mass 
spectrometry are combined to create a powerful analytical technique amenable 
to automation. The separation and reduction in complexity of biological samples 
by liquid chromatography reduces ion suppression and enables the percentage 
of proteome or metabolome coverage achievable by the mass spectrometer to 
be considerably increased. This in turn maximises the biomarker discovery 
potential available using this methodology (de Hoffmann and Stroobant 2013). 
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1.4.9 Basic principles of mass spectrometry 
 
Mass spectrometry is an analytical technique that separates ions according to 
their mass-to-charge (m/z) ratio (Griffiths and Wang 2009). To achieve this 
outcome all mass spectrometers are composed of three main components: an 
ion source, a mass analyser and a detector (Figure 1.7). 
 
 
 
Figure 1.7 Schematic representation of the basic components of a mass 
spectrometer. 
 
1.4.10  The ion source 
 
In the ion source, the analyte of interest becomes ionised prior to analysis in the 
mass spectrometer. A number of ionisation techniques are available, the choice 
of which is dependent on the physico-chemical properties of the sample/analyte 
under investigation.  
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1.4.11  Electrospray ionisation   
 
In 1989, John Fenn introduced electrospray ionisation (ESI), a soft ionisation 
technique, with the ability to ionise intact non-volatile, thermally labile 
biomolecules. The charged ions resulting from ESI are transferred into the 
gaseous phase where they can be subjected to mass analysis. The ESI process 
begins following the elution of biomolecules from a liquid chromatography 
column where they enter a static ion source through a narrow-bore metal or 
glass capillary tip which has a high electrical potential applied, (1.5 – 6.0 kV) 
relative to the counterelectrode (Fenn et al., 1989). As the liquid begins to exit 
the capillary, the surface becomes highly charged and assumes a conical 
shape, referred to as the Taylor cone. At the tip of the Taylor cone, the liquid 
changes shape into a fine jet. This jet however, becomes unstable, breaking up 
into a fine mist of finely charged droplets (Figure 1.8). Once the droplets are 
airborne, the solvent evaporates, with the aid of nitrogen drying gas and the 
surface area of the charged droplet decreases until the charge density on the 
surface of the droplet reaches a critical limit termed the Raleigh limit. Once the 
Raleigh limit is surpassed the ions become so unstable they explode to form 
even smaller droplets in what is known as the Coulomb explosion (Chapman 
2000; Ho et al., 2003). Finally, the electrical field becomes large enough to 
allow desorption of the ions which can then be transported to the mass 
spectrometer through a series of focusing lenses by electrical fields and are 
held in a vacuum (Iribarne and Thomson 1976; Thomson and Iribarne 1979). 
The type of mass analyser used for analysis is dependent on the information 
required.  
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Figure 1.8  Schematic representation of an electrospray ionisation 
source. N2 = nitrogen gas. 
 
An important feature of ESI as with other soft ionisation techniques is that 
minimal fragmentation of the molecule of interest is produced allowing its 
molecular mass to be determined. When coupled to a mass spectrometer this 
provides a sensitive, robust and reliable tool for studying biomolecules some of 
which are not amenable to analysis by other conventional techniques. ESI can 
also be combined with UPLC™ for in-line molecular fractionation prior to mass 
spectrometric analysis allowing analysis of both small and large molecules of 
various polarities in a complex biological sample (Banerjee and Mazumdar 
2012).  
 
 
1.4.12  The mass analyser 
 
The mass analyser is crucial to mass spectrometry analyses. Its key 
parameters include sensitivity, resolution, mass accuracy and the ability to 
generate spectra. A number of mass analysers are available including time-of- 
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flight, quadrupole time-of-flight, ion trap sector and triple quadrupole 
instruments. Each is different in design and performance and possesses its own 
strengths and weaknesses (Aebersold and Mann 2003).   
 
1.4.13  Time-of-flight mass spectrometry 
 
The basic principle of time-of-flight (ToF) MS is relatively simple and often used 
for the detection of peptides and proteins (Figure 1.9). A rapidly pulsing 
electrical field introduces product ions into the (field-free drift path) flight tube of 
the ToF mass analyser. Initially, ions are accelerated from the same position, at 
the same time, at identical kinetic energy. As a result, lighter ions fly faster and 
arrive earlier at the detector than heavier ones. The velocity of an ion is 
unambiguously related to its mass-to-charge (m/z) ratio therefore, the time it 
takes for an ion to travel through the flight tube and reach the detector directly 
indicates its mass (Gross 2011). 
 
1.4.14  Quadrupole time-of-flight mass spectrometry  
 
The quadrupole time-of-flight (QToF) is a hybrid mass spectrometer which 
combines quadrupole/collision cell technology with an orthogonally situated 
time-of-flight analyser (Figure 1.9). QToF instruments have been used 
extensively for both the detection of peptides and the identification of 
metabolites. Following ESI, ions enter the quadrupole mass analyser (MS1), 
which functions to filter/select ions based on their m/z ratio. The instrument 
consists of four parallel circular metal rods, around which an electric field is 
generated by applying a combination of a direct current DC (U) and a radio 
frequency AC (V) voltage of opposite polarities to opposite connected pairs. The 
field causes the ions to oscillate in x and y directions and it is alterations in both 
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these frequencies that allow ions, with a selected m/z, to pass through the mass 
analyser and either into a second mass analyser or a detector in a stable 
trajectory field. Other ions that have unstable trajectories, under that specific 
voltage, collide with the rods and are ejected from the quadrupole.  
 
 
 
 
Figure 1.9 Schematic representation of a quadrupole time of flight mass 
spectrometer. Note: in ToF-MS the first quadrupole (MS1) is operated in scan 
mode and functions only to focus ions into the collision cell and second 
quadrupole (MS2) for subsequent detection. 
Ions of a selected m/z (precursor ions) then enter the collision cell where they 
are fragmented by collision-induced dissociation using an inert gas such as 
argon. The fragments (product ions) are formed mainly by the cleavage of 
amide bonds between amino acids and can be categorised into b and y ions. 
The formation of b-ions occurs when the charge is retained by the amino-
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terminal fragment, whereas y-ions are formed when the charge is retained by 
the carboxy-terminal fragment (Steen and Mann, 2004). Product ions are then 
introduced into the orthogonally situated flight tube of the ToF mass analyser 
(MS2) for detection and an MS/MS spectrum of the fragments (y- and/or b-ions) 
is generated (Figure 1.10). It should be noted that by operating in MSE mode, 
the simultaneous fragmentation of all ions in a single LC-MS run without 
selecting a specific precursor ion is possible. In this mode the energy in the 
collision cell is alternated between low energy (MS) and higher energy (MSE) 
scans. The low energy data provide information about intact precursor ions, 
whereas high energy data contain ion fragmentation data. The precursor and 
their product ions are easily linked and combined by their common retention 
times (Ivleva, Yu and Gilar 2010).    
Ideally, the resulting MS/MS spectrum for a particular peptide ion would consist 
of a series of b- and y-ions, where each neighbouring fragment ion differed by 
one amino acid. The fact that each amino acid has a unique mass, with the 
exception of leucine and isoleucine, therefore allows the mass difference 
between neighbouring ions to be used to determine the amino acid sequence of 
that peptide. In effect, sequence determination by MS is based on the mass of 
the amino acids (de Hoffmann and Stroobant, 2002).  
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Figure 1.10 Schematic representation of fragmentation into b- and y-ions. 
Peptide fragments are indicated by b, if the charge is retained on the N-
terminus and by y, if the charge is maintained on the C-terminus.  
 
1.4.14.1 Label-free quantitative proteomics  
 
The ability to profile high numbers of proteins, from multiple sets of complex 
biological mixtures, provides huge potential for disease biomarker discovery. 
Label-free quantitative proteomics is a novel adaptation of the protein 
sequencing method described in section 1.4.14 and allows the simultaneous 
identification and quantitation of proteins from complex biological samples. The 
process is based on the observation that the concentration of a detected ion is 
linearly proportional to the intensity in ESI-MS (Levin et al., 2007). As a result, 
protein samples can be spiked with known concentrations of standard proteins 
from an unrelated species and comparisons made between the intensities of the 
internal standard peptide ions. The use of nano UPLC-QToF-MS for label-free 
quantitative proteomics allows each sample to be analysed individually and 
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sequentially and puts virtually no constraint on the number of samples being 
compared. The relatively low cost of this methodology, in comparison to label-
based methods such as iTRAQ which require expensive reagents, as well as 
the ability to add intact enolase prior to digestion thereby providing 
compensation for the trypsin efficiency, also make this an attractive analytical 
option. However, to be used for biomarker discovery, it is essential that 
reproducibility exists across multiple control samples to ensure that detected 
differences reflect biological and not experimental variation. Label-free 
quantitative proteomics provides an alternative or complementary technique to 
label-based proteomic methodologies and is a valuable tool in biomarker 
discovery with the potential to increase our understanding of the aetiology of 
disease.  
 
1.4.15  Ion trap mass analysers  
 
Ion-trap mass analysers work on the basic principle of trapping ions in circular 
orbit and use an electric or magnetic field to isolate molecules of specific m/z 
prior to mass spectrometric analysis.  
 
1.4.15.1 Fourier transform ion cyclotron resonance mass 
spectrometry  
 
Fourier transform ion cyclotron resonance mass spectrometry (FT-MS) 
determines m/z ratio based on the cyclotron frequency of an ion in a fixed 
magnetic field. Ions are first trapped where they are excited to a larger cyclotron 
radius by an oscillating electric field orthogonal to the magnetic field. Following 
the removal of the excitation field, ions rotate in “packets” at their cyclotron 
frequency. As these “packets” of ions pass a pair of electrodes a charge is 
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induced and the resultant free induction decay (FID) signal is extracted by 
performing a Fourier transform to produce a mass spectrum (Marshall, 
Hendrickson, and Jackson 1998).  
The strengths of FT-MS are high sensitivity, mass accuracy, resolution and 
dynamic range. However, the expense, complexity and low peptide-
fragmentation achievable using this technique have limited its use in mass 
spectral research.      
 
1.4.15.2 Orbitrap™ mass analyser 
 
The Orbitrap™ mass analyser is comprised of two outer electrodes and a 
central electrode which holds the trap together. Ions are injected into the 
volume between central and outer electrodes where the electrostatic attraction 
towards the central electrode is compensated by a centrifugal force that arises 
from the initial tangential velocity of ions. The electrostatic field ions are 
subjected to inside the Orbitrap™ causes them to move in complex spiral 
patterns. The axial component of these oscillations is independent of initial 
energy, angles and positions and can be detected as an image current on the 
two halves of an electrode encapsulating the Orbitrap™ (Figure 1.11). A Fourier 
transform is used to obtain oscillation frequencies enabling accurate m/z ratios 
to be determined (Scigelova and Makarov 2006).      
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Figure 1.11 A cut-away model of an orbitrap mass analyser. Reproduced 
from Scigelova and Makarov 2006. Ions move in spirals around a central 
electrode (a). An outer electrode (b) is split in half by an insulating ceramic ring 
(c). An image current induced by moving ions is detected via a differential 
amplifier between the two halves of the outer orbitrap electrode. The m/z of 
different ions is determined from respective frequencies of oscillation after a 
Fourier transform. 
 
1.4.16  Data acquisition and analysis 
 
Following data acquisition the MS spectra obtained from both metabolomic and 
proteomic methodologies can be performed automatically. The analysis of 
metabolomic ToF-MS spectra can be achieved using a software program such 
as MarkerLynx XS™ to assess which metabolites represent candidate 
biomarkers and therefore require structural elucidation by QToF-MS. Likewise 
- 90 - 
 
ProteinLynx™ and Progenesis LC-MS software can be used to perform the 
analysis of QToF-MS spectra obtained from proteomic analyses. Following 
which, the peptide sequence is searched against known protein sequences in 
databases such as Swiss-Prot to enable protein identification.    
Following the identification of a protein or metabolite, its applicability as a 
biomarker requires validation. Traditionally, immunoassay platforms such as 
western blot or ELISA have been used however, whilst this approach is suitable 
for the development of single biomarkers, the process becomes inefficient and 
costly for larger panels of multiplexed biomarkers. In addition methodologies 
such as these suffer from increased levels of variability and consequently 
increases in the coefficient of variation. The benefits of developing a tandem 
mass spectrometry based assay include rapid analysis times, high specificity, 
quantitation, ease of multiplexing and automation, making them suitable for 
translation for use within in clinical laboratories as functional assays.   
  
1.4.17  Tandem mass spectrometry  
 
The tandem mass spectrometer (MS/MS) utilises two quadrupole mass 
analysers coupled together in series. In a typical MS/MS analysis, ions of a 
selected mass (precursor or parent ions) are isolated by the first mass analyser 
(MS1) before transmission into a collision cell. In the collision cell ions collide 
with the neutral atoms of an inert gas usually argon, helium or nitrogen resulting 
in an increase in internal energy causing the molecule to fragment in a process 
called collision induced dissociation (CID). The subsequent fragments (product 
or daughter ion) produced are then analysed by the second mass analyser 
(MS2) (Figure 1.12). Tandem mass spectrometers are highly specific and 
sensitive instruments which enable the identification and quantification of 
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extremely low abundant molecules with a high degree of accuracy (de 
Hoffmann and Stroobant 2013).   
 
 
 
Figure 1.12 Schematic representation of a tandem mass spectrometer. 
Ions of a selected mass to charge (m/z) ratio are selected in the first quadrupole 
(MS1), fragmented in a collision cell and fragments separated in the second 
quadrupole (MS2).    
 
1.4.17.1 Possible configurations of a tandem mass spectrometer 
 
The first and second mass analysers (MS1 and MS2) can be operated in either 
fixed mass mode, whereby only ions of a certain mass are measured, or in scan 
mode, where ions of a range of masses are measured sequentially. By 
operating MS1 and MS2 in various combinations of fixed mass and scan mode, 
a number of different types of tandem mass spectrometric analyses are 
possible.  
 
1.4.17.1.1 Straight scan mode 
 
The tandem mass spectrometer can be operated as a simple, single quadrupole 
mass spectrometer by utilising only the first mass analyser in scan mode. In 
straight scan mode the mass analyser scans ions sequentially.  
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1.4.17.1.2 Product ion scan 
 
In a product ion scan a precursor ion is selected in the first mass analyser 
(MS1) to be focused into the collision cell to undergo CID. The second mass 
analyser (MS2) is set to scan mode to analyse the characteristic fragmentation 
spectra of the resultant product ions.    
 
1.4.17.1.3 Precursor ion scan 
 
In a precursor ion scan, MS2 is fixed for a specific product ion produced by CID 
in collision cell. Scanning of MS1, while MS2 is fixed allows all precursor ions 
which fragment to give a specific product ion or class of molecules to be 
analysed.  
 
1.4.17.1.4 Neutral loss scan 
 
During a neutral loss scan both mass analysers (MS1 and MS2) are set in scan 
mode. However, MS2 is offset from MS1 by a mass corresponding to that of a 
neutral loss.   
 
1.4.17.1.5 Selected reaction monitoring or multiple reaction monitoring 
 
Selected or multiple reaction monitoring allows the selection of a specific 
precursor ion or ions in MS1 and following CID in the collision cell the selection 
of a specific product ion or ions in MS2. By operating both mass analysers in 
fixed mass mode sensitivity is dramatically increased making this configuration 
ideal for use in quantitative proteomic and metabolomic analyses. 
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1.5 Aims of thesis 
The general aims of this thesis were to use proteomic and metabolic mass-
spectrometry based techniques to identify potential biomarkers and disease 
mechanisms in Fabry disease. Specific aspects of the research were to; 
 
(i) Use a label-free quantitative proteomic methodology to identify potential 
biomarkers in the urine of paediatric Fabry disease patients. 
 
(ii) Develop and validate a rapid MRM-based tandem mass spectrometry 
assay for the quantitation of these potential biomarkers of lysosomal 
storage disorders and of pre-symptomatic kidney disease. 
   
(iii) Use a metabolomic methodology to identify new and existing small 
molecule biomarkers in the plasma of Fabry disease patients. 
 
(iv) Investigate globotriaosylceramide (Gb3) and globotriaosylsphingosine 
(lyso-Gb3) toxicity in the Fabry mouse model with particular focus on 
protein: glycosphingolipid interactions. 
  
(v) Investigate mitochondrial respiratory chain enzyme activities in a Fabry 
mouse model. 
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2.0  Materials and methods 
 
2.1  Materials 
 
2.1.1  General materials 
 
All standard reagents were of AnalaR grade or equivalent and obtained from 
Sigma-Aldrich Company (Gillingham, Dorset, UK). All solvents used were LC-
MS grade and were obtained from BDH Ltd. (Poole, Dorset, UK). Trypsin used 
was of sequencing grade and was obtained from Promega UK Ltd 
(Southampton, Hants, UK). Zeba™ spin desalting columns, 7 K molecular 
weight cut-off (MWCO), 5 ml were obtained from Thermo Scientific Pierce 
(Northumberland, UK). Amicon® Ultra-0.5, 30 kDa and Ultra-15, 3 kDa 
centrifugal filter devices, were obtained from Sigma Aldrich Company (Dorset, 
UK). Oasis® MCX cartridges, 30 mg, 60 µm, were obtained from Waters Corp., 
(Milford, MA, USA). PD10 desalting columns were obtained from GE Healthcare 
Life Sciences (Buckinghamshire, UK). RS100 ProteinChip Arrays were obtained 
from Bio-Rad Laboratories (Hemel Hempstead, UK). Dynabeads® M-270 Epoxy 
were obtained from Invitrogen (Paisley, Renfrewshire, UK). An ATP synthase 
enzyme activity microplate assay kit was obtained from Abcam (Cambridge, 
UK). Pure custom synthesised peptides were obtained from GenScript Corp 
(Piscataway, NJ, USA). A stable isotope labelled internal standard (“AQUA™ 
peptide”) was obtained from Sigma-Aldrich Company (Dorset, UK). 
Glycosphingolipids were obtained from Biological Chemicals (Cambridge, UK) 
and Matreya (Pleasant Gap, PA, USA). 
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2.1.2  Sample materials  
 
2.1.2.1 Ethical approval 
 
Ethical approval was obtained from the Ethics Committees of University College 
London/University College London Hospital/Great Ormond Street 
Hospital/Institute of Child Health or the Faculty of Medicine and Health Sciences 
and the Centre Hospitalier Universitaire de Sherbrooke (CHUS). Written 
informed consent was obtained from adults, parents and children or young 
people where appropriate.  
 
2.1.2.2 Urine samples 
 
For proteomic analyses random urine samples were obtained from male 
paediatric Fabry disease patients (n = 10; age range 6 to 16 years; mean 12.5 
years; for patient demographics see Table 2.1) prior to ERT, with corresponding 
samples collected following 12 months of treatment. Diagnosis had been 
confirmed by demonstrating marked enzyme deficiency in leukocytes or by 
mutation analysis. Urinary Gb3 and creatinine was measured by HPLC-MS/MS 
(section 2.2.1 and 2.2.3, respectively) and patients classified according to their 
Gb3 concentrations (see Table 2.1). For proteomic validation experiments 
random urine samples from male paediatric type-I diabetic patients (n = 10; age 
range 7.8 to 18.4 years; mean 12.9 years) with an average disease duration of 
5 years were analysed as a positive control group. Glycosylated haemoglobin 
(HbA1c) was measured as part of the standard clinical appointment using the 
Diabetes Control and Complications Trial (DCCT) aligned Bayer 2000+ system 
(Siemens Healthcare Diagnostics, Inc., Deerfield, IL, USA). In addition, 10 age- 
and sex-matched healthy control subjects were drawn from the University 
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College London (UCL) Fetal Growth Study. This study consists of 1650 
consecutive mothers who delivered a singleton, Caucasian baby free of 
pregnancy complications and whose offspring’s growth had been followed for 
the last 10 years. For renal assay development as well as the paediatric type I 
diabetic patient and control groups, random urine samples from a second male 
paediatric Fabry disease group (n = 10; age range 4 to 18 years; mean 9.7 
years; see Table 2.2), and an age- and sex-matched obese paediatric group 
were obtained. In addition, an adult male Fabry disease group (n = 10; age 
range 34 to 62 years; mean 49.4 years), an age- and sex-matched adult type II 
diabetic group and an age- and sex-matched adult control group were also 
analysed. All paediatric patient groups displayed normal glomerular filtration 
rates with no signs of microalbuminuria using conventional methods. All urine 
samples were stored at -20°C prior to analysis.   
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Table 2.1 Demographics of male paediatric Fabry disease patients used in 
the proteomic study showing total Gb3 levels pre-treatment and 12 months 
post-treatment. Treatment status of patients is indicated by ↓DB for those with 
the least disease burden and ↑DB for those with the most disease burden.  
 
Patient 
identification 
Age 
Urinary Gb3 
pre-treatment 
(µmol/mmol 
creatinine) 
Urinary Gb3 
post-treatment 
(µmol/mmol 
creatinine) 
Treatment 
status 
1 9 0.35 0.06 ↓DB 
2 13 0.14 0.02 ↓DB 
3 15 0.18 0.15 ↑DB 
4 13 0.36 0.03 ↓DB 
5 15 0.56 0.02 ↓DB 
6 15 0.65 0.24 ↑DB 
7 14 0.47 0.04 ↓DB 
8 7 0.98 0.04 ↓DB 
9 11 0.67 0.06 ↓DB 
10 13 1.50 0.02 ↓DB 
Mean 
(min/max) 
12.5  
(7/15) 
0.59 
(0.14/1.50) 
0.07 
(0.02/0.24) 
- 
Normal 
control 
value 
- 
<0.05 µmol/mmol 
creatinine 
<0.05 µmol/mmol 
creatinine 
- 
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Table 2.2 Demographics of male paediatric Fabry disease patients used in the development of the renal assay showing total 
Gb3 levels pre-treatment and following one-, two- and three-years of ERT. Treatment status of patients is indicated by ↓DB for those 
with the least disease burden and ↑DB for those with the most disease burden.   
Patient 
identification 
Age at start 
of treatment 
Urinary Gb3 
pre-treatment 
(µmol/mmol 
creatinine) 
Urinary Gb3 
1 yr post-ERT 
(µmol/mmol 
creatinine) 
Urinary Gb3 
2 yrs post-ERT 
(µmol/mmol 
creatinine) 
Urinary Gb3 
3 yrs post-ERT 
(µmol/mmol 
creatinine) 
Treatment 
status 
11  12 1.19 1.26 0.88 0.74 ↑DB 
12 8 1.10 0.25 0.67 0.31 ↑DB 
13  6 0.41 1.68 1.22 0.47 ↑DB 
14  6 0.58 0.29 0.41 0.41 ↑DB 
15  6 0.36 0.05 0.11 0.14 ↑DB 
16  4 0.23 0.02 0.01 0.01 ↓DB 
17 15 0.18 0.02 0.01 0.02 ↓DB 
18  6 0.35 0.07 0.08 0.01 ↓DB 
19  18 0.36 0.04 0.02 0.01 ↓DB 
20  16 0.21 0.02 0.02 0.02 ↓DB 
Total mean 
(min/max) 
9.7 
(4/18) 
0.50 
(0.18/1.19) 
0.74 
(0.02/1.68) 
0.34 
(0.02/1.22) 
0.21 
(0.01/0.74) 
- 
Mean ↑DB 
(min/max) 
7.6 
(6/12) 
0.73 
(0.36/1.19) 
0.71 
(0.05/1.68) 
0.66 
(0.11/1.22) 
0.41 
(0.14/0.74) 
- 
Mean ↓DB 
(min/max) 
11.8 
(4/18) 
0.27 
(0.18/0.36) 
0.03 
(0.02/0.07) 
0.03 
(0.01/0.08) 
0.01 
(0.01/0.02) 
- 
Normal 
control value 
- 
<0.05 µmol/mmol 
creatinine 
<0.05 µmol/mmol 
creatinine 
<0.05 µmol/mmol 
creatinine 
<0.05 µmol/mmol 
creatinine 
- 
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2.1.2.3 Plasma samples 
 
For metabolomic analyses random plasma samples were collected from adult 
male Fabry patients (n = 12; age range 18 to 52 years; mean 30.5 years; see 
Table 2.3) and adult female Fabry patients (n = 12; age range 25 to 54 years; 
mean 39.3 years; see Table 2.4) in whom the diagnosis had been confirmed by 
demonstrating marked enzyme deficiency in leukocytes or by mutation analysis. 
Where paired urine samples were available Gb3 and lyso-Gb3 analyses were 
also performed as an additional measure to assess the level of disease burden 
(Tables 2.3 and 2.4). None of the patients had ever received ERT at the time of 
sample collection. Plasma lyso-Gb3 and corresponding urinary Gb3 and lyso-
Gb3 was measured by HPLC-MS/MS as described in sections 2.2.1 and 2.2.2. 
Creatinine was measured by HPLC-MS/MS as described in section 2.2.3. For 
comparison, plasma samples obtained from healthy reference control males (n 
= 8; age range 18 to 57 years; mean 37.8 years) and females (n = 8; age range 
21 to 63 years; mean 36 years) were studied. Plasma specimens were obtained 
from 2 ml of blood collected in potassium ethylenediaminetetraacetic acid 
(EDTA) tubes and centrifuged at 10,000g for 5 min. All samples were stored at -
20°C prior to analysis.  
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Table 2.3 Demographics of adult male Fabry disease patients used in the metabolomic study showing total urinary Gb3, lyso-
Gb3 and plasma lyso-Gb3 levels.
  A urine sample was not available for patient 11a. 
Patient  
identification 
Age 
Urinary Gb3  
(µg/mmol creatinine) 
Urinary lyso-Gb3  
(pmol/mmol creatinine) 
Plasma lyso-Gb3 
 (nmol/l) 
1a 36 4059 220 88 
2a 40 1079 79 105 
3a 35 327 159 91 
4a 18 1857 95 166 
5a 23 837 205 137 
6a 35 507 91 107 
7a 34 2452 181 90 
8a 25 150 353 232 
9a 20 14 149 227 
10a 18 1402 38 76 
11a 52 - - 124 
12a 30 92 87 172 
Mean 
(min/max) 
30.5 
(18/52) 
1161 
(14/2452) 
151 
(38/353) 
135 
(76/227) 
Normal 
control value 
- 
< 25 µg/mmol 
creatinine 
Not  
Detectable 
Not  
detectable 
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Table 2.4 Demographics of adult female Fabry disease patients used in the metabolomic study showing total urinary Gb3, lyso-
Gb3 and plasma lyso-Gb3 levels. Urine samples were not available for Gb3 analysis for patients 6b, 7b, 8b and 11b. 
Patient 
identification 
Age 
Urinary Gb3 
(µg/mmol creatinine) 
Urinary lyso-Gb3 
(pmol/mmol creatinine) 
Plasma lyso-Gb3 
(nmol/l) 
1b 48 51 29 11 
2b 26 68 30 7 
3b 45 121 15 18 
4b 27 127 50 15 
5b 51 725 77 15 
6b 30 - 8 6 
7b 25 - 29 11 
8b 28 - 23 13 
9b 54 7 2 3 
10b 51 15 35 10 
11b 48 - 48 19 
12b 38 58 44 8 
Mean 
(min/max) 
39.3 
(25/54) 
147 
(7/725) 
33 
(2/77) 
11 
(3/19) 
Normal 
control value 
- 
< 25 µg/mmol 
creatinine 
Not 
Detectable 
Not  
Detectable 
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2.1.2.4 Tissue samples 
 
For proteomic profiling analyses (Chapter 5) organs from male knock-out mice 
hemizygous for the gla gene meaning that this gene has no allelic counterparts, 
as well as homozygous female gla knock-out mice (referred to as Fabry mice; 
C57BL6/SVJ129) and wild-type control mice of the same genetic background 
were obtained as part of collaborative project with Dr Joan Keutzer, Genzyme 
Corporation, a Sanofi company, Cambridge, Massachusetts, USA.  
For analysis of mitochondrial respiratory chain enzyme activities (Chapter 6) 
organs from hemizygous male gla knock-out mice (referred to as Fabry mice; 
C57BL6/SVJ129) and wild-type control mice of the same genetic background 
were obtained as part of a collaborative project with Dr Raphael Schiffmann, 
Baylor University Medical Centre, Dallas, Texas, USA. All organs were stored at 
-80°C until required for analysis.   
For complex V enzyme activity analyses (Chapter 5) liver from male 12 week 
old Sprague Dawley rats were obtained from UCL Biological Services Unit, 
London, UK.  
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2.2  Methods 
 
2.2.1  Globotriaosylceramide (Gb3) measurement by HPLC-MS/MS 
 
The method described by Mills et al., (2005) was used to analyse Gb3 levels in 
urine and tissue as follows;  
 
2.2.1.1 Urine and tissue Gb3 extraction 
 
Each urine or tissue homogenate was thawed and well mixed, and 200 µl was 
sonicated for 10 s, at amplitude 6, using a Soniprep 150 Plus (MSE, London, 
UK) to fully disrupt any cellular debris or sediment. Forty microlitres of sonicate 
was added to 200 µl chloroform-methanol (2:1 v/v) containing 0.025 µg C17-
Gb3 internal standard (synthesised in house at the Biological Mass 
Spectrometry Unit, UCL Institute of Child Health, London, UK) in a 2 ml screw-
cap glass vial. Urine samples were left to shake for 30 min and tissue 
homogenates for 60 min in a VIBRAX VXR orbital shaker (IKA, Chelmsford, UK) 
to extract Gb3. Precipitated protein and any other particulate matter were 
removed by centrifugation at 40,000g for 10 min. The supernatant was removed 
into a 2 ml glass autosampler vial and stored at -20°C prior to analysis.     
 
2.2.1.2 Analysis of Gb3 in urine and tissue 
 
An Alliance HT 2795 HPLC coupled to a Quattro Micro triple quadrupole mass 
spectrometer (Waters Corp, Manchester, UK) was used for the direct analysis 
of the eluate in section 2.2.1.1. The instrument was operated in positive ion 
mode. The capillary voltage was maintained at 3.7 kV, with source temperature 
held constant at 150°C and nitrogen used as the nebulizing gas at a flow rate of 
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650 l/h. A Waters Spherisorb HPLC C8-guard column (4.6 x 10 mm ID., 5 µm) 
was used for separation with solution A (100 % methanol; MeOH) and solution 
B (4 mM ammonium acetate in ddH2O). The LC gradient is shown in Table 2.5.  
 
Table 2.5 The liquid chromatography gradient used to analyse Gb3 in urine 
 
Time (min) Solution A (%) Solution B (%) Curve 
0 50 50 1 
1 50 50 1 
2 100 0 6 
4 100 0 6 
4.01 50 50 1 
6 50 50 1 
 
The optimum flow rate was 0.5 ml/min, with a column oven temperature of 
40°C. The divert valve of the mass spectrometer was programmed to discard 
the HPLC effluent before (0 to 2 min) and after (5 to 6 min) the elution of Gb3 
isoforms and the C17-Gb3 internal standard to prevent system contamination. A 
35 µl injection volume was used with partial loop mode.  
 
2.2.1.3 Quantitation of Gb3 in urine and tissue 
 
Multiple reaction monitoring mode was used for the measurement of Gb3. Data 
were acquired over a time window of 3 min and quantitative data were taken 
from the Gb3 transitions shown in Table 2.6. Quantitation was achieved using 
peak areas processed by QuanLynx software (Waters Corp.) and ratioing the 
peak areas of the native Gb3 isoforms, shown in Table 2.6, to the peak area of 
the C17-Gb3 internal standard (m/z 1060.90). Total Gb3 levels (µmol) were 
expressed per mmol creatinine.  
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Table 2.6 Isoforms of Gb3 detected by UPLC-MS/MS. The internal standard 
(C17-Gb3) is shown underlined.  
 
Gb3 isoform Precursor m/z 
Cone 
voltage 
Product 
m/z 
Collision 
energy 
Lyso-Gb3 808.60 110 646.94 55 
C16-Gb3 1046.62 110 884.07 60 
C17-Gb3 1060.90 110 898.53 60 
C18-Gb3 1074.31 110 912.13 60 
C20-Gb3 1102.78 110 940.17 65 
C22:1-Gb3 1128.48 110 966.12 65 
C22-Gb3 1130.46 110 968.42 65 
C24:2-Gb3 1154.82 110 992.06 65 
C24:1-Gb3 1156.60 110 994.10 65 
C24-Gb3 1158.86 110 996.37 65 
C24:2-OH-Gb3 1170.68 110 1008.17 65 
C24:1-OH-Gb3 1172.69 110 1010.17 65 
C24-OH-Gb3 1174.59 110 1012.14 65 
C26-Gb3 1186.51 110 1024.18 65 
 
2.2.2  Globotriaosylsphingosine (lyso-Gb3) analysis in urine, 
plasma and tissue by HPLC-MS/MS 
 
2.2.2.1 Lyso-Gb3 analysis in urine 
 
The method described by Auray-Blais et al., (2010) was used to analyse lyso-
Gb3 levels in urine as follows;  
 
2.2.2.2 Sample preparation for the analysis of lyso-Gb3 in urine 
 
For each analysis 500 µl well mixed urine was added to 500 µl 1-β-ᴅ-
glucosylsphingosine (GSG) (4 nmol/l in MeOH) internal standard (Matreya, 
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Pleasant Gap, PA, USA), 20 µl of 50 % acetonitrile (ACN)/0.1 % formic acid 
(FA)/ddH2O and 100 µl hydrochloric acid (1 mmol/l). Solid phase extraction 
(SPE) was performed by transferring sample mixtures with glass pipettes to 
mixed-mode cation-exchange cartridges (Oasis® MCX, 30 mg, 60 µm, Waters 
Corp., Milford, MA, USA) preconditioned successively with 1200 µl MeOH and 
1200 µl hydrochloric acid (1 mol/l). Cartridges were washed with 1200 µl 2 % 
FA in ddH2O followed by 1200 µl 0.2 % FA in MeOH. Lyso-Gb3 and GSG were 
then eluted into glass tubes with 600 µl 2 % ammonia in MeOH. Eluates were 
evaporated to dryness under nitrogen. Residues were reconstituted in 200 µl 
50% ACN/0.1% FA/ddH2O, and transferred to glass vials for LC-MS/MS 
analysis. A calibration curve was prepared in the same way except the patient 
urine sample was substituted for 500 µl of control urine, and the 20 µl of 50% 
ACN/0.1% FA/ddH2O was replaced with the same volume of one of the 
following standard solutions: 0, 160, 400, 800, 1600, 3000 and 5000 pmol/l of 
lyso-Gb3 in 50% ACN/0.1% FA/ddH2O. The control urine used for the 
generation of the calibration curve contained no detectable lyso-Gb3.  
 
2.2.2.3 Analysis of lyso-Gb3 in urine  
 
An Alliance HT 2795 HPLC system coupled to a Quattro Micro triple quadrupole 
mass spectrometer (Waters Corp.) was used for the LC-MS/MS analysis of 
lyso-Gb3. The instrument was operated in positive ion mode. The capillary 
voltage was maintained at 3.2 kV, with source temperature held constant at 
120°C and nitrogen used as the nebulizing gas at a flow rate of 30 l/h. A Halo 
C18 column (2.1 x 50 mm ID., 2.7 µm; Advanced Materials Technology, 
Wilmington, DE, USA) was used for separation with solution A (0.2 % FA/ACN) 
and solution B (5 % ACN/0.2 % FA/ddH2O). The gradient run was: 3 min of a 
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linear gradient from 20 % to 70 % of A, followed by a 4 min wash period with 70 
% of A, then immediate return to initial conditions and equilibration with 20 % of 
A for 3 min. The optimum flow rate was 0.4 ml/min, with injector and oven 
temperatures of 20°C and 30°C, respectively. The divert valve of the mass 
spectrometer was programmed to discard the HPLC effluent before (0 to 2.8 
min) and after (3.5 to 10 min) the elution of lyso-Gb3 and GSG to prevent 
system contamination. A 25 µl injection volume was used with partial loop with 
needle overfill mode. The calibration curve was quadratic with 1/x weighing 
function, and the origin was excluded.  
 
2.2.2.4 Quantitation of lyso-Gb3 in urine  
 
Multiple reaction monitoring (MRM) mode was used for the measurement of 
lyso-Gb3. Data were acquired over a time window of 2 min and quantitative data 
were taken from transition 786.6>282.3 for lyso-Gb3 and 460.5>280.3 for the 
GSG internal standard. Lyso-Gb3 calibrators were measured at concentrations 
of 0, 160, 400, 800, 1600, 3000 and 5000 pmol/l. An example of a calibration 
curve generated in the analysis of lyso-Gb3 in urine is shown in Figure 2.1. 
Quantitation was achieved using peak areas processed by QuanLynx software 
(Waters Corp.).  
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Figure 2.1 Calibration curve generated during the analysis of lyso-Gb3 in 
urine. R2 = 0.996. 
 
2.2.2.5 Lyso-Gb3 analysis in plasma 
 
The method described by Boutin et al., (2012) was used to analyse lyso-Gb3 
levels in plasma as follows; 
 
2.2.2.6 Sample preparation for the analysis of lyso-Gb3 in plasma 
 
Sample preparation for the analysis of lyso-Gb3 in plasma was performed as 
described in section 2.2.2.1 with the exception that for each analysis 200 µl well 
mixed plasma was added to 500 µl phosphoric acid (H3PO4) (2 % in ddH2O), 
500 µl GSG (4 nmol/l in MeOH) internal standard, and 20 µl of 50 % ACN/0.1 % 
FA/ddH2O prior to SPE. A calibration curve was prepared in the same way 
except the plasma sample was substituted for 200 µl of plasma stripped twice 
with charcoal (Bioreclamation, Hicksville, NY, USA), and the 20 µl of 50% 
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ACN/0.1% FA/ddH2O was replaced with the same volume of one of the 
following standard solutions: 0, 4, 10, 40, 140, 400 nmol/l of lyso-Gb3 in 50% 
ACN/0.1% FA/ddH2O. The charcoal stripped plasma used for the generation of 
the calibration curve contained no detectable lyso-Gb3.  
 
2.2.2.7 Analysis of lyso-Gb3 in plasma  
 
Analysis of lyso-Gb3 in plasma by HPLC-MS/MS was performed as described in 
section 2.2.2.3 with the following exceptions; the capillary voltage was 
maintained at 3.4 kV, flow rate of the nitrogen nebulizing gas 50 l/h, the gradient 
run was: 5 min of a linear gradient from 20 % to 100 % of A, followed by a 3 min 
wash period with 100 % of A, then immediate return to initial conditions and 
equilibration with 20 % of A for 2 min.  
 
2.2.2.8 Quantitation of lyso-Gb3 in plasma  
 
Quantitation of lyso-Gb3 in plasma by LC-MS/MS was performed as described 
in section 2.2.2.4 with the exception that lyso-Gb3 calibrators were measured at 
concentrations of 0, 4, 10, 40, 140, 400 nmol/l. An example of a calibration 
curve generated in the analysis of plasma lyso-Gb3 is shown in Figure 2.2. 
 
 
 
Figure 2.2 Calibration curve generated during the analysis of lyso-Gb3 in 
plasma. R2 = 0.998. 
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2.2.3  Creatinine analysis by HPLC-MS/MS 
 
The method used to measure creatinine concentrations was developed in-
house by the Biological Mass Spectrometry Unit at UCL Institute of Child 
Health, London, UK and is as follows; 
 
2.2.3.1 Sample preparation for creatinine analysis 
 
Each urine sample was thawed, well mixed and 200 µl centrifuged at 40,000g 
for 10 min. For each analysis, 10 µl supernatant was added to 10 µl 5 mM d3-
creatinine internal standard (synthesised in house by the Biological Mass 
Spectrometry Unit at UCL Institute of Child Health, London, UK) and 200 µl 
ddH2O and vortexed for 30 sec. Calibration curves were constructed by spiking 
control urine with increasing amounts creatinine (0, 0.625, 1.25, 2.5, 5, 10 and 
20 mmol/l). 
 
2.2.3.2 Analysis of creatinine  
 
An Alliance HT 2795 HPLC coupled to Quattro Micro triple quadrupole mass 
spectrometer (Waters Corp.) was used for the LC-MS/MS analysis of creatinine. 
The instrument was operated in positive ion mode. The capillary voltage was 
maintained at 3.7 kV, with source temperature held constant at 150°C and 
nitrogen used as the nebulizing gas at a flow rate of 50 l/h. A Discovery® HS F5 
Supelguard™ column (2 x 2.1 mm ID., 5 µm) followed by a Discovery® HS F5-5 
HPLC column (5 cm x 2.1 mm ID., 5 µm; Sigma Aldrich, Dorset, UK) were used 
for separation with solution A (100 % MeOH) and solution B (4 mM ammonium 
acetate in ddH2O with 4 mM heptafluorobutyric acid). The LC gradient is shown 
in Table 2.7. 
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Table 2.7 The liquid chromatography gradient used to analyse creatinine 
 
Time  
(min) 
Solution A  
(%) 
Solution B 
(%) 
Flow rate 
(ml/min) 
Curve 
0.00 5 95 0.2 1 
1.90 5 95 0.2 1 
2.00 100 0 0.5 6 
2.10 100 0 0.6 6 
4.00 100 0 0.6 6 
4.01 5 95 0.6 1 
6.00 5 95 0.6 1 
 
The column oven temperature was 20°C. The divert valve of the mass 
spectrometer was programmed to discard the HPLC effluent before (0 to 2 min) 
and after (4 to 6 min) the elution of creatinine to prevent system contamination. 
A 5 µl injection volume was used with partial loop mode. 
 
2.2.3.3 Quantitation of creatinine 
 
MRM mode was used for the measurement of creatinine. Data were acquired 
over a 2 min time window and quantitative data were taken from transition 
113.70>43.90 for creatinine and 116.70>46.90 for the d3-creatinine internal 
standard. Creatinine calibrators were measured at concentrations of 0, 0.625, 
1.25, 2.5, 5, 10 and 20 mmol/l. An example of a calibration curve generated in 
the analysis of urine creatinine is shown in Figure 2.3. Endogenous creatinine 
concentrations in the control urine were determined by the intercept on the x-
axis of the un-spiked urine (0 calibrator point) and this correction value was 
subtracted from each subsequent calibrator point (0.625 - 20 mmol/l). 
Quantitation was achieved by ratioing the peak areas obtained from QuanLynx 
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software (Waters Corp.) of the native creatinine to the peak area of the d3-
creatinine internal standard (m/z 116.70).  
 
 
 
Figure 2.3 Calibration curve generated during the analysis of creatinine. 
R2 = 0.99. 
  
2.2.3.4 Urinary creatinine expression 
 
In this study, urinary concentrations of compounds of interest were corrected for 
dilution differences by measuring the urinary creatinine concentration as 
creatinine is filtered but not absorbed by the kidneys.     
 
2.2.4  Bicinchoninic acid (BCA) protein assay 
 
A standard curve with known concentrations of bovine serum albumin (BSA) 
(Sigma-Aldrich, Dorset, UK) was prepared (Table 2.8). Serial dilutions of the 
protein sample were also prepared in the protein storage buffer and 5 µl of each 
dilution was mixed with 45 µl of ddH2O. This was followed by the addition of 1 
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ml of bicinchoninic acid (Sigma-Aldrich, Dorset, UK) to each sample and 
incubated at 37°C for 10 min. Twenty microlitres of copper sulphate solution 
was added and incubated at 37°C for a further 20 min. The absorbance of each 
sample was measured with a Cecil CE 2040 spectrophotometer (Cecil 
Instruments, Cambridge, UK) at 562 nm and the protein concentrations (mg/ml) 
were calculated from the standard curve.  
 
Table 2.8 Concentrations of BSA (stock solution 1 mg/ml) used to create a 
standard curve. The buffer (5 µl) that was added to each sample corresponded 
to the storage buffer of the protein and accounted for any background noise.  
 
BSA conc. (mg/ml) BSA (µl) Buffer (µl) 
0 0 50 
0.05 2.5 47.5 
0.1 5 45 
0.2 10 40 
0.4 20 30 
0.6 30 20 
1 50 0 
 
2.2.4.1 Protein expression 
 
In this study, tissue concentrations of compounds of interest were corrected for 
protein concentrations.   
 
2.2.5   Proteomic analysis and method development   
 
The methods outlined in section 2.2.5 below are used in the proteomic study 
described in Chapter 3 to identify and validate potential urinary biomarkers in 
Fabry disease.   
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2.2.5.1 Urine preparation prior to proteomic analysis (QToF-MS)   
 
For each analysis, urine (Table 2.1) was desalted and the protein concentrated 
using Zeba™ spin desalting columns, 7 K MWCO, 5 ml (Thermo Scientific 
Pierce, Northumberland, UK). The Zeba™ column was centrifuged at 1,000g for 
2 min to remove storage solution. Five ml of 50 mM ammonium bicarbonate 
buffer pH 7.8 was added and centrifuged at 1,000g for 2 min. This step was 
repeated 3 times and the buffer was discarded. Finally 4 ml of urine was added 
and collected for analysis following centrifugation at 1,000g for 2 min. 
Thereafter, 400 µg of protein was aliquoted into 1.8 ml proteomic grade vials, 
lyophilised and stored at -20°C until required for in-solution digestion (section 
2.2.5.4) prior to analysis (section 2.2.5.5). 
 
2.2.5.2 Urine preparation prior to proactivator polypeptide and 
ganglioside GM2 activator protein analysis by UPLC-MS/MS 
 
For each analysis 500 µl of urine was applied to an Amicon Ultra-0.5 ml 
centrifugal filter for protein purification and concentration (30 kDa, Sigma 
Aldrich, Dorset, UK) and centrifuged at 14,000g for 12 min. Proactivator 
polypeptide (prosaposin; PSAP) was distinguished from the processed saposins 
A, B, C and D with the use of these size exclusion filters. After centrifugation the 
lower fraction contained proteins < 30 kDa, which included saposins A, B, C 
and D (molecular weights ~ 10 kDa), and ganglioside GM2 activator protein 
(GM2AP; 21 kDa). The fraction containing proteins > 30 kDa were removed from 
the filter using a pipette, this fraction contained prosaposin (65 - 73 kDa). To 
both the > 30 kDa recovered fraction and the < 30 kDa recovered fraction, 5 µl 
(7.62 fmol) of a synthesised stable isotope labelled GM2AP internal standard 
peptide (SEFVV[13C6P]DLELPSWLTTGNYRIESVL) was added (“AQUA
TM 
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peptide,” Sigma-Aldrich, Dorset, UK), lyophilised and stored at -20°C until 
required for in-solution digestion (section 2.2.5.4) prior to analysis (section 
2.2.5.7).  
 
2.2.5.3 Urine preparation prior to renal biomarker analysis by UPLC-
MS/MS 
 
For each analysis 1 ml of urine and 2.5 µl of a 0.1 µg/µl enolase intact protein 
as internal standard was applied to an Amicon Ultra-1 ml centrifugal filter for 
protein purification and concentration (3 kDa, Sigma Aldrich, Dorset, UK) and 
centrifuged at 4000g for 50 min. The concentrate (> 3 kDa) recovered was then 
lyophilised and stored at -20°C until required for in-solution digestion (section 
2.2.5.4) prior to analysis (section 2.2.5.8).  
 
2.2.5.4 In-solution digestion protocol  
 
The lyophilised protein was reconstituted in 20 µl of 100 mM Tris, pH 7.8, 
containing 6 M urea, and left shaking gently for 60 min at room temperature to 
denature the protein. Disulphide bridges were reduced by the addition of 1.5 µl 
of 100 mM Tris-HCl buffer, pH 7.8, containing 5 M dithioerythritol (DTE), 
followed by incubation at room temperature for 60 min. Free thiol groups were 
carboamidomethylated by incubation with 6 µl of 100 mM Tris-HCl, pH 7.8, 
containing 5 M iodoacetamide (IAA) for 30 min at room temperature. The 
reaction mixture was then diluted with 155 µl of ddH2O and vortexed. To 
proteolytically digest the proteins, 1 µg of trypsin (Sigma-Aldrich, Dorset, UK) 
was added to the reaction mixture, followed by incubation overnight at 37°C in a 
water bath. 
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2.2.5.5 Label-free quantitation by NanoAcquity UPLC-QToF-MS 
 
Urine and tissue proteins were identified and quantitated by direct analysis of 
the reaction mixtures described in sections 2.2.5.1 and 2.2.7.1.2, respectively. 
Prior to analysis each digest was spiked with 1 pmol of an enolase tryptic 
digestion (Saccharomyces cerevisiae). All analyses were performed using a 
NanoAcquity UPLC and QToF Premier mass spectrometer (Waters 
Corporation, Manchester, UK). Peptides were trapped and desalted prior to 
reverse phase separation using a Symmetry C18 5 µm, 5 mm x 300 µm pre-
column. Peptides were then separated prior to mass spectral analysis using a 
15 cm x 75 µm C18 reverse phase analytical column. Peptides were loaded 
onto the pre-column at a flow rate of 4 µl/min in 0.1 % FA for a total time of 4 
min. Peptides were eluted off the pre-column and separated on the analytical 
column using a gradient of 3 - 40 % ACN containing 0.1 % FA over a period of 
120 min and at a flow rate of 250 nl/min. The column was washed and re-
generated at 300 nl/min for 10 min using a 99 % ACN containing 0.1 % FA. 
After all non-polar and non-peptide materials were removed, the column was re-
equilibrated under the initial starting conditions for 20 min. All columns were 
maintained at 35ºC. Mass accuracy was maintained during the run using a lock 
spray of the peptide [glu1]-fibrinopeptide B delivered through the auxiliary pump 
of the NanoAcquity at a concentration of 500 nmol/l and at a flow rate of 300 
nl/min. 
Peptides were analysed in positive ion mode with the QToF operated in v-mode 
with a typical resolving power of 10,000 FWHM. Prior to analyses, the ToF 
analyser was calibrated using [glu1]-fibrinopeptide B fragments obtained using 
a collision energy of 25 V and over the mass range m/z 50 – 2000. Post-
calibration of data files was corrected using the doubly charged precursor ion of 
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[glu1]-fibrinopeptide B (m/z 785.8426) with a sampling frequency of 30 
s. Accurate mass LC-MS data were collected in a data-independent and 
alternating, low and high collision energy mode. Each low/high acquisition was 
1.5 s with 0.1 s interscan delay. Low energy data collections were performed at 
a constant collision energy of 4 V, high collision energy acquisitions were 
performed using a 15 - 40 eV ramp over a 1.5 s time period and a complete 
low/high energy collision acquisition achieved every 3.2 s. 
 
2.2.5.6 Data analysis by UPLC-QToF-MS  
 
ProteinLynx Global Server version 2.4 (Waters, UK) was used to process all 
data acquired. Protein identifications were obtained by searching the 
appropriate proteome UniProt database (human or mouse) to which the 
sequence of P00924 yeast enolase and P00761 porcine trypsin were added 
manually. Protein identification from the low/high collision spectra for each 
sample was processed using a hierarchical approach where more than three 
fragment ions per peptide, seven fragment ions per protein and more than two 
peptides per protein had to be matched. Lock mass window was set at 0.1 Da, 
low and elevated energy thresholds set at 150 and 50 counts, respectively. 
Elution start and end times were 15 and 110 min, respectively and with 
chromatographic peak width set to automatic. Protein identification parameters 
used in the database searching included a < 10 ppm mass accuracy tolerance, 
fixed modifications of carboamidomethylation of cysteines, dynamic 
modifications of deamidation of asparagine/glutamine and oxidation of 
methionine, up to 3 missed cleavage sites and maximum protein mass 400 kDa. 
Quantitation of urinary proteins using MSE analyses were determined as fmol of 
total protein in 1 l of urine and then standardized and expressed per mmol of 
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creatinine (fmol of protein/mmol of creatinine). Statistical differences between 
sample groups were analysed using Microsoft Excel and Graphpad Prism with 
statistical significance obtained using standard Student’s t-test.  
 
2.2.5.7 Development of a high-throughput UPLC-MS/MS assay for 
confirmation and validation of prosaposin and GM2AP  
 
Based on ESI-QToF analyses the peptides m/z 865.9681 (EIVDSYLPVILDIIK2+) 
from the saposin A region of the prosaposin protein (see Figure 2.4) and m/z 
775.6234 (SEFVVPDLELPSWLTTGNYR3+) from GM2AP produced the largest 
response and optimum product ion scans and were therefore selected as the 
“marker” peptides for optimization and development of a MRM-based assay.  
 
 
 
Figure 2.4 Prosaposin sequence with each mature saposin chain 
highlighted and the protein coverage observed in the ESI-QToF analyses 
underlined.   
 
- 124 - 
 
These sequences were checked for uniqueness and post-translational 
modifications by verification with UniProt (http://www.uniprot.org). Pure custom 
synthesized peptides were ordered from GenScript Corp, Piscataway, NJ, USA. 
A stable isotope labeled GM2AP internal standard peptide was synthesized, 
which included a single missed cleavage site with a short peptide “tag” of IESVL 
(SEFVV[13C6P]DLELPSWLTTGNYRIESVL) this compensates for any 
inefficiencies in the trypsin protease reaction. This method has been applied 
previously to plasma proteins (Heywood et al., 2012a) and has now been 
developed for urinary prosaposin and GM2AP quantitation. Confirmation of the 
identification of the marker peptides for prosaposin m/z 865.97 and GM2AP m/z 
775.62 in urine was verified by comparison to their retention time with the 
synthesised versions of the peptides when spiked into urine. This provided a 
third level of identification in addition to precursor and product ion mass allowing 
the unequivocal identification of each peptide/protein. Quantitative data were 
taken from transition 865.97>215.19 for prosaposin, 775.62>213.18 for GM2AP 
and 777.46>463.12 for the stable isotope labeled internal standard. Calibration 
curves were constructed by spiking male control urine with 7.62 fmol of the 
GM2AP stable isotope labelled internal standard and increasing amounts (10, 
25, 50, 75 and 100 fmol/l) of the synthesised marker peptides used to quantitate 
the prosaposin and GM2AP proteins (Figure 9.1 of supplementary data, section 
9.1.1). Endogenous concentrations of prosaposin and GM2AP concentrations in 
the male control urine were determined by the intercept on the x-axis of the un-
spiked urine (0 calibrator point) and this correction value was subtracted from 
each subsequent calibrator point (10-100 fmol/l). Quantitation of prosaposin and 
GM2AP was performed by ratioing the peak area of the native peptide to the 
peak area of the stable isotope-labelled internal standard for GM2AP (m/z 
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777.46). Urinary creatinine concentrations were determined as described in 
section 2.2.3.4. Urinary prosaposin and GM2AP concentrations were 
determined relative to urinary creatinine concentrations.    
A Waters Acquity UPLC coupled to a Xevo™ TQ-S triple quadrupole mass 
spectrometer (Waters Corp, Manchester, UK) was used for validation and 
clinical assay development experiments. The instrument was operated in 
positive ion mode. The capillary voltage was maintained at 3.7 kV, with source 
temperature held constant at 150°C and nitrogen used as the nebulizing gas at 
a flow rate of 30 l/h. For each peptide precursor ion masses were determined in 
scan mode with product ion masses determined following collision-induced 
dissociation with argon. Optimum cone and collision energies for each peptide 
are shown in Table 2.9. Two transitions from each peptide were selected for 
confirmatory purposes. A Waters ACQUITY UPLC BEH C18 column (2.1 x 100 
mm ID., 1.7 µm) was used for separation with solution A (99.9% H20 and 0.1% 
FA) and solution B (99.9% ACN and 0.1% FA). The flow rate was set to 0.8 
ml/min and a linear gradient of 0 - 97% sol A over 7 min. The total run time was 
10 min due to loading, cleaning and reconditioning. A 30 µl injection volume 
was used with partial loop with needle overfill mode.  
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Table 2.9 MRM transitions for the UPLC-MS/MS analysis of prosaposin, 
GM2AP and the stable isotope-labelled GM2AP internal standard. Ions 
charge is indicated by 2+ for doubly charged or 3+ for triply charged ions. Product 
ions underlined are those used for quantitation whilst non-underlined ions were 
used for confirmation only. 
 
Protein 
name 
Tryptic peptide sequence 
Precursor 
m/z 
Cone 
voltage 
Product 
m/z 
Collision 
energy 
 
PSAP 
 
 
EIVDSYLPVILDIIK 
 
865.97
2+
 70 215.19 36 
865.97
2+
 70 538.50 40 
 
GM2AP 
 
 
SEFVVPDLELPSWLTTGNYR 
 
775.62
3+
 20 213.18 44 
775.62
3+
 20 769.64 12 
AQUA 
peptide 
 
SEFVV[
13
C6P]PDLELPSWLTTGNYR 
 
777.46
3+
 20 216.97 20 
777.46
3+
 20 463.12 20 
 
 
2.2.5.8 Development of a high-throughput UPLC-MS/MS assay for 
pre-symptomatic kidney disease 
 
Suitable peptide regions, from a number of proteins of interest, were checked 
for uniqueness and post-translational modifications by verification with the 
UniProt database (http://www.uniprot.org) and selected as “marker” peptides for 
optimization and development of a multiple reaction monitoring (MRM)-based 
assay (Table 2.10). Selection of “marker” peptides was based on QToF 
analyses and with the use of the Global Proteome Machine (GPM; 
www.thegpm.org), a proteomic platform containing datasets contributed by 
researchers enabling the selection of peptide marker sequences based on 
previously tested and validated MS analyses. In addition, Skyline (MacCoss 
Lab, University of Washington) a targeted proteomic application for building 
MRM quantitative methods was used to assess optimum peptides and their 
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transitions. Pure custom synthesized peptides were ordered from GenScript 
Corp (Piscataway, NJ, USA). In addition, a yeast enolase whole protein was 
purchased from Sigma-Aldrich (Gillingham, Dorset, UK) to act as an internal 
standard to control for sample processing. Confirmation of the identification of 
all marker peptides in urine was verified by comparison to their retention time 
with the synthesised versions of the peptides when spiked into urine. This 
provided a third level of identification in addition to precursor and product ion 
mass allowing the unequivocal identification of each peptide/protein. 
Quantitative data for each peptide were taken from one transition, shown 
underlined in Table 2.10 with a second transition included for identification 
purposes only.  
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Table 2.10 MRM transitions for the UPLC-MS/MS analysis of renal 
proteins. Ions charge is indicated by 2+ for doubly charged or 3+ for triply 
charged ions. Product ions underlined are those used for quantitation whilst 
non-underlined ions were used for confirmation only. 
 
Protein name Tryptic peptide sequence 
Precursor 
m/z 
Cone 
voltage 
Product 
m/z 
Collision 
energy 
Albumin AVMDDFAAFVEK 
671.82
2+
 35 811.43 24 
671.82
2+
 35 1041.49 24 
Cubilin DGVDSDAPILSK 
609.10
2+
 34 830.74 16 
609.10
2+
 34 945.79 16 
Endothelial 
protein C 
receptor 
TLAFPLTIR 
515.85
2+
 12 215.17 26 
515.85
2+
 12 299.82 22 
Ig gamma-4 
chain C region 
 
EPQVYTLPPSQEEMTK 
 
938.94
2+
 52 408.37 34 
938.94
2+
 52 436.37 28 
Lysosomal α-
glucosidase 
AGYIIPLQGPGLTTTESR 
937.46
2+
 22 405.38 30 
937.46
2+
 22 518.48 24 
Megalin TVLVSEGIVTPR 
636.16
2+
 44 413.44 14 
636.16
2+
 44 858.79 22 
Neutrophil 
gelatinase-
associated 
lipocalin 
VPLQQNFQDNQFQGK 
597.61
3+
 50 414.41 14 
597.61
3+
 50 591.89 10 
Osteopontin AIPVAQDLNAPSDWDSR 
927.90
2+
 84 511.36 34 
927.90
2+
 84 835.81 26 
Prostaglandin-
H2 D- 
isomerase 
TMLLQPAGSLGSYSYR 
872.33
2+
 60 459.44 20 
872.33
2+
 60 587.50 20 
Retinol 
binding 
protein 
WIEGDELHLEMR 
509.74
3+
 56 504.07 14 
509.74
3+
 56 614.37 14 
Sortilin DPIYFTGLASEPGAR 
797.84
2+
 26 489.44 22 
797.84
2+
 26 857.76 26 
Vitamin D 
binding 
protein 
 
VPTADLEDVLPLAEDITNILSK 
 
789.54
3+
 16 657.24 22 
789.54
3+
 16 1053.93 20 
Yeast enolase 
1. SIVPSGASTGVHEALEMR 
2. GNPTVEVELTTEK 
3. AVDDFLISLDGTANK 
614.58
3+
 46 771.73 16 
709.06
2+
 46 948.68 16 
790.16
2+
 46 661.49 18 
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Calibration curves were constructed by spiking male control urine with 2.5 µl of 
0.1 µg/µl of the yeast enolase internal standard and increasing amounts (0.1 - 
150 nmol/l or 0.7 - 172 pmol/l) of each of the synthesised marker peptides used 
to quantitate the proteins of interest (Figures 9.2.1 and 9.2.2 of supplementary 
data, section 9.1.1). Endogenous concentrations of the proteins of interest in 
the male control urine were determined by the intercept on the x-axis of the un-
spiked urine (0 calibrator point) and this correction value was subtracted from 
each subsequent calibrator point.  
Quantitation of each of the proteins was performed by ratioing the peak area of 
the native peptide to the peak area of the yeast enolase internal standard (m/z 
614.58 > 771.73, 709.06 > 948.68 or 790.16 > 661.49). Urinary creatinine 
concentrations were determined as described in section 2.2.3. Urinary 
concentrations of the proteins of interest were determined relative to urinary 
creatinine concentrations.   
A Waters Acquity UPLC coupled to a Xevo™ TQ-S triple quadrupole mass 
spectrometer (Waters Corp, Manchester, UK) was used for validation and 
verification experiments. The instrument was operated in positive ion mode. The 
capillary voltage was maintained at 2.5 kV, with source temperature held 
constant at 150°C and nitrogen used as the nebulizing gas at a flow rate of 30 
l/h. For each peptide precursor ion masses were determined in scan mode with 
product ion masses determined following collision-induced dissociation with 
argon. Optimum cone and collision energies for each peptide are shown in 
Table 2.10. Two transitions from each peptide were selected for confirmatory 
purposes. A Waters ACQUITY UPLC BEH C18 column (2.1 x 100 mm ID., 1.7 
µm) was used for separation with solution A (99.9% ddH20 and 0.1% FA) and 
solution B (99.9% ACN and 0.1% FA). The flow rate was set to 0.8 ml/min and a 
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linear gradient of 0 - 97% sol A over 7 min. The total run time was 10 min due to 
loading, cleaning and reconditioning. A 25 µl injection volume was used with 
partial loop mode.  
 
2.2.5.9 Data analysis  
 
All data were analysed using MassLynx version 4.1. Statistical differences 
between sample groups were analysed using Microsoft Excel and Graphpad 
Prism with statistical significance obtained using standard Student’s t-test. 
 
2.2.6  Metabolomic analyses  
 
The methods outlined in section 2.2.6 below are used in the metabolomic study 
described in Chapter 4 to identify new Gb3-related biomarkers in the plasma of 
Fabry disease patients.   
 
2.2.6.1 Plasma sample preparation prior to metabolomic analysis 
(UPLC-ToF-MS)  
 
Plasma samples (section 2.1.2.3) were processed by liquid-liquid extraction 
using a method adapted from Sullards et al., (2011). Two-hundred microlitres of 
well mixed plasma from untreated Fabry patients and healthy controls was 
transferred to individual glass tubes and mixed with 3 ml of MeOH and 1.5 ml of 
chloroform, sonicated for 30 s, and incubated for 15 hrs at 48°C. Thereafter, 
450 µl of potassium hydroxide (KOH) 1M (in MeOH) was added to each tube to 
hydrolyse unwanted species that would interfere with the liquid-liquid 
extractions. After the KOH addition, the samples were vortexed for 30 s, 
sonicated for 30 s, and incubated for 2 hrs at 37°C. The solutions were 
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neutralised by the addition of 18 µl of glacial acetic acid. For the liquid-liquid 
extraction, 2 ml of chloroform and 4 ml of water were added and vortexed for 30 
s, sonicated for 30 s, and centrifuged for 5 min at 10,000g. The lower organic 
phase was aspirated using a Pasteur pipette, taking care not to disturb the 
interface and transferred to new test tubes. The aqueous phase was re-
extracted with a second 2 ml of chloroform. The combined lower organic phases 
were dried under a stream of nitrogen and re-suspended in 100 µl of MeOH/5 
mM ammonium formate/0.1 % FA. 
 
2.2.6.2 Nomenclature used in metabolomic analyses  
 
Gb3 isoforms: Gb3 with different fatty acid chains coupled by amide linkage to 
an unmodified sphingosine moiety. The principle sphingosine species is 
described as d18:1, with a total of 18 carbon atoms and a single double bond 
(Figure 2.5). 
 
 
 
 
Figure 2.5 Structure of Gb3 with behenic acid (C22) fatty acid as an 
example; a.) Native Gb3; b.) Methylated Gb3. 
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Gb3 analogs: Gb3 with modified sphingosine moieties. We express the structure 
of Gb3 isoforms and analogs in the following way: 
 
Gb3(dv:w)(Cx:y)Z 
 
Where d = the sphingosine group; w = the number of double bonds in the 
sphingosine moiety; v = the number of carbons in the sphingosine moiety;  C = 
the fatty acid group; x = the number of carbon atoms in the fatty acid moiety; y = 
the number of carbon-carbon double bonds in the fatty acid moiety; Z = other 
modifications of sphingosine structure (e.g. methylation (Me) or hydration (H2O). 
 
2.2.6.3 Metabolomic analysis by UPLC-ToF-MS 
 
The ultra-performance electrospray ionization time-of-flight mass spectrometry 
(UPLC-ESI-ToF-MS) analyses were performed with the use of a Synapt™ (ESI-
Quadrupole-ToF-MS) coupled to an ACQUITY UPLC®, both from Waters Corp. 
(Milford, MA). Between these two systems, a Rheodyne injection valve model 
MXP9900-000 from IDEX® Health and Science (Oak Harbour, WA) was 
installed to direct the UPLC eluent toward the mass spectrometer or to divert it 
to waste. The UPLC and MS methods programmed to analyse the metabolites 
in the plasma samples under study are shown in Table 2.11.  
To increase the mass accuracy during the analysis of plasma metabolites, the 
“lock mass” option was activated for real-time calibration. For this purpose, a 
HPLC isocratic pump model 515 from Waters Corp. (Milford, MA) was used to 
inject the calibrating solution (500 nM terfenadine) through the reference 
ionisation probe during the sample analysis. The flow rate was decreased to 
approximately 10 µl min using a “T” splitter before its introduction into the mass 
spectrometer. 
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Table 2.11 UPLC and ESI-Tof-MS methods for the analysis of urinary 
metabolites. 
 
UPLC method ESI-ToF-MS method 
Column Acquity UPLC® BEH C8 Scan mode MS-ToF 
Company Waters Corp. (Milford, MA) Ionisation mode ESI 
Length 50 mm Polarity Positive 
Internal 
diameter 
2.1 mm Analyser mode V 
Particle 
diameter 
1.7 µm Dynamic range Extended 
Temperature 30 °C Capillary voltage 3.2 kV 
Flow rate 0.5 ml/min 
Sampling cone 
voltage 
20 V 
Mobile phase A 
MeOH/5 mM ammonium 
formate/0.1 % FA 
Extraction cone 
voltage 
5 V 
Mobile phase B 
H2O/5 % MeOH/5 mM 
ammonium formate/0.1 % FA 
Source temperature 120 °C 
Gradient 
0-1 min → 50 % A 
 
1-6 min → 50 – 80% A 
 
6-12 min → 80 – 100% A 
 
12-15 min → 100 % A 
 
15-16 min → 100 % A 
 
16-20 min → 50 % A 
Desolvation 
temperature 
450 °C 
Cone gas flow 30 l/hr 
Desolvation gas flow 700 l/hr 
Trap collision energy 6 V 
Transfer collision 
energy 
4 V 
Data format Centroid 
Weak wash 50 % phase A/50 % phase B Mass range 50-2000 Da 
Strong wash MeOH/0.1 % FA Scan time 0.1 s 
Injection volume 7.5 µl Lock mass 
Injection mode Partial loop overfill Compound 
Terfenadine (500 
nM) 
Autosampler 
temperature 
15 °C Exact mass 472.3215 Da 
Solvent delay 0-1 min 
Solvent 
H2O/5 % 
ACN/0.5% FA 
Scan time 0.5 s 
Interval 5 s 
Sampling cone 
voltage 
3 V 
Trap collision energy 6 V 
Mass window ± 0.2 Da 
Scan average 3 
Flow rate ~ 10 µl/min 
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2.2.6.4 Structural characterisation of Fabry disease biomarkers 
 
For the elucidation of the structures of Fabry disease biomarkers by UPLC-ESI-
QToF-MS, a 500 µl plasma aliquot from an untreated Fabry male was 
processed by the procedure mentioned above and re-suspended in 100 µl of 
phase A. 
 
2.2.6.5 Effects of sample processing 
 
To evaluate the potential effects of sample preparation on the structure of Gb3 
analogs and other potential biomarkers, 150 µl of a synthetic internal standard 
(Gb3(d18:1)(C17:0); 0.05 mg/ml in MeOH) was processed as described above 
with and without the matrix (200 µl of plasma from a healthy control). The Gb3 
synthetic internal standard was chosen for its odd number of carbon atoms on 
the fatty acid, which is not present in human urine samples.  
 
2.2.6.6 Data mining and multivariate data analysis 
 
The UPLC-ESI-ToF-MS results generated during the metabolomic study were 
processed using MarkerLynx™ XS (Waters Corp.). This data mining software 
aligned the metabolites detected in different samples according to their exact 
mass and retention time, and also measured their peak areas. For the process, 
the mass range chosen was between 995 and 1200 Da, the intensity threshold 
was 5 counts, the mass window was 0.20 min. The results treated with 
MarkerLynx™ XS were downloaded into EZInfo, a software of UMETRICS 
(Umeå, Sweeden) integrated with the Extended Statistics Tool Box of MassLynx 
V4.1 (Waters Corp.) for multivariate analysis. Using EZInfo, a supervised 
Orthogonal Partial Least Square-Discriminant Analysis (OPLS-DA) was 
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performed to discriminate the 12 untreated Fabry males from the 8 healthy 
control males. For OPLS-DA, the Pareto scaling (Equation 2.1) was used which 
increases the weight of medium intensity metabolites without inflating baseline 
noise: 
 
Equation 2.1: 
 
        
   
√  
 
 
Where   = area of the metabolite;   = mean area of the metabolite;    = 
standard deviation of the area of the metabolite.   
 
An S-plot was generated to highlight the metabolites contributing the most to 
the discrimination of the two groups of samples during OPLS-DA and 
considered to be potential Fabry disease biomarkers. The more abundant a 
biomarker is in patient samples and absent in control samples, the more it will 
be revealed by the S-Plot. For that reason, only male samples were used for the 
metabolomic study because, in general, the clinical, physiological and 
biochemical manifestations of Fabry disease are more severe for male patients 
compared to females. 
 
2.2.6.7 System stability evaluation 
 
To evaluate the system stability over the metabolomic run, a quality control 
plasma sample comprised of 10 µl from each Fabry and control sample was 
analysed 3 times at the beginning of the analytical run, then at every 6 samples 
and 3 times at the end of the run for a total of 9 replicates.   
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2.2.6.8 Structural characterisation of Fabry disease biomarkers 
 
The biomarkers identified by multivariate statistical analysis were structurally 
characterised by tandem mass spectrometry. The UPLC and MS methods were 
the same as those shown in Table 2.11 for the identification of plasma 
metabolites, except that the MS mode was Quardrupole-ToF-MS instead of 
ToF-MS. The precursor ions were thus isolated in the quadrupole (Q), 
fragmented in the collision cell, and the exact mass of resulting fragments 
analysed in the ToF system.  
 
2.2.6.9 Relative quantitation of Fabry disease biomarkers  
 
The Fabry disease biomarkers identified by multivariate data analysis were 
quantitated relatively by integration of peak areas using the QuanLynx™ 
software (Waters Corp.). The Apex track integration algorithm was employed 
using a mass window of 0.2 Da and a retention time window of 0.2 min. For 
smoothing, 3 integrations of the “mean” method were used with a smoothing 
width of 2.         
 
2.2.7  Investigation of Gb3 and lyso-Gb3 toxicity in the Fabry mouse 
model 
 
The methods outlined in section 2.2.7 below are used in the study described in 
Chapter 5 to investigate Gb3 and lyso-Gb3 toxicity in the Fabry disease mouse 
model.    
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2.2.7.1 Proteomic profiling of Fabry mouse tissues 
 
2.2.7.1.1 Tissue preparation prior to proteomic profiling (UPLC-QToF-
MS) 
 
Mouse organs (liver, kidney, heart and brain) from Fabry mice (n = 3) and wild-
type controls (n = 3) (section 2.1.2.4) were homogenised in 9 ml of 50 mM 
ammonium bicarbonate (pH 7.4) per gram of tissue using a Potter-Elvehjem 
tissue grinder. Homogenates of the same tissue type were combined and a 
BCA protein assay performed as described in section 2.2.4. Thereafter, 400 µg 
of protein from each tissue type was aliquoted into 1.8 ml proteomic grade vials, 
lyophilised and stored at -80°C until required for in-solution digestion (section 
2.2.5.4) and fractionation (section 2.2.7.1.2).  
 
2.2.7.1.2 Fractionation of Fabry mouse tissues using high pH C18 
chromatography 
 
Following in solution digestion (section 2.2.5.5) Isolute C18 chromatography 
columns (50 mg/1 ml; Biotage, Hengoed, UK) were successively primed with 1 
ml of 50 % ACN containing 0.1 % ammonia and 2 ml of 0.1 % ammonia. One-
hundred microlitres of the tissue digest (section 2.2.7.1.1) and 100 µl of 0.2 % 
ammonia were combined and applied to the pre-conditioned C18 column and 
allowed to flow though under gravity. This breakthrough fraction was captured 
and re-applied to the column and the subsequent elution retained. A 500 µl 
solution of 0.1 % ammonia was then applied to the column and the eluting wash 
fraction collected and retained. Thereafter, peptides were eluted from the 
column with 500 µl of a solution containing an increasing percentage of ACN (3 
%, 5 %, 8 %, 10 %, 12 %, 15 %, 20 % and 100 %) with 3 % ammonia and each 
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fraction captured. All fractions were then lyophilised and reconstituted in 30 µl of 
3 % ACN containing 0.1 % trifluroacitic acid (TFA) prior to label-free quantitative 
analysis by UPLC-QToF-MS (section 2.2.5.5).  
 
2.2.7.1.3 Data analysis of Fabry mouse tissues by UPLC-QToF-MS  
 
Analysis of data acquired from all tissue fractions was processed by 
ProteinLynx Global Server version 2.4 as described in section 2.2.5.6. With the 
exception that elution start and end times were 5 and 55 min, respectively. 
Quantitation of mouse proteins using MSE analyses were determined as fmol of 
total protein per mg of tissue. In addition, data was also analysed using 
Progensis LC-MS (Nonlinear Dynamics, Waters Corp.) a data analysis program 
which identifies and quantitates peptides and proteins detected in label-free 
analyses based on ion abundance. Differences between groups were assessed 
by identifying fold changes greater than 2.   
 
2.2.7.2 Protein: glycosphingolipid interaction experiments 
 
2.2.7.3 Sample preparation 
 
Control mouse brain or kidney tissue (100 mg) was homogenised using a 
Potter-Elvehjem tissue grinder, in 900 µl 150 mM PBS, pH 7.2 and centrifuged 
for 10 min at 40,000g to remove particulate. Thereafter, tissue homogenate 
supernatant was aliquoted into Eppendorf tubes, a BCA protein assay 
performed as described in section 2.2.4 and aliquots stored at -80°C until 
required for analysis.    
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2.2.7.4 Glycosphingolipid preparation 
 
Glycosphingolipids were solubilised in chloroform: methanol (2:1 v/v) and then 
centrifugally evaporated. Thereafter, glycosphingolipids were reconstituted in 
150 mM phosphate buffered saline (PBS; pH 7.4) to a final concentration of 30 
µmol/l.   
 
2.2.7.5 ProteinChip® RS100 array technology  
 
2.2.7.5.1 Coupling glycosphingolipids to the RS100 array surface 
 
Five microlitres of 30 µmol/l glycosphingolipid was added to each spot on the 
ProteinChip array. The RS100 chip was incubated overnight at 4°C in a 
humidity chamber to prevent the sample from evaporating. Excess liquid was 
removed using a clean tissue. Any unreacted carbonyl diiamidazole sites 
present on the surface of the RS100 chip were blocked by the addition of 5 μl of 
0.5 M ethanolamine, 50 mM Tris, pH 8.0, followed by incubation at room 
temperature (20°C), for 30 min in a humidity chamber. After this time, excess 
blocking solution was removed using a tissue and the array was washed in a 
conical tube containing 8 ml of PBS, pH 7.4, 0.1 % Triton X-100, which was 
agitated for 15 min. The RS100 chip was washed for 15 min in 8 ml PBS 
containing no Triton X-100, followed by a final wash with 10 ml PBS, pH 7.4 
containing no Triton X-100 for 10 min. Excess PBS wash buffer was removed 
from the areas around the spots using a tissue. Care was taken not to touch the 
surface of the spots containing the bound glycosphingolipids.  
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2.2.7.5.2 Tissue binding and extraction 
 
For the analysis 400 µg of mouse brain tissue homogenate supernatant (section 
2.2.7.3) was applied to each binding site and aspirated several times to mix and 
optimise binding. The RS100 chip was then incubated for 2 hrs at room 
temperature (20°C) in a humidity chamber. Excess sample solution was 
removed from the spots and the RS100 chip was washed twice in 8 ml of PBS, 
pH 7.4 containing 0.1 % Triton X-100 for 15 min. The RS100 chip was 
transferred to a fresh tube and washed in 8 ml PBS, containing no Triton X-100, 
for 5 min. Bound proteins were removed from the surface of the RS100 chip by 
the addition of 5 μl FAPHs reagent (50 % FA, 25 % ACN, 15 % isopropyl 
alcohol), followed by repeated aspiration of the solution. Each wash was 
combined and collected in Eppendorf tubes. The protein solutions were 
lyophilised and stored at -20°C prior to in-solution digestion (section 2.2.5.4) 
and label-free quantitation by UPLC-QToF-MS (section 2.2.5.5). 
 
2.2.7.6 Dynabeads® M-270 epoxy  
 
2.2.7.6.1 Preparation and binding of glycosphingolipids to 
Dynabeads®   
 
For each analysis 1.5 mg of Dynabeads® were prepared by washing with 1 ml 
150 mM PBS, pH 7.2, vortexed for 30 sec and incubated with mixing at room 
temperature (20°C) for 10 min. The wash solution was removed from the beads 
by placing the vial on the magnet and carefully pipetting off the supernatant, 
leaving the beads undisturbed. This wash step was repeated 3 times. 
One-hundred microlitres of 30 µmol/l lyso-Gb3, galactosylsphingosine, 
sphingosine (section 2.2.7.4) or PBS was added to each aliquot of washed 
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beads and incubated with mixing for 18 hrs at 4°C. Following incubation 
glycosphingolipid bound beads were washed as previously described.       
 
2.2.7.6.2 Tissue sample binding and extraction 
 
The glycosphingolipid bound Dynabeads® were then incubated with 400 µg 
protein from mouse kidney tissue homogenate supernatant (section 2.2.7.3) 
with mixing for 18 hrs at 4°C. Following incubation with tissue homogenate 
beads were washed as previously described and after all residual liquid 
removed stored at -20°C prior to in-solution digestion (section 2.2.5.4) and 
label-free quantitation by UPLC-QToF-MS (section 2.2.5.5). 
 
2.2.7.7 Data analysis 
 
Data obtained from the RS100 ProteinChip array analysis and the Dynabead M-
270 epoxy analysis were analysed using ProteinLynx Global Server version 2.4 
as described in section 2.2.5.6. With the exception that elution start and end 
times were 5 and 55 min, respectively. Proteins identified were considered to 
interact with a glycosphingolipid if they were not detected as binding to the 
negative control group. 
 
2.2.7.8 Von Frey assay to assess pain thresholds 
 
In order to assess touch thresholds in mice following exposure to Gb3 and lyso-
Gb3 a von Frey assay was performed by Professor John Wood, Molecular 
Nociception Group at UCL, as part of a collaborative project.    
 
 
- 142 - 
 
2.2.7.8.1 Glycosphingolipid preparation for von Frey assay 
 
The glycosphingolipids Gb3 and lyso-Gb3 were solubilised in 
chloroform/methanol (2:1 v/v) at final concentrations of 300 µmol/l and 30 
µmol/l, respectively. Compounds were lyophilised and stored at -20°C until 
required for analysis. Prior to analysis each lyophilised compound was 
reconstituted in 100 µl 150 mM PBS, pH 7.2. 
 
2.2.7.8.2 Von Frey assay 
 
For the von Frey assay C57BL/6 mice were used. Each subject mouse was 
assigned an identification key and placed into one of the following test groups; 
Gb3 (n = 9) lyso-Gb3 (n = 9) and control/PBS (n = 6). Identification keys and test 
groups were assigned by someone other than the test operator so as not to 
introduce testing bias.   
 
2.2.7.8.3 Von Frey assay – habituation 
 
Subject mice were placed into their assigned, specific test compartment and left 
to explore, undisturbed for 1 hr. After exploratory behaviour had stopped or 
decreased to a minimal level the test operator entered the room for 5 min before 
starting the test. 
 
2.2.7.8.4 Von Frey assay – testing 
 
Following the intraplantar injection of Gb3, lyso-Gb3 or saline (Figure 2.6) the 
von Frey assay was performed 0, 0.5, 1, 2, 4, 6 and 24 hr post injection. The 
first von Frey hair was applied perpendicular to the paw (Figure 2.6), until it 
buckled slightly and was held for 3 sec. If a response (pain behaviour) was 
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observed the first column of a scoring grid was marked with an “X”. If no 
response was observed it was marked with an “O”. It should be noted that the 
mouse should not be asleep or grooming during testing as this may influence 
the response (Callahan et al., 2008). If the hair used produced a response the 
next lower weight hair was selected for the following use. Conversely, if the hair 
used failed to produce a response the next higher weight hair was selected for 
the following use. A minimum interval of 1 min was left between each 
application. Increasing or decreasing application of weighted hairs was applied 
and the results marked into the first column of a scoring grid until a change in 
response occurred – e.g., “XXXO” or simply “OX”. Once the perception 
threshold had been crossed, the continued application of increasing (no 
response) or decreasing (response) weighted hairs, for the next five 
applications was recorded. 
 
 
 
Figure 2.6 Mouse paw with the circle indicating the area of the plantar 
surface of the paw to be stimulated with von Frey hair as well as the site 
for intraplantar injection  
 
2.2.7.8.5 Von Frey assay – threshold calculation   
 
Using the reference table (Table 2.12) the corresponding ĸ value for each 
response series was allocated and used in equation 2.2 to calculate the 50 % 
threshold (grams).  
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Table 2.12 Von Frey kappa value reference table. The number of responses 
before the response threshold is crossed determines the column. The following 
pattern of responses determines the row. Note that the ĸ value is inverted if the 
response series prior to threshold crossing is X. 
 
ĸ for test series whose first part is: 
 O OO OOO OOOO  
XOOOO -0.547 -0.547 -0.547 -0.547 OXXXX 
XOOOX -1.250 -1.247 -1.246 -1.246 OXXXO 
XOOXO 0.372 0.380 0.381 0.381 OXXOX 
XOOXX -0.169 -0.144 0.142 -0.142 OXXOO 
XOXOO 0.022 0.039 0.040 0.040 OXOXX 
XOXOX -0.500 -0.458 -0.453 -0.453 OXOXO 
XOXXO 1.169 1.237 1.247 1.248 OXOOX 
XOXXX 0.611 0.732 0.756 0.758 OXOOO 
XXOOO -0.296 -0.266 -0.263 -0.263 OOXXX 
XXOOX -0.831 -0.763 -0.753 -0.752 OOXXO 
XXOXO 0.831 0.935 0.952 0.945 OOXOX 
XXOXX 0.296 0.463 0.500 0.504 OOXOO 
XXXOO 0.500 0.648 0.678 0.681 OOOXX 
XXXOX -0.043 0.187 0.244 0.252 OOOXO 
XXXXO 1.603 1.917 2.000 2.014 OOOOX 
XXXXX 0.893 1.329 1.465 1.496 OOOOO 
 X XX XXX XXXX  
- ĸ for test series whose first part is: 
 
 
Equation 2.2: 
 
                  [    ]          
 
Where; x = log of the final von Frey hair used; ĸ = tabular value and ; δ  = log of 
mean difference between stimuli (typically 0.224 for most von Frey sets) 
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2.2.7.8.6 Data analysis of von Frey assay 
 
Statistical differences between sample groups were analysed using Microsoft 
Excel and Graphpad Prism with statistical significance obtained using standard 
Student’s t-test. 
 
2.2.7.9  ATP synthase (complex V) enzyme activity assay 
 
An ATP synthase enzyme activity microplate assay kit was purchased from 
Abcam (Cambridge, UK).  
 
2.2.7.9.1 Isolation of mitochondria from rat liver  
 
Following the sacrifice of a rat (section 2.1.2.4), the liver was removed, washed 
with ice cold saline and the mitochondria isolated immediately. The liver was 
homogenised with ice cold homogenisation buffer (250 mM sucrose, 2 mM 
hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES) and 0.1 M ethylene 
glycol tetraacetic acid (EGTA), pH 7.4) and centrifuged at 25,000g for 10 min at 
4°C. The supernatant (S1) was removed with care taken not to disrupt the pellet 
and stored on ice. To maximise mitochondrial yield the pellet was re-suspended 
in homogenisation buffer and the homogenisation process repeated. The 
supernatant was removed, combined with S1 and centrifuged at 25,000g for 10 
min at 4°C. The supernatant was removed and the resultant mitochondrial pellet 
transferred to an Eppendorf tube, a BCA protein assay performed as described 
in section 2.2.4 and stored at -80°C until required for analysis.    
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2.2.7.9.2 Sample preparation for ATP synthase assay 
 
The mitochondrial pellet was thawed and re-suspended in 4 volumes of buffer 
solution and the protein concentration adjusted to 5.5 mg/ml. An extraction was 
performed by adding 1/10 volume detergent to the sample making the final 
protein concentration 5 mg/ml, vortexed immediately and incubated on ice for 
30 min. The sample was then centrifuged at 38,000g for 20 min. The 
supernatant was saved as sample and the pellet discarded. The sample was 
diluted in buffer solution to a final concentration of 1 µg/5 µl. Diluted samples 
were kept on ice until required for analysis.  
 
2.2.7.9.3 ATP synthase assay         
 
Fifty microlitres of sample was added to each individual well on the plate 
required for analysis. Buffer (50 µl) was added to 1 well to act as a null control 
or background reference. The plate was incubated at room temperature for 3 
hrs. 
Following incubation, during which time the bound antibody immobilises the 
enzyme in the wells, all liquid was removed by turning the plate over and 
shaking. Once emptied, 300 µl of buffer solution was added to each well in a 
wash step, all liquid was removed by turning the plate over and shaking. This 
step was repeated twice. Once the wells were empty 40 µl of a high medium or 
low concentration lipid of lyso-glycosphingolipid (see Table 2.13) was added to 
each well required for analysis and incubated at room temperature for 45 min. 
Following incubation 200 µl of reagent mix was added to each well. All bubbles 
were removed with a fine needle. The plate was then placed in an Infinite® 200 
PRO plate reader (Tecan, Theale, Reading, UK) and the absorbance read at 
340 nm at 1 min intervals for 120 min.  
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Table 2.13 Lipids and lyso-glycosphingolipids concentrations used to 
assess the effect on levels of ATP synthase activity. 
 
Lipid High Medium Low 
Globotriaosylceramide (Gb3) 300 µmol/l 30 µmol/l 0.3 µmol/l 
Lyso-Gb3 30 µmol/l 0.3 µmol/l 0.003 µmol/l 
Sulfatide 300 µmol/l 30 µmol/l 0.3 µmol/l 
Lyso-sulfatide 30 µmol/l 0.3 µmol/l 0.003 µmol/l 
GM1 ganglioside 300 µmol/l 30 µmol/l 0.3 µmol/l 
Lyso-GM1 ganglioside 30 µmol/l 0.3 µmol/l 0.003 µmol/l 
Glucosylceramide 300 µmol/l 30 µmol/l 0.3 µmol/l 
Lyso-glucosylceramide 30 µmol/l 0.3 µmol/l 0.003 µmol/l 
Galactosylceramide 300 µmol/l 30 µmol/l 0.3 µmol/l 
Lyso-galactosylceramide 30 µmol/l 0.3 µmol/l 0.003 µmol/l 
Lactosylceramide 300 µmol/l 30 µmol/l 0.3 µmol/l 
lyso-lactosylceramide 30 µmol/l 0.3 µmol/l 0.003 µmol/l 
Cardiolipin 300 µmol/l 30 µmol/l 0.3 µmol/l 
 
 
2.2.7.9.4 Data analysis     
 
The activity of the ATP synthase enzyme is coupled to the molar conversion of 
NADH to NAD+ measured as a decrease in absorbance at 340 nm. The activity 
rate is expressed as the change in absorbance at optical density (OD) 340 
nm/min/amount loaded into the well.  
Therefore, to calculate a value for ATP synthase the rate of decrease in 
absorbance at 340 nm over time is analysed. The rate is calculated between 
two time points when the fastest most linear rate of activity is seen (Figure 2.7) 
using equation 2.3.   
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Figure 2.7 Example of a trace obtained during the analysis of ATP 
synthase. Indicating the time points between which rate should be calculated 
using equation 2.3.    
 
Equation 2.3: 
 
Rate (mOD/min) = 
                         
          
 
 
Statistical differences between groups were analysed using Microsoft Excel with 
statistical significance obtained using standard Student’s t-test. 
 
2.2.8  Mitochondrial respiratory chain enzymes 
 
The methods outlined in section 2.2.8 below are used in the investigation of 
mitochondrial respiratory chain enzyme activities described in Chapter 6.  
 
2.2.8.1 Sample preparation 
 
Mouse organs (liver, kidney, heart and brain) from Fabry (n = 8) and wild-type 
control (n = 8) mice (see section 2.1.2.4) were homogenised using a Potter-
Elvehjem tissue grinder in 9 ml of a muscle isolation buffer (320 mM sucrose, 1 
mM EDTA, 10 mM Trizma-base in H2O, pH 7.4) or a liver and kidney isolation       
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buffer (250 mM sucrose, 1 mM EDTA, 10 mM Trizma-base in ddH2O, pH 7.4) 
per gram of tissue. Thereafter, tissue homogenates were aliquoted into 
Eppendorf tubes® and stored at -80°C until required for analysis.  
 
2.2.8.2 Complex I (NADH-ubiquinone oxidoreductase) assay 
 
The method described by Ragan et al., (1987) was modified and used to 
measure complex I activity in tissue homogenates. This assay measures the 
oxidation of NADH, at the decrease in absorbance at 340 nm, during the 
reduction of ubiquinone to ubiquinol by complex I. The specific complex I 
inhibitor rotenone is used to determine the proportion of NADH oxidation which 
is independent of complex I.   
Tissue homogenates were successively thawed and refrozen in liquid nitrogen 
(twice) following which, for each analysis, a sample and corresponding 
reference cuvette were prepared as shown in Table 2.14.  
 
Table 2.14 Preparation of sample and reference cuvettes required for the 
analysis of complex I. 
 
Reagent 
Sample 
 (µl) 
Reference  
(µl) 
25 mM potassium phosphate / 10 mM 
magnesium chloride (pH 7.2) 
800 800 
50 mg/ml bovine serum albumin (BSA) 50 50 
5 mM β-NADH 30 30 
100 mM potassium cyanide (KCN) 10 10 
Homogenate 20 20 
ddH2O 80 90 
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The cuvettes were then gently mixed and placed in a Uvikon 941 
spectrophotometer (Northstar Scientific, Potton, UK) and left for 2 min to reach 
30 °C. The reaction was started by the addition of 10 µl 5 mM ubiquinone to the 
sample cuvettes only. Cuvettes were again gently mixed and the reaction was 
measured at 340 nm at 30 sec intervals for 5 min. After 5 min 20 µl 1 mM 
rotenone was added to sample cuvettes only and measurement continued for a 
further 5 min. 
To calculate a value for complex I activity the change in absorbance at 340 nm 
following rotenone addition was subtracted from that before rotenone inhibition. 
Absorbance was converted to molar concentration using the NADH extinction 
coefficient 6.81 x 103 M-1 cm-1 (path length 1 cm, total volume 1 ml), taking 
account of ubiquinone, using a re-arrangement of Beer-Lambert law, equation 
2.4: 
 
Equation 2.4: 
 
  
 
   
 
Where ∆A is the specific change in absorbance; ε = extinction coefficient; and c 
= mole/min/ml. Results are expressed as a ratio to citrate synthase activity 
(section 2.2.8.5).   
 
2.2.8.3 Complex II/III (succinate dehydrogenase cytochrome c 
reductase) assay 
 
The method described by King (1967) was modified and used to measure 
complex II/III activity in tissue homogenates. This assay measures the 
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succinate dependent reduction of cytochrome c by measuring the increase in 
absorbance at 550 nm. The complex III inhibitor antimycin A is used to 
determine the proportion of cytochrome c oxidation which is independent of 
complex II/III activity.    
Tissue homogenates were successively thawed and refrozen in liquid nitrogen 
(twice) following which, for each analysis, a sample and corresponding 
reference cuvette were prepared as shown in Table 2.15.  
 
Table 2.15 Preparation of sample and reference cuvettes required for the 
analysis of complex II/III. 
 
Reagent 
Sample  
(µl) 
Reference 
(µl) 
166 mM Potassium phosphate (pH 7.4) 600 600 
15 mM EDTA 20 20 
100 mM KCN 10 10 
0.8 mM Cytochrome C 125 125 
Homogenate 20 20 
ddH2O 185 225 
 
The cuvettes were then gently mixed and placed in a Uvikon 941 
spectrophotometer (Northstar Scientific) and left for 2 min to reach 30 °C. The 
reaction was started by the addition of 40 µl 0.5 M succinate to the sample 
cuvettes only. Cuvettes were again gently mixed and the reaction was 
measured at 550 nm at 30 sec intervals for 5 min. After 7 min 10 µl 1 mM 
antimycin A was added to sample cuvettes only and measurement continued for 
a further 5 min. 
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To calculate a value for complex II/III activity the change in absorbance at 550 
nm following antimycin A addition was subtracted from that before antimycin A 
inhibition. Absorbance was converted to molar concentration using Beer-
Lambert law (equation 2.4; section 2.2.8.2) and the extinction coefficient of 
cytochrome c, 19.2 x 103 M-1 cm-1 (path length 1 cm, total volume 1ml). Results 
are expressed as a ratio to citrate synthase (section 2.2.8.5). 
 
2.2.8.4 Complex IV (cytochrome C oxidase) assay 
 
The method described by Wharton and Tzagoloff (1967) was modified and used 
to measure complex IV activity in tissue homogenates. This assay measures 
the reduction of cyctochrome c catalysed by complex IV.  
Prior to analysis of tissue homogenates, reduced cytochrome c was prepared 
by the addition of a few crystals of ascorbic acid to 10 mg/ml oxidised 
cytochrome c in water. A PD10 desalting column (GE Healthcare Life Sciences, 
Buckinghamshire, UK) equilibrated with 10 mM potassium phosphate (pH 7.0) 
in ddH2O, was then used to remove ascorbate from the reduced cytochrome c. 
Thereafter, 50 μl reduced cytochrome c was added to 950 μl ddH2O in a sample 
and reference cuvette. The sample cuvette was blanked against the reference 
at 550 nm using a Uvikon 941 spectrophotometer (Northstar Scientific). 
Cytochrome c in the reference cuvette was then oxidised by the addition of 10 
μL 100 mM ferricyanide. The absorbance was recorded after 1 min and used to 
determine the concentration of reduced cytochrome c using Beer-Lambert law 
(see equation 2.2; section 2.2.8.2) and the extinction coefficient for cytochrome 
c, 19.2 x 103 M-1 cm-1 (path length 1 cm, total volume 1 ml).  
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Tissue homogenates were successively thawed and refrozen in liquid nitrogen 
(twice) following which, for each analysis, a sample and corresponding 
reference cuvette were prepared as shown in Table 2.16. 
 
Table 2.16 Preparation of sample and reference cuvettes required for the 
measurement of complex IV. X = volume of stock reduced cytochrome c to 
give a final concentration of 50 µM. 
 
Reagent 
Sample  
(µl) 
Reference  
(µl) 
100 mM Potassium phosphate (pH 7.0) 100 100 
Cytochrome c (reduced) X X 
ddH2O 880-X 890-X 
 
The cuvettes were then gently mixed and placed in a Uvikon 941 
spectrophotometer (Northstar Scientific) and the sample cuvette blanked 
against the reference cuvette at 550 nm. Thereafter, 10 µl 100 mM ferricyanide 
was added to the reference cuvette to oxidise cytochrome c. The reaction was 
started by the addition of 20 µl homogenised tissue sample to the sample 
cuvette and the change in absorbance at 550 nm was recorded over 3 min at 
30°C. 
The reaction of complex IV with cytochrome c follows first order kinetics as it is 
dependent on the concentration of cytochrome c. Activity is therefore expressed 
as a first order rate constant (k). k is calculated by plotting the natural log of 
absorbance against time and determining the slope. Results are expressed as 
k/mol when divided by citrate synthase activity.   
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2.2.8.5 Citrate synthase assay 
 
Mitochondrial citrate synthase is the first enzyme of the tricarboxylic acid cycle 
responsible for catalysing the condensation of acetyl-Coenzyme A and 
oxaloacetate to yield citric acid and CoA. Citrate synthase activity is frequently 
used as a mitochondrial marker and also as a measure of mitochondrial 
enrichment (Winder and Holloszy 1977; Fatania and Dalziel 1980; Hargreaves, 
Heales, and Land 1999). The method described by Shepherd and Garland 
(1969) was modified and used to measure citrate synthase activity in tissue 
homogenates.   
Tissue homogenates were successively thawed and refrozen in liquid nitrogen 
(twice) following which, for each analysis, a sample and corresponding 
reference cuvette were prepared as shown in Table 2.17.  
 
Table 2.17 Preparation of sample and reference cuvettes required for the 
analysis of citrate synthase  
 
Reagent 
Sample  
(µl) 
Reference 
(µl) 
100 mM Tris/0.1 % v/v Triton (pH 8.0) 950 960 
Homogenate 20 20 
Acetyl-CoA 10 10 
5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB) 10 10 
 
The cuvettes were then gently mixed and placed in a Uvikon 941 
spectrophotometer (Northstar Scientific). The reaction was started by the 
addition of 10 µl 20 mM oxaloacetate to the sample cuvettes only. Cuvettes 
were again gently mixed and the reaction was measured at 412 nm at 30 sec 
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intervals for 5 min at 30°C. After 7 min 10 µl 1 mM antimycin A was added to 
sample cuvettes only and measurement continued for a further 5 min. 
Absorbance was converted to molar concentration using Beer-Lambert law (see 
equation 2.4; section 2.2.8.2) and the extinction coefficient of DTNB, 13.6 x 103 
M-1 cm-1 (path length 1 cm, total volume 1 ml).  
 
2.2.8.6 Transformation of data 
 
Prior to statistical analysis complex I, II/III and IV activities when expressed as a 
ratio to citrate synthase were transformed by the following calculation (equation 
2.5): 
 
Equation 2.5: 
 
       √        
 
Where percentage values were first divided by 100 to give a ratio. This 
transformation yielded data with a normal distribution to enable statistical 
analysis to be performed (Gegg et al., 2003).  
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3.0 A proteomic study to identify and validate potential urinary 
biomarkers in Fabry disease 
 
3.1 Introduction 
 
Fabry disease is an X-linked lysosomal storage disorder caused by 
abnormalities in the GLA gene, which results in a deficiency of the enzyme α-
galactosidase A (α-GAL) (Bishop, Kornreich and Desnick 1988; Zarate and 
Hopkin 2008). This leads to the progressive accumulation of neutral 
glycosphingolipids, primarily globotriaosylceramide (Gb3, CTH or GL-3) in the 
lysosome of the cell. With time accumulation of Gb3 leads to hypertrophy of the 
lysosome and leakage of these metabolites into the circulation. The clinical 
consequences of α-GAL deficiency are varied and include acroparathesia and 
painful crises, hypohidrosis, gastrointestinal symptoms, angiokeratoma and 
corneal opacities. As the disease progresses proteinuric kidney complications, 
the same as those experienced by diabetic patients, as well as cardiac 
involvement and cerebrovascular events can be life limiting (Zarate and Hopkin 
2008; Schiffmann 2009; O’Mahony and Elliott 2010).      
Enzyme replacement therapy (ERT) has been shown to stabilise renal function 
and cardiac size, as well as improve pain and quality of life (Eng et al., 2001; 
Schiffmann et al., 2001). Some reduction in frequency of occurrence of 
established renal failure and cardiovascular events has also been reported, but 
ERT cannot reverse established disease and it is not yet clear whether early 
treatment can prevent development of significant end organ involvement 
(Hughes et al., 2008; Warnock et al., 2012). More recently, pharmacological 
chaperone therapy has been developed as a therapeutic treatment for Fabry 
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disease. Following promising results in preclinical studies (Benjamin et al., 
2012; Young-Gqamana et al., 2013), further clinical trials to assess the use of 
pharmacological chaperone therapy both as an oral monotherapy and in 
combination with ERT are underway.   
Currently, Gb3 is used as a biomarker to monitor response to therapy and urine 
and plasma Gb3 concentrations can be measured reliably by tandem mass 
spectrometry (Young et al., 2005; Mills et al., 2004; Mills et al., 2005). However, 
whilst it has been suggested that urinary Gb3 concentration is more useful than 
Gb3 concentration in plasma (Young et al., 2005), Gb3 has not proven to be an 
ideal biomarker for measuring the response to treatment in all patients; i.e., falls 
in urinary Gb3 concentrations are not sustained in all cases despite clinical 
improvement (Mills et al., 2005). More recently, plasma and urinary lyso-Gb3, a 
deacylated form of Gb3, has been proposed as a potentially useful diagnostic 
biomarker of Fabry disease, and studies have shown lyso-Gb3 to exhibit a 
better degree of correlation with disease severity and progression (Aerts et al., 
2008). However, in a study by Auray-Blais et al., (2010) no significant 
correlation between lyso-Gb3 in urine and estimated glomerular filtration rates 
were found suggesting that lyso-Gb3 is not a good predictive biomarker for 
kidney involvement.   
Therefore, there is a growing need for additional biomarkers that can enable 
detection of Fabry disease at an early stage of disease progression and that are 
more specific for monitoring responses to treatment than urinary Gb3 and/or 
lyso-Gb3 concentrations alone. In addition, as it can take many years for 
detectable cardiac or renal disease to develop, it is currently very difficult to 
assess the efficacy of therapy in children. A biomarker that would allow 
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monitoring of disease burden, as chitotriosidase does in Gaucher disease 
(Aerts et al., 2005), or glucose tetrasaccharide does in Pompe disease 
(Manwaring et al., 2012), would provide a useful tool in guiding treatment.  
In the present study a label-free proteomic methodology was used to identify 
potential biomarkers in the urine of paediatric Fabry disease patients. For the 
purpose of this study patients were identified and grouped according to their 
biochemical level of disease burden. Those patients having Gb3 levels that fell 
to < 0.05 µmol/mmol creatinine following instigation of ERT were identified as 
having the least disease burden and those patients in whom Gb3 levels 
remained > 0.05 µmol/mmol creatinine following instigation of ERT were 
identified as having the most disease burden. Following the discovery of two 
potential biomarkers, prosaposin and ganglioside GM2 activator protein, 
independent of level of disease burden, an initial rapid multiple reaction 
monitoring ultra-performance liquid chromatography-tandem mass spectrometry 
(MRM UPLC-MS/MS) assay was developed for verification and validation 
purposes. Following the success of the initial assay a second MRM UPLC-
MS/MS assay was developed in order to identify biomarkers capable of 
detecting and monitoring pre-symptomatic kidney disease in those patients 
most at risk.  
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3.2  Results 
 
3.2.1 Biomarker discovery experiments 
 
MSE label-free quantitative proteomic methodologies using UPLC-QToF-MS 
have been used previously for the identification of novel biomarkers from a 
number of biological fluids and tissues (Bennett et al., 2010; Bostanci et al., 
2010; Heywood et al., 2012b). This methodology (section 2.2.5) has now been 
developed for the identification of urinary biomarkers for Fabry disease. 
 
3.2.2 Proteomic profile of Fabry disease urine samples 
 
Ten pre-treatment paediatric urine samples and the corresponding post-
treatment samples (Table 2.1) following 12 months of ERT were analysed by 
label-free quantitative proteomics. Altogether, 191 proteins were detected using 
this technique, 144 proteins in pre-treatment samples and 118 in post-treatment 
samples. Figures 3.1 and 3.2 show an averaged profile of the urinary proteome 
of the proteins detected in pre-treatment urine samples. The most abundant 
proteins observed were uromodulin and serum albumin which constituted 
approximately 8 and 6 % of the total protein detected, respectively.  
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Figure 3.1. Schematic representation of a typical proteome of urine from paediatric Fabry disease patients prior to ERT. Proteins 
are represented as % fmol of protein of total proteins detected.  
For proteins that 
constitute in fmol  
 < 1 % of total 
proteins detected 
see Figure 3.2 
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Figure 3.2. Schematic representation of lower abundance proteins. Proteins that constitute in fmol < 1% of total proteins detected in 
a typical proteome of urine from paediatric Fabry disease patients prior to ERT.  
< 0.01% < 0.05% 
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3.2.3 Proteins that decreased following 12 months of ERT 
 
The concentration of the lysosomal protein prosaposin was increased 
significantly in the urine of Fabry patients prior to ERT. Following 12 months of 
treatment prosaposin was observed to be statistically decreased (p = 0.03) in 
both those patients with the most disease burden and those with the least 
disease burden (Figure 3.3). This significance was increased when patients with 
most disease burden were excluded from the analysis (p = 0.005). 
 
 
 
Figure 3.3. Urinary prosaposin concentrations, using QToF-MS, pre-
treatment and post-treatment in patients with the least (↓) and the most (↑) 
disease burden. Error bars represent mean ± standard deviation (SD). 
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Although only one protein showed a significant and statistical change pre- and 
post-treatment using t-test analyses, the data were also reanalysed for fold 
changes. Using this type of analysis the concentration of 12 additional proteins 
showed a greater than 2-fold change following 12 months of treatment (Figures 
3.4 and 3.5).  
Included in these 12 proteins was another lysosomal protein and also a 
genetically distinct saposin, ganglioside GM2 activator protein (GM2AP) (Figure 
3.4.1e). While this protein did not reach statistical significance using t-test 
analyses (p = 0.2) this protein had a 2.1-fold change reduction following 
treatment represented by a mean value of 6.58 fmol/mmol creatinine pre-
treatment falling to 3.10 fmol/mmol creatinine post-treatment. Therefore, 
although not significant the variation shown by this protein was considered of 
potential importance and developed into the initial targeted MRM assay for 
evaluation in addition to the prosaposin molecule. By using a targeted 
methodological approach improved discrimination of GM2AP and better 
determination of significance between patient groups may be achievable.  
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Figure 3.4.1. Urinary proteins showing a greater than two-fold decrease 
following 12 months of ERT, using QToF-MS; a.) Alpha-1-acid glycoprotein 
1; b.) Cubilin; c.) Ig gamma-4 chain C region; d.) Lysosomal alpha-glucosidase; 
e.) Ganglioside GM2 activator protein and; f.) Keratin, type I cytoskeletal 16. 
Error bars represent mean ± SD.  
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Figure 3.4.2. Urinary proteins showing a greater than two-fold decrease 
following 12 months of ERT, using QToF-MS; a.) Keratin, type II cytoskeletal 
1B; b.) Keratin, type II cytoskeletal 5; c.) Keratin, type II cytoskeletal 6C; d.) 
Megalin; e.) Retinol binding protein 4 and; f.) Vitamin D binding protein. Error 
bars represent mean ± SD.  
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3.2.4 Proteins that increased following 12 months of ERT 
 
Of the 118 proteins detected in post-treatment samples none were shown to be 
increased significantly using t-test analyses. However, the concentrations of 6 
proteins showed a greater than 2-fold increase following 12 months of ERT 
(Figure 3.5).      
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Figure 3.5 Urinary proteins showing a greater than two-fold increase 
following 12 months of ERT, using QToF-MS; a.) Alpha-2-HS glycoprotein; 
b.) Endothelial protein C receptor; c.) Galectin-3-binding protein; d.) Ig kappa 
chain V-III region SIE; e.) Osteopontin and; f.) Vitelline membrane protein 1 
homolog. Error bars represent mean ± SD.  
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3.2.5 Verification and validation of prosaposin and GM2AP  
 
A rapid, 10 minute, MRM-assay using UPLC-MS/MS was developed as 
described in section 2.2.5.7 and used to verify prosaposin and GM2AP 
concentration in urine samples from 10 pre- and corresponding post-treatment 
paediatric Fabry disease patients (Figure 3.6 and Table 3.1). Prosaposin 
concentrations were distinguished from the processed saposins A, B, C and D 
by the use of size exclusion filters (30 kDa). In addition to the paediatric Fabry 
disease patient groups, 10 age- and sex-matched diabetic samples and 10 age- 
and sex-matched control samples were used as positive and negative controls, 
respectively. Type-I diabetic patients were chosen as a positive control group 
due to the fact that the developing proteinuric kidney complications experienced 
are the same as those in Fabry disease.     
Intra-batch coefficient of variation for prosaposin and GM2AP of 5.9 and 4.3 %, 
respectively were determined by a repeated injection of a pooled Fabry urine 
sample (10 patient urines, analysed 20 times). Inter-batch coefficient of 
variation for prosaposin and GM2AP of 8.3 and 6.9 %, respectively were 
obtained by analysing the same sample over a period of 3 consecutive days (3 
x 20 analyses over 3 days). 
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Figure 3.6 Typical UPLC-MS/MS chromatogram of the lower MW cut-off fraction from patient urine showing the 10 min 
assay developed for the quantitation of individual saposins A, B, C and D and GM2AP. For each peptide and internal 
standard, two transitions were used, one for quantitation and one for secondary confirmation purposes.    
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Table 3.1. Summary of urinary prosaposin and GM2AP results obtained by 
MRM UPLC-MS/MS.    
 
Biomarker 
Fabry pre- 
Treatment 
Mean ± SEM 
(min/max) 
Fabry post- 
Treatment 
Mean ± SEM 
(min/max) 
Diabetic 
 
Mean ± SEM 
(min/max) 
Control 
 
Mean ± SEM 
(min/max) 
Prosaposin 
 
(fmol/mmol 
creatinine) 
78.3 ± 20.5 
(51.4/234.6) 
22.6 ± 7.1 
(1.3/60.4) 
25.0 ± 6.1 
(6.7/64.3) 
13.7 ± 2.8 
(2.5/32.2) 
GM2AP 
 
(fmol/mmol 
creatinine) 
11.09 ± 3.64 
(2.1/36.3) 
2.3 ± 0.7 
(0.4/5.6) 
7.7 ± 3.0 
(0.9/24.2) 
1.5 ± 0.6 
(0.5/5.9) 
 
The concentrations of prosaposin were found to be reduced statistically and 
significantly, between pre- and post-treatment groups (p = 0.01), between pre-
treatment and diabetic groups (p = 0.009) and between pre-treatment and 
control groups (p = 0.002) (Figure 3.7). The significance of prosaposin was 
again shown to be increased when those patients with the most disease burden 
were excluded from the analysis (p = 0.002), data not shown.  
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Figure 3.7 Confirmatory urinary prosaposin concentrations using a 
targeted MRM-UPLC-MS/MS assay in pre- and post-treatment Fabry 
disease patients and diabetic and control groups. Error bars represent 
mean ± SD.  
 
The lower filtrate from the size exclusion experiments (< 30 kDa) which should 
contain the processed saposins A, B, C and D and GM2AP were also analysed. 
The concentrations of GM2AP were also found to be reduced statistically and 
significantly between pre- and post-treatment groups (p = 0.01) and between 
pre-treatment and control groups (p = 0.003). GM2AP was also reduced 
significantly between diabetic and control groups (p = 0.049) (Figure 3.8).  
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Figure 3.8 Confirmatory urinary GM2AP concentrations using a targeted 
MRM-UPLC-MS/MS assay in pre- and post-treatment Fabry disease 
patients and diabetic and control groups. Error bars represent mean ± SD.  
 
To assess if any correlation between urinary prosaposin or GM2AP and the 
current biomarker Gb3 existed, concentrations both pre- and post-treatment 
were examined. However, no significant correlation between either prosaposin 
and Gb3 or GM2AP and Gb3 was observed (data not shown).   
 
The urinary saposins A-D were also able to be detected in the lower filtrate in 
diabetic, control and Fabry pre- and post-treatment patient groups (Figure 3.6). 
However, while saposin A was detectable in all samples analysed, detectable 
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concentrations of saposin B, C and D were only present in approximately 50 % 
of patient samples, making statistical analysis not possible. Saposin A 
concentrations were found to be reduced 4-fold following treatment, with the 
post-treatment samples falling to within the control range, although these 
concentrations were not statistically significant. The mean saposin A 
concentrations in the diabetic cohort were observed to be 1.4-fold higher than 
the control group mean but were not statistically significantly raised (p = 0.6).       
 
3.2.6 Potential biomarkers of pre-symptomatic kidney disease 
 
Of the proteins that showed a greater than 2-fold alteration by QToF-MS during 
the proteomic profiling aspect of this study (Figures 3.4.1, 3.4.2 and 3.5) a 
number have been described previously in diseases of the kidney (Christensen 
and Birn 2001; Xie et al., 2001; Frey et al., 2008; Thrailkill et al., 2011; Nozza et 
al., 2012 Filatov et al., 2012) . In addition, following a literature review (Edelstein 
2010; Fassett et al., 2011; Dajak et al., 2011; Bolignano et al., 2009; Kirsztajn et 
al., 2002) and personal communication with Professor David Warnock (Director 
of the Division of Nephrology, University of Alabama at Birmingham, USA) the 
proteins albumin (1.3-fold decrease), retinol binding protein 4 (4.5-fold 
decrease), Ig gamma-4 chain C region (2.5-fold decrease), lysosomal α-
glucosidase (6.3-fold decrease), osteopontin (2.6-fold increase), prostaglandin-
H2 D-isomerase (1.8-fold decrease), endothelial protein C receptor (2.3-fold 
increase), vitamin D binding protein (2.5-fold increase), cubilin (3.9-fold 
decrease), megalin (4.5-fold increase), neutrophil gelatinase-associated 
lipocalin (not detected), and sortilin (not detected) were all considered as 
potential renal biomarkers. Therefore these proteins were included in the 
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development of a multiplex assay to assess their application as biomarkers of 
pre-symptomatic kidney disease. 
 
3.2.7 Pre-symptomatic kidney disease assay 
 
To confirm the biomarkers showing fold change alterations observed in the MSE 
analyses, these proteins together with known biomarkers of kidney function 
were developed in a multiplex, 10 minute, MRM assay using UPLC-MS/MS as 
described in section 2.2.5.8. This assay was then used to assess those 
biomarkers with the potential to detect and monitor pre-symptomatic kidney 
disease in urine samples from 10 pre- and corresponding (3 year) post-
treatment paediatric Fabry disease patients (see Table 2.2). In addition urine 
samples from 10 paediatric type I diabetic patients, 10 obese paediatric 
patients, 10 paediatric controls, 10 adult Fabry patients, 10 adult type II diabetic 
patients and 10 adult controls (section 2.1.2.2) were analysed. Urine samples 
were desalted and concentrated using size exclusion filters (3 kDa).    
As well as the use of type I diabetic patient samples as a positive control group, 
an obese paediatric patient group was also used due to the fact that obesity is a 
major risk factor for developing kidney disease (Ejerblad et al., 2006; Gunta and 
Mak 2013). In addition to the paediatric cohorts, adult Fabry disease patient 
samples, age- and sex-matched type II diabetic patient samples and age- and 
sex-matched control samples were analysed as positive and negative control 
groups, respectively.     
Twelve proteins were included in the multiplex assay for assessment (see Table 
2.10 for protein details and Tables 3.2 and 3.3 for a summary of results). To 
identify the significant and statistical changes t-test analyses were performed. In 
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addition, the data were also examined to identify changes greater than 2-fold 
between patient groups.  
 
3.2.8 The effect of ERT on potential biomarkers 
 
The effect of ERT on the twelve proteins included in the pre-symptomatic kidney 
disease assay was also assessed in paediatric Fabry disease patients. Ten pre-
treatment urine samples and corresponding urine samples collected one-, two-, 
and three-years post treatment (see Table 2.2) were analysed. The patients 
were again classified as those with the least disease burden (n = 5) or those 
with the most disease burden (n = 5) according to their Gb3 levels (Figure 3.9; 
section 2.2.1). 
 
 
 
 
Figure 3.9 Globotriaosylceramide (Gb3) concentrations in those patients 
with a.) Least disease burden and; b.) Most disease burden; pre-treatment, 
and one, two, and three years’ post-ERT. Columns represent mean. Error bars 
represent SD.  
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Table 3.2 Summary of potential pre-symptomatic kidney disease biomarker results obtained by MRM UPLC-MS/MS in paediatric 
Fabry disease patients with the least disease burden (↓DB) and the most disease burden (↑DB) prior to ERT and following one, 
two and three years of treatment.   
Biomarker 
Fabry 
 pre-ERT  
Mean ± SEM 
(min/max) 
Fabry ↓DB 
1 yr ERT 
Mean ± SEM 
(min/max) 
Fabry ↓DB 
2 yr ERT 
Mean ± SEM 
(min/max) 
Fabry ↓DB 
3 yr ERT 
Mean ± SEM 
(min/max) 
Fabry ↑DB 
Pre-ERT 
Mean ± SEM 
(min/max) 
Fabry ↑DB 
1 yr ERt 
Mean ± SEM 
(min/max) 
Fabry ↑DB 
2 yr ERT 
Mean ± SEM 
(min/max) 
Fabry ↑DB 
3 yr ERT 
Mean ± SEM 
(min/max) 
Albumin  
nmol/mmol creatinine 
14.9 ± 14.0 
(0.5/70.9) 
14.8 ± 8.8 
(0.2/39.3) 
28.7 ± 23.1 
(0.7/120.7) 
19.8 ± 15.5 
(1.2/81.4) 
0.8 ± 0.2 
(0.2/1.2) 
9.2 ± 7.1 
(0.5/37.4) 
2.4 ± 1.0 
(0.8/5.9) 
6.2 ± 2.2 
(1.4/12.6) 
Vitamin D binding protein 
pmol/mmol creatinine 
8.5 ± 2.5 
(0.7/12.6) 
137.7±104.5 
(0.8/542.3) 
30.2 ± 12.5 
(2.4/66.1) 
26.3 ± 10.2 
(8.6/65.1) 
3.7 ± 1.4 
(nd/6.1) 
113.2 ± 98.0 
(2.5/504.4) 
40.6 ± 18.8 
(0.7/97.7) 
21.1 ± 8.3 
(0.9/49.1) 
Cubilin  
nmol/mmol creatinine 
0.1 ± 0.1 
(0.01/0.5) 
0.1 ± 0.1 
(0.01/0.4) 
0.4 ± 0.3 
(0.02/1.5) 
0.3 ± 0.1 
(0.1/0.7) 
0.1 ± 0.02 
(0.01/0.1) 
0.2 ± 0.1 
(0.01/0.7) 
0.2 ± 0.1 
(0.01/0.6) 
0.1 ± 0.02 
(0.01/0.1) 
Osteopontin  
nmol/mmol creatinine 
54.5 ± 18.1 
(28.9/124.7) 
57.3 ± 14.6 
(15.2/101.9) 
182.0 ± 129.8 
(3.4/695.9) 
61.2 ± 25.2 
(19.7/153.2) 
72.4 ± 31.5 
(11.6/185.0) 
163.9 ± 101.9 
(27.5/117.3) 
103.1 ± 24.3 
(25.2/163.4) 
66.5 ± 13.4 
(27.7/110.3) 
Megalin 
nmol/mmol creatinine 
0.2 ± 0.1 
(0.04/0.7) 
0.3 ± 0.1 
(0.02/0.5) 
0.5 ± 0.3 
(0.1/1.7) 
0.4 ± 0.1 
(0.2/0.6) 
0.1 ± 0.04 
(0.002/0.2) 
0.4 ± 0.2 
(0.03/1.2) 
0.2 ± 0.1 
(0.005/0.3) 
0.1 ± 0.02 
(0.1/0.2) 
Prostaglandin-H2  
D-isomerase  
nmol/mmol creatinine 
15.0 ± 8.7 
(0.6/48.5) 
9.4 ± 2.5 
(3.9/16.6) 
44.2 ± 24.5 
(0.5/111.1) 
22.3 ± 11.3 
(2.1/51.4) 
7.6 ± 2.8 
(0.5/16.6) 
19.0 ± 11.4 
(0.5/63.4) 
10.4 ± 3.7 
(1.7/23.5) 
13.8 ± 3.3 
(5.6/24.7) 
Endothelial protein C 
receptor 
nmol/mmol creatinine 
1.5 ± 0.7 
(0.4/4.1) 
2.0 ± 1.1 
(0.4/6.1) 
3.4 ± 1.4 
(0.5/7.5) 
1.7 ± 0.3 
(0.6/2.5) 
0.8 ± 0.3 
(0.1/1.6) 
4.8 ± 4.2 
(0.3/21.6) 
1.2 ± 0.6 
(0.2/3.1) 
1.0 ± 0.4 
(0.3/2.2) 
Lysosomal alpha 
glucosidase 
nmol/mmol creatinine 
2.1 ± 0.7 
(0.5/3.8) 
1.7 ± 0.4 
(0.5/3.0) 
3.0 ± 1.3 
(0.5/7.9) 
1.6 ± 0.4 
(0.6/2.8) 
1.4 ± 0.8 
(0.2/4.3) 
2.1 ± 1.1 
(0.2/6.2) 
1.0 ± 0.4 
(nd/2.2) 
0.8 ± 0.2 
(0.4/1.2) 
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Sortilin 
fmol/mmol creatinine 
1.4 ± 0.9 
(nd/3.3) 
0.2 ± 0.2 
(nd/0.8) 
1.0 ± 0.8 
(nd/4.3) 
1.4 ± 0.9 
(nd/4.7) 
nd 
n/a 
nd 
n/a 
nd 
n/a 
Nd 
n/a 
Retinol binding protein 
fmol/mmol creatinine 
0.9 ± 0.5 
(nd/2.7) 
2.1 ± 1.0 
(nd/5.4) 
11.1 ± 13.4 
(nd/62.4) 
0.7 ± 0.5 
(nd/2.7) 
2.5 ± 1.6 
(nd/8.6) 
1.6 ± 0.6 
(nd/3.5) 
0.4 ± 0.8 
(nd/4.2) 
0.8 ± 0.3 
(nd/1.4) 
Ig gamma chain C region 
fmol/mmol creatinine 
54.7 ± 33.9 
(1.3/184.0) 
7.2 ± 3.8 
(nd/20.7) 
7.6 ± 4.2 
(nd/20.1) 
17.9 ± 13.1 
(nd/67.9) 
28.3 ± 19.9 
(nd/103.1) 
17.3 ± 17.3 
(nd/86.4) 
31.4 ± 29.6 
(nd/149.9) 
26.5 ± 25.3 
(nd/127.5) 
Neutrophil gelatinase-  
associated lipocalin 
fmol/mmol creatinine 
0.2 ± 0.2 
(nd/0.8) 
3.7 ± 2.8 
(nd/14.6) 
35.4 ± 14.3 
(4.7/84.5) 
7.8 ± 6.6 
(nd/34.2) 
3.1 ± 2.3 
(nd/12.0) 
0.3 ± 0.3 
(nd/1.7) 
1.2 ± 0.8 
(nd/4.2) 
0.9 ± 0.7 
(nd/3.7) 
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Table 3.3 Summary of potential pre-symptomatic kidney disease biomarker results obtained by MRM UPLC-MS/MS in a 
paediatric type I diabetic group, a paediatric obese group, a paediatric control group, an adult Fabry disease group, an adult 
type II diabetic group and an adult control group.   
Biomaker 
Paediatric type I 
diabetic group 
Mean ± SEM 
(min/max) 
Paediatric obese 
group 
Mean ± SEM 
(min/max) 
Paediatric control 
group 
Mean ± SEM 
(min/max) 
Adult Fabry 
disease group 
Mean ± SEM 
(min/max) 
Adult type II 
diabetic group 
Mean ± SEM 
(min/max) 
Adult control 
group 
Mean ± SEM 
(min/max) 
Albumin 
nmol/mmol creatinine 
66.0 ± 55.4 
(0.1/562.4) 
4.6 ± 1.8 
(0.1/14.2) 
7.4 ± 2.5 
(0.3/17.0) 
349.0 ± 140.5 
(6.6/1450.0) 
412.1 ± 152.9 
(nd/1187.8) 
29.9 ± 13.5 
(0.2/121.2) 
Vitamin D binding 
protein 
pmol/mmol creatinine 
93.1 ± 40.6 
(nd-347.1) 
34.4 ± 14.0 
(nd-146.8) 
41.0 ± 11.9 
(3.5-114.5) 
1294.7 ± 718.5 
(1.0/6967.7) 
583.3 ± 160.6 
(nd/1410.1) 
135.7 ± 65.7 
(nd/507.3) 
Cubilin 
nmol/mmol creatinine 
0.5 ± 0.2 
(nd/2.3) 
0.1 ± 0.03 
(nd/0.3) 
0.1 ± 0.02 
(0.01/0.1) 
0.6 ± 0.2 
(0.1/1.5) 
3.5 ± 1.5 
(nd/12.9) 
0.4 ± 0.1 
(0.03/1.3) 
Osteopontin 
nmol/mmol creatinine 
128.1 ± 34.6 
(6.8/397.1) 
72.9 ± 14.1 
(12.9/156.4) 
66.3 ± 15.0 
(6.0/166.5) 
340.6 ± 51.9 
(114.9/621.2) 
2394.9 ± 757.5 
(445.9/8055.1) 
280.2 ± 62.0 
(43.4/702.2) 
Megalin 
nmol/mmol creatinine 
0.3 ± 0.1 
(nd/1.1) 
0.2 ± 0.1 
(0.02/1.1) 
0.1 ± 0.02 
(0.01/0.2) 
0.8 ± 0.2 
(0.001/1.8) 
3.0 ± 1.0 
(0.6/11.2) 
0.4 ± 0.1 
(0.01/0.9) 
Prostaglandin-H2 D-
isomerase 
nmol/mmol creatinine 
6.8 ± 2.1 
(0.04/15.5) 
17.5 ± 10.3 
(0.1/100.8) 
3.1 ± 0.6 
(0.6/5.4) 
60.9 ± 23.2 
(0.8/223.6) 
628.2 ± 379.7 
(73.9/3982.2) 
10.3 ± 3.4 
(0.2/29.6) 
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Endothelial protein C 
receptor 
nmol/mmol creatinine 
4.8 ± 2.2 
(0.2/22.0) 
1.4 ± 0.3 
(0.2/2.9) 
2.0 ± 0.3 
(0.7/3.9) 
8.2 ± 2.5 
(0.6/23.8) 
34.5 ± 14.1 
(nd/140.3) 
8.7 ± 1.6 
(1.8/17.8) 
Lysosomal alpha 
glucosidase 
nmol/mmol creatinine 
2.5 ± 0.9 
(0.2/8.6) 
1.8 ± 0.6 
(0.3/4.3) 
1.2 ± 0.3 
(0.2/3.5) 
8.6 ± 1.2 
(3.3/15.2) 
26.2 ± 11.8 
(nd/115.8) 
5.0 ± 1.2 
(1.2/12.7) 
Sortilin 
fmol/mmol creatinine 
4.2 ± 2.4 
(nd/23.7) 
1.7 ± 0.7 
(nd/7.3) 
1.9 ± 0.7 
(nd/4.7) 
35.0 ± 25.9 
(nd/264.3) 
61.0 ± 27.6 
(nd/291.5) 
12.5 ± 6.9 
(nd/64.9) 
Retinol binding 
protein 
fmol/mmol creatinine 
6.2 ± 2.7 
(nd/24.2) 
1.2 ± 0.5 
(nd/4.3) 
0.7 ± 0.7 
(nd/6.4) 
20.2 ± 9.6 
(nd/83.6) 
34.4 ± 16.9 
(nd/146.2) 
7.0 ± 4.4 
(nd/46.0) 
Ig gamma chain C 
region 
fmol/mmol creatinine 
468.8 ± 466.1 
(nd/4663.6) 
148.1 ± 97.6 
(nd/813.2) 
25.2 ± 24.7 
(nd/247.4) 
283.3 ± 218.9 
(nd/2234.5) 
170.5 ± 120.8 
(nd/1228.3) 
4.1 ± 2.6 
(nd/23.9) 
Neutrophil gelatinase- 
associated lipocalin 
nmol/mmol creatinine 
3.1 ± 2.0 
(nd/17.8) 
0.9 ± 0.5 
(nd/4.3) 
5.6 ± 2.6 
(nd/20.9) 
114.1 ± 91.0 
(nd/922.4) 
61.8 ± 31.1 
(nd/275.5) 
0.4 ± 0.1 
(0.01/0.9) 
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3.2.9  Verification and validation of albumin 
 
Albumin (Figure 3.10) was found to be statistically and significantly elevated in 
both adult Fabry disease patients (p = 0.04) and adult type II diabetics (p = 
0.03) compared to the adult control group. Following analysis to identify fold 
changes, the paediatric type I diabetic group were shown to have an 8.9-fold 
elevation in albumin concentrations above that of the paediatric control group. 
 
 
 
Figure 3.10 Urinary serum albumin concentrations using a targeted MRM-
UPLC-MS/MS assay in paediatric and adult cohorts. Error bars represent 
mean ± SD. FC = fold change; FD = Fabry disease; ↓DB = least disease 
burden; ↑ = most disease burden.   
 
Albumin concentrations statistically significantly below that of the control group 
(p = 0.02) were observed in those patients with most disease burden prior to 
ERT (Figure 3.10). When the effect of ERT on this protein was assessed in this 
patient group (Figure 3.11b) consecutive increases in albumin concentration 
above those of baseline pre-treatment levels were observed at all-time points 
studied. These elevations did not reach statistical significance following one 
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(12.2-fold elevation) or two years (3.2-fold elevation) of treatment however, 
following three years of ERT albumin concentrations became statistically and 
significantly elevated above those of baseline pre-treatment concentrations (p = 
0.04).   
Although no statistically significant alterations in albumin concentration were 
observed in those patients with the least disease burden, fold change elevations 
above that of the paediatric control group were detected at all-time points 
studied (Figure 3.11a). In addition, patients with the least disease burden were 
found to have elevated albumin concentrations above those of the patients with 
most disease burden at the pre-treatment (19.6-fold), two (12.0-fold) and three 
(3.2-fold) year post-treatment time points.  
 
 
 
Figure 3.11 Urinary serum albumin concentrations in paediatric Fabry 
disease patients with a.) Least disease burden and; b.) Most disease 
burden; pre-treatment, and one, two, and three years’ post-ERT.  Columns 
represent mean. Error bars represent SD.  
 
3.2.10  Verification and validation of megalin 
 
Statistical and significant elevations were observed in the adult Fabry disease 
(p = 0.03) and adult type II diabetic patient groups (p = 0.03) compared to the 
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adult control group for the protein megalin (Figure 3.12). In addition, a 2.5-fold 
change in megalin concentrations in the paediatric type I diabetic group above 
that of the paediatric control group was observed.    
 
 
 
Figure 3.12 Urinary megalin concentrations using a targeted MRM-UPLC-
MS/MS assay in paediatric and adult cohorts. Error bars represent mean ± 
SD. FC = fold change; FD = FD; ↓DB = least disease burden; ↑DB = most 
disease burden.   
 
No statistically significant differences were observed in the concentrations of 
megalin in paediatric Fabry disease patients with either the least or the most 
disease burden at any time point studied (Figure 3.13). However, when the data 
were re-analysed to identify fold change alterations, those patients with the 
least disease burden were observed to have elevations in megalin 
concentration at the one (2.2-fold), two (4.7-fold) and three year (3.1-fold) post-
treatment time points, above that of the paediatric control group. Megalin 
concentrations at the two-year time point also displayed a 2.6-fold elevation 
above that of the baseline pre-treatment levels (Figure 3.13a). Those patients 
with the most disease burden were found to have megalin concentrations 
increased 4.0-fold above baseline pre-treatment levels and 3.2-fold increased 
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above concentrations observed in the paediatric control group, at the one-year 
post-treatment time point (Figure 3.13b). However, this is as the result of a 
single patient displaying an elevation in megalin concentration and was not 
observed at any other time point studied.  
The paediatric Fabry disease group with the least disease burden were also 
found to have megalin concentrations higher than those of the corresponding 
patient groups with the most disease burden at the pre-treatment (2.3-fold), two 
(3.2-fold) and three (3.5-fold) year post-treatment time points.   
 
 
 
Figure 3.13 Urinary megalin concentrations in paediatric Fabry disease 
patients with a.) Least disease burden and; b.) Most disease burden; pre-
treatment, and one, two, and three years’ post-ERT. Columns represent mean. 
Error bars represent SD.  
 
3.2.11  Verification and validation of vitamin D binding protein 
 
Vitamin D binding protein (Figure 3.14) was shown to be statistically and 
significantly elevated in the adult type II diabetic group compared to the adult 
control group (p = 0.02). Concentrations of this protein were also found to be 
2.3-fold elevated in the type I diabetic group compared to the paediatric control 
group. In addition, the adult Fabry disease patient group was shown to have 
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vitamin D binding protein levels 9.5-fold elevated above those of the adult 
control group. 
 
 
 
Figure 3.14 Urinary vitamin D binding protein concentrations using a 
targeted MRM-UPLC-MS/MS assay in paediatric and adult cohorts. Error 
bars represent mean ± SD. FC = fold change; FD = Fabry disease; ↓DB = least 
disease burden; ↑DB = most disease burden. 
 
In the paediatric Fabry disease groups the concentrations of vitamin D binding 
protein were found to be statistically and significantly lower prior to the 
instigation of ERT in both those patients with the least disease burden (p = 
0.02) and in those with the most disease burden (p = 0.01), compared to 
concentrations of the paediatric control group (Figures 3.14). Analysis of the 
data to identify fold changes also revealed greater than 2.0-fold elevations of 
this protein in both groups above baseline pre-treatment concentrations 
following the first-, second-, and third-year of ERT (Figure 3.15). However, no 
differences in the concentration of this protein, compared to those of the 
paediatric control group, were observed at these time points.   
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Figure 3.15 Urinary vitamin D binding protein concentrations in paediatric 
Fabry disease patients with a.) Least disease burden and; b.) Most 
disease burden; pre-treatment, and one, two, and three years’ post-ERT.  
Columns represent mean. Error bars represent SD.  
 
3.2.12  Verification and validation of prostaglandin-H2 D-isomerase 
 
Prostaglandin-H2 D-isomerase (Figure 3.16) was shown to be significantly and 
statistically elevated in the adult Fabry disease group compared to the adult 
control group (p = 0.049). Following analysis to identify fold changes, the type II 
diabetic group was shown to have a 61.2-fold elevation compared to the adult 
control group however, this increase did not reach statistical significance. In 
addition, all paediatric groups displayed fold change elevations above that of 
the paediatric control group.  
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Figure 3.16 Urinary prostaglandin-H2 D-isomerase concentrations using a 
targeted MRM-UPLC-MS/MS assay in paediatric and adult cohorts. Error 
bars represent mean ± SD. FC = fold change; FD = Fabry disease; ↓DB = least 
disease burden; ↑DB = most disease burden.   
 
A significant elevation (p = 0.03) in the concentrations of prostaglandin-H2 D-
isomerase were also observed in the paediatric Fabry disease group with the 
most disease burden, following three years of treatment, above that of the 
control group (Figures 3.16). Following analysis to assess the effect of ERT, 
fold changes elevations were observed at all-time points studied in those 
patients with the least disease burden, and in those with the most disease 
burden, above the levels of the paediatric control group (Figure 3.17). In 
addition, those patients with the least disease burden displayed elevations in 
prostaglandin-H2 D-isomerase levels, both pre-treatment (2.0-fold) and 
following one year of treatment (4.3-fold), above those levels detected in those 
patients with the most disease burden at the corresponding time points. 
However, a 2.0-fold elevation in patients with the most disease burden, 
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following one-year of ERT, above that of patients with the least disease burden 
at the corresponding time points was also observed.     
 
 
 
Figure 3.17 Urinary prostaglandin-H2 D-isomerase concentrations 
paediatric Fabry disease patients with a.) Least disease burden and; b.) 
Most disease burden; pre-treatment, and one, two, and three years’ post-
ERT.  Columns represent mean. Error bars represent SD. 
 
3.2.13  Verification and validation of lysosomal alpha-glucosidase  
 
The adult Fabry disease group was found to have statistical and significant 
elevations (p = 0.049) in the protein lysosomal alpha glucosidase in comparison 
to the adult control group (Figure 3.18). In addition, both the type I and type II 
diabetic groups were shown to have fold changes of 2.1-fold and 5.3-fold 
respectively, above their corresponding control groups.  
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Figure 3.18 Urinary lysosomal alpha glucosidase concentrations using a 
targeted MRM-UPLC-MS/MS assay in paediatric and adult cohorts. Error 
bars represent mean ± SD. FC = fold change; FD = Fabry disease; ↓DB = least 
disease burden; ↑DB = most disease burden.   
 
No statistically significant alterations were observed for the protein lysosomal 
alpha glucosidase in either the paediatric Fabry disease patient group with the 
least, or with the most, disease burden compared to those levels detected in the 
paediatric control group (Figure 3.19). A 2.5-fold change elevation, above that 
of the control group, was observed in those patients with the least disease 
burden following two years of ERT (Figure 3.19a). However, this was due to a 
single patient displaying an elevation in this protein, at this time point, and was 
not observed at any other time point studied. Lysosomal alpha glucosidase 
levels in those patients with the most disease burden (Figure 3.19b) were 
comparable with those of the control group throughout the duration of this study.  
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Figure 3.19 Urinary lysosomal alpha glucosidase concentrations in 
paediatric Fabry disease patients with a.) Least disease burden and; b.) 
Most disease burden; pre-treatment, and one, two, and three years’ post-ERT.  
Columns represent mean. Error bars represent SD. 
 
3.2.14  Verification and validation of endothelial protein C receptor 
 
Changes in the protein endothelial protein C receptor, whilst not statistically 
significant, were observed in both the paediatric type I diabetic group (2.4-fold 
elevation) and the adult type II diabetic group (4.0-fold elevation), compared to 
their respective control groups (Figure 3.20). 
The levels of endothelial protein C receptor in the paediatric Fabry disease 
patients with the most disease burden were statistically and significantly lower 
than those of the paediatric control group both prior to treatment (p = 0.02) and 
following three years of ERT (p = 0.049) (Figure 3.20). When the effect of ERT 
was assessed in this group of patients a 2.4-fold change increase was also 
observed, above that of the control group, following one year of treatment 
(Figure 3.21b). However, this was as the result of an elevation in this protein in 
a single patient at this time point and was not observed at any other time point 
studied. Those patients with the least disease burden (Figure 3.21a) displayed 
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levels comparable with those of the paediatric control group at all-time points 
studied.  
 
 
 
Figure 3.20 Urinary endothelial protein C receptor concentrations using a 
targeted MRM-UPLC-MS/MS assay in paediatric and adult cohorts. Error 
bars represent mean ± SD. FC = fold change; FD = Fabry disease; ↓DB = least 
disease burden; ↑DB = most disease burden. 
 
 
 
 
Figure 3.21 Endothelial protein C receptor concentrations in paediatric 
Fabry disease patients with a.) Least disease burden and; b.) Most 
disease burden; pre-treatment, and one, two, and three years’ post-ERT.  
Columns represent mean. Error bars represent SD. 
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3.2.15  Verification and validation of osteopontin 
 
Statistical and significant elevations were observed in the adult type II diabetic 
group (p = 0.02), compared to the adult control group, for the protein 
osteopontin (Figure 3.22). Osteopontin was also found to be 2.0-fold higher in 
the paediatric type I diabetic patient group compared to the paediatric control 
group. However, all other patient groups displayed levels comparable with those 
of their respective control group. 
 
 
 
 
Figure 3.22 Urinary osteopontin concentrations using a targeted MRM-
UPLC-MS/MS assay in paediatric and adult cohorts. Error bars represent 
mean ± SD. FC = fold change; FD = Fabry disease; ↓DB = least disease 
burden; ↑DB = most disease burden. 
 
When the effect of ERT on osteopontin levels following one, two and three 
years of treatment was assessed, those patients with least disease burden 
displayed a fold change elevation following two years of treatment (Figure 
3.23a). Whilst in those patients with most disease burden a fold change 
elevation following one year of treatment was observed (Figure 3.23b). 
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However, in both groups this fold change elevation was due to a single outlying 
result and no other changes were detected during the time period studied.   
  
 
 
Figure 3.23 Urinary osteopontin concentrations in paediatric Fabry 
disease patients with a.) Least disease burden and; b.) Most disease 
burden; pre-treatment, and one, two, and three years’ post-ERT.  Columns 
represent mean. Error bars represent SD.  
 
3.2.16  Verification and validation of cubilin 
 
No statistical significant alterations were observed in the concentrations of the 
protein cubilin (Figure 3.24). However, an 8.5-fold elevation in the adult type II 
diabetic patient group and a 5.3-fold elevation in the paediatric type I diabetic 
group above that of their respective control groups was observed. The 
paediatric Fabry disease group with the least disease burden were shown to 
have fold change increases at the two and three year post-treatment time 
points, above that of the paediatric control group, when the effect of ERT was 
assessed (Figure 3.25a). At the two year post-treatment time point this was as 
the result of a single patient with an elevation in cubilin levels. However, at the 
three year post-treatment time point an additional patient was also displaying 
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elevations in cubilin excretion. Those patients with the most disease burden 
(Figure 3.25b) displayed increases at the one and two year post-treatment time 
points above both baseline pre-treatment levels (3.5-fold and 2.9-fold, 
respectively) and those levels observed in the control group (2.3-fold and 2.0-
fold, respectively). However, this was due to elevation in cubilin excretion from 
different patients at these time points and if these outlying results are excluded 
from the analysis levels comparable with those of the control group are obtained 
at all-time points studied. Cubilin concentrations were also found to be higher in 
those patients with the least disease burden compared to those of the 
corresponding patients with the most disease burden at the pre-treatment (2.5-
fold), two (2.4-fold) and three (3.8-fold) year time points. 
  
 
 
Figure 3.24 Urinary cubilin concentrations using a targeted MRM-UPLC-
MS/MS assay in paediatric and adult cohorts. Error bars represent mean ± 
SD. FC = fold change; FD = Fabry disease; ↓DB = least disease burden; ↑DB = 
most disease burden.  
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Figure 3.25 Urinary cubilin concentrations in paediatric Fabry disease 
patients with a.) Least disease burden and; b.) Most disease burden; pre-
treatment, and one, two, and three years’ post-ERT. Columns represent mean. Error 
bars represent SD. 
 
3.2.17  Verification and validation of sortilin 
 
Alterations in the levels of the protein sortilin (Figure 3.26), whilst not statistically 
significant, were found to be increased by fold change in both the adult Fabry 
disease patient group (2.8-fold) and the adult type II diabetic patient group (4.9-
fold), compared to those levels observed in the adult control group. In addition, 
sortilin was shown to be 2.3-fold increased in the paediatric type I diabetic 
patients compared to the paediatric control group. No detectable levels of 
sortilin were present in those Fabry disease patients with the most disease 
burden at any time point studied resulting in statistically significant reductions (p 
= 0.02), compared to the paediatric control group (Figure 3.27b). In addition, 
sortilin concentrations in those patients with the least disease burden, at the 
one-year time point, were found to be reduced statistically and significantly (p = 
0.03) compared to those levels observed in the paediatric control group (Figure 
3.27a). 
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Figure 3.26 Urinary sortilin concentrations using a targeted MRM-UPLC-
MS/MS assay in paediatric and adult cohorts. Error bars represent mean ± 
SD. FC = fold change; FD = Fabry disease; ↓DB = least disease burden; ↑DB = 
most disease burden.  
 
 
 
 
 
Figure 3.27 Urinary sortilin concentrations in paediatric Fabry disease 
patients with a.) Least disease burden and; b.) Most disease burden; pre-
treatment, and one, two, and three years’ post-ERT. Columns represent mean. 
Error bars represent SD. 
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3.2.18  Verification and validation of retinol binding protein 
 
Fold change elevations were observed for retinol binding protein in the adult 
Fabry disease patient group (2.9-fold), the adult type II diabetic patient group 
(4.9-fold) and the paediatric type I diabetic patient group (6.5-fold), compared to 
their respective control groups (Figure 3.28).  
 
 
 
Figure 3.28  Urinary retinol binding protein concentrations using a 
targeted MRM-UPLC-MS/MS assay in paediatric and adult cohorts. Error 
bars represent mean ± SD. FC = fold change; FD = Fabry disease; ↓DB = least 
disease burden; ↑DB = most disease burden.    
 
The concentrations of retinol binding protein in the paediatric Fabry disease 
patient group with the least disease burden (Figure 3.29a) were found to be 
elevated at the one- and two-year post-treatment time points above baseline 
pre-treatment levels (2.4-fold and 12.9-fold, respectively) and those of the 
paediatric control group (2.9-fold and 15.6-fold, respectively). However, at all 
other time points studied retinol binding protein concentrations in this group 
were comparable with those of the paediatric control group. In those patients 
with the most disease burden (Figure 3.29b) the pre-treatment retinol binding 
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protein concentrations were 3.5-fold higher than those of the control group. 
However, these levels were reduced following one- (1.5-fold), two- (5.8-fold) 
and three-years (3.3-fold) of treatment.  
Differences between patients with the least disease burden and those with the 
most disease burden were also observed. Those patients with the most disease 
burden were found to have higher levels (2.9-fold) of retinol binding protein, 
than those patients with the least disease burden, prior to ERT. However, at the 
two year time point those patients with the least disease burden had retinol 
binding protein concentrations 25.7-fold higher than the corresponding patients 
with the most disease burden.      
 
 
 
Figure 3.29  Urinary retinol binding protein concentrations paediatric 
Fabry disease patients with a.) Least disease burden and; b.) Most 
disease burden; pre-treatment, and one, two, and three years’ post-ERT. 
Columns represent mean. Error bars represent SD. 
 
3.2.19  Verification and validation of Ig gamma-4 chain C region 
 
The concentrations of the protein Ig gamma-4 chain C region (Figure 3.30) were 
shown to be increased by fold change in the paediatric type I diabetic patient 
group, the obese paediatric patient group, the adult Fabry disease patient group 
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and the adult type II diabetic patient group by 18.6-fold, 5.9-fold, 69.8-fold and 
42.0-fold respectively.    
 
 
Figure 3.30 Urinary Ig gamma-4 chain C region concentrations using a 
targeted MRM-UPLC-MS/MS assay in paediatric and adult cohorts. Error 
bars represent mean ± SD. FC = fold change; FD = Fabry disease; ↓DB = least 
disease burden; ↑DB = most disease burden. 
 
The paediatric Fabry disease patient group with the least disease burden 
(Figure 3.31a) were shown to have fold change reductions of 7.6-fold, 7.2-fold 
and 3.1-fold following one-, two- and three-years of ERT, below that of baseline 
pre-treatment concentrations. However, at the pre-treatment time point, levels 
of this protein were 2.2-fold higher than those of the paediatric control group. 
Following one- and two-years of treatment, levels in this patient group were 
reduced 3.5-fold and 3.3-fold below that of the paediatric control group. No 
differences were observed in those patients with the most disease burden 
compared to the paediatric control group during the time period studied. 
However, Ig gamma-4 chain C region concentrations were 2.4-fold and 4.1-fold 
higher than those of the corresponding group with the least disease burden at 
the one- and two-year time points, respectively. 
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Figure 3.31 Urinary Ig gamma chain C region concentrations in paediatric 
Fabry disease patients with a.) Least disease burden and; b.) Most 
disease burden; pre-treatment, and one, two, and three years’ post-ERT.  
Columns represent mean. Error bars represent SD. 
 
3.2.20  Verification and validation of neutrophil gelatinase-
associated lipocalin 
 
Increases in the concentration of neutrophil gelatinase-associated lipocalin were 
observed in the adult Fabry disease and type II diabetic patient groups (55.8-
fold and 30.2-fold, respectively) compared to the adult control group (Figure 
3.32). In addition, a decrease of 6.7-fold below that of the paediatric control 
group was observed in the paediatric obese patient group. 
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Figure 3.32 Urinary neutrophil gelatinase-associated lipocalin 
concentrations using a targeted MRM-UPLC-MS/MS assay in paediatric 
and adult cohorts. Error bars represent mean ± SD. FC = fold change; FD = 
Fabry disease; ↓DB = least disease burden; ↑DB = most disease burden.   
 
A statistically significant elevation (p = 0.04) was observed in neutrophil 
gelatinase-associated lipocalin concentrations in the paediatric Fabry disease 
patient group with the least disease burden (Figure 3.33a) at the two-year time 
point, above that of the baseline pre-treatment concentrations. When the data 
were re-analysed for fold changes increases of 24.1-fold and 50.5-fold were 
also observed at the one- and three-year post-treatment time points compared 
to the baseline pre-treatment levels. The opposite was found in those patients 
with the most disease burden (Figure 3.33b) with 9.0-fold, 2.5-fold and 3.5-fold 
reductions in the concentrations of neutrophil gelatinase-associated lipocalin 
below those of baseline pre-treatment concentrations. An elevation in neutrophil 
gelatinase-associated lipocalin in one patient pre-ERT assisted the fold change 
reductions observed. If this single outlier is excluded from the analysis a fold 
change reduction in the level of this protein is still observed at the one year 
post-ERT time point however, pre-treatment and two and three year post-ERT 
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levels become comparable with pre-treatment concentrations. Levels at the 
one-, two- and three-year post treatment levels in those patients with most 
disease burden are also lower than those of the control group by 16.6-fold, 4.6-
fold and 6.4-fold, respectively.  
Neutrophil gelatinase associated lipocalin was also found to be increased 19.8-
fold in those pre-treatment patients with the most disease burden compared to 
those patients with the least disease burden at the same time period. However, 
at the one-, two- and three-year time points this protein was 10.9-fold, 29.2-fold 
and 8.9-fold reduced in those patients with most disease burden compared to 
patients with the least disease burden at the corresponding time points.      
 
 
 
 
Figure 3.33 Urinary neutrophil gelatinase-associated lipocalin 
concentrations in paediatric Fabry disease patients with a.) Least disease 
burden and; b.) Most disease burden; pre-treatment, and one, two, and three 
years’ post-ERT.  Columns represent mean. Error bars represent SD. 
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3.3 Discussion 
 
Urine has been used for decades for the diagnosis and assessment of disease. 
Recent advances in proteomic profiling techniques have demonstrated that 
urine contains an appreciable number of proteins and peptides making it an 
attractive medium for biomarker discovery studies (Decramer et al., 2008). 
Among the advantages of using urine for analyses are that it requires non-
invasive collection and allows repeated sampling for disease monitoring. In 
addition, the urinary proteome content is very stable for a number of years when 
stored under optimum conditions (-80°C). 
Using label-free quantitative proteomics a number of alterations in urinary 
proteins were identified following 12 months of ERT in Fabry disease patients. 
Using MSE, prosaposin was the only protein reduced statistically and 
significantly (p = 0.03) following treatment (Figure 3.3). However, another 
lysosomal protein of interest, GM2AP, also demonstrated a 2.1-fold change 
decrease following treatment (Figure 3.4.1e). As an initial pilot study to verify 
the results, a rapid MRM-based UPLC-MS/MS assay was developed to 
quantitate prosaposin and GM2AP in the urine of these patients as well as in a 
positive diabetic and negative control group. This confirmed that prosaposin 
was reduced significantly (p = 0.01) following treatment in Fabry disease 
patients (Figure 3.7). In addition, a significant difference was also observed 
between pre-treatment Fabry disease patients, and diabetic (p = 0.009) and 
control (p = 0.002) patient groups (Figure 3.7).  
Prosaposin is the precursor protein for sphingolipid activator proteins (SAPs) A, 
B, C and D, which are four small, heat stable glycoproteins. All four mature 
saposins are structurally similar and have specific roles in activating their 
respective lysosomal hydrolases, which are required for the metabolism of 
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various sphingolipids (Kishimoto, Hiraiwa, and O’Brien 1992) (see Figure 1.2). 
Prosaposin has been shown to be secreted into body fluids, whereas the 
mature saposins are located within the lysosome, and unsurprisingly 
accumulation of the mature saposins has been reported previously in the 
plasma (Chang et al., 2000) and tissue (Morimoto et al., 1990) of various 
lysosomal storage disorders. Following identification and confirmation of 
prosaposin, the protein of interest, we attempted to identify the mature saposin 
chains in the filtrate fraction containing proteins < 30 kDa obtained from the size 
exclusion protein purification columns. While we were able to identify saposin A 
in all samples analysed, saposins B, C and D were not detectable in all patient 
samples analysed in this study. There could be a number of reasons for this 
such as endogenous concentrations lower than the limit of detection for this 
method or that the ion suppression is too great. However, we also considered 
perturbation of prosaposin processing into the mature saposin forms resulting in 
disrupted transport to the lysosome. Hiraiwa et al., (1997) have reported the 
involvement of cathepsin D in the hydrolysis of prosaposin into a 48 kDa 
product containing two trisaposins including a domain for saposins A, B and C 
and a domain for saposins B, C and D and a 29 kDa product containing two 
disaposins including a domain for saposins A and B and a domain for saposins 
C and D. Cathepsin D then further processes the disaposins into mature 
saposin A and small fragments containing saposins B, C and D with portions of 
interdomain sequences. These small fragments then require processing by 
other proteases to obtain mature saposins B, C and D within the lysosome. In 
view of this the effect of Gb3 and lyso-Gb3 on cathepsin D activity was 
assessed. However, no inhibition of cathepsin D activity was observed by either 
Gb3 or lyso-Gb3 (data not shown).  
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As well as saposins A – D derived from prosaposin, encoded by the PSAP 
gene, the known saposins include the genetically distinct GM2AP, encoded by 
the GM2A gene. GM2AP is larger, has a different secondary structure and is 
responsible for the breakdown of ganglioside GM2 and glycolipid GA2 by beta 
hexosaminidase A (Bradová et al., 1993; Schuette et al., 2001). GM2AP was 
found to be reduced following treatment in Fabry disease patients (2.1-fold 
change) using label-free quantitative proteomics (Figure 3.4.1e). This protein 
was combined into the initial MRM UPLC-MS/MS assay for verification and 
confirmed that GM2AP was reduced following treatment. By using this highly 
sensitive and specific technique, the reduction was shown to be significant both 
between pre- and post-treatment Fabry disease patients (p = 0.01) and 
between pre-treatment and control groups (p = 0.003) (Figure 3.8). The majority 
of research of GM2AP investigates its role as a cofactor of β-hexosaminidase A 
to catalyse the degradation of ganglioside GM2 and a deficiency of which results 
in the lysosomal storage disorder GM2 gangliosidosis, AB variant. However, 
GM2AP has also been reported to bind to and act in transport of, a wide variety 
of lipids including phosphatidylcholine, in addition to binding to platelet 
activating factor (PAF) within β-cup and hydrolysing it to inactive lyso-PAF 
(Rigat et al., 2009). Increased concentrations of platelet activating factor have 
been associated with a number of clinical conditions including stroke, 
myocardial infarction, colitis and multiple sclerosis (Lindsberg, Hallenbeck and 
Feuerstein 1991; Frangogiannis, Smith and Entman 2002; Callea et al., 1999). 
To our knowledge this is the first study to investigate GM2AP concentrations in 
Fabry disease. The relevance of elevated GM2AP concentrations in pre-
treatment Fabry disease patients and their correction following 12 months of 
ERT requires further investigation. However, the reduction of lysosomal proteins 
- 207 - 
 
prosaposin and GM2AP following ERT may be indicative of improved lysosomal 
function.  
GM2AP was also found to be increased significantly (p = 0.049) in diabetic 
patients compared to a control group (Figure 3.8), this differs from our finding in 
prosaposin concentrations where no significant difference was observed 
between diabetic and control groups (p = 0.2). Higashi et al., (2011) 
demonstrated that administration of GM2AP in vivo, significantly lowered blood 
glucose concentrations and stimulated insulin secretion. HbA1c concentrations 
provide a measure of circulating glucose over a 2 – 3 month period and can be 
used as a simple and reliable marker of insulin resistance. In view of this 
GM2AP concentrations in this paediatric diabetic patient group were compared 
with HbA1c concentrations to establish if there was any correlation. However, 
an R2 value of 0.3 was observed in this small sample group indicating no 
correlation between urinary GM2AP concentrations and HbA1c levels in blood 
(data not shown). The elevation of GM2AP in both untreated Fabry and diabetic 
patients may suggest that GM2AP is a sensitive marker of pre-symptomatic 
kidney disease.             
The population prevalence of chronic kidney disease (CKD) exceeds 10% rising 
to over 50% in at risk populations including those with diabetes, high blood 
pressure and obesity. This is a recognised major public health burden (Eckardt 
et al., 2013). Renal involvement is also a major contributor to morbidity in Fabry 
disease and it has been suggested that at present biopsy is required in order to 
detect changes in the glomerular and vascular architecture indicative of renal 
disease that are evident even before detectable proteinuria in these patients 
(Tøndel et al., 2008). Therefore a panel of biomarkers with the ability to detect 
pre-symptomatic kidney disease would provide a vital, non-invasive tool for the 
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identification of those patients most ‘at risk’ and enable therapies and/or lifestyle 
changes to be instigated before the occurrence of irreversible CKD. To assess 
whether a number of the proteins identified in the initial label-free experiment, 
as well as known or previously described biomarkers of kidney disease, could 
detect pre-symptomatic kidney disease a larger multiplex MRM UPLC-MS/MS 
assay was developed. This assay was then used to assess the ability of these 
proteins to detect pre-symptomatic kidney disease in samples from a number of 
‘at risk’ patient groups. Included in the study was a paediatric Fabry disease 
patient group categorised for the purpose of this study into those patients with 
the least disease burden and those with the most disease burden, with samples 
collected pre-treatment and following one-, two- and three-years of therapy. 
Also included in the study was a paediatric type I diabetic patient group, an 
obese paediatric patient group and a paediatric control group. In addition, 
samples from an adult Fabry disease patient group, an adult type II diabetic 
patient group and an adult control group were also analysed.     
Serum albumin was included in the pre-symptomatic kidney disease assay as it 
is currently the principal biomarker used to monitor kidney function in a number 
of clinical conditions. Albumin is a serum protein manufactured by the liver that 
functions as both a building block and a carrier molecule (Lehman 2009). In 
healthy kidneys albumin is filtered in renal glomeruli but, the large molecular 
weight of this protein prevents it from passing through the glomerulus and 
instead it is effectively reabsorbed in the proximal tubule by endocytosis (Gekle 
1998). However, when the glomerulus is damaged increasing amounts of 
albumin pass freely through this barrier and can be detected in the urine. The 
degree of albumin present is reflective of the degree of damage (Nayak and 
Nayak 2007).   
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Albumin was the second most abundant protein detected in the label-free 
proteomic experiment representing 6 % of the total protein detected in pre-
treatment Fabry disease patients (Figure 3.1). Although the mean levels of 
albumin increased in post-treatment Fabry disease patients this change was not 
statistically or significantly elevated (p = 0.4) and represented a fold change of 
1.3. Following analysis by UPLC-MS/MS albumin concentrations were found to 
be increased statistically and significantly between both adult Fabry disease 
patient (p = 0.04) and adult type II diabetic patient (p = 0.03) groups, compared 
to the adult control group (Figure 3.10). Microalbuminuria was not evident in the 
paediatric patient cohorts using conventional methods and whilst no statistically 
significant elevations in albumin concentration above that of the control group 
were observed, fold change elevations were observed. Fabry disease patients 
with the least disease burden both pre-treatment and following three years of 
ERT and the type I diabetic patient group displayed >2-fold elevations above 
the control group, inferring that kidney function may already be reduced, at this 
early stage, in these patient groups. Albumin concentrations in those patients 
with most disease burden showed significant reductions (p = 0.02) below those 
of the control group. However, a significant elevation (p = 0.04) was seen 
following three years of ERT resulting in mean concentrations of this group 
comparable with the control group. Although albumin concentrations in those 
patients with the least disease burden were consistently elevated above those 
patients with the most disease burden and those of the control group no 
elevations were observed above baseline pre-treatment levels suggesting that 
ERT may be halting the progression of further kidney involvement in this patient 
group. Contrastingly, in those patients with the most disease burden elevations 
above baseline pre-treatment levels were seen at each time point studied 
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suggesting that ERT may not be as effective in this patient group. During this 
study the consecutive elevation in albumin levels at each time point resulted in 
albumin concentrations comparable with those of the control group. However, if 
this pattern continued exponentially levels would rapidly become increased 
above those of the control group.  
The multi-ligand endocytic receptors megalin and cubilin were selected for 
inclusion in the pre-symptomatic kidney disease assay due in part to the role 
they play in the normal tubular reabsorption of proteins, including albumin and 
vitamin D binding protein. Megalin is heavily expressed in the renal proximal 
tubule and in addition to acting as a receptor, studies suggest that megalin also 
plays a role in the metabolism and homeostasis of essential vitamins 
(Christensen and Birn 2001). In this study, significant and statistical elevations 
were observed in megalin excretion in both the adult Fabry disease (p = 0.03) 
and type II diabetic (p = 0.03) groups compared to the control group (Figure 
3.12). Whilst no statistically significant changes were observed in the paediatric 
cohorts, a 2.5-fold elevation in megalin was observed between the type I 
diabetic and control group. The concentrations of megalin in those patients with 
least disease burden (Figure 3.13a) displayed fold change elevations above 
baseline pre-treatment levels and those of the control group following one-, two- 
and three-years of ERT. However, megalin concentrations in those patients with 
most disease burden (Figure 3.13b), despite a slight elevation following one 
year of ERT, remained stable during the time frame studied with levels 
comparable to those of the control group.      
Cubilin is co-expressed with megalin in the renal proximal tubule and although 
structurally very different, cubilin possesses many similar features and shares 
many ligands with megalin (Christensen and Birn 2001). However, in this study 
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whilst statistically significant results were obtained for megalin the same was 
not true for cubilin, although similar patterns were observed in some patient 
groups. Increases of 5.3-fold and 8.5-fold above their control groups were 
observed for the type I and type II diabetic groups, respectively (Figure 3.24). 
However, whilst significant elevations in megalin concentrations were observed 
in the adult Fabry disease group, cubilin concentrations in this group were 
comparable with those of the control group. The concentrations of cubilin in the 
group of patients with least disease burden (Figure 3.25a), like megalin, 
displayed fold change elevations above baseline pre-treatment levels and those 
of the control group following two- and three-years of ERT. Megalin 
concentrations in the group of patients with most disease burden (Figure 3.25b) 
again, despite slight elevations following one- and two-years of ERT, remained 
mostly stable during the time frame studied with levels comparable to those of 
the control group following three-years of ERT.  
Vitamin D binding protein is a multifunctional protein found in a number of 
biological fluids and belongs to the albumin gene family. Increases in vitamin D 
binding protein have been reported previously in patients with chronic kidney 
disease and tubulointerstitial damage (Mirković et al., 2013). Urinary vitamin D 
binding protein has also been shown to increase with increasing severity of 
diabetic nephropathy (Thrailkill et al., 2011). Findings in this study are in 
agreement with previous reports with a statistical and significant elevation 
observed in urinary vitamin D binding protein concentrations in type II diabetic 
patients (p = 0.02) (Figure 3.14). Vitamin D binding protein was also shown to 
be increased by fold change in Fabry disease adults and paediatric type I 
diabetic patients (9.5-fold and 2.3-fold, respectively). Vitamin D binding protein 
concentrations behaved in a similar way in the groups of patients with the least 
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and the most disease burden (Figure 3.15). Levels of both those patients with 
the least disease burden and those with the most disease burden were 
statistically and significantly lower than those of the control group prior to ERT. 
A slight elevation was observed in both groups following one year of ERT 
however, this normalised at the two and three year time points resulting in 
stable values consistent with those of the control group. These findings may 
suggest that there is little tubulointerstitial damage in those Fabry disease 
patients who develop renal involvement. This is in agreement with previous 
studies where no change in tubulointerstitial damage was detected following 
ERT (Branton, Schiffmann, and Kopp 2002; Schiffmann et al., 2001).   
Prostaglandin-H2 D-isomerase is an enzyme involved in controlling smooth 
muscle contraction/relaxation, is a potent inhibitor of platelet aggregation and 
catalyses the conversion of prostaglandin H2 to prostaglandin D2. 
Prostaglandin-H2 D-isomerase also binds small non-substrate lipophilic 
molecules such as bilirubin and may act as a scavenger for harmful 
hydrophobic molecules. The use of urinary and serum prostaglandin-H2 D-
isomerase levels have been suggested previously as a sensitive indicator of 
renal damage in diabetes mellitus, chronic kidney disease and hypertension 
(Dajak et al., 2011; Hirawa et al., 2001). In this study a statistically significant 
elevation in prostaglandin-H2 D-isomerase levels (p = 0.049) was found in the 
adult Fabry patient group (Figure 3.16). However, although a 61.2-fold change 
was apparent in the adult type II diabetic group this change was not statistically 
significant. Prostaglandin-H2 D-isomerase concentrations behaved similarly in 
both Fabry disease groups with the least and the most disease burden (Figure 
3.17) displaying elevations above the control group at baseline and at each 
consecutive time point evaluated. Following three-years of treatment this level 
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had reached a statistically significant increase above the control group in those 
patients with most disease burden (p = 0.03). Elevations in prostaglandin-H2 D-
isomerase were also detected in all other paediatric patient cohorts. 
Prostaglandin-H2 D-isomerase was the only protein included in the pre-
symptomatic kidney disease assay where elevations in all paediatric and adult 
patient groups, above those of their respective control group, were observed. 
However, whether this protein is in fact a very sensitive indicator or renal 
damage requires further investigation.   
The lysosomal protein lysosomal alpha glucosidase is essential for the 
degradation of glycogen to glucose within lysosomes and a statistically 
significant elevation of this protein was observed in adult Fabry patients (p = 
0.05), above those of the control group (Figure 3.18). However, in the paediatric 
Fabry disease patients with the least and the most disease burden pre-
treatment levels were only elevated marginally above those of the control group 
(Figure 3.19). Apart from a 2.5-fold increase observed in those patients with 
least disease burden following two years of ERT, levels in both groups were 
lower than those of the baseline pre-treatment concentrations following three-
years of treatment resulting in levels comparable with those of the control 
group. Whilst elevations in lysosomal alpha glucosidase may not be indicative 
of pre-symptomatic kidney disease the statistically significant increase observed 
only in the adult Fabry disease patient group may represent a degree of 
impaired lysosomal function (Figure 3.18). It is possible that this may be 
corrected by ERT when instigated at an early stage of disease progression as 
demonstrated by the finding that no statistically significant alterations in either 
the paediatric Fabry disease patients with the least or the most disease burden, 
compared to that of the control group, were apparent (Figure 3.19). In addition 
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both type I and type II diabetic patients had 2.1-fold and 5.3-fold elevations 
compared to their respective control groups (Figure 3.18). This could be as a 
direct response to increased glucose and/or perturbation of the lysosomal 
system resulting in downstream effects such as impairment of the transduction 
mechanism for glucose-induced insulin release. (Salehi et al., 1999; Moheimani 
et al., 2012).             
Membrane bound endothelial protein C receptor plays an important role within 
the protein C pathway in regulating coagulation and inflammation. Following 
cleavage by a protease endothelial protein C receptor is also found as a soluble 
protein and provides a sensitive indicator of endothelial damage (Nozza et al., 
2012). In addition, urinary levels have been suggested as a biomarker to detect 
the rejection of renal transplantation (Lattenist et al., 2013). In this study, 
endothelial protein C receptor concentrations were significantly lower in the 
paediatric Fabry disease patients with most disease burden compared to the 
control group both prior to treatment and following three-years of ERT (Figure 
3.21). However, levels observed in the paediatric Fabry disease group with 
least disease burden and adult Fabry patient groups were comparable with 
those of their respective control groups. Fold change elevations were however 
seen in endothelial protein C receptor concentrations in both the type I and type 
II diabetic patient groups above those of their respective control groups (Figure 
3.20). This may indicate that these patients possess a degree of endothelial 
damage, a complication often seen in diabetic patients, which is a risk factor for 
progression of atherosclerosis and in turn has been shown to accelerate 
progression to retinopathy, nephropathy and neuropathy (Garcia et al., 2001; 
Calles-Escandon and Cipolla 2001).        
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Osteopontin is a multifunctional secreted, phosphorylated glycoprotein 
expressed in bone, macrophages, T lymphocytes and NK cells. Osteopontin is 
present in the loop of Henle and distal nephrons in healthy kidneys and studies 
have shown that kidney cells produce high levels of this protein following an 
insult suggesting that osteopontin could play an important role in kidney injury 
(Xie et al., 2001; Zhang et al., 2010). A statistically significant elevation was 
observed in type II diabetic patients (p = 0.02) compared to the adult control 
group and a 2.0-fold increase was also observed in type I diabetic patients 
(Figure 3.22). However, levels of osteopontin in all other patient groups were 
comparable to those of their respective control groups suggesting that these 
patients have sustained comparatively less kidney injury than those patients of 
a similar age with diabetes.  
Sortilin is a multifunctional protein that in addition to its role as a multi-ligand 
receptor for neuropeptides including neurotensin has been shown to mediate 
lysosomal trafficking of several enzymes and non-enzymatic proteins (Coutinho, 
Prata and Alves 2012) including prosaposin, GM2AP (Lefrancois et al., 2003), 
acid sphingomyelinase (Ni, Canuel and Morales 2006) and cathepsins D and H 
(Canuel et al., 2008). Increases in sortilin concentration were observed in both 
the type I and type II diabetic patient groups as well as the ERT naïve adult 
Fabry disease group in this study (Figure 3.26). However, concentrations of this 
protein in the paediatric Fabry disease group with least disease burden were 
comparable to those of the control group pre-treatment and during the three-
years following instigation of ERT (Figure 3.27). Interestingly, sortilin wasn’t 
detectable in those patients with most disease burden either pre-treatment or at 
any of the consecutive time points analysed. A recent study by Prabakaran et 
al., (2012) identified mannose 6-phosphate receptor and sortilin as alpha 
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galactosidase A receptors in cultured renal endothelial cells. The study went on 
to show that in addition to mannose 6-phosphate, sortilin is able to internalise 
circulating recombinant alpha-galactosidase A during ERT. This finding 
combined with the absence of sortilin in those patients with most disease 
burden in the present study may provide some explanation as to the inability of 
ERT to reduce or stabilise the Gb3 concentrations in this subset of patients. 
Neutrophil gelatinase-associated lipocalin (NGAL) is a ubiquitous lipocalin iron 
carrying protein (Bolignano et al., 2009) expressed in the tubular epithelial cells 
of the distal nephron and has shown to be released from tubular epithelial cells 
following acute kidney injury (Fassett et al., 2011). In the present study 
statistically significant elevations above baseline pre-treatment levels were 
found two-years post-ERT with fold change elevations at all other time points 
studied in the paediatric Fabry disease patients with least disease burden 
(Figure 3.33a). Interestingly, decreases in neutrophil gelatinase-associated 
lipocalin were detected in those patients with most disease burden following 
treatment (Figure 3.33b). Fold change increases above the adult control group 
were found in both the adult Fabry disease and type II diabetic groups (Figure 
3.32). Urinary neutrophil gelatinase-associated lipocalin concentrations have 
been documented previously in non-diabetic patients with chronic kidney 
disease (Malyszko et al., 2009) as well as in a diabetic patient group (Bolignano 
et al., 2009) suggesting that this protein may play an important role in the 
pathophysiology of renal adaptation and associated nephropathy (Fassett et al., 
2011).        
Statistically significant results were not obtained in, or between, any patient 
group analysed for the proteins Ig gamma-4 chain c region or retinol binding 
protein. Retinol binding protein was identified previously in the label-free 
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quantitative proteomic initial study as having a >2-fold decrease between pre-
treatment and one year post-treatment Fabry disease groups. Using the pre-
symptomatic kidney disease assay this finding was also observed in the 
paediatric Fabry disease patients with most disease burden (Figure 3.29b). 
Concentrations of retinol binding protein in this group were 3.5-fold higher than 
those of the control group prior to treatment. However, consecutive reductions 
from baseline pre-treatment levels were seen at each time point analysed 
resulting in retinol binding protein concentrations comparable with those of the 
control group. In the paediatric Fabry disease patients with least disease 
burden, apart from a fluctuation at the two-year post-ERT time point, levels 
comparable with those of the control group were apparent at each time point 
studied. However, elevations of retinol binding protein were seen in the 
paediatric type I diabetic group and the adult Fabry and type II diabetic groups. 
(Figure 3.28) Retinol binding protein is the transporter of retinol and is often 
found bound to transthyretin but a small unbound fraction passes through 
glomerular membranes and is reabsorbed by the renal proximal tubule cells 
where it is catabolised. Due to extensive tubular reabsorption, under normal 
conditions very little filtered retinol binding protein appears in the final excreted 
urine. Therefore, an increase in the excretion of retinol binding protein indicates 
proximal tubule damage and/or impaired proximal tubule function (Kirsztajn et 
al., 2002). The decrease in retinol binding proteins in the paediatric Fabry 
disease patients with most disease burden following instigation of treatment 
may therefore indicate that ERT, when instigated at an early point of disease 
progression, may have a beneficial effect on proximal tubule damage.        
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3.4 Conclusion 
 
Label-free quantitative proteomics identified a number of potential biomarkers, 
in the urine of paediatric Fabry disease patients. The development of an initial 
targeted and rapid peptide based assay to validate these findings confirmed 
that prosaposin and GM2AP were reduced significantly following one year of 
ERT in Fabry disease patients. The addition of age- and sex- matched type I 
diabetic patients, as a positive control group, demonstrated that whilst 
prosaposin levels were comparable with those of the control group, the levels of 
GM2AP were increased significantly. The increase in GM2AP levels in both the 
paediatric Fabry disease and type I diabetic patients suggested that this protein 
may be a sensitive indicator of pre-symptomatic kidney disease. This protein 
was therefore incorporated with other biomarkers of kidney disease into a rapid, 
10 minute, multiplex MRM UPLC-MS/MS, to assess if this group of biomarkers 
had the ability to detect pre-symptomatic kidney disease in those patients most 
at risk.    
The inclusion of albumin, the current gold standard biomarker for monitoring 
kidney disease, demonstrated that this assay has the ability to detect pre-
symptomatic kidney disease as alterations in these paediatric patient groups 
were detectable before any abnormal results were obtained using conventional 
methods. In addition, other known biomarkers of established kidney disease 
displayed alterations in these ‘at risk’ patient groups. However, although there 
are some common pathways to kidney disease progression, there are many 
primary causes, each with its own specific pathophysiological mechanism and 
this may go some way in explaining some of the variations observed within 
these patient groups for each protein.  
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The effect of ERT on the proteins included in the pre-symptomatic kidney 
disease assay requires interpretation with care and in order to draw informative 
conclusions, the investigation of these proteins in a paediatric patient group not 
receiving ERT would be required. In this way an assessment as to the levels 
and rates of progression of these proteins in patients not receiving ERT could 
be made and therefore establish to what degree ERT is able to reduce kidney 
involvement. This study may however demonstrate that differences exist 
between those patients in whom Gb3 levels fall following instigation of treatment 
(those with least disease burden) and those in who they do not (those with most 
disease burden).     
The detection of pre-symptomatic kidney disease in order to instigate 
concomitant therapies at an early stage of the disease is becoming more 
important to not only prevent development to end stage renal disease but also 
to alleviate the burden to health services worldwide. A panel of biomarkers, 
such as those investigated during this study, detectable by MRM UPLC-MS/MS 
a technique which has the ability to allow the panel to be expanded may be 
what is required. However, to fully understand the meaning and implications of 
these results further investigation and longitudinal observational studies are 
required in order to fully validate these biomarkers prior to their routine use. 
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4.0 A metabolic study to identify new globotriaosylceramide-related 
biomarkers in the plasma of Fabry disease patients 
 
4.1 Introduction 
 
In the study described in the previous chapter a proteomic approach was used 
to identify a number of protein biomarkers in the urine of Fabry disease patients. 
However, to study smaller molecules requires the use of metabolomics which 
enables the characterisation and cataloguing of small molecule metabolites 
(Griffiths and Wang 2009). In the present study a targeted metabolomic 
approach was used to identify new and existing Gb3-related biomarkers in the 
plasma of Fabry disease patients.   
The study and characterisation of small molecule metabolites has evolved 
significantly in the last decade with advances in both the tools required to 
perform analyses and with the development of the necessary bioinformatic 
software to analyse the wealth of data acquired. With continuing advances in 
these areas our knowledge of the metabolome continues to grow. Metabolites 
are the intermediates and products of metabolism and are sensitive to short 
temporal variations making them ideal candidates for biomarkers. Mass 
spectrometry based metabolomics has proven to be the analytical tool of choice 
in the search and identification of such biomarkers due to the high sensitivity, 
specificity and robustness achievable using this methodology (Griffiths and 
Wang 2009; Milne et al., 2013).  
Currently, two metabolite biomarkers for Fabry disease, globotriaosylceramide 
(Gb3) and globotriaosylsphingosine (lyso-Gb3) (Figure 1.3) are recognised as 
important diagnostic tools and are used in high-risk urinary screening studies of 
Fabry patients. In addition, these metabolites are routinely used to assess 
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disease burden and monitor response to therapy. Recently, the presence of 
newly defined Gb3-related analogs and isoforms in urine (Auray-Blais and 
Boutin 2012) and lyso-Gb3 related analogs and isoforms in urine (Auray-Blais et 
al., 2012) and plasma (Dupont et al., 2013) has been demonstrated. Following 
the development of a methodology to measure plasma lyso-Gb3 analogs and 
isoforms in urine by Boutin et al., (2012) the excretion of the majority of these 
analogs was found to be above the level of lyso-Gb3 itself. This observation 
combined with the reduction of these analogs following enzyme replacement 
therapy suggests that measurement of these novel biomarkers may provide 
further information as to disease status and response to treatment than the 
analysis of simply Gb3 and/or lyso-Gb3 alone (Auray-Blais et al., 2012; Dupont 
et al., 2013).   
In the present study, a metabolomic approach was used to identify potential 
biomarkers in plasma from twelve untreated Fabry males and eight age- and 
sex-matched controls using time-of-flight mass spectrometry (ToF-MS). Whilst 
Gb3 levels in plasma haven’t proven to be an ideal biomarker (Mills et al., 2005) 
as elevations in plasma Gb3 concentrations are not observed in a large 
proportion of female heterozygotes, this study aimed to identify and assess the 
levels of structural isoforms and potential analogs of Gb3 by focusing on mass-
to charge (m/z) ratios between 995 and 1200 Da. In addition, following the 
identification of Gb3-related analogs and isoforms the levels of these biomarkers 
were assessed in plasma from ten untreated Fabry females. Finally, findings 
from this study were compared and correlated with a previous study in urine to 
draw conclusions regarding the presence of these metabolites in the biological 
fluids of Fabry patients.  
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4.2 Results 
 
4.2.1 Effects of sample processing 
 
A control plasma sample was spiked with a synthetic standard 
(Gb3(d18:1)(C17:0)) to ensure that the Gb3 analogs detected in this study were 
not generated by sample processing (section 2.2.6.5). This was clearly 
demonstrated as no chemical modifications such as methylation, addition of a 
double bond or hydration were observed on the synthetic standard after 
processing procedures.   
 
4.2.2 System stability evaluation 
 
Quality controls were analysed throughout the metabolomic run (section 
2.2.6.7) and used to evaluate the reproducibility of the mass and retention time, 
thus determining the smallest mass (0.05 Da) and retention time window (0.2 
min), to ensure good alignment in MarkerLynx™.  
 
4.2.3 Data mining and multivariate analysis 
 
Following analysis of the UPLC-ESI-ToF-MS metabolomic results of plasma 
samples obtained from twelve untreated Fabry males and eight healthy controls 
with MarkerLynx™ (as described in section 2.2.6.6), a total of 14,514 markers 
aligned according to their exact masses and retention time. Using these 
markers, an OPLS-DA score plot (Figure 4.1) was created and showed clear 
differentiation between the two sample groups.  
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Figure 4.1 OPLS-DA score plot derived from the UPLC-ESI-ToF-MS 
metabolomic analysis of plasma samples from untreated Fabry males (n = 
12) and healthy control males (n = 8). The ellipse corresponds to the Hotelling 
T2 range with a significance level of p = 0.05. The statistical analysis revealed a 
R2 = 0.815, a Q2 = 0.383, and a root mean square error of validation (RMSEV) 
= 0.77.  
 
Each symbol in the plot corresponds to one sample. The x-axis represents the 
intergroup variation and the y-axis represents the intragroup variation. The 
ellipse corresponds to the Hotelling T2 range with a significance level of 95 % (p 
= 0.05). The Fabry sample (Patient 12, Table 2.3) was outside the Hotelling T2 
ellipse. This sample was thus considered an outlier and excluded from the 
analysis. Further statistical analyses performed produced an R2 value of 0.815, 
a Q2 value of 0.383 and an RMSEV value of 0.77 for this data set.  
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This data was then used to create an S-plot (Figure 4.2A) where each point 
corresponds to a marker as defined by MarkerLynx™. The S-plot shows the 
reliability (y-axis) as a function of covariance (x-axis) for each metabolite. The 
more a metabolite is located at the top right or at the bottom left of the graph, 
the greater the influence on the discrimination of the sample groups in the 
OPLS-DA score plot. Metabolites located at the top right corner of the S-plot 
were found at a higher concentration in the Fabry patient group compared to the 
control group, and the metabolites at the bottom left were found at a lower 
concentration in the Fabry patient group compared to the control group. Fabry 
disease metabolites are considered as potential biomarkers if they are present 
in Fabry patient samples but not in normal control samples. The S-plot in Figure 
4.2B shows a zoomed image of the potential metabolite biomarkers. Of the 
potential biomarkers of interest, seventeen had previously been identified in 
urine as isoforms or analogs of Gb3 (Auray-Blais and Boutin 2012), these are 
highlighted in red and annotated with a lower case initial on the S-plot. The 
remaining seven markers were considered as potential new biomarkers and are 
shown highlighted in blue on the S-plot and annotated with a number. These 
new potential biomarkers required further investigations for structural 
elucidation and characterisation.    
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Figure 4.2 (A) S-plot showing the correlation in function of the covariance 
for the metabolites used to discriminate the two sample groups in the 
OPLS-DA score plot. (B) Zoom of the section of the S-plot where the Fabry 
disease biomarkers are shown. Those highlighted in red are previously 
described Gb3 analogs or isoforms with the letter corresponding to the analog or 
isoform in Table 4.1 Those highlighted in blue and annotated with numbers are 
newly discovered potential Fabry disease biomarkers.  
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4.2.4 Plasma Gb3-related metabolites in Fabry patients 
 
The nomenclature used in metabolomic analyses to describe Gb3-related 
isoforms and analogs is outlined in section 2.2.6.2. Identification and relative 
area counts of the new Gb3-related analogs and isoforms and the Gb3-related 
analogs and isoforms previously described in urine (Auray-Blais and Boutin 
2012) and now identified during this study in plasma were obtained using 
QuanLynx™ (as described in section 2.2.6.9). Table 4.1 summarises the data 
obtained for Gb3-related analogs and isoforms detected in this study in plasma 
and also data for those Gb3-related analogs and isoforms previously detected in 
urine. The majority of these Gb3-related analogs and isoforms were also 
revealed in the multivariate analysis and are shown in the S-plot (Figure 4.2B). 
Previously identified biomarkers are highlighted in red and annotated with a 
lowercase letter corresponding to their Gb3-related analog/isoform displayed in 
Table 4.1. As expected, the relative area counts for plasma Gb3-related analogs 
and isoforms were found to be higher in Fabry patients compared to controls.    
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Table 4.1 Retention time and relative abundance of the biomarkers in plasma from the current study revealed by the S-plot 
(Figure 4.2) in untreated Fabry males and healthy control males. Corresponding information for biomarkers in urine from a previous 
study (Auray-Blais and Boutin 2012) is also supplied for comparison. Those biomarkers depicted in bold are novel biomarkers detected in 
this study. AUC: Area under the ROC curve for plasma. *These biomarkers were not revealed by the S-plot but were detected by 
extracted ion chromatogram. nd: not detectable; na: not applicable. 
 
Category Biomarkers 
S-plot 
ID 
Retention 
time (min) 
Fabry males mean 
(min-max) 
Control males mean 
(min-max) 
AUC t-test 
Urine and 
plasma 
Plasma 
[Area] 
Urine 
Area/[creat.] 
Plasma 
[Area] 
Urine 
Area/[creat.] 
Plasma 
Fabry 
plasma 
vs control 
plasma 
Fabry 
plasma vs 
Fabry 
urine 
1 Gb3(d18:1)(C16:0) a 8.8 
81.8 
(69.2-94.5) 
5.4 
(0.3-25.5) 
21.0 
(15.5-27.8) 
0.01 
(nd-0.1) 
1 p < 0.001 p < 0.001 
1 Gb3(d18:1)(C18:0) b 9.2 
8.8 
(4.9-15.2) 
3.2 
(0.1-13.3) 
1.7 
(1.1-2.2) 
nd 1 p < 0.001 p < 0.001 
1 Gb3(d18:1)(C20:0) c 9.7 
5.4 
(3.7-8.4) 
7.4 
(0.30-31.73) 
1.4 
(0.7-2.3) 
0.01 
(nd-0.1) 
1 p < 0.001 p < 0.4 
1 Gb3(d18:1)(C22:0) d 10.1 
8.3 
(4.7-12.2) 
28.2 
(1.6-68.3) 
1.5 
(1.2-1.7) 
0.2 
(nd-0.8) 
1 p < 0.001 p < 0.004 
1 Gb3(d18:1)(C24:0) e 10.4 
11.5 
(7.5-16.4) 
59.8 
(2.5-214.2) 
1.7 
(1.2-2.3) 
0.4 
(0.1-1.2) 
1 p < 0.001 p < 0.001 
1 Gb3(d18:1)(C26:0) f 10.7 
0.8 
(0.5-1.3) 
2.4 
(0.4-8.7) 
0.1 
(0.01-0.2) 
0.01 
(nd-0.1) 
1 p < 0.001 p < 0.01 
2 Gb3(d18:1)(C16:0)Me g 9.0 
0.3 
(0.1-0.5) 
0.3 
(nd-1.3) 
nd nd 1 p < 0.001 p < 0.74 
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2 Gb3(d18:1)(C18:0)Me * 9.5 nd 
0.2 
(nd-0.9) 
nd nd na na na 
2 Gb3(d18:1)(C20:0)Me h 9.9 
1.0 
(0.7-1.7) 
1.7 
(0.1-4.2) 
0.4 
(0.2-0.6) 
0.03 
(nd-0.2) 
1 p < 0.001 p < 0.03 
2 Gb3(d18:1)(C22:1)Me i 9.9 
1.6 
(1.1-2.5) 
1.3 
(0.1-4.4) 
0.2 
(0.04-0.3) 
nd 1 p < 0.001 p < 0.3 
2 Gb3(d18:1)(C22:0)Me j 10.3 
3.3 
(2.2-5.1) 
6.1 
(0.3-17.6) 
0.9 
(0.7-1.3) 
0.01 
(nd-0.1) 
1 p < 0.001 p < 0.03 
2 Gb3(d18:1)(C24:1)Me * 10.2 
0.5 
(0.3-0.6) 
0.8 
(nd-2.4) 
0.2 
(0.04-1.0) 
nd 1 p < 0.001 p < 0.04 
2 Gb3(d18:1)(C24:0)Me k 10.5 
1.2 
(0.7-1.8) 
2.2 
(nd-6.4) 
nd nd 1 p < 0.001 p < 0.03 
3 
Gb3(d18:1)(C16:1) + 
Gb3(d18:2)(C16:0) 
1 8.4 
10.6 
(7.8-13.0) 
nd 
2.2 
(1.7-3.5) 
nd 1 p < 0.001 na 
3 
Gb3(d18:1)(C18:1) + 
Gb3(d18:2)(C18:0) 
2 8.9 
3.3 
(2.1-5.0) 
nd 
0.7 
(0.5-1.1) 
nd 1 p < 0.001 na 
3 
Gb3(d18:1)(C20:1) + 
Gb3(d18:2)(C20:0) 
l 9.4 
3.5 
(2.3-4.6) 
0.9 
(0.02-4.1) 
1.0 
(0.7-1.8) 
nd 1 p < 0.001 p < 0.001 
3 
Gb3(d18:1)(C22:1) + 
Gb3(d18:2)(C22:0) 
m 9.8 
10.2 
(7.1-16.0) 
4.5 
(0.1-18.4) 
3.6 
(2.2-5.3) 
nd 1 p < 0.001 p < 0.003 
3 
Gb3(d18:1)(C24:1) + 
Gb3(d18:2)(C24:0) 
n 10.1 
11.3 
(7.2-15.3) 
41.7 
(2.1-133.5) 
3.2 
(2.4-4.3) 
0.3  
(nd-1.5) 
1 p < 0.001 p < 0.001 
3 
Gb3(d18:1)(C26:1) + 
Gb3(d18:2)(C26:0) 
o 10.5 nd 
1.1 
(0.2-3.6) 
nd nd na na na 
4 Gb3(d18:0)(C24:1)H2O p 9.9 
1.5 
(1.0-2.1) 
2.1 
(0.2-8.0) 
0.5 
(0.2-0.7) 
nd 1 p < 0.001 p < 0.27 
5 
Gb3(d18:1)(C22:2) + 
Gb3(d18:2)(C22:1) 
3 9.5 
1.3 
(0.8-1.7) 
nd 
0.4 
(0.1-0.8) 
nd 0.989 p < 0.001 na 
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5 
Gb3(d18:1)(C24:2) + 
Gb3(d18:2)(C24:1) 
q 9.9 
11.9 
(8.5-16.5) 
5.7 
(0.2-27.0) 
4.1 
(3.1-6.6) 
nd 1 p < 0.001  p < 0.002 
6 
Gb3(d16:1)(C16:0) + 
Gb3(d18:1)(C14:0) 
4 8.3 
3.0 
(2.1-4.8) 
nd 
0.6 
(0.4-0.9) 
nd 1 p < 0.001 na 
7 
Gb3(d16:1)(C16:0)Me + 
Gb3(d18:1)(C14:0)Me 
5 8.5 
2.9 
(2.2-3.7) 
nd 
0.6 
(0.4-0.9) 
nd 1 p < 0.001 na 
- 
Not yet identified  
(m/z 1042.74) 
6 8.5 
1.1 
(0.7-1.4) 
nd 
0.2 
(0.1-0.4) 
nd 1 p < 0.001 na 
- 
Not yet identified 
(m/z 1018.64) 
7 8.3 
1.9 
(1.4-3.2) 
nd 
0.3 
(0.01-0.5) 
nd 1 p < 0.001 na 
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The biomarkers detected during this study have been classified into categories. 
The majority of biomarkers detected were able to be classified into one of the 
five existing categories described by Auray-Blais and Boutin (2012). However, 
two additional categories have been created specifically for plasma Gb3-related 
analogs/isoforms, resulting in the following seven categories: 1) Gb3-related 
isoforms with saturated fatty acids; 2) Methylated Gb3-related isoforms; 3) Gb3-
related isoforms/analogs with one double bond; 4) Gb3 analogs with an 
hydrated sphingosine; 5) Gb3-related isoforms/analogs with two double bonds; 
6) Short chain Gb3-related isoforms/analogs; and 7) Short chain methylated 
Gb3-related isoforms/analogs.  
Area under the ROC curve (AUC) data were also calculated for each Gb3-
related analog and isoform detected in plasma from untreated Fabry males and 
values are displayed in Table 4.1. For the majority of Gb3-related 
analogs/isoforms an AUC value of 1 was obtained. Only one biomarker 
displayed an AUC value of less than 1, this biomarker in category 5, 
Gb3(d18:1)(C22:2)+Gb3(d18:2)(C22:1), obtained an AUC value of 0.989.  
 
4.2.5  Gb3-related metabolites present in plasma that have previously 
been identified in urine 
 
Within the first five categories of biomarker, seventeen had previously been 
identified in urine (Auray-Blais and Boutin 2012). In category 1, one saturated 
Gb3 isoform Gb3(d18:1)(C16:0) was highly excreted compared to the excretion 
of all other Gb3 isoforms with saturated fatty acids. In category 2, the extent of 
methylation was greatest for the isoform Gb3(d18:1)(C22:0)Me. No detectable 
levels of methylation were observed for the isoform Gb3(d18:1)(C18:0)Me 
previously identified in urine and the least amount of methylation was observed 
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on the isoform Gb3(d18:1)(C16:0)Me, the most excreted saturated Gb3 isoform 
in category 1. The structural isomer mixture Gb3(d18:1)(C24:1) + 
Gb3(d18:2)(C24:0) was the most highly excreted in category 3 whilst the lowest 
levels of excretion in plasma were observed for the structural isomer 
Gb3(d18:1)(C26:1) + Gb3(d18:2)(C26:0). In categories 4 and 5, the Gb3 
hydrated at the sphingosine level and the mixture of isoforms with two double 
bonds Gb3(d18:1)(C24:2) + Gb3(d18:2)(C24:1) present in urine were both also 
detected in plasma.  
All biomarkers were shown to be statistically and significantly elevated (p 
<0.001) in plasma from untreated Fabry males as compared to healthy control 
reference plasma specimens following t-test analyses (Table 4.1). In addition, 
statistical and significant differences were also observed in the extent of 
excretion of the biomarkers between plasma and urine in Fabry patients. The 
excretion of the biomarkers, Gb3(d18:1)(C16:0), Gb3(d18:1)(C18:0), 
Gb3(d18:1)(C20:1) + Gb3(d18:2)(C20:0), Gb3(d18:1)(C22:1) + 
Gb3(d18:2)(C22:0) and Gb3(d18:1)(C24:2) + Gb3(d18:2)(C24:1) was 
significantly higher in plasma compared to urine. Whereas the biomarkers, 
Gb3(d18:1)(C22:0), Gb3(d18:1)(C24:0), Gb3(d18:1)(C26:0), 
Gb3(d18:1)(C20:0)Me, Gb3(d18:1)(C22:0)Me, Gb3(d18:1)(C24:1)Me, 
Gb3(d18:1)(C24:0)Me, Gb3(d18:1)(C24:1) + Gb3(d18:2)(C24:0) were 
significantly higher in urine compared to plasma.  
 
4.2.6 Structural characterisation of novel Fabry disease biomarkers in 
plasma    
 
In addition to the seventeen previously described Gb3-related analogs/isoforms 
detected in this study, seven new plasma Fabry disease biomarkers, not 
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detected in urine, were revealed by the S-plot (Figure 4.2B). These are shown 
highlighted in blue and annotated with a number. Data corresponding to the 
relative abundance of the biomarkers is shown in Table 4.1. To elucidate the 
structure of these seven new biomarkers, tandem mass spectrometry analyses 
were performed on a 500 µl plasma sample from an untreated Fabry male (as 
described in section 2.2.6.8). Of these seven potential new biomarkers, five 
showed fragmentation profiles similar to Gb3 and were therefore considered to 
be structurally related to Gb3. Exact mass and empirical formula of Gb3 analogs 
and fragments are shown in Figures 4.3 – 4.6. Of the seven newly detected 
biomarkers two, at m/z 1018.64 and m/z 1042.74, did not show fragmentation 
profiles similar to Gb3 and are therefore not considered to be related to Gb3. 
However, their abundance was too low to obtain a sufficient number of 
characteristic fragments with accurate mass measurements to allow their 
structural elucidation. The S-plot revealed six biomarkers belonging to category 
3, corresponding to Gb3 with an extra double bond. Among these, four had 
previously been detected in urine (C20 to C26). The two remaining biomarkers 
with m/z 1022.6701 (point 1 on the S-plot, Figure 4.2B) and m/z 1050.6637 
(point 2 on the S-plot, Figure 4.2B) correspond to Gb3 with C16 and C18 fatty 
acid chains, respectively. Figure 4.3 presents the fragmentation spectrum and 
Table 4.2 presents the exact mass and empirical formula of the peaks detected 
for the biomarker with the C16 fatty acid. This biomarker presents a mixture of 
two structural isomers, one with the extra double bond on the sphingosine 
(Gb3(d18:2)(C16:0)) and the other with the extra double bond on the fatty acid 
(Gb3(d18:1)(C16:1)).  
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Figure 4.3 ESI-QToF-MS fragmentation spectra of Gb3(d18:2)(C16:0) + 
Gb3(d18:1)(C16:1) 
 
Table 4.2 Exact mass and empirical formula of Gb3(d18:2)(C16:0) + 
Gb3(d18:1)(C16:1). Fragments observed in Figure 4.3. 
Fragment Formula 
Calculated 
Mass 
Da 
Measured 
Mass 
Da 
Δ Mass 
ppm 
A C52H96NO18 1022.6627 1022.6701 7.2 
B C52H94NO17 1004.6522 1004.6504 -1.8 
C C46H84NO12 842.5994 842.5850 -17.1 
D C40H74NO7 680.5465 680.5419 -6.8 
E C34H66NO3 536.5043 536.5037 -1.1 
F C34H64NO2 518.4937 518.4956 3.7 
G C34H62NO 500.4831 500.4839 1.6 
H C18H34NO 280.2640 280.2654 5.0 
I C18H34N 264.2691 264.2690 -0.4 
J C18H32N 262.2535 262.2543 3.1 
K C16H34NO 256.2640 256.2632 -3.1 
 
In Figure 4.3 peak A corresponds to the molecular ion and peak B the 
dehydrated molecular ion. Peaks B, C, D and F are each separated by 162 Da 
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(C6H10O5) corresponding to the consecutive loss of the three sugar units 
(galactose, galactose, glucose) to generate the dehydrated ceramide (peak F). 
This fragmentation profile was also observed for all the other fragmentation 
spectra shown in Figures 4.4 – 4.6, and will thus not be further described. The 
fragment corresponding to the ceramide (peak E) in Figure 4.3 then undergoes 
two consecutive dehydrations to generate peaks F and G. Peak H corresponds 
to the sphingosine with an extra double bond (d18:2). Unfortunately, the 
sensitivity was not sufficient enough to allow the observation of the d18;1 
sphingosine. In the mass spectrum, the presence of the two structural isomers 
is revealed by peaks J and I. These peaks separated by 2 Da, correspond 
respectively to dehydrated sphingosine with one extra double bond (d18:2-H2O) 
and regular dehydrated sphingosine (d18:1-H2O). Peak K corresponds to the 
saturated C16:0 fatty acid which is the counterpart of sphingosine with an extra 
double bond (d18:2). However, the sensitivity was not sufficient to observe the 
fatty acid with the extra double bond (C16:1), the counterpart of regular 
sphingosine (d18:1).  
The S-plot also revealed two biomarkers belonging to category 4, 
corresponding to Gb3 isoforms with two extra double bonds. The first (point p in 
Figure 4.2B) was previously observed in urine (Auray-Blais and Boutin 2012) 
and corresponds to the mixture of two structural isomers: one with one extra 
double bond on the sphingosine and one extra double bond on the fatty acid 
(Gb3(d18:2)(C24:1)), and the other with both extra double bonds on the fatty 
acid (Gb3(d18:1)(C24:2)). One Gb3 isoform with two extra double bonds and a 
C22 fatty acid was observed in plasma during this study but had not previously 
been detected in urine (point 3 in Figure 4.2B), the fragmentation profile of 
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which is shown in Figure 4.4 and the exact mass and empirical formulas of each 
detected peak are shown in Table 4.3. 
 
 
Figure 4.4  ESI-QToF-MS fragmentation spectra of Gb3(d18:1)(C22:2) + 
Gb3(d18:2)(C22:0) 
 
Table 4.3  Exact mass and empirical formula of Gb3(d18:1)(C22:2) + 
Gb3(d18:2)(C22:0). Fragments observed in Figure 4.4. 
 
Fragment Formula 
Calculated 
Mass 
Da 
Measured 
Mass 
Da 
Δ Mass 
ppm 
A C58H106NO18 1104.7410 1104.7417 0.6 
B C58H104NO17 1086.7366 1086.7366 0.0 
C C52H96NO13 942.6882 942.7061 19.0 
D C52H94NO12 924.6776 924.6943 18.1 
E C46H86NO8 780.6353 780.5909 -56.9 
F C46H84NO7 762.6248 762.6255 0.9 
G C40H76NO3 618.5825 618.5884 9.5 
H C40H74NO2 600.5720 600.5701 -3.2 
I C40H72NO 582.5614 582.5630 2.7 
J C18H36NO 282.2797 282.2796 -0.4 
K C18H34NO 280.2640 280.2677 13.2 
L C18H34N 264.2691 264.2651 -15.1 
M C18H32N 262.2535 262.2632 37.0 
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Peaks J and K in Figure 4.4 correspond to regular sphingosine (d18:1) and to 
sphingosine with one extra double bond (d18:2), respectively. Peaks L and M 
correspond to their dehydrated counterparts (d18:1-H2O and d18:2-H2O, 
respectively). Unfortunately the mass spectrum was not sufficiently sensitive to 
observe the peaks corresponding to the mono- and di-unsaturated fatty acid. 
However, the mass difference between the ceramide fragment (peak G) and the 
sphingosine fragments (d18:2) (peak K) and (d18:1) (peak J) allows the 
calculation of their fatty acid counterparts (C22:1) and (C22:2), respectively. 
Figure 4.5 shows the fragmentation profile and Table 4.4 displays the exact 
mass and empirical formula of the peaks obtained for the biomarker (point 4, 
Figure 4.2B) which corresponds to a mixture of two structural isomers: the first 
with a d16:1 sphingosine and a C16:0 fatty acid (Gb3(d16:1)(C16:0)) and the 
other with a d18:1 sphingosine and a C14:0 fatty acid (Gb3(d18:1)(C14:0)). 
These two isomeric biomarkers were considered as a short chain Gb3-related 
analog/isoform (Category 6). 
 
 
 
Figure 4.5 ESI-QToF-MS fragmentation spectra of Gb3(d16:1)(C16:0) + 
Gb3(d18:1)(C14:0). 
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Table 4.4 Exact mass and empirical formula of Gb3(d16:1)(C16:0) + 
Gb3(d18:1)(C14:0). Fragments observed in Figure 4.5.  
 
Fragment Formula 
Calculated 
Mass 
Da 
Measured 
Mass 
Da 
Δ Mass 
ppm 
A C50H94NO18 996.6741 996.6636 -16.6 
B C50H92NO17 978.6365 978.6511 14.9 
C C44H82NO12 816.5837 816.5922 10.4 
D C38H72NO7 654.5309 654.5290 -2.9 
E C32H62NO2 492.4781 492.4763 -3.7 
F C32H60NO 474.4675 474.4690 3.2 
G C18H36NO 282.2797 282.2761 -12.8 
H C18H34N 264.2691 264.2652 -14.8 
I C16H34NO 256.2640 256.2586 -21.1 
J C16H32NO 254.2484 254.2432 -20.5 
K C16H30N 236.2378 236.2340 -16.1 
L C14H30NO 228.2327 228.2358 13.6 
 
 
In Figure 4.5 peaks I, J and K correspond to the fatty acid fragment (C16:0), the 
sphingosine fragment (d16:1) and the dehydrated sphingosine fragment (d16:1-
H2O) of Gb3(d16:1)(C16:0), respectively. The peaks G, H and L correspond to 
the sphingosine fragment (d18:1), the dehydrated sphingosine fragment (d18:1-
H2O), and the fatty acid fragment (C14:0) of Gb3(d18:1)(C14:0), respectively. 
The Gb3(d16:1)(C16:0) analog shown in Figure 4.5 is also present in its 
methylated form. This biomarker is thus classified as a methylated short chain 
Gb3-related isoform/analog and falls into category 7. The Gb3(d16:1)(C16:0)Me 
fragmentation spectrum is shown in Figure 4.6 and the exact mass and 
empirical formulas of those peaks detected are shown in Table 4.5.  
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Figure 4.6 ESI-QToF-MS fragmentation spectra of Gb3(d16:1)(C16:0)Me + 
Gb3(d18:1)(C14:0)Me 
 
Table 4.5 Exact mass and empirical formula of Gb3(d16:1)(C16:1)Me + 
Gb3(d18:1)(C14:0)Me. Fragments observed in Figure 4.6. 
 
Fragment Formula 
Calculated 
Mass 
Da 
Measured 
Mass 
Da 
Δ Mass 
ppm 
A C51H96NO18 1010.6833 1010.6627 -20.4 
B C51H94NO17 992.6522 992.6709 18.8 
C C45H84NO12 830.5994 830.5991 -0.4 
D C39H74NO7 668.5465 668.5449 -2.4 
E C33H64NO2 506.4937 506.4904 -6.5 
F C33H62NO 488.4831 488.4799 -6.6 
G C18H34N 264.2691 264.2676 -5.7 
H C16H34NO 256.2640 256.2621 -7.4 
I C17H32N 250.2535 250.2534 -0.4 
J C16H30N 236.2378 236.2318 -25.4 
 
Peak I of Figure 4.6 corresponds to dehydrated methylated sphingosine 
(d16:1)Me-H2O) which loses its methyl group to generate the d16:1-H2O 
sphingosine (peak J), peak H corresponds to the C16:0 fatty acid fragment. The 
- 241 - 
 
peak at m/z 264.2746 is not attributed to the Gb3(d16:1)(C16:0)Me biomarker. It 
probably arises from another structural isomer. However, no other fragments 
from that molecule are present on the spectrum preventing the elucidation of its 
structure.      
 
4.2.7 Gb3-related metabolites present in plasma from untreated Fabry 
females  
 
Following the identification of Gb3-related analogs and isoforms in plasma from 
untreated Fabry males, the levels of these biomarkers were assessed in ten 
untreated Fabry females. Identification and relative area counts of all Gb3-
related analogs and isoforms were obtained using QuanLynx™. A summary of 
the data obtained is shown in Table 4.6. Of the Gb3-related analogs/isoforms 
previously detected in urine from untreated Fabry males, six were not 
detectable in plasma from untreated Fabry females. Of these two, 
Gb3(d18:1)(C18:0)Me and Gb3(d18:1)(C26:1) + Gb3(d18:2)(C26:0) were also 
undetectable in plasma from untreated Fabry males. All five of the newly 
identified Gb3-related isoforms/analogs detected in this study in plasma from 
untreated Fabry males were also identified in plasma from Fabry females. Four 
of these showed statistically significant elevations in excretion (p < 0.05) 
compared to an age- and sex-matched control group. One, Gb3(d16:1)(C16:0) + 
Gb3(d18:1)(C14:0) which showed the lowest levels of excretion was the only 
analog not found to be statistically and significantly elevated compared to the 
control group. AUC data were also calculated for each Gb3-related analog and 
isoform resulting in values ranging from 0.633 to 0.883.  
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Table 4.6 Retention time and relative abundance of the biomarkers in plasma from untreated Fabry females and healthy control 
females. Those biomarkers depicted in bold are novel biomarkers detected in this study. AUC: Area under the ROC curve for plasma. 
nd: not detectable; na: not applicable. 
Category Biomarkers 
Retention 
time (min) 
Fabry females mean 
(min-max) 
Control females mean 
(min-max) 
AUC t-test 
Plasma 
Plasma 
[Area] 
Plasma 
[Area] 
Plasma 
Fabry females vs 
 female control 
1 Gb3(d18:1)(C16:0) 8.8 
23.2 
(18.1-30.6) 
20.8 
(16.9-25.0) 
0.675 p < 0.16 
1 Gb3(d18:1)(C18:0) 9.2 
2.9 
(2.4-3.7) 
2.4 
(1.8-2.9) 
0.800 p < 0.007 
1 Gb3(d18:1)(C20:0) 9.7 
2.3 
(1.7-3.6) 
1.7 
(1.2-2.5) 
0.758 p < 0.02 
1 Gb3(d18:1)(C22:0) 10.1 
2.5 
(1.7-4.5) 
2.1 
(1.5-2.8) 
0.633 p < 0.15 
1 Gb3(d18:1)(C24:0) 10.4 
2.6 
(1.8-3.9) 
2.1 
(1.5-3.1) 
0.750 p < 0.06 
1 Gb3(d18:1)(C26:0) 10.7 nd nd na na 
2 Gb3(d18:1)(C16:0)Me 9.0 nd nd na na 
2 Gb3(d18:1)(C18:0)Me 9.5 nd nd na na 
2 Gb3(d18:1)(C20:0)Me 9.9 
0.5 
(0.2-0.9) 
0.3 
(nd-0.6) 
0.742 p < 0.02 
2 Gb3(d18:1)(C22:1)Me 9.9 nd nd na na 
2 Gb3(d18:1)(C22:0)Me 10.3 
1.6 
(1.0-3.6) 
0.1 
(0.8-1.4) 
0.783 p < 0.04 
2 Gb3(d18:1)(C24:1)Me 10.2 nd nd na na 
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2 Gb3(d18:1)(C24:0)Me 10.5 
0.4 
(0.1-1.1) 
0.1 
(nd-0.4) 
0.850 p < 0.01 
3 
Gb3(d18:1)(C16:1) + 
Gb3(d18:2)(C16:0) 
8.4 
5.2 
(2.9-14.6) 
2.9 
(1.6-4.7) 
0.858 p < 0.05 
3 
Gb3(d18:1)(C18:1) + 
Gb3(d18:2)(C18:0) 
8.9 
1.5 
(0.8-3.0) 
0.9 
(0.6-1.1) 
0.883 p < 0.01 
3 
Gb3(d18:1)(C20:1) + 
Gb3(d18:2)(C20:0) 
9.4 
1.8 
(1.3-2.9) 
1.4 
(0.9-2.2) 
0.792 p < 0.03 
3 
Gb3(d18:1)(C22:1) + 
Gb3(d18:2)(C22:0) 
9.8 
6.1 
(4.3-8.9) 
4.1 
(3.0-5.8) 
0.875 p < 0.003 
3 
Gb3(d18:1)(C24:1) + 
Gb3(d18:2)(C24:0) 
10.1 
3.9 
(2.4-8.3) 
2.7 
(1.9-4.0) 
0.742 p < 0.07 
3 
Gb3(d18:1)(C26:1) + 
Gb3(d18:2)(C26:0) 
10.5 nd nd na na 
4 Gb3(d18:0)(C24:1)H2O 9.9 
0.7 
(0.4-1.3) 
0.5 
(0.3-0.7) 
0.717 p < 0.06 
5 
Gb3(d18:1)(C22:2) + 
Gb3(d18:2)(C22:1) 
9.5 
0.6 
(0.3-1.1) 
0.4 
(0.1-0.6) 
0.817 p < 0.01 
5 
Gb3(d18:1)(C24:2) + 
Gb3(d18:2)(C24:1) 
9.9 
1.0 
(0.3-1.1) 
4.2 
(3.0-6.4) 
0.817 p < 0.01 
6 
Gb3(d16:1)(C16:0) + 
Gb3(d18:1)(C14:0) 
8.3 
1.3 
(0.5-3.2) 
0.9 
(0.6-1.3) 
0.650 p < 0.14 
7 
Gb3(d16:1)(C16:0)Me + 
Gb3(d18:1)(C14:0)Me 
8.5 
1.2 
(0.5-2.9) 
0.7 
(nd-1.2) 
0.758 p < 0.04 
- 
Not yet identified  
(m/z 1042.74) 
8.5 
0.3 
(nd-0.5) 
0.2 
(0.1-0.4) 
0.717 p < 0.15 
- 
Not yet identified 
(m/z 1018.64) 
8.3 
0.9 
(0.5-1.4) 
0.7 
(0.3-1.2) 
0.758 p < 0.06 
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4.3 Discussion 
 
Using a mass-spectrometry based metabolomic methodology 14,514 markers 
were detected from the plasma of twelve untreated Fabry males and eight age-
and sex-matched healthy controls. The creation of an OPLS-DA score plot 
demonstrated that one male Fabry patient (Patient 12, Table 2.3) fell outside 
the Hotelling T2 ellipse, this patient was thus considered an outlier and excluded 
from the multivariate statistical analysis. This patient displayed both low urinary 
Gb3 and lyso-Gb3 excretion (Table 2.3) therefore, low Gb3-related biomarker 
excretion would be expected. Further statistical analyses of this data set 
revealed a goodness of fit value approaching unity (R2 = 0.815). However, the 
predicted variation value obtained (Q2 = 0.383) was low compared to the 
goodness of fit which may be due to the presence of some extreme values 
within the data set.  
Of the potential biomarkers of interest identified by the S-plot (Figure 4.2), the 
majority had previously been identified in the urine of Fabry patients (Auray-
Blais and Boutin 2012). However, seven potential new biomarkers were also 
detected and following structural elucidation and characterisation, five were 
found to be Gb3-related analogs/isoforms and assigned to one of seven 
categories.  
All biomarkers within category 1 had been identified previously in urine. 
However, the excretion profiles observed for these saturated Gb3 isoforms 
differs significantly between urine and plasma. The saturated Gb3 isoform    
Gb3(d18:1)(C16:0) was the most highly excreted in plasma, from both males 
and females with Fabry disease, compared to the excretion of all other Gb3 
isoforms with saturated fatty acids. This differs from the urinary Gb3 profile of 
Fabry patients where Gb3(d18:1)(C22:0) and Gb3(d18:1)(C24:0) are the most 
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highly excreted. The excretion of all saturated Gb3 isoforms in plasma from 
Fabry males was shown to be statistically and significantly elevated compared 
to an age- and sex-matched control group. However, in Fabry females, only the 
excretion of the saturated Gb3 isoforms Gb3(d18:1)(C18:0) and 
Gb3(d18:1)(C20:0) reached statistical significance. Differences in excretion 
profiles in Fabry patients have previously been described and the findings in 
this study are in accordance with the literature (Kitagawa et al., 2005). 
In category 2, the levels of excretion of the methylated Gb3-related isoforms are 
statistically and significantly elevated in urine from Fabry males compared to the 
excretion levels detected in plasma from Fabry males, for all but the 
Gb3(d18:1)(C22:1)Me isoform. However, the excretion profiles observed for the 
two biological matrices are similar. The extent of methylation observed in 
plasma from both Fabry males and females was greatest for the isoform 
Gb3(d18:1)(C22:0)Me, the same as that observed in urine (Auray-Blais and 
Boutin 2012). The least amount of methylation in plasma from Fabry males was 
observed for the Gb3(d18:1)(C16:0)Me isoform, with no detectable levels of 
excretion for this isoform in Fabry females, however, this is the most excreted 
saturated Gb3 isoform in both males and females in category 1. This shows that 
the level of methylated Gb3 is not proportional to the level of its un-methylated 
counterpart. No detectable levels of excretion were observed in plasma from 
Fabry males or females for the methylated Gb3-related isoform 
Gb3(d18:1)(C18:0)Me, which also displayed the lowest levels of excretion in 
urine (Auray-Blais and Boutin 2012). In addition, no detectable levels of 
excretion were observed in plasma from Fabry females for Gb3(d18:1)(C22:1) 
or Gb3(d18:1)(C24:1). 
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Two new biomarkers detected in this study, Gb3(d18:1)(C16:1) + 
Gb3(d18:2)(C16:0) and Gb3(d18:1)(C18:1) + Gb3(d18:2)(C18:0), which were not 
previously identified in urine were assigned to category 3. One of these 
structural isomer mixtures, Gb3(d18:1)(C16:1) + Gb3(d18:2)(C16:0) was among 
the most highly excreted in this category as well as the structural isomer 
mixtures, Gb3(d18:1)(C22:1) + Gb3(d18:2)(C22:0) and Gb3(d18:1)(C24:1) + 
Gb3(d18:2)(C24:0), the latter of which was also the most highly excreted in 
urine. The structural isomer mixture Gb3(d18:1)(C26:1) + Gb3(d18:2)(C26:0) 
showed the lowest levels of excretion in plasma from Fabry males whilst it was 
undetectable in Fabry females. This differs to findings in urine where 
Gb3(d18:1)(C20:1) + Gb3(d18:2)(C22:0) showed the least amount of excretion.  
In category 4, the Gb3 hydrated at the sphingosine level, 
Gb3(d18:0)(C24:1)H2O, identified previously and which showed moderate 
excretion in urine, showed similar levels of excretion in plasma from Fabry 
males whilst lower levels of excretion were observed in plasma from Fabry 
females. This biomarker was shown to be statistically elevated in plasma from 
Fabry males (p < 0.0001) compared to an age- and sex-matched control group 
however, levels in Fabry females failed to reach statistical significance (p < 
0.06).  
Another biomarker detected during this study which comprised a mixture of 
isoforms with two double bonds, Gb3(d18:1)(C22:2) + Gb3(d18:2)(C22:1), was 
added to category 5. Although this biomarker displayed low levels of excretion 
in plasma from both male and female Fabry patients, levels were statistically 
and significantly elevated above their respective age- and sex-matched control 
groups. It was however, the other biomarker in this category, Gb3(d18:1)(C24:2) 
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+ Gb3(d18:2)(C24:1), that had been previously identified in urine which 
displayed the highest levels of excretion in plasma.  
The identification during this study of two new biomarkers, Gb3(d16:1)(C16:0) + 
Gb3(d18:1)(C14:0) and its methylated counterpart, required the creation of two 
additional categories, category 6) short chain Gb3-related isoforms/analogs and 
category 7) short chain methylated Gb3-related isoforms/analogs. Whilst 
previous studies have demonstrated the presence of lyso-Gb3 with d16:1 
sphingosine in the urine (Auray-Blais et al., 2012) and plasma (Dupont et al., 
2013) of Fabry patients this is the first study to report a Gb3 analog with a d16:1 
sphingosine moiety. Gb3 analogs with a d16:1 sphingosine moiety or a C14:0 
fatty acid were not detected in the urine of Fabry patients (Auray-Blais and 
Boutin 2012). In the case of the structural isomer mixture Gb3(d16:1)(C16:0) + 
Gb3(d18:1)(C14:0), the Gb3(d16:1)(C16:0) isomer becomes significantly more 
abundant compared to Gb3(d18:1)(C14:0) due to the fact that the C16:0 fatty 
acid was found to be considerably more abundant than the C14:0 fatty acid.   
The short chain methylated Gb3-related analog/isoform, Gb3(d16:1)(C16:0)Me + 
Gb3(d18:1)(C14:0)Me was also detected during this study. Although the 
fragmentation spectra generated was limited, confirmation of the structure of 
this biomarker was obtained due to the fact that in nature, an even number of 
carbons are present in the fatty acid backbone and therefore in the sphingosine 
backbone, which is constructed from fatty acids. Owing to this, the presence of 
the methylation was additionally confirmed by the detection of the methylated 
ceramide fragment containing an odd number of carbons in its empirical formula 
(C33H64NO2).  
Whilst the Gb3 analog with a d16:1 sphingosine moiety was only found to be 
significantly elevated in the plasma of Fabry males, its methylated counterpart 
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was statistically and significantly elevated in the plasma of both male (p < 
0.0001) and female (p < 0.04) Fabry patients compared to their respective 
control groups.  
Area under the curve (AUC) values were obtained for each of the Gb3-related 
analogs and isoforms in both untreated Fabry males and females. An AUC of 1 
indicates complete discrimination between patients and controls whereas 0.5 
indicates no discrimination. Complete discrimination was observed for the 
majority of biomarkers detected in the untreated Fabry males. Only one 
biomarker, Gb3(d18:1)(C22:2) + Gb3(d18:2)(C22:1), displayed an AUC value of 
less than 1 (AUC = 0.989). The AUC values obtained for the Gb3-related 
analogs and isoforms in Fabry females showed a more variable discrimination 
with complete discrimination between patients and controls unachievable in any 
of the biomarkers (AUC values ranging from 0.633 to 0.883). This variability 
further confirms that women are often less severely affected than their male 
counterparts.        
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4.4 Conclusion 
 
This metabolomic study has used time-of-flight mass spectrometry focusing on 
Gb3 isoforms/analogues with m/z ratios between 995 and 1200 Da to identify 
new and existing biomarkers in the plasma of Fabry disease patients. 
Seventeen biomarkers revealed by the S-plot were isoforms/analogues of Gb3 
that had been previously detected in the urine of Fabry patients (Auray-Blais 
and Boutin 2012). This enabled relative concentrations of these biomarkers in 
plasma to be obtained and statistical analyses performed. Statistical and 
significant elevations in the excretion of all of these biomarkers were observed 
in the plasma of treatment naïve male Fabry disease patients compared to an 
age- and sex-matched control group. In addition, significant differences in the 
levels of excretion of these biomarkers between the biological matrices, urine 
and plasma, are apparent.     
Five novel biomarkers were also identified and characterised as 
analogues/isoforms of Gb3. Three of these new biomarkers correspond to Gb3 
having an extra double bond on the sphingosine chain (d18:2) with C16:0, 
C18:0 and C22:1 fatty acids. The fourth biomarker corresponds to a mixture of 
two structural isomers, the first with a d16:1 sphingosine and a C16:0 fatty acid 
and the second with a d18:1 sphingosine and a C14:0 fatty acid. This is the first 
time that a Gb3 analogue with a d16:1 sphingosine moiety has been reported. In 
addition, this Gb3 analogue was also present in its methylated form. Further 
studies are needed in order to better understand the underlying metabolic 
process occurring in Fabry patients. However, considering the presence and 
also the important variation in the relative quantification of these biomarkers in 
plasma compared to urine, assessment and monitoring could provide further 
insights than measurement of Gb3 and/or lyso-Gb3 alone.     
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5.0 Investigation of globotriaosylceramide (Gb3) and globotriaosyl-
sphingosine (lyso-Gb3) toxicity in the Fabry mouse model 
 
5.1 Introduction 
 
In the study described in Chapter 4, a number of new and existing Gb3-related 
biomarkers were identified in the plasma of Fabry disease patients using a 
metabolomic methodology. In Fabry disease a deficiency of the enzyme α-
galactosidase A (α-GAL) results in the accumulation of Gb3 as the primary 
metabolite. However, in a number of patients the level of stored Gb3 does not 
always correlate with the presenting clinical symptoms (Mills et al., 2004; 
Linhart 2006). Therefore, this study aimed to identify proteins which interact with 
Gb3 in order to gain a better understanding of the underlying disease 
mechanisms associated with disease pathology.  
Authentic animal models are required for studies to enable progression in our 
understanding of the underlying pathological mechanisms associated with 
Fabry disease that, for ethical and practical reasons, are not able to be 
completed in humans. In nature, lysosomal storage disorders are known to 
occur in both dogs and cats, inherited in an autosomal recessive manner, as 
they are in humans. However, to date no large animal model for Fabry disease 
has been discovered (Haskins, Giger and Patterson 2006). This has resulted in 
the development of a knockout mouse model for Fabry disease which displays 
a complete lack of α-GAL activity (Ohshima et al., 1997). However, in contrast 
to the painful small-fibre peripheral neuropathy, renal, cerebral and 
cardiovascular dysfunction that are experienced in humans as a result of the 
absence of α-GAL, Fabry knockout mice appear clinically normal and have a 
normal adult lifespan (Ohshima et al., 1997; Ohshima et al., 1999). Studies 
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have however, demonstrated an accumulation of Gb3 and lyso-Gb3 in the urine, 
plasma and tissues of these mice (Ohshima et al., 1997; Ohshima et al., 1999; 
Ioannou et al., 2001; Shiozuka et al., 2011; Durant et al., 2011). In addition, 
lamellar inclusions have been observed in the lysosomes of Kupffer cells and 
also hepatocytes of affected mice. Increased numbers of lamellar bodies within 
proximal and distal tubular cells, as well as within glomerular epithelial cells and 
peripheral tubular capillary endothelial cells have also been reported (Haskins, 
Giger, and Patterson 2006).      
In the present study, a label-free proteomic methodology was used to create a 
proteomic profile of Fabry mice tissues (liver, kidney, heart and brain). Data 
obtained during the label-free study was analysed, using two different software 
platforms, and a number of proteins that were identified as altered by both 
analysis methods were selected for further investigation. Protein interactions 
with molecules in the glycosphingolipid biosynthetic pathway and with particular 
interest on Gb3 were also investigated. The results of this aspect of the study 
led to the assessment of touch thresholds in mice following exposure to Gb3 
and lyso-Gb3. In addition, the effect of glycosphingolipids and their deacylated 
counterparts on ATP synthase activity has been investigated.   
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5.2  Results 
 
5.2.1  Gb3 and lyso-Gb3 analyses in the tissues of a Fabry mouse 
model 
 
Gb3 and lyso-Gb3 analyses were performed on all male, female and control 
mouse tissue samples (liver, kidney, heart and brain) as described in Section 
2.2.1. Both Gb3 (Figure 5.1) and lyso-Gb3 (Figure 5.2) concentrations were 
found to be significantly elevated (p < 0.05) in all tissue types compared to their 
respective control group. 
 
   
 
Figure 5.1 Globotriaosylceramide (Gb3) concentrations in male, female 
and control mouse, liver, kidney, heart and brain tissue.  Data expressed as 
mean ± SD. * p < 0.05; ** p < 0.01. 
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Figure 5.2 Globotriaosylsphingosine (lyso-Gb3) concentrations in male, 
female and control mouse, liver, kidney, heart and brain tissue.  Data 
expressed as mean ± SD. * p < 0.05; ** p < 0.01. 
 
5.2.2  Proteomic profiling of tissues from a Fabry mouse model 
 
The liver, kidney, heart and brain of three Fabry mice were homogenised as 
described in section 2.2.7.1.1. In order to reduce biological variation, 
homogenised tissue samples were pooled and subsequently fractionated to 
achieve the highest possible proteome coverage (see section 2.2.7.1.2). A MSE 
label-free quantitative proteomic methodology using UPLC-QToF-MS (section 
2.2.5.6) was used to analyse all tissue fractions and data acquired was 
processed by ProteinLynx Global Server version 2.4 (ProteinLynx; Waters 
Corp.) as described in section 2.2.7.1.3. Using this methodology a total of 5280 
proteins were detected in Fabry and/or control mouse tissues. In addition, the 
data was also analysed using Progenesis LC-MS (Nonlinear Dynamics, Waters 
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Corp.), a data analysis program which identifies and quantifies peptides and 
proteins detected in label-free analyses based on ion abundance (see section 
2.2.7.1.3). This software uses a ‘quantify-then-identify’ approach which 
promotes identification of low abundance proteins. Using this technique 3950 
proteins were identified in the tissues from Fabry and/or control mice. 
Differences between groups were assessed by identifying fold changes greater 
than two.  
 
5.2.2.1 Analysis of liver tissues from a Fabry mouse model 
 
Data analysis with ProteinLynx identified a total of 1060 proteins in liver tissues 
from Fabry and/or control mice. Twenty-three of the 1060 proteins detected 
were found to have a greater than two-fold alteration in both male and female 
Fabry mice compared to levels observed in the control group (Table 5.1). Of 
these 23 proteins, 7 were found to have levels greater than two-fold increased 
and 16 proteins were found to have levels greater than two-fold decreased.  
The levels of 1037 of the 1060 proteins detected using ProteinLynx displayed 
no fold change alterations between both the male and female Fabry and control 
mice groups.  
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Table 5.1 Proteins detected as altered by a fold change greater than two in 
liver tissues of male and female Fabry mice by ProteinLynx. FM = Fabry 
mice 
 
Description 
Control 
fmol/mg 
protein 
Male FM 
fmol/mg 
protein 
Fold 
change 
Female FM 
fmol/mg 
protein 
Fold 
change 
↑ or ↓ 
28S ribosomal protein S10, 
mitochondrial 
1.3 0.0 Infinity 0.0 Infinity ↓  
60S acidic ribosomal protein P2 5.6 0.0 Infinity 0.0 Infinity ↓  
Agmatinase, mitochondrial 193.9 34.0 5.71 19.5 10.0 ↓  
Alcohol dehydrogenase 1 137.5 0.0 Infinity 0.0 Infinity ↓  
Aldehyde dehydrogenase family 
8 member A1 
227.0 0.0 Infinity 30.9 7.3 ↓  
Arginase-1 18.3 715.8 39.11 219.7 12.0 ↑  
Aspartate aminotransferase, 
mitochondrial  
0.0 92.0 Infinity 51.9 Infinity ↑  
ATP-binding cassette sub-family 
D member 3 
13.6 6.7 2.03 0.0 Infinity ↑  
ATP synthase subunit beta, 
mitochondrial 
0.0 63.3 Infinity 40.5 Infinity ↑  
Cbp/p300-interacting 
transactivator 4 
2.4 0.0 Infinity 0.0 Infinity ↓  
Coiled-coil domain-containing 
protein 45  
26.8 0.0 Infinity 0.0 Infinity ↓  
Fructose-1, 6-bisphosphatase 1 126.0 0.0 Infinity 0.0 Infinity ↓  
Fumarylacetoacetase 0.0 37.0 Infinity 104.1 Infinity ↑  
Glutamate dehydrogenase1, 
mitochondrial  
0.0 7.6 Infinity 8.8 Infinity ↑  
Glyceraldehyde-3-phosphate 
dehydrogenase 
32.3 0.0 Infinity 9.7 3.3 ↓  
Kinesin-1 heavy chain  1.7 0.0 Infinity 0.0 Infinity ↓  
NADH dehydrogenase 
[ubiquinone] flavoprotein 1, 
mitochondrial 
171.0 0.0 Infinity 0.0 Infinity ↓ 
Ornithine aminotransferase, 
mitochondrial  
0.0 97.6 Infinity 12.8 Infinity ↑  
Pyruvate dehydrogenase protein 
X component, mitochondrial 
7.8 0.0 Infinity 0.0 Infinity ↓  
Ribonuclease UK114 10.6 205.4 19.41 137.8 13.0 ↑  
Ribosomal protein, large, P0 10.9 0.0 Infinity 0.0 Infinity ↓  
S-adenosylmethionine 
synthetase isoform type-1 
28.2 0.0 Infinity 0.0 Infinity ↓  
Ubiquitin subunit 1  10.4 0.0 Infinity 0.0 Infinity ↓  
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When data were analysed using the Progenesis LC-MS software a total of 720 
proteins were detected in liver tissue from Fabry and/or control mice. Of the 720 
proteins detected, 9 were found to have greater that two-fold alterations in the 
average normalised abundance detected in both male and female Fabry mice, 
compared to those levels detected for the control group (Table 5.2). Of the 9 
proteins found to be altered in both male and female Fabry mice, a greater than 
two-fold elevation was detected in 4 proteins and a greater than two-fold 
reduction was detected in 5 proteins.  
The average normalised abundance of 711 of the 720 proteins detected by 
Progenesis LC-MS did not display fold change alterations between both the 
male and female Fabry and control mice groups.   
 
Table 5.2 Proteins detected as altered by a fold change greater than two in 
liver tissues of male and female Fabry mice by Progenesis LC-MS. FM = 
Fabry mice; ANA = Average normalised abundance 
 
Description 
Control 
ANA 
Male FM 
ANA 
Fold 
change 
Female FM 
ANA 
Fold 
change 
↑ or ↓ 
Agmatinase, mitochondrial 3069.9 1240.4 2.5 1036.2 3.0 ↓  
ATP synthase subunit beta, 
mitochondrial 
3315.2 6989.6 2.1 7388.7 2.2 ↑  
Calcium-binding mitochondrial 
carrier protein Aralar2 
63.2 0.0 Infinity 0.5 131.8 ↓  
Catalase 347.7 1133.0 3.3 2131.0 6.1 ↑  
Elongation factor 1-alpha 1 630.1 0.0 Infinity 8.8 71.8 ↓  
Inositol polyphosphate 5- 
phosphatase K 
1159.8 215.6 5.4 250.7 4.6 ↓  
L-lactate dehydrogenase A 
chain 
24.8 49.8 2.0 241.2 9.7 ↑  
Mitofusin-1 87.2 25.0 3.5 0.0 Infinity ↓  
Ribonuclease UK114 7985.8 17100.0 2.1 16600.0 2.1 ↑  
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When results obtained from liver tissues using ProteinLynx and Progenesis LC-
MS were cross referenced 3 proteins were confirmed by both analysis methods 
as showing fold change alterations. Of these 3 proteins, ATP synthase subunit 
beta (mitochondrial) and ribonuclease UK114, were detected to have greater 
than two-fold increases in both male and female Fabry mice compared to that of 
the control group (Figure 5.3). ATP synthase subunit beta (mitochondrial), 
which together with the alpha subunit forms the catalytic core in the F1 portion 
of ATP synthase (Figure 5.23), was not detected in control tissue by the 
ProteinLynx software but was detected in both male and female Fabry mice. 
Using Progenesis LC-MS this protein was detected to be increased 2.1-fold and 
2.2-fold in male and female Fabry mice liver tissues, respectively. Ribonuclease 
UK114 is an endoribonuclease responsible for inhibiting translation by cleaving 
mRNA and this protein was also found to be increased by both analysis 
methods. Using ProteinLynx increases of 19.4-fold in male and 13.0-fold in 
female Fabry mice were detected. Using Progenesis-LC/MS the same protein 
was found to be increased in male Fabry mice 2.1-fold with increases of 2.1-fold 
detected in female Fabry mice. 
Agmatinase (mitochondrial), which is responsible for the hydrolysis of agmatine 
to putrescine and urea, was the only protein found to be decreased in liver 
tissues of both male and female Fabry mice by both analysis methods. Using 
ProteinLynx reductions of 5.7-fold in male and 10.0-fold in female Fabry mice 
were detected. Using Progenesis LC-MS, agmatinase (mitochondrial) was 
found to be 2.5-fold and 3.0-fold reduced in male and female Fabry mice, 
respectively. 
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Figure 5.3 Proteins detected as showing a greater than two-fold alteration in pooled liver tissues from both male Fabry mice (n 
= 3) and female Fabry mice (n = 3) by a.) ProteinLynx and; b.) Progenesis LC-MS  
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5.2.2.2 Analysis of kidney tissues from a Fabry mouse model 
 
Data analysis of kidney tissues with ProteinLynx identified a total of 353 
proteins in Fabry and/or control mice. Of the 353 proteins detected in kidney 
tissue, 8 were found to have levels displaying a greater than two-fold alteration 
in both male and female Fabry mice, compared to levels detected in the control 
group (Table 5.3). Increases greater than two-fold above levels detected in 
control mice were detected in 3 proteins, with 5 proteins having levels greater 
than two-fold decreased below that of the control group.   
The levels of 345 of the 353 proteins detected using ProteinLynx displayed no 
fold change alterations between both the male and female Fabry and control 
mice groups.  
 
Table 5.3 Proteins detected as altered by a fold change greater than two in 
kidney tissues of male and female Fabry mice by ProteinLynx. FM = Fabry 
mice 
 
Description 
Control 
fmol/mg 
protein 
Male FM 
fmol/mg 
protein 
Fold 
change 
Female FM 
fmol/mg 
protein 
Fold 
change 
↑ or ↓ 
ATP synthase subunit beta, 
mitochondrial 
17.9 36.6 2.0 55.6 3.1 ↑  
Beta-actin FE-3  27.8 59.0 2.1 105.9 3.8 ↑  
Dyslexia susceptibility 1 
candidate gene 1 protein 
homolog 
7.3 0.0 Infinity 0.0 Infinity ↓  
Epidermal growth factor receptor 1.1 0.0 Infinity 0.0 Infinity ↓  
GRAM domain-containing 
protein 1B 
61.0 0.0 Infinity 0.0 Infinity ↓ 
Lmo7 protein 38.5 0.0 Infinity 0.0 Infinity ↓ 
Ribonuclease UK114 11.8 36.4 3.1 44.5 3.8 ↑  
Serine protease inhibitor A3K 8.0 0.0 Infinity 0.0 Infinity ↓  
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Following analysis with the Progenesis LC-MS software 171 proteins were 
detected in kidney tissue from Fabry and/or control mice. Of the 171 proteins 
detected, 10 were found to have greater than two-fold increases in the average 
normalised abundance of both male and female Fabry mice compared to those 
levels observed in the control group (Table 5.4). No protein was found to display 
a greater than two-fold decrease in both male and female Fabry mice compared 
to the control group. 
The average normalised abundance of 161 of the 171 proteins detected by 
Progenesis LC-MS did not display fold change alterations between both the 
male and female Fabry and control mice groups.   
 
Table 5.4 Proteins detected as altered by a fold change greater than two in 
kidney tissues of male and female Fabry mice by Progenesis LC-MS. FM = 
Fabry mice; ANA = average normalised abundance.   
 
Description 
Control 
ANA 
Male FM 
ANA 
Fold 
change 
Female FM 
ANA 
Fold 
change 
↑ or ↓ 
Actin, aortic smooth muscle 64.3 3595.2 56.0 2321.8 36.1 ↑  
ATP synthase subunit alpha, 
mitochondrial 
25.2 2010.5 79.9 558.1 22.2 ↑  
ATP synthase subunit beta, 
mitochondrial 
0.0 328.1 Infinity 481.5 Infinity ↑  
Complement component 1 Q 
subcomponent-binding protein, 
mitochondrial 
0.0 291.2 Infinity 49.4 Infinity ↑  
Fructose-1,6-bisphosphatase 1 0.0 315.1 Infinity 132.3 Infinity ↑  
Fumarylacetoacetase 0.0 73.2 Infinity 57.2 Infinity ↑  
Myelin proteolipid protein 0.0 90.6 Infinity 44.6 Infinity ↑  
Myosin-9 0.0 16.1 Infinity 189.1 Infinity ↑  
Ribonuclease UK114 2358.1 12300.0 5.2 6056.1 2.6 ↑  
Sodium/potassium-transporting 
ATPase subunit alpha-2 
0.0 464.3 Infinity 89.6 Infinity ↑  
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When data obtained from ProteinLynx and Progenesis LC-MS analyses were 
cross-referenced two proteins, ATP synthase subunit beta (mitochondrial) and 
ribonuclease UK114, were detected as having fold change increases in both 
male and female Fabry mice compared to levels observed in the control group 
(Figure 5.4). Interestingly, these proteins were the same proteins detected as 
showing increases in liver tissues from both male and female Fabry mice. In 
kidney tissues elevations in ATP synthase subunit beta (mitochondrial) of 2.0-
fold in male and 3.1-fold in female Fabry mice were detected using ProteinLynx. 
Using Progenesis LC-MS the same protein was not detectable in control kidney 
tissue but was detected in both male and female Fabry mice. Ribonuclease 
UK114 was also found to be increased, elevations of 3.1-fold in male and 3.8-
fold in female Fabry mice were detected with ProteinLynx whilst the same 
protein showed elevatations of 5.2-fold in male and 2.6-fold in female Fabry 
mice with Progenesis LC-MS.  
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Figure 5.4 Proteins detected as showing a greater than two-fold alteration in pooled kidney tissues from both male Fabry mice 
(n = 3) and female Fabry mice (n = 3) by a.) ProteinLynx and; b.) Progenesis LC-MS 
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5.2.2.3 Analysis of heart tissues from a Fabry mouse model 
 
Following analysis with ProteinLynx, a total of 960 proteins were detected in 
heart tissue from Fabry and/or control mice. Twenty-two proteins were found to 
be altered by a fold change greater than two in both male and female Fabry 
mice compared to levels observed in the control group (Table 5.5). Of these 22 
proteins, 2 were shown to have levels greater than two-fold increased and 20 
proteins were shown to have levels greater than two-fold decreased. 
The levels of 938 of the 960 proteins detected using ProteinLynx displayed no 
fold change alterations between both the male and female Fabry and control 
mice groups.  
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Table 5.5 Proteins detected as altered by a fold change greater than two in 
heart tissues of male and female Fabry mice by ProteinLynx. FM = Fabry 
mice 
 
Description 
Control 
fmol/mg 
protein 
Male FM 
fmol/mg 
protein 
Fold 
change 
Female FM 
fmol/mg 
protein 
Fold 
change 
↑ or ↓ 
Alpha-cardiac actin  699.7 0.0 Infinity 0.0 Infinity ↓  
Alpha-globin 165.1 0.0 Infinity 17.2 9.6 ↓  
ATP synthase subunit alpha, 
mitochondrial 
28.9 3142.3 108.7 997.9 34.5 ↑  
Beta-actin-like protein 2 1.4 0.0 Infinity 0.0 Infinity ↓  
Calcium-binding protein p22 4.2 0.0 Infinity 0.0 Infinity ↓  
Creatine kinase S-type, 
mitochondrial 
308.7 0.0 Infinity 0.0 Infinity ↓  
Desmin 114.5 0.0 Infinity 0.0 Infinity ↓  
Dihydropyrimidinase-related 
protein 4 
6.6 0.0 Infinity 0.0 Infinity ↓  
Elongation factor - alpha 1 21.4 0.0 Infinity 0.0 Infinity ↓  
Hemoglobin subunit alpha 291.1 0.0 Infinity 0.0 Infinity ↓  
Kallikrein 1-related peptidase b8 5.8 0.0 Infinity 0.0 Infinity ↓  
Long chain specific acyl-CoA 
dehydrogenase, mitochondrial 
23.5 0.0 Infinity 0.0 Infinity ↓  
Myosin-7B 0.0 7.9 Infinity 9.5 Infinity ↑ 
Myosin, heavy polypeptide 1, 
skeletal muscle, adult 
8.6 0.0 Infinity 0.0 Infinity ↓ 
Myosin, heavy polypeptide 8, 
skeletal muscle, perinatal 
2.1 0.0 Infinity 0.0 Infinity ↓ 
NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 9, 
mitochondrial  
2.6 0.0 Infinity 0.0 Infinity ↓ 
NADH dehydrogenase 
[ubiquinone] iron-sulfur protein 
3, mitochondrial 
8.1 0.0 Infinity 0.0 Infinity ↓  
Rab40b, member RAS 
oncogene family 
9.2 0.0 Infinity 0.0 Infinity ↓ 
Sarcoplasmic/endoplasmic  
reticulum calcium ATPase 2  
18.5 0.0 Infinity 0.0 Infinity ↓ 
Transcription termination factor 
2 
3.5 0.0 Infinity 0.0 Infinity ↓ 
Tripartite motif-containing 
protein 72 
9.6 0.0 Infinity 0.0 Infinity ↓ 
Tropomyosin alpha-1 chain 34.9 0.0 Infinity 0.0 Infinity ↓  
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When data were analysed with the Progenesis LC-MS software a total of 729 
proteins were detected in heart tissue from Fabry and/or control mice. Of the 
729 proteins detected, 5 were found to have greater than two-fold alterations in 
the average normalised abundance detected in both male and female Fabry 
mice compared to those levels detected in the control group (Table 5.6). Of the 
5 proteins found to be altered in both male and female Fabry mice, a greater 
than two-fold elevation was detected in 4 proteins, with a greater than two-fold 
reduction observed in only a single protein.   
The average normalised abundance of 724 of the 729 proteins detected by 
Progenesis LC-MS did not display fold change alterations between both the 
male and female Fabry and control mice group.  
 
Table 5.6 Proteins detected as altered by a fold change greater than two in 
heart tissue of male and female Fabry mice by Progenesis LC-MS. FM = 
Fabry mice; ANA = average normalised abundance 
 
Description 
Control 
ANA 
Male FM 
ANA 
Fold 
change 
Female FM 
ANA 
Fold 
change 
↑ or ↓ 
ATP synthase subunit alpha, 
mitochondrial 
0.7 380.2 551.0 80.2 116.3 ↑  
Baz2a protein  1.3 21.0 15.8 23.1 17.4 ↑  
Long-chain specific acyl-CoA 
dehydrogenase, mitochondrial  
533.2 11.0 48.7 8.0 66.3 ↓ 
Myosin light chain 1/3, skeletal 
muscle isoform 
0.0 77.1 Infinity 1.1 Infinity ↑  
Tropomyosin alpha-3 chain 97.6 632.4 6.5 691.7 7.1 ↑ 
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When results obtained from ProteinLynx and Progenesis LC-MS were cross 
referenced 2 proteins, ATP synthase subunit alpha (mitochondrial) and long 
chain specific acyl-CoA dehydrogenase (mitochondrial) were confirmed by both 
analysis methods as having greater than two-fold alterations (Figure 5.5). Using 
ProteinLynx, ATP synthase subunit alpha (mitochondrial), which together with 
the beta subunit forms the catalytic core in the F1 portion of ATP synthase 
(Figure 5.23), was found to be increased by 108.7-fold in male Fabry mice and 
by 34.5-fold in female Fabry mice, compared to levels observed in the control 
group. When the data were analysed using Progenesis LC-MS the same protein 
was found to be increased 551.0-fold in male Fabry mice and 116.3-fold in 
female Fabry mice. Long chain specific acyl-CoA dehydrogenase 
(mitochondrial), is one of the four enzymes that catalyse the initial step of 
mitochondrial beta-oxidation of straight chain fatty acids and was found to be 
decreased in heart tissues from both male and female Fabry mice, by both 
analysis methods. This protein was detected in only control tissues using 
ProteinLynx with no detectable levels observed in either male or female Fabry 
mice. Using Progenesis LC-MS, long chain specific acyl-CoA (mitochondrial) 
was found to be 48.7-fold reduced in male Fabry mice and 66.3-fold reduced in 
female Fabry mice.    
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Figure 5.5 Proteins detected as showing a greater than two-fold alteration in pooled heart tissues from both male Fabry mice (n 
= 3) and female Fabry mice (n = 3) by a.) ProteinLynx and; b.) Progenesis LC-MS 
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5.2.2.4 Analysis of brain tissues from a Fabry mouse model 
 
Data analysis with ProteinLynx identified a total of 2917 proteins in brain tissue 
from Fabry and/or control mice. Of the 2917 proteins detected in brain tissues, 
13 were found to have levels displaying a greater than two-fold alteration in both 
male and female Fabry mice, compared to levels detected in the control group 
(Table 5.7). Of these 13 proteins, 4 were found to have levels greater than two-
fold increased and 9 were found to have levels greater than two-fold decreased.  
The levels of 2904 of the 2917 proteins detected using ProteinLynx displayed 
no fold change alterations between both the male and female Fabry and control 
mice groups.  
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Table 5.7 Proteins detected as altered by a fold change greater than two in 
brain tissues of male and female Fabry mice by ProteinLynx. FM = Fabry 
mice 
 
Description 
Control 
fmol/mg 
protein 
Male FM 
fmol/mg 
protein 
Fold 
change 
Female FM 
fmol/mg 
protein 
Fold 
change 
↑ or ↓ 
14-3-3 protein epsilon 45.5 275.0 6.0 145.0 3.2 ↑  
Actin-related protein 3 694.4 304.5 2.3 310.2 2.2 ↓  
Alpha-synuclein 78.2 28.9 2.7 31.3 2.5 ↓ 
Aspartate aminotransferase, 
mitochondrial 
3.6 38.3 10.6 33.4 9.3 ↑ 
ATP-binding cassette sub-family 
B member 8, mitochondrial 
59.4 0.0 Infinity 0.0 Infinity ↓  
Calcium/calmodulin-dependent 
protein kinase II subunit beta 
859.3 117.1 7.3 48.4 17.8 ↓ 
Dihydropyrimidinase-related 
protein 2 
0.0 170.1 Infinity 81.5 Infinity ↑ 
Guanine nucleotide-binding 
protein G(I)/G(S)/G(T) subunit 
beta-2 
2657.8 647.7 4.1 666.4 4.0 ↓  
Interferon-stimulated 20 kDa 
exonuclease-like 2 
22.2 5.1 4.4 3.2 7.0 ↓  
Microtubule-associated protein 4 542.6 196.1 2.8 155.7 3.5 ↓ 
Nascent polypeptide-associated 
complex subunit alpha, muscle-
specific form 
126.2 58.8 2.2 36.1 3.5 ↓  
OXR1 short isoform C7C 2.6 41.5 16.1 22.4 8.7 ↑  
Tubulin alpha-4A chain 4848.3 786.2 6.2 612.8 7.9 ↓  
 
Following analysis with the Progenesis LC-MS software a total of 2340 proteins 
were detected in brain tissues from Fabry and/or control mice. Of the 2340 
proteins detected, 12 were found to have greater than two-fold alterations in 
their average normalised abundance, compared to the average normalised 
abundance of the control group (Table 5.8). Of these 12 proteins, 4 were found 
to have a greater than two-fold increase and 8 proteins were detected as having 
greater than two-fold decreases. 
- 274 - 
 
The average normalised abundance of 2328 of the 2340 proteins detected 
using Progenesis LC-MS displayed no fold change alterations between both the 
male and female Fabry and control mice groups.  
 
Table 5.8 Proteins detected as altered by a fold change greater than two in 
brain tissue of male and female Fabry mice by Progenesis LC-MS. FM = 
Fabry mice; ANA = average normalised abundance 
 
Description 
Control 
ANA 
Male FM 
ANA 
Fold 
change 
Female FM 
ANA 
Fold 
change 
↑ or ↓ 
Actin-related protein 2/3 
complex subunit 4 
2.6 41.4 16.2 41.9 16.4 ↑  
Alpha-actinin-2 18.9 52.7 2.8 57.7 3.1 ↑  
Alpha-synuclein 859.3 117.1 7.3 48.4 17.8 ↓  
ATPase, Ca++ transporting, 
plasma membrane 3 
192.8 86.5 2.3 83.7 2.3 ↓  
ATP-binding cassette sub-family 
B member 8, mitochondrial 
2657.8 647.7 4.1 666.4 4.0 ↓  
Calm4 protein 694.4 304.5 2.3 310.2 2.2 ↓ 
Cell cycle exit and neuronal 
differentiation protein 1 
22.2 5.1 4.4 3.2 7.0 ↓ 
Elongation factor 1-alpha 1 62.9 238.6 3.8 193.4 3.1 ↑  
Exocyst complex component 7 2507.6 887.9 2.8 595.7 4.2 ↓ 
Heat shock 70 kDa protein 14 395.9 129.1 3.1 68.9 5.8 ↓ 
L-asparaginase 0.0 62.7 Infinity 52.3 Infinity ↑ 
MKIAA4098 protein  4848.3 786.2 6.2 612.8 7.9 ↓ 
 
When results obtained from ProteinLynx and Progenesis LC-MS were cross 
referenced 2 proteins, alpha-synuclein and ATP-binding cassette sub-family B 
member 8 (mitochondrial), were confirmed by both analysis methods as 
showing greater than two-fold reductions in male and female Fabry mice (Figure 
5.6). Using ProteinLynx alpha-synuclein, a pre-synaptic neuronal protein with a 
genetic and neuropathological link to Parkinson’s disease was found to be 2.7-
fold reduced and 2.5-fold reduced in brain tissues of male and female Fabry 
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mice, respectively. Using Progenesis LC-MS the same protein was found to be 
reduced 7.3-fold in male and 17.8-fold in female Fabry mice. ATP-binding 
cassette sub-family B member 8 (mitochondrial) is an ATP-dependent 
transporter that may mediate the passage of organic and inorganic molecules 
out of the mitochondria and was also found to be reduced. This protein was not 
detectable in male or female Fabry mice brain tissues using ProteinLynx but 
was found in the control group. Using Progenesis LC-MS this protein was found 
to be 4.1-fold reduced in male and 4.0-fold reduced in female Fabry mice.  
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Figure 5.6 Proteins detected as showing a greater than two-fold alteration in pooled brain tissues from both male Fabry mice (n 
= 3) and female Fabry mice (n = 3) by a.) ProteinLynx and; b.) Progenesis LC-MS 
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5.2.2.5 Classification of proteins showing alterations in Fabry mouse 
tissues using the Gene Ontology annotation system 
 
Those proteins that were shown to have alterations by both ProteinLynx and 
Progenesis LC-MS in Fabry mouse tissues were investigated with the Gene 
Ontology (GO) annotation system using the PANTHER website. The GO 
annotation system classifies proteins according to their molecular functions, 
biological processes and biological pathways this enables common features 
between proteins of interest to be grouped and identified.  
 
5.2.2.6 Molecular functions associated with proteins that show 
alterations in Fabry mouse tissues  
 
Six molecular functions were shown to be associated with proteins identified as 
having alterations during the proteomic profiling aspect of the study (Figure 5.7). 
ATP synthase subunits alpha (increased in the heart) and beta (increased in the 
liver and kidney), were shown to have a role in five of the six molecular 
functions. This suggests that an increase in these proteins could affect a variety 
of functional activities performed at the molecular level.     
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Figure 5.7 Molecular functions associated with proteins identified as showing alterations by both ProteinLynx and Progenesis 
LC-MS in Fabry mouse tissues during the proteomic profiling study. Arrowed boxes indicate an increase or decrease of the 
detected protein.   
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5.2.2.7 Biological processes associated with proteins that show 
alterations in Fabry mouse tissues 
 
Nine biological processes were revealed to be associated with proteins shown 
to have an alteration during the proteomic profiling study (Figure 5.8). 
Interestingly, all biological processes were associated with at least one protein 
that was found to be decreased during the proteomic profiling study. A 
biological process by definition involves more than one distinct step. A disease-
related perturbation affecting any or all of these steps, for example an alteration 
of a vital protein such as those shown to be altered in this study, could therefore 
result in abnormal execution of a number of biological processes.  
 
5.2.2.8 Biological pathways associated with proteins that show 
alterations in Fabry mouse tissues 
 
Only three of the proteins showing alterations in the proteomic profiling study 
were shown to be associated with biological pathways using the GO annotation 
system. Of the three proteins two, ATP synthase subunits alpha and beta 
(mitochondrial) which were found to be increased in heart and liver and kidney 
tissues respectively, were shown to be involved in ATP synthesis. The third 
protein, alpha synuclein, has a well-established roll in the Parkinson’s disease 
pathway. This protein was found to be reduced in Fabry mouse brain tissues.  
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Figure 5.8 Biological processes associated with proteins identified as showing alterations by both ProteinLynx and Progenesis 
LC-MS in Fabry mouse tissues during the proteomic profiling study. Arrowed boxes indicate an increase or decrease of the 
detected protein.  
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5.2.3  Identification of protein: glycosphingolipid interactions 
 
In this aspect of the study two complementary technologies were used to 
identify proteins that interact with a number of lipids in the glycosphingolipid 
biosynthetic pathway with particular interest on Gb3. These complementary 
strategies were used in order to evaluate the best method for performing lipid-
binding experiments.    
 
5.2.3.1 RS100 ProteinChip array technology for the study of protein: 
glycosphingolipid interactions 
 
RS100 technology is a type of ProteinChip Array that has been used previously 
to study antibody-antigen interactions (Mills et al., 2006). RS100 ProteinChip 
arrays are pre-activated with carbonyl diimidazole active groups present on 
large C12-linker arms bound to the chip surface. These active groups bind 
covalently to free primary amine groups of amino acids present on the exterior 
of antibodies/proteins, while maintaining their active conformation and biological 
activity. Potential binding proteins/antigens can be used as ‘bait’ and can 
capture proteins, which can then subsequently be analysed and identified by 
mass spectrometry.  
In the present study, a novel method based on RS100 technology was 
developed to investigate proteins captured using Gb3 as the target. In addition, 
to distinguish those proteins that bind exclusively to Gb3, with those proteins 
that interact non-selectively with glycosphingolipids, interactions with GM1 
ganglioside were also investigated in brain tissues from a control mouse. In 
order to bind the glycosphingolipids to the surface of the RS100 ProteinChip, 
deacylated versions of each glycosphingolipid which possess a primary free 
amine group were used. The covalent bond that is formed via the free amine 
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group of the deacylated glycosphingolipid and the C12-linker arm on the surface 
of the chip effectively restores each glycosphingolipid to its acylated form 
(Figure 5.9). In addition, to ensure the specificity of the interactions with the 
glycosphingolipids, non-specific binding to the chip surface was detected with 
the use of phosphate buffered saline (PBS), which blocks the C12-linker arm 
and therefore acts as a negative control. 
 
 
 
Figure 5.9 Schematic representation of how deacylated sphingolipids bind 
to the surface of the RS100 ProteinChip through the primary amine group, 
(shown circled in red) to form a.) C12-globotriaosylceramide; b.) C12-GM1 
ganglioside.  
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5.2.3.2 The interaction of proteins with Gb3 when immobilised on a 
RS100 ProteinChip 
 
Following the extraction of proteins which interacted with Gb3 and GM1 
ganglioside when bound to the surface of the RS100 ProteinChip and 
subsequent analysis by UPLC-QToF-MS, a total of 157 proteins were identified 
using ProteinLynx. Following the exclusion of those proteins that displayed non-
specific binding, a total of 62 proteins were identified that bound to Gb3 in 
mouse brain tissue (Figure 5.10). 
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Figure 5.10 Schematic representation of proteins that interact with Gb3 in mouse brain tissue a.) proteins that constitute > 30 fmol 
protein; b.) proteins that constitute 30 - 10 fmol protein and c.) proteins that constitute < 10 fmol protein. Those sections of the pie chart 
which are extracted were also shown to interact with GM1 ganglioside. 
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5.2.3.3 The interaction of proteins with GM1 ganglioside when 
immobilised on a RS100 ProteinChip 
 
Of the 157 proteins that were identified in mouse brain by ProteinLynx as 
binding to the RS100 ProteinChip, 101 proteins were found to interact with GM1 
ganglioside (Figure 5.11).  
 
5.2.3.4 The interaction of proteins with Gb3 and GM1 ganglioside 
when immobilised on a RS100 ProteinChip 
 
Thirty-two of the 157 proteins that were identified by ProteinLynx as binding to 
the RS100 ProteinChip were detected binding to both Gb3 and GM1 ganglioside, 
shown as the extracted segments of the pie charts in Figures 5.10 and 5.11. It 
is most likely that these 32 proteins recognise the sphingosine portion of the 
molecule, common to both Gb3 and GM1 ganglioside and not the sugar portion 
of the molecule which is unique to each glycosphingolipid.    
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Figure 5.11 Schematic representation of proteins that interact with GM1 ganglioside in mouse brain tissue a.) proteins that 
constitute > 30 fmol protein; b.) proteins that constitute 30 - 10 fmol protein and c.) proteins that constitute < 10 fmol protein. Those 
sections of the pie chart which are extracted were also shown to interact with Gb3. 
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5.2.3.5 Classification of proteins interacting with glycosphingolipids 
 
In order to identify common molecular functions, biological processes and 
pathways associated with the proteins identified as binding to Gb3 and GM1 
ganglioside, interactions were investigated with the GO annotation system using 
the PANTHER website. Of the 131 protein identifications entered into the 
PANTHER website 24 proteins could not be detected using this software. Of 
those proteins that were identified a large proportion were found to be located in 
the mitochondria or to possess catalytic activity involving ATP. This suggests 
that those proteins that interact with Gb3 and/or GM1 ganglioside may have a 
role in mitochondrial energy production which may be affected by binding to a 
glycosphingolipid.   
 
5.2.3.6 Molecular functions associated with proteins that interact 
with Gb3 and GM1 ganglioside  
 
Two molecular functions, catalytic activity and protein binding, were found to be 
the molecular functions that the most proteins interacting with Gb3 and/or GM1 
ganglioside shared. Of the 131 proteins detected as binding with Gb3 and/or 
GM1 ganglioside, 62 proteins were detected as having catalytic activity. Further 
investigation was able to subdivide these proteins into those with RNA splicing 
factor, helicase, hydrolase, isomerase, ligase, lyase, oxidoreductase, and 
transferase activities (Figure 5.12). Of these subcategories, the highest number 
of proteins (18 proteins) were detected to possess hydrolase activity. In 
addition, many proteins were found to possess transferase (16 proteins) and 
oxidoreductase (15 proteins) activities. Thirty-one of the 131 proteins detected 
were also identified as having binding capability. This category was further 
subdivided into those protein binding, calcium ion binding, chromatin ion binding 
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and nucleic acid binding proteins (Figure 5.10). The most proteins were 
identified as protein binding proteins with 18 proteins falling into this 
subcategory.  
Other common molecular functions associated with proteins that interact with 
Gb3 and GM1 ganglioside in mouse brain tissue are shown in Figure 5.12. 
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Figure 5.12 Molecular functions associated with proteins found to interact with Gb3 and/or GM1 ganglioside (shown in black and 
bold). Those proteins that interact with Gb3 only (shown in blue) and those that interact with GM1 ganglioside only (shown in green). 
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5.2.3.7 Biological processes associated with proteins that interact 
with Gb3 and GM1 ganglioside     
 
The proteins that were found to interact with Gb3 and/or GM1 ganglioside were 
also investigated to establish if any common biological processes existed. Fifty-
one proteins found to interact with Gb3 and GM1 ganglioside were grouped by 
the GO annotation system as having ‘primary metabolic processes’ as their 
biological function. This classification was further subdivided into carbohydrate, 
cellular amino acid and derivative, lipid, protein and nucleobase, nucleoside, 
nucleotide and nucleic acid, metabolic processes (Figure 5.13). Following sub-
classification 18 proteins were found to have nucleobase, nucleoside, 
nucleotide and nucleic acid metabolic processes as their biological function. 
Carbohydrate and protein metabolic processes were also common biological 
processes shared by proteins binding to Gb3 and GM1 ganglioside with 16 and 
14 proteins in each of these categories, respectively.      
Other biological processes that many proteins interacting with Gb3 and GM1 
ganglioside were found to share were cellular processes, transport and cell 
communication with 33, 24 and 20 proteins assigned to these categories, 
respectively. All biological processes associated with the proteins detected as 
interacting with Gb3 and GM1 ganglioside in mouse brain tissue as defined by 
the GO annotation system are shown in Figure 5.13.     
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Figure 5.13 Biological processes associated with proteins found to interact with Gb3 and/or GM1 ganglioside (shown in black 
and bold). Those proteins that interact with Gb3 only (shown in blue) and those that interact with GM1 ganglioside only (shown in green). 
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5.2.3.8 Biological pathways associated with proteins that interact 
with Gb3 and GM1 ganglioside     
 
In total 51 biological pathways were identified by the GO annotation system as 
having involvement with one or more protein which binds to Gb3 and/or GM1 
ganglioside. Figure 5.14 shows only those biological pathways that have two or 
more proteins assigned that were detected as interacting with Gb3 and/or GM1 
ganglioside. Of the 51 biological pathways indentified, the Huntington’s disease 
and glycolysis pathways involved the most proteins. A total of 7 proteins were 
identified as interacting with Gb3 and/or GM1 ganglioside in each of these 
biological pathways. Huntington’s disease is a progressive neurodegenerative 
disorder which leads to extensive degeneration of the basal ganglia (Bard et al., 
2014). Whilst neurodegeneration is not a prominent feature of Fabry disease, 
both Fabry and Huntington diseases are associated with protein mis-folding 
(Chaudhuri and Paul 2006). Furthemore, 6 of the 7 proteins involved in the 
Huntington’s disease pathway were found to interact with GM1 ganglioside. 
Accumulation of GM1 ganglioside in the basal ganglia is a prominent feature of 
GM1 gangliosidosis and is thought to be responsible for the neurologic picture 
(Campdelacreu et al., 2002). Interestingly, 3 biological pathways, tyrosine, 
phenylalanine and asparagine and aspartate were only assosicated with 
proteins that bound to both Gb3 and GM1 ganglioside. The pentose pathway 
was also the only biological pathway containing only proteins that bound GM1 
ganglioside. Other common biological pathways associated with proteins that 
interact with Gb3 and/or GM1 ganglioside in mouse brain tissue are shown in 
Figure 5.14. 
- 293 - 
 
 
Figure 5.14 Biological pathways associated with proteins found to interact with Gb3 and/or GM1 ganglioside (shown in black 
and bold). Those proteins that interact with Gb3 only (shown in blue) and those that interact with GM1 ganglioside only (shown in green). 
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5.2.3.9 The use of Dynabeads® M-270 Epoxy for the study of protein: 
glycosphingolipid interactions 
 
An alternative strategy to the RS100 ProteinChip array technology was also 
used to study protein: glycosphingolipid interactions. This additional analysis, 
using Dynabeads® M-270 Epoxy, was performed not only to evaluate the best 
method for performing lipid binding experiments but also to compare the effect 
of differing acyl-chain lengths on observed interactions. Dynabeads® M-270 
Epoxy are superparamagnetic hydrophilic beads coated with surface epoxy 
groups to allow the direct covalent binding of primary amino and sulfhydryl 
groups present in proteins and peptides. This allows the coupling of a desired 
ligand to the beads which can then be used as ‘bait’ to capture proteins. 
Captured proteins are separated, washed and eluted using a DynaMag™ 
magnet and the magnetic separation properties of the Dynabeads®. Eluted 
proteins can then subsequently be analysed and identified by mass 
spectrometry.  
In this aspect of the study Dynabead® technology was used to investigate 
proteins captured using Gb3 as the target. In addition, interactions of proteins 
with the glycosphingolipids GM1 ganglioside, galactosylceramide and ceramide 
were investigated as further controls to identify those proteins which interact 
solely with the protein of interest, Gb3, and those which also interact with other 
glycosphingolipids in mouse kidney tissues. In order to bind the 
glycosphingolipids to the Dynabeads®, again deacylated versions of each 
glycosphingolipid possessing a primary free amine group were used. The 
covalent bond that is formed via the free amine group of the deacylated 
glycosphingolipid and the C5-linker arm of the epoxy group coating the surface 
of the Dynabeads® effectively restores each glycosphingolipid to its acylated 
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form (Figure 5.15). In addition, to ensure the specificity of the interactions with 
the glycosphingolipids, non-specific binding to the ‘bead’ surface was detected 
with the use of PBS, which blocks the C5-linker arm and therefore acts as a 
negative control.   
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Figure 5.15 Schematic representation of how the deacylated sphingolipids a.) Lyso-GM1 ganglioside (Lyso-GM1);                                   
b.) Globotriaosylsphingosine (Lyso-Gb3); c.) Galactosylsphingosine and d.) Sphingosine bind to Dynabeads® M-270 Epoxy through the 
primary amine group, shown circled in red.  
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5.2.3.10 The interaction of proteins with glycosphingolipids when 
bound to Dynabeads®  
 
Following the extraction of proteins which interacted with those 
glycosphingolipids bound to Dynabeads® and analysis by UPLC-QToF-MS, a 
total of 100 proteins were identified using ProteinLynx Global Server version 
2.4. Following the exclusion of those proteins that displayed non-specific 
binding, a total of 22 proteins were identified that bound to one or more of the 
glycosphingolipids (Figure 5.16).    
 
 
 
 
 
Figure 5.16 A modified Venn diagram showing proteins that interact with 
globotriaosylceramide (Gb3), GM1 ganglioside, galactosylceramide and 
ceramide.  
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5.2.3.11 Classification of proteins interacting with glycosphingolipids 
 
In order to identify common molecular functions, biological processes and 
pathways associated with the proteins identified as binding to Gb3, GM1 
ganglioside, galactosylceramide and/or ceramide, interactions were investigated 
with the GO annotation system, using the PANTHER website.  
 
5.2.3.12 Identification of proteins that bind only to Gb3 
 
Six proteins were detected that interacted with only the glycolipid of interest, 
Gb3 (Figure 5.16). Further analysis of these proteins using the GO annotation 
system revealed that 2 of the 6 proteins, 60 kDa heat shock protein 
(mitochondrial) and cyclin-dependant kinase like-4, possessed the molecular 
function to interact selectively and covalently with ATP. A further association 
was identified with a third protein, cytochrome C oxidase subunit 6B1, for which 
the biological function has a role in the respiratory electron transport chain from 
which ATP is generated.  
 
5.2.3.13 Identification of proteins that bind only to the control GM1 
ganglioside array 
 
Three proteins were detected binding solely to GM1 ganglioside (Figure 5.16). 
Further analysis using the GO annotation system did not reveal any common 
biological processes, pathways or molecular functions associated with the 
identified proteins. However, all three proteins were again found to be involved 
in energy metabolism.     
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5.2.3.14 Identification of proteins that bind only to the control 
galactosylceramide array 
 
The most protein interactions were detected binding to the glycosphingolipid 
galactosylceramide. In total 8 proteins were identified which interacted with 
galactosylceramide (Figure 5.16). Functional analysis revealed that 6 of the 8 
proteins identified possessed oxidoreductase activity as one of, or their sole, 
molecular function. In addition, 3 of the proteins, hydroxyacid oxidase 1, 
peroxiredoxin-5 and peroxisomal bifunctional enzyme were all shown to be 
located in the peroxisome.  
 
5.2.3.15 Identification of proteins that bind only to the control 
ceramide array 
 
The least amount of protein interactions were detected when the 
glycosphingolipid ceramide was bound to the surface of the beads. Two 
proteins were identified, alpha-actinin-4 and histone H3.2. Unfortunately due to 
the limited amount of interactions detected and their non-specific nature 
functional analysis was not able to reveal any common biological processes, 
pathways or molecular functions associated with the identified proteins (Figure 
5.16). 
 
5.2.3.16 Identification of proteins that bind to more than one 
glycosphingolipid when bound to Dynabeads® M-270 Epoxy 
 
Although no protein was identified that bound to all four glycosphingolipids, one 
protein was detected that bound to Gb3, galactosylceramide and ceramide. This 
protein, voltage dependent anion selective channel protein 1 (Figure 5.16), 
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partly functions to form a channel through the mitochondrial outer membrane to 
allow the diffusion of small hydrophilic molecules. Another ion channel, 
potassium-voltage gated channel subfamily H member 1, was also detected in 
this study and was found to interact exclusively with Gb3. One protein, NADH 
dehydrogenase [ubiquinone] iron sulfur protein 6 (mitochondrial), was also 
identified that bound to both Gb3 and galactosylceramide. This protein shares a 
common molecular function and/or biological process with proteins that were 
detected interacting individually with either Gb3 or galactosylceramide as it 
displays both oxidoreductase activity and is essential to the mitochondrial 
electron transport chain. In addition a single protein, aspartate aminotransferase 
(mitochondrial), was detected that bound to both Gb3 and GM1 ganglioside. This 
protein is important for metabolite exchange between the mitochondria and the 
cytosol and in addition facilitates the cellular uptake of long-chain free fatty 
acids.  
 
5.2.3.17 Comparison of RS100 ProteinChip and Dynabead® M-270 
Epoxy methods for the study of protein: glycosphingolipid interactions 
 
The study of protein: glycosphingolipid interactions using complementary 
RS100 ProteinChip and Dynabeads® methods revealed the proteins beta-actin-
like protein 2 and tubulin alpha-1B chain to interact solely with GM1 ganglioside. 
In addition, aspartate aminotransferase (mitochondrial) was found to bind to 
both Gb3 and GM1 ganglioside using both analysis techniques. Although only a 
small number of proteins were confirmed to bind to Gb3 and/or GM1 ganglioside 
using both analysis methods a variety of mitochondrial proteins were also 
revealed to interact with the glycosphingolipids using both methods. Of these 
proteins the mitochondrial ATP synthase subunits alpha, beta and delta were 
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detected binding to both Gb3 and GM1 ganglioside when immobilised on the 
RS100 ProteinChip. This confirmed results observed in the proteomic profiling 
aspect of the study where ATP synthase subunit beta was found to be 
increased in both Fabry mouse liver and kidney tissues and ATP synthase 
subunit alpha was found to be increased in Fabry mouse heart tissues. A 
number of proteins with the ability to interact selectively and covalently to ATP 
were also identified binding to Gb3 during the protein: glycosphingolipid 
interaction study when using Dynabeads®. As a result the effect of various 
glycosphingolipids and their deacylated counterparts on ATP synthase activity 
were investigated (section 5.2.4). 
 
5.2.4  ATP synthase activity 
 
A functional assay to assess ATP synthase activity was performed as described 
in section 2.2.7.9. As well as Gb3 a number of other glycosphingolipids involved 
in the glycosphingolipid biosynthetic pathway (GM1 ganglioside, sulfatide, 
lactosylceramide, glucosylceramide, and galactosylceramide) were also 
assessed with regards to their effect on ATP synthase activity. In addition 
cardiolipin, a lipid which has been shown previously to affect the 
supramolecular organisation of ATP synthase in mitochondria, was included for 
comparison. The effect of the lyso-glycosphingolipids lyso-Gb3, lyso-GM1 
ganglioside, lyso-sulfatide, lyso-lactosylceramide, lyso-glucosylceramide, and 
lyso-galactosylceramide were also evaluated. Three concentration levels of 
each glycosphingolipid and lyso-glycosphingolipid were evaluated on the effect 
of ATP synthase activity. The high level consisted of glycosphingolipids at 300 
µmol/l a concentration based on plasma Gb3 levels in Fabry patients with a 
severe disease phenotype. High level lyso-glycosphingolipids were ten times 
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less concentrated than their acylated counterparts at 30 µmol/l. The medium 
level comprised glycosphingolipids at a concentration of 30 µmol/l based on 
plasma Gb3 levels in Fabry patients with a mild disease phenotype. Medium 
level lyso-glycosphingolipids were one-hundred times less concentrated than 
their acylated counterparts at 0.3 µmol/l. The low level consisted of 
glycosphingolipids at a concentration of 0.3 µmol/l based on plasma Gb3 levels 
in a healthy control group. The low level lyso-glycosphingolipids were one-
hundred times less concentrated than their acylated counterparts at 0.003 
µmol/l. A control sample was also analysed, this was prepared in the same way 
as all samples (section 2.2.7.9) but without the addition of any lipid or lyso-
glycosphingolipid.    
 
5.2.4.1 The effect of glycosphingolipids on ATP synthase activity 
 
Following the analysis of the effect of seven lipids at three concentration levels 
on ATP synthase activity, using students t-test statistically significant increases 
were observed with the highest concentrations of cardiolipin (p < 0.01), GM1 
ganglioside (p < 0.007), Gb3 (p < 0.006), sulfatide (p < 0.04) and 
lactosylceramide (p < 0.006) (Figure 5.17). Statistically significant increases in 
ATP synthase activity were also observed with the medium concentration level 
of cardiolipin (p < 0.002), GM1 ganglioside (p < 0.0003) and lactosylceramide (p 
< 0.003). In addition, a statistically significant increase was observed with the 
lowest level of cardiolipin (p < 0.01), this was the only compound to cause a 
statistically significant increase at the low concentration.  
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5.2.4.2 The effect of lyso-glycosphingolipids on ATP synthase 
activity 
 
Following analysis of the effect of six lyso-glycosphingolipids at three 
concentration levels on ATP synthase activity, a number of statistical and 
significant increases were observed (Figure 5.18). The highest concentration of 
lyso-glycosphingolipids displayed the most effect on ATP synthase activity with 
statistical and significant increases observed with lyso-GM1 ganglioside (p < 
0.00007), lyso-Gb3 (p < 0.003), lyso-sulfatide (p < 0.0003), lyso-
lactosylceramide (p < 0.0001) and lyso-glucosylceramide (p < 0.009). Statistical 
and significant increases were also observed with the medium level lyso-GM1 
ganglioside (p < 0.001), lyso-Gb3 (p < 0.002) and lyso-glucosylceramide (p < 
0.01). No statistically significant increases were observed with any of the lowest 
level lyso-compounds.      
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Figure 5.17 The effect of various lipids at high, medium and low concentrations on ATP synthase activity in a mitochondrial 
preparation from rat liver. Data expressed as mean ± standard deviation. * p < 0.05, ** p < 0.01, *** p < 0.001 
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Figure 5.18 The effect of various lyso-glycosphingolipids at high, medium and low concentrations on ATP synthase activity in a 
mitochondrial preparation from rat liver. Data expressed as mean ± standard deviation. ** p < 0.01, *** p < 0.001, **** p < 0.0001  
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5.2.4.3 The effect of high level glycosphingolipids on ATP synthase 
activity in comparison to their deacylated counterparts 
 
When the effect of high level glycosphingolipids are compared with that of high 
level lyso-glycosphingolipids (Figure 5.19), it appears that with the exception of 
GM1 ganglioside and sulfatide and their deacylated counterparts, that most high 
level compounds induce similar increases in ATP synthase activity. GM1 
ganglioside and cerebroside however, were shown to exhibit a 4.6-fold and 2.7-
fold greater effect on ATP synthase activity than their deacylated counterparts. 
In addition, GM1 ganglioside was the only glycosphingolipid to affect ATP 
synthase activity to a similar extent as shown by cardiolipin. When interpreting 
these results consideration must however be made to the fact that the high level 
of glycosphingolipids assessed in this study was ten times more concentrated 
than that of the corresponding high level of lyso-glycosphingolipids.   
 
 
Figure 5.19 A graph showing the effect of high level glycosphingolipids 
(back row) on ATP synthase activity in comparison to high level lyso-
glycosphingolipids (front row).  
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5.2.4.4 The effect of medium level glycosphingolipids on ATP synthase 
activity in comparison to their deacylated counterparts 
 
When the effect of medium level glycosphingolipids on ATP synthase activity 
were compared against the effect of medium level lyso-glycosphingolipids 
(Figure 5.20), lyso-Gb3 and lyso-galactosylceramide were shown to produce 
more of an effect on ATP synthase activity than their acylated counterparts. In 
contrast lactosylceramide was shown to increase ATP synthase activity 3.5-fold 
more than its deacylated counterpart. It is of interest that at the medium level 
GM1 ganglioside did not exhibit as great an effect on ATP synthase activity as 
cardiolipin, as observed at the high concentration. Consideration must again be 
made to the fact that the medium level glycosphingolipids used in this study 
were one-hundred times more concentrated than the medium level lyso-
glycosphingolipids.        
 
 
 
Figure 5.20 A graph showing the effect of medium level 
glycosphingolipids (back row) on ATP synthase activity in comparison to 
medium level lyso-glycosphingolipids (front row).  
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5.2.4.5 The effect of low level glycosphingolipids on ATP synthase activity 
in comparison to their deacylated counterparts 
 
Although no significant differences between the low level glycosphingolipids or 
their acylated counterparts and the control were observed some differences 
between the acylated and deacylated groups were noted. Lyso-GM1 and lyso-
Gb3 were shown to have a greater than 2.0-fold increase on ATP synthase 
activity compared to their acylated counterparts. This was not so for 
lactosylceramide where a 3.3-fold increase in ATP synthase activity was seen 
compared to that of lyso-lactosylceramide. This pattern was the same as that 
observed at the medium concentration for this compound. It should be noted 
that the low level concentration of glycosphingolipids were one-hundred times 
more concentrated than that of the low level lyso-glycosphingolipids.  
      
 
Figure 5.21 A graph showing the effect of low level glycosphingolipids 
(back row) on ATP synthase activity in comparison to low level lyso-
glycosphingolipids (front row).  
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5.2.5  The effect of glycosphingolipids on behavioural measures of 
pain thresholds in mice 
 
Of particular interest during the protein: glycosphingolipid interaction study was 
the discovery that voltage dependent anion selective channel protein 1 bound to 
three glycosphingolipids (Gb3, galactosylceramide and ceramide). In addition, 
one protein potassium voltage-gated channel subfamily H, member 1 was 
detected to bind exclusively to Gb3. As voltage-gated potassium channels have 
been associated with neuropathic pain (Wood et al., 2004) and patients with 
Fabry disease are afflicted with neuropathic pain from an early stage of disease 
progression, the effect of Gb3 and lyso-Gb3 on behavioural measures of pain 
thresholds was investigated in a mouse model using a von Frey assay (section 
2.2.7.4).  
 
5.2.5.1 Von Frey nociception assay 
 
Subject mice were assigned an identification key and placed into a test group 
(section 2.2.7.8.2). The Gb3 test group (n = 9) received a 300 µmol/l solution 
injection of Gb3, which is the equivalent of Gb3 plasma concentrations observed 
in patients with a severe disease phenotype. The lyso-Gb3 test group (n = 9) 
received a 30 µmol/l solution injection of lyso-Gb3 and the control test group (n 
= 6) received an injection of saline. All injections were received into the plantar 
surface of the right hind paw of the mouse. Following the injection of Gb3 or 
lyso-Gb3, or the injection of saline as a control the reactions of the mice were 
monitored immediately and then 0.5, 1, 2, 4, 6 and 24 hr post-injection (Figure 
5.22).  
Following analysis using students t-test statistically significant differences were  
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observed between the Gb3 and control group at the 0.5 (p < 0.02), 2 hr (p < 
0.004) and 4 hr (p < 0.03) post injection time points. Statistically significant 
differences were also observed between the lyso-Gb3 and control group at the 
0.5 (p < 0.01), 1 hr (p < 0.03), 2 (p < 0.0003) and 4 (p < 0.002) hr post injection 
time points. No differences were observed between the Gb3 and lyso-Gb3 
groups. These results demonstrate that the mechanical nociceptive threshold of 
mice, following injection with 300 µmol/l Gb3 or 30 µmol/l lyso-Gb3, is reduced 
statistically and significantly compared to that of a control group. This results in 
the mice becoming more sensitive to the pain of the applied mechanical 
stimulus.   
 
 
 
Figure 5.22 The effect of Gb3 and lyso-Gb3 on behavioural measures of 
pain thresholds as assessed by the von Frey assay. 
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5.3 Discussion 
 
In recent years much progress has been made in defining the molecular basis 
of genetic diseases in humans. However, in some diseases, such as Fabry 
disease, this has not translated into an appreciable increase in the 
understanding of the underlying mechanisms associated with disease 
pathology. The use of authentic animal models is required to enable studies to 
expand our knowledge of the underlying pathological mechanisms associated 
with disease. Although the phenotype exhibited by Fabry mice is discreet, this 
has not prevented its use in a number of preclinical studies (Ioannou et al., 
2001) where assessment of Gb3 concentrations in plasma and various tissue 
types, and its reduction following treatment, have provided the predominant 
outcome measures (Marshall et al., 2010; Choi et al., 2010; Ogawa et al., 
2009).  
Using a UPLC-MS/MS method statistically significant increases in the 
concentrations of Gb3 and lyso-Gb3 in liver, kidney, heart and brain tissues 
obtained from male and female Fabry knockout mice was demonstrated (Figure 
5.1 and 5.2). This confirmed that an accumulation of these toxic metabolites 
was present and hence the organs were suitable for subsequent investigations 
in this study. Interestingly, the ratio of Gb3 to lyso-Gb3 was higher in liver (27:1), 
kidney (40:1) and heart (54:1) tissues. However, in the brain the concentration 
of lyso-Gb3 was higher than that detected in other tissue types resulting in a 
ratio of 1:1 with Gb3. Various hypotheses have been suggested as to the origin 
of lyso-Gb3 including, its spontaneous formation from stored Gb3, active 
formation by the action of a specific enzyme and formation by sequential 
glycosylation of sphingoid bases (Aerts et al., 2008). However, as yet the origin 
of lyso-Gb3 remains unknown despite numerous studies to identify the ‘elusive 
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deacylase’. The higher Gb3 to lyso-Gb3 ratio as seen in liver, kidney and heart in 
this study may be suggestive of a lower ‘deacylase’ activity or availability in 
these organs. Alternatively, the increased levels of lyso-Gb3 observed in brain 
tissue compared to other tissues analysed in this study may support the findings 
of Kobayashi et al., (1992) which suggest, based on the analysis of sphingoid 
base composition in brain tissue from patients with GM1 or GM2 gangliosidosis, 
that elevated levels of lysosphingolipids might originate from biosynthesis and 
not from deacylation of corresponding sphingolipids. In addition, biosynthesis of 
galactosylsphingosine from sphingosine has also been reported (Cleland and 
Kennedy 1960; Vanier and Svennerholm 1976).  
Following the proteomic profiling of Fabry mouse tissues using label-free 
quantitative proteomics, a number of protein alterations were detected in the 
tissues of male and female Fabry mice. These alterations were confirmed with 
the use of two data analysis software platforms. The first software used was 
“ProteinLynx” and provides absolute quantitation based on the peak intensities 
of identified proteins and their comparison to the peak intensities of an added 
known peptide acting as an internal standard. The second software package 
“Progenesis LC-MS”, provides relative quantification based on the ion 
intensities recorded in the MS data. Differences in the identification of proteins 
obtained during this study are most likely due to differences in the processing 
parameters available from the software packages as well as thresholds and cut-
off values used in the data analysis. An advantage of using ProteinLynx to 
obtain identifications is that absolute quantitation of data is achievable 
compared to relative quantitation obtained with Progenesis LC-MS. Both 
analysis methods enable quantification of peptide ions without MS/MS data, this 
is achieved by analysing data at the LC-MS rather than the MS/MS level to 
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locate peaks exhibiting significant expression change between experiment 
groups. However, Progenesis LC-MS is designed to avoid ‘missing data’ 
thereby minimising the technical error and improving quantitative precision. 
Each software package uses different methods of inferring the protein 
quantitation from the peptide ions in order to calculate the numeric and 
ultimately, there are pros and cons associated with using both software 
programs. Therefore, in this study proteins that were found to be altered by 
each methodology were cross-referenced revealing those proteins found to be 
altered using both software platforms, and therefore providing an enhanced 
level of confidence in the identification, to be selected for further investigation. 
Of the proteins detected to be altered in male and female Fabry mice by both 
software platforms, ATP synthase subunit beta (mitochondrial) was found to be 
increased in both liver and kidney tissues. Another subunit of ATP synthase, 
ATP synthase subunit alpha (mitochondrial) was also found to be increased in 
heart tissue. ATP synthase (complex V; Figure 5.23) is a highly complex 
enzyme responsible for the synthesis of ATP from ADP in the mitochondrial 
matrix using the energy provided by the proton electrochemical gradient which 
is generated by complexes I, III and IV of the electron transport chain. ATP 
synthase consists of two functional domains, F1 which contains the 
extramembraneous catalytic core, and F0 which contains the membrane proton 
channel. The two domains are linked together by a central and peripheral stalk. 
The catalytic domain F1 is composed of three copies of each alpha and beta 
subunit, both of which were detected as elevated in Fabry disease mouse 
tissues during the proteomic profiling study. During catalysis, ATP synthesis in 
the F1 domain, is coupled via a rotary mechanism of the central stalk subunits 
(gamma, delta and epsilon) to proton translocation. Rotation of the central stalk 
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against the surrounding alpha and beta subunits leads to hydrolysis of ATP in 
three separate catalytic sites on the beta subunits. The inner mitochondrial 
membrane phospholipid, cardiolipin, binds tightly to complex V and is essential 
for its catalytic and structural operation. This reaction is however reversible and 
when the H+ gradient across the mitochondrial inner membrane decreases ATP 
synthase can utilise ATP hydrolysis in the F1 domain to induce the rotation of 
the F0 rotor in the reverse direction thereby driving proton pumping (Orriss et 
al., 1998; Stock, Leslie and Walker 1999; Walker and Dickson 2006).  
 
 
 
Figure 5.23 A schematic representation of mitochondrial ATP synthase 
(complex V) showing the architecture and subunit composition.   
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The only other protein found to be increased during the proteomic profiling 
study was ribonuclease UK114. This protein was found to be increased in both 
male and female Fabry mouse liver and kidney tissues, where it is reported to 
be expressed predominantly. Ribonuclease UK114 is an endoribonuclease that 
functions to inhibit translation by cleaving mRNA. This enzyme is also 
responsible for the cleavage of phosphodiester bonds in single stranded RNA 
and the inhibition of cell-free protein synthesis. Levels of ribonuclease UK114 
have also been shown to be reduced in human hepatocellular carcinoma 
leading to the suggestion that this protein may be an important biomarker for 
hepatic carcinoma (Chong et al., 2008).    
In contrast to the increases detected in the levels of the mitochondrial proteins 
ATP synthase subunit alpha and ATP synthase subunit beta (mitochondrial), 
the other mitochondrial proteins of interest detected during this study, 
agmatinase, ATP-binding cassette, sub-family B, member 8 and long chain 
specific acyl CoA dehydrogenase, were found to be reduced. Agmatinase 
(mitochondrial) was reduced in the liver tissue of both male and female Fabry 
mice. This protein is responsible for the hydrolysis of agmatine to putrescine 
and urea. Reduced levels of this enzyme may therefore result in a build-up of 
agmatine which has been reported to stimulate hepatic fatty acid oxidation 
(Nissim et al., 2006).  
 
Long chain specific acyl CoA dehydrogenase (mitochondrial; LCAD) is one of 
the four enzymes that catalyses the initial step of mitochondrial beta-oxidation 
of straight chain fatty acids in mice (Chegary et al., 2009) and this enzyme was 
found to be reduced in heart tissues of both male and female Fabry mice. 
Mitochondrial dysfunction has been shown to result in a reduction of the 
enzymes involved in beta-oxidation and importantly reduced cardiac fatty acid 
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oxidation has been proposed as a consequence of pathological left ventricular 
hypertrophy (Ingwall 2009; Ellis et al., 2011), the most common cardiac 
abnormality experienced in patients with Fabry disease. In addition, in a mouse 
model of LCAD deficiency, 10% of male adult mice were shown to develop 
cardiomyopathy. Furthermore sudden death was observed in 3% of LCAD 
deficient mice (Kurtz et al., 1998). This underlines the vital role of mitochondrial 
fatty acid oxidation and LCAD in vivo. The finding in this study that LCAD is 
reduced significantly in Fabry mice requires further investigation to establish if 
this enzyme could play a role in the underlying pathological mechanism of 
cardiomyopathy in Fabry disease.  
The third mitochondrial protein shown to be altered, ATP-binding cassette sub-
family B member 8, was found to be reduced in brain tissue and as yet the 
function of this ATP-dependent transporter has not been fully elucidated. 
However, it has been postulated to be involved in the transport of both organic 
and inorganic molecules out of the mitochondria. In a mouse model with loss of 
function for the related gene that encodes for this protein, a disruption of iron 
homeostasis between the mitochondria and cytosol has been demonstrated 
(Allikmets et al., 1996).   
Alpha-synuclein was also found to be reduced in male and female Fabry mouse 
brain tissue. This protein is highly abundant in brain and whilst the exact 
function of alpha-synuclein remains unclear it is known to be the major 
component in Lewy bodies and Lewy neurites (Marques and Outeiro 2012; 
Olanow and Brundin 2013). In contrast to the reduction of alpha-synuclein 
observed in this study, Nelson et al., (2014) have reported an accumulation of 
an aberrant phosphorylated form of α-synuclein in the brain of α-Gal A deficient 
mice. Further studies are therefore required in order to validate these findings 
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before conclusions as to the implications for the neuropathology of Fabry 
disease can be made. Loss of alpha-synuclein, as detected in this study, has 
been observed in the aging mouse brain with one study suggesting that alpha-
synuclein could contribute to, or be a marker of, synaptic dysfunction (Mak et 
al., 2009). Synaptic dysfunction has been associated with depression (Duman 
and Aghajanian 2012), which is a frequent but under-recognised finding in 
Fabry disease, however as yet there are no reports linking synaptic dysfunction 
with depression in Fabry disease.    
Further to the label-free proteomic profiling of Fabry mouse tissues those 
proteins of interest, i.e. those proteins shown by both analysis platforms as 
having alterations, were interrogated with the GO annotation system using the 
PANTHER website. By analysing the data in this way the molecular functions, 
biological processes and/or biological pathways that each protein is connected 
to is revealed thereby enabling common links between proteins to be 
established. Following this analysis six molecular functions were revealed to be 
associated with the proteins of interest. Three of these, catalytic activity, binding 
and transporter activity, were shown to involve proteins found to be increased, 
as well as proteins that were shown to be decreased, in the tissue in which they 
were detected. A possible explanation for this is the fact that each organ has a 
specific function and therefore a generalised increase or decrease in a 
molecular function such as transporter activity is unlikely. However, identifying 
increases or decreases in proteins associated with a molecular function and a 
specific tissue type could help elucidate underlying molecular mechanisms. Five 
of the six molecular functions revealed by the GO annotation system were 
shown to involve ATP synthase subunits alpha and beta (mitochondrial), both of 
which were found to be increased during the label-free analysis. This illustrates 
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what a critical role these proteins perform and reinforces the suggestion that 
increases in the levels of these proteins will most likely have an effect on 
molecular function. Interestingly, two molecular functions, ion channel and 
receptor activity, were shown to be associated with only the ATP synthase 
subunits, of the proteins of interest detected in the label-free study. Potential 
increases in these molecular functions could influence cellular and functional 
activities performed at the molecular level and potentially have a role in the 
underlying molecular mechanism of Fabry disease.      
Nine biological processes were revealed from the GO annotation analysis to be 
associated with one or more of the proteins of interest detected during the label-
free proteomic aspect of the study. Each biological process is a collection of 
multiple molecular events pertinent to the correct functioning of cells, tissues 
and organs. The proteins alpha synuclein and ATP-binding cassette, sub-family 
B, member 8 (mitochondrial), both of which were found to be decreased in 
Fabry mouse brain tissue, were shown to be involved in seven of the nine 
biological processes revealed. A number of these biological processes including 
immune system response, cell communication and response to stimulus have 
been shown to be involved with the nervous system (Kawli, He and Tan 2010; 
Susuki K 2010). A number of neurological manifestations including peripheral 
and central nervous system involvement have been described in patients with 
Fabry disease (Schiffmann and Moore 2006) and therefore it seems probable 
that a decrease in a protein involved in one or multiple steps of a biological 
process will have an effect on the optimal operation of that process resulting in 
biological consequences.   
Of the seven proteins of interest identified during the label-free analysis three 
were found to be involved in biological pathways using the GO annotation 
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system. ATP synthase subunits alpha and beta (mitochondrial) are heavily 
involved in the ATP synthesis pathway and the role that these subunits have 
within ATP synthase (complex V) and ATP synthesis has been discussed. The 
third protein, alpha synuclein, was shown to be involved in the Parkinson’s 
disease pathway. This protein was found to be decreased in Fabry mouse brain 
tissue and could support the observations that neurodegeneration is not a 
prominent feature in Fabry disease, unlike some of the other lysosomal storage 
disorders (Jeyakumar et al., 2005). However, a common factor that these 
diseases do share is that both are associated to be protein-misfolding disorders 
(Garman 2007). The literature describes only two patients with both Fabry 
disease and Parkinson’s disease (Orimo et al., 1994; Buechner et al., 2006) 
nevertheless one of these studies postulates that Fabry disease may provoke 
Parkinsonism as a result of some of the common neurological manifestations 
observed in Fabry disease including lacunas in the basal ganglia and Gb3 
accumulation in the substantia nigra (Buechner et al., 2006). These suggestions 
may be supported by Nelson et al., (2014) where in a recent study the 
accumulation of aberrant phosphorylated-α-synuclein in the brains of α-Gal A 
deficient mice was demonstrated. However, further investigations are required 
to fully understand the implications of these findings not only on the 
neuropathology associated with Fabry disease but also before any potential 
links between Fabry disease and the pathogenesis of age-related 
neurodegenerative disorders such as Parkinson’s disease can be made.  
Following the proteomic profiling aspect of this study two novel protein: 
glycosphingolipid interaction methodologies were used in order to identify 
proteins that interact solely with Gb3 and also proteins that interact with a group 
of glycosphingolipids to gain an understanding of the underlying disease 
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mechanisms associated with Fabry disease and other lysosomal storage 
disorders in the glycosphingolipid biosynthetic pathway (Figure 1.2). The first 
methodology used a novel method based on RS100 ProteinChip technology to 
bind deacylated or ‘lyso’ versions of the glycosphingolipid of interest through a 
C12-linker arm. The second, Dynabead® M-270 epoxy methodology, uses 
similar principles to bind deacylated glycosphingolipids to beads, rather than a 
ProteinChip, and through a C5 rather than a C12-linker arm. Thus, the classes 
of proteins binding to each array differ by their affinities to the hydrophobicities 
of the acyl moiety of the glycosphingolipids (C5 versus C12). Both 
methodologies effectively restore the deacylated glycosphingolipids to their 
acylated counterparts. However, it should be noted that in both protein: 
glycosphingolipid methodologies an inherent limitation of binding the 
glycosphingolipids to the surface of the chip/beads through the fatty acid group 
is that the number of interactions available with this portion of the molecule are 
limited. Consequently, some interactions will not be able to be formed and 
subsequently detected. However, the carbohydrate region which is unique to 
each of the molecules and the sphingosine moiety, which is common to each of 
the molecules, are readily available for interaction. In this study, many more 
protein interactions were identified using the RS100 ProteinChip than the 
Dynabead® M-270 epoxy methodology. There could be a number of reasons 
for this including the fact that the RS100 ProteinChip binds through a C12 rather 
than a C5-linker arm, as used in the Dynabeads® M-270 Epoxy methodology. 
This may suggest that binding interactions are more readily formed when a 
longer acyl moiety is available. Other possibilities for the differences between 
the two methodologies may be that control mouse brain tissue was used with 
the RS100 ProteinChip and control mouse kidney tissue was used with the 
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Dynabeads®, and therefore a direct comparison of the interactions observed 
with each methodology may be inappropriate. Furthermore, although PBS was 
used to control for any for non-specific binding with both methodologies, the 
high number of interactions identified with the RS100 ProteinChip suggests that 
a more stringent wash procedure may be required with this methodology. 
Unfortunately, due to time constraints optimisation of binding conditions in order 
to minimise non-specific binding was not possible for the purpose of this thesis. 
However, before further experimentation using this methodology is performed 
optimum binding conditions should be established.  
Following the exclusion of those proteins displaying non-specific binding, using 
both analysis methods, three common interactions were detected. The proteins 
beta-actin-like protein 2 and tubulin alpha-1B chain were detected to bind only 
to GM1 ganglioside and aspartate aminotransferase (mitochondrial) was 
detected to bind to both Gb3 and GM1 ganglioside. In addition, a number of 
mitochondrial proteins were revealed to interact with the glycosphingolipids 
using both methods. Interestingly, no lysosomal proteins (e.g. saposins) and 
associated lysosomal pathways were detected during the protein: 
glycosphingolipid binding experiments. This suggests that in order to identify 
these interactions may require experimentation under acidic conditions 
representative of that of the lysosome. 
During the RS100 ProteinChip analysis, proteins that interacted with Gb3 and/or 
GM1 ganglioside in control mouse brain tissue were identified. Of the 157 
proteins detected in total as binding to Gb3 and/or GM1 ganglioside during the 
study, 32 proteins were found to interact with both glycosphingolipids.  
Interestingly, 3 proteins detected during the proteomic profiling study, ATP 
synthase subunit alpha (mitochondrial), ATP synthase subunit beta 
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(mitochondrial) and alpha-synuclein were also found to bind to both Gb3 and 
GM1 ganglioside. All proteins that interact with Gb3 and/or GM1 ganglioside 
were subsequently classified according to the GO annotation system using the 
PANTHER website to enable proteins to be grouped according to common 
functions, processes or pathways. This analysis identified the most common 
molecular functions associated with proteins that bind to Gb3 and/or GM1 
ganglioside to be catalytic activity and binding. Following further interrogation of 
the catalytic activity category most proteins were found to possess hydrolase, 
transferase and/or oxidoreductase activities. Proteins that bound to Gb3 and/or 
GM1 ganglioside and possessed binding activity were also able to be further 
subdivided showing that most proteins detected were protein binding proteins.   
When the biological processes associated with the proteins identified as binding 
to Gb3 and/or GM1 ganglioside were defined, the most proteins detected were 
found to be associated with metabolic processes. When this category was 
further sub-divided, the most common sub-category was nucleobase, 
nucleoside, nucleotide and nucleic acid metabolic processes. Other common 
metabolic processes associated with the proteins that bind to Gb3 and/or GM1 
ganglioside included carbohydrate and protein metabolism. It is not unexpected 
that proteins responsible for these metabolic processes would interact with 
glycosphingolipids that accumulate as a result of a deficiency of a lysosomal 
enzyme as in addition to these lipids the lysosome is responsible for the 
catabolism of various proteins, carbohydrates and nucleic acids via a variety of 
acid hydrolases. Interestingly, three categories of biological processes, nitrogen 
compound metabolic processes, lipid metabolic processes and cell adhesion 
were all found to contain proteins that bound only to GM1 ganglioside.  
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The proteins identified as binding to Gb3 and/or GM1 ganglioside were found to 
be associated with a large number of biological pathways, with most proteins 
detected found to be connected to the Huntington disease biological pathway. 
Huntington’s disease is a progressive neurodegenerative disorder and recently 
a link between lysosomal dysfunction and neurodegenerative diseases such as 
Huntington’s, as well as Parkinson’s disease and Alzheimer’s disease, has 
been shown (Usenovic and Krainc 2012). In addition, similaraties also exist 
between the dyshomeostasis of Ca2+ and/or the mitochondrial stress that is 
involved in Huntington’s disease with that observed in lysosomal storage 
disorders (Giacomello, Hudec and Lopreiato 2011). Interestingly, like Fabry 
disease and Parkinson’s disease, Huntington’s disease is also associated with 
protein mis-folding (Garman 2007). Of the proteins detected to be involved in 
the Huntington’s disease pathway more were found binding to GM1 ganglioside 
than Gb3. The age of onset of GM1 gangliosidosis type III and some of the 
clinical features including dystonia and parkinsonian features are the same as 
that experienced in Huntington’s disease (Roze et al., 2005; Louis et al., 1999). 
Another biological pathway involving a number of proteins was glycolysis. The 
free energy released during glycolysis is used to form ATP and NADH and as 
many proteins that interact with Gb3 and/or GM1 ganglioside have been 
identified as mitochondrial proteins or possessing catalytic activity involving 
ATP it is unsuprising that this biological pathway is one which most proteins are 
commonly assigned to by the GO annotation system.  
A second, complimentary protein: glycosphingolipid interaction study used 
Dynabeads® M-270 epoxy to identify proteins that interacted with Gb3 and a 
wider range of glycosphingolipids in control mouse kidney tissue. Of the 
proteins identified binding to Gb3 using this methodology a common association 
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with ATP was revealed with two proteins found to interact selectively and 
covalently with ATP and another functioning in the mitochondrial respiratory 
chain from which ATP is generated. In a study by Lücke et al., (2004) 
mitochondrial respiratory chain enzyme activities were investigated in 
fibroblasts from Fabry patients. This study demonstrated disruption of the 
mitochondrial respiratory chain enzymes (investigated and discussed in Chapter 
6) but no significant alteration in ATP production was shown.  
The glycosphingolipid that most proteins were detected binding to was 
galactosylceramide and of the proteins detected binding to this 
glycosphingolipid, three were found to be peroxisomal proteins. This was of 
particular interest as in a study by Khan et al., (2005), in which the effects of 
galactosylceramide on peroxisomal function and the relationship with reactive 
oxygen species were investigated, peroxisomal beta-oxidation was shown to be 
inhibited and very long chain fatty acids and free radicals were shown to be 
increased in cells treated with galactosylceramide. The study concluded that 
inhibition of peroxisomal function and increased free radical production by 
galactosylceramide may be partly be responsible for the oligodendrocyte and 
myelin loss observed in Krabbe’s disease (Khan et al., 2005).   
Whilst the proteins found to interact with GM1 ganglioside were limited, a 
common connection involving all three proteins with energy metabolism was 
established however, no other common connections could be determined. 
Unfortunately the limited number of proteins detected to interact with ceramide 
was not sufficient to establish any further relationship between functions, 
processes or pathways beyond that of both proteins possessing binding 
capacity.  
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Of the proteins detected as interacting with more than one glycosphingolipid 
using the Dynabeads® one, aspartate aminotransferase (mitochondrial) was 
found to interact with both Gb3 and GM1 ganglioside. This protein was also 
detected to bind to both Gb3 and GM1 ganglioside when these 
glycosphingolipids were immobilised on an RS100 ProteinChip. Aspartate 
aminotransferase is responsible for the catalysis and irreversible transamination 
of the L-tryptophan metabolite, L-kynurenine to form kynurenic acid. In addition, 
this protein is involved in amino acid metabolism, metabolite exchange between 
the mitochondria and the cytosol and facilitates the cellular uptake of long-chain 
fatty acids (Zhou et al., 1998). Aspartate aminotransferase levels are frequently 
used to diagnose myocardial infarction and viral hepatitis. Increases in 
aspartate aminotransferase levels have been reported in a small number of 
patients with Fabry disease treated with the ERT preparation Fabrazyme 
(Genzyme Corporation) (eHealthMe 2004). However, in a preclinical efficacy 
and safety study of 1-deoxygalactonojirimycin in mice for Fabry disease, levels 
of aspartate aminotransferase were unchanged (Ishii et al., 2009). Likewise a 
study by Ohshima et al., (1999) found no changes in aspartate 
aminotransferase levels in Fabry mice. Interestingly, activities of aspartate 
aminotransferase have also been shown to be increased in the cerebrospinal 
fluid (CSF) of dogs with GM1 gangliosidosis, leading to the suggestion that it be 
used as a biomarker to assess central nervous system degeneration in this 
animal model (Satoh et al., 2007).  
Another protein was found to interact with two glycosphingolipids, NADH 
dehydrogenase [ubiquinone] iron sulfur protein 6 (mitochondrial), interacted with 
both Gb3 and galactosylceramide. This protein is an accessory subunit of the 
mitochondrial respiratory chain enzyme, complex I but is not believed to be 
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involved in catalysis. Complex I activity has been shown to be reduced 
significantly in fibroblasts from Fabry patients (Lücke et al., 2004). In addition, 
galactosylsphingosine has been shown to inhibit complex I by interacting at this 
site and causing a change in the lipid environment of the membrane which is 
ultimately responsible for the mitochondrial dysfunctions observed to be 
induced by galactosylsphingosine (Tapasi, Padma, and Setty 1998).      
Although no protein was found to bind to all four glycosphingolipids when bound 
to the Dynabeads®, one protein, voltage dependent anion selective channel 
protein 1 (VDAC1), was found to interact with Gb3, galactosylceramide and 
sulfatide. This protein forms a channel through the mitochondrial membrane to 
allow the diffusion of small hydrophilic molecules and also through the plasma 
membrane where it is involved in regulation of cell volume and apoptosis. In 
addition, VDAC has been shown to be involved in the transport of ATP, ADP, 
pyruvate and other metabolites. A number of ATP-dependent enzymes have all 
been found to bind VDAC (Törnroth-Horsefield and Neutze 2008). VDAC is also 
an important regulator of Ca2+ transport in and out of the mitochondria (Báthori 
et al., 2006). 
Another ion channel, potassium-voltage gated channel subfamily H member 1, 
was found to bind explicitly to Gb3. Voltage-gated ion channels are associated 
with neuronal excitability and voltage-gated potassium channels (KV) have been 
shown to be important regulators of membrane potentials, action potential 
shape and firing adaptation in excitable tissues including nociceptive sensory 
neurons. Injury and inflammation of peripheral nerves has been shown to 
reduce the densities of potassium-voltage gated channels implicating them in 
the development of neuropathic/inflammatory pain (Takeda et al., 2011). As 
neuropathic pain is one of the most frequent, early and debilitating clinical 
- 327 - 
 
manifestations experienced in patients with Fabry disease and this KV channel 
was found binding explicitly to Gb3, the effect of Gb3 and in addition lyso-Gb3, 
on pain thresholds in mice was assessed using a von Frey assay. This assay 
was performed by Professor John Woods molecular nociception group at UCL 
as part of a collaborative project.      
The results of this study demonstrated that the injection of either Gb3 or lyso-
Gb3 into the hind paw of a mouse results in a significant increase in sensitivity 
to mechanical stimuli. Statistically significant increases in sensitivity were 
obtained using students t-test, 0.5, 1, 2 and 4 hrs post injection, with the highest 
degree of sensitivity observed at the 2 hr post injection time point. Increases in 
sensitivity continued to be observed 6 hrs post injection, although not to the 
point of statistical significance and sensitivity 24 hrs post injection had reverted 
back to almost baseline/control responses. No difference in the effect on 
sensitivity between injection with Gb3 or lyso-Gb3 was observed when each 
metabolite was injected at a high concentration level. The high Gb3 
concentration level used in this study is the equivalent to those levels observed 
in the plasma of Fabry patients with a severe disease phenotype. However, in 
order to assess sensitivity, using this methodology, required the injection of 
lyso-Gb3, at levels although one-hundred times less concentrated than that of 
Gb3 are significantly more concentrated than lyso-Gb3 levels observed in vivo. 
Injection at these concentrations resulted in almost identical pain thresholds 
between the two metabolites suggesting that lyso-Gb3 is one-hundred times 
more potent in creating a pain response than Gb3. However, it is unlikely that 
lyso-Gb3 levels in vivo would ever reach concentrations as high as those used 
in this study. Therefore, this finding may suggest that in vivo Gb3 is responsible 
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for the nociceptive pain experienced in Fabry disease however, this requires 
further investigation.   
Of particular interest during this study was the observation that ATP synthase 
subunits alpha and beta (mitochondrial) were increased in either the heart or 
liver and kidney tissues from male and female Fabry mice. In addition, these 
subunits were found to bind to both Gb3 and GM1 ganglioside when immobilized 
on the RS100 ProteinChip. As a result the effect of several glycosphingolipids in 
the glycosphingolipid biosynthetic pathway and their corresponding deacylated 
or ‘lyso’ counterparts, were assessed regarding their effect on ATP synthase 
activity. In addition, as a comparison the effect of cardiolipin, a complex 
phospholipid found almost exclusively in the inner mitochondrial membrane and 
required to maintain ATP synthase (complex V) structure and function was also 
assessed as a positive control molecule (Lee 1995).  
Following the assessment of all lipids on complex V activity at high, medium 
and low concentrations the phospholipid cardiolipin, as expected, was shown to 
produce the most pronounced effect. Statistically significant increases in ATP 
synthase activity were observed at all concentration levels tested which are 
most likely as a result of the phospholipids high binding affinity for complex V.  
At the highest concentration level assessed the glycosphingolipids GM1 
ganglioside, Gb3, sulfatide and lactosylceramide were all shown to increase 
significantly ATP synthase activity. In addition, all lyso-glycosphingolipids, with 
the exception of lyso-galactosylceramide, were also shown to increase 
significantly ATP synthase activity. When the effect of high level 
glycosphingolipids were compared with the effects of high level lyso-
glycosphingolipids on ATP synthase activity most high level compounds were 
shown to induce similar effects on ATP synthase activity. The exceptions to this 
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were the glycosphingolipids GM1 ganglioside and sulfatide which were shown to 
increase ATP synthase to a greater extent than their deacylated counterparts. 
Furthermore, at this high concentration level GM1 ganglioside was the only 
glycosphingolipid to effect ATP synthase activity to a similar extent as that 
shown by cardiolipin. Interestingly, this was only observed at the high 
concentration level and not at the medium or low concentration levels used in 
this study.    
When the medium concentration level of compounds were assessed, only GM1 
ganglioside and lactosylceramide were shown to increase significantly ATP 
synthase activity. Of the lyso-glycosphingolipids, lyso-GM1, lyso-Gb3, and lyso-
glucosylceramide were also found to increase significantly ATP synthase 
activity. On comparison of the effects of glycosphingolipids and their deacylated 
counterparts lyso-Gb3 and lyso-galactosylceramide were shown to have more of 
an effect on ATP synthase activity. However, the opposite was so for 
lactosylceramide, with this glycosphingolipid producing more of an effect on 
ATP synthase activity that its deacylated counterpart.         
No significant increases in ATP synthase activity were demonstrated using any 
glycosphingolipid or lyso-glycosphingolipid at the lowest concentration level 
assessed. However, lyso-Gb3 and lyso-GM1 were shown to increase ATP 
synthase activity to a greater extent than their acylated counterparts. As 
observed at the medium concentration level lactosylceramide produced more of 
an effect on ATP synthase activity than lyso-lactosylceramide.      
As the levels of lyso-glycosphingolipids used to assess the effect on ATP 
synthase activity were significantly less concentrated than those of the 
corresponding levels of glycosphingolipids this, as observed in the von Frey 
nociception assay, supports the hypothesis that lyso-Gb3 is more toxic than 
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Gb3. However, in this study the concentrations of the high, medium and low 
level glycosphingolipid concentrations are based on plasma Gb3 levels 
described in patients with severe Fabry disease, mild Fabry disease and those 
with no detectable disease, respectively. In comparison the levels of lyso-
glycosphingolipids, although considerably less concentrated, are still higher 
than those levels observed in a diseased state. In fact, in an assessment of 
Fabry patients the low concentration level of lyso-glycosphingolipids was found 
to be the equivalent of physiological levels observed in plasma. At this level the 
lyso-glycosphingolipids did not produce any effect on ATP synthase activity. 
Therefore it is most likely that it is the glycosphingolipids and not their 
deacylated counterparts that are affecting ATP synthase activity in vivo.       
One hypothesis to account for the increase in ATP synthase activity shown by 
some glycosphingolipids could be that in lysosomal storage disorders where 
glycosphingolipids accumulate, the extra availability of certain 
glycosphingolipids are able to displace cardiolipin and bind to ATP synthase in 
its place. Further evidence to support this, is the finding demonstrated in this 
study, that ATP synthase subunits alpha and beta were shown to bind to the 
glycosphingolipids Gb3 and GM1 ganglioside when immobilised on a RS100 
ProteinChip. However, the observation that increased concentrations of pure 
glycosphingolipids and their deacylated counterparts increase ATP synthase 
activity may not be concomitant with an increase in ATP or indeed any 
noticeable disruption to this pathway in vivo. In fact, a single study analysing 
complex V activity in fibroblasts from three Fabry patients has shown a 
significant decrease in complex V (Lücke et al., 2004). However as 
mitochondria isolated from control rat liver were used to perform this experiment 
assumptions relating to the findings obtained from the study by Lücke et al., 
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(2004) may not be appropriate. Mitochondria isolated from control rat liver 
tissue were used as the starting material in this study as a limitation of the ATP 
synthase assay used was incompatibility with mouse tissues. The analysis of 
tissues from Fabry mice utilising a different methodology is required in order to 
confirm the findings in this study and also to provide more information as to ATP 
synthase activity and ATP production in vivo. Only these further analyses will 
enable a more in-depth understanding of the complex mechanism associated 
with this essential pathway to be obtained and conclusions to be drawn 
regarding its role in Fabry disease.  
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5.4 Conclusion 
This study has used a number of complimentary rationales to investigate the 
toxicity of Gb3 and lyso-Gb3 in the Fabry mouse model in order to gain a better 
understanding of the underlying disease mechanisms associated with Fabry 
disease pathology. Following an initial label-free quantitative proteomic study to 
create a proteomic profile of Fabry mouse tissues a number of proteins were 
found to have fold change alterations by the software platforms ProteinLynx and 
Progenesis LC-MS. Two of these proteins, ATP synthase subunit alpha and 
ATP synthase subunit beta (mitochondrial) were of particular interest and were 
selected for further investigation. Subsequently a number of glycosphingolipids 
and their deacylated counterparts were assessed as to their effect on ATP 
synthase activity. The results obtained from this aspect of the study showed that 
a number of these compounds significantly alter ATP synthase activity and 
suggest that in environments where there are increased levels of some 
glycosphingolipids e.g. Gb3 as in Fabry disease, the glycosphingolipid could 
theoretically displace the cofactor cardiolipin, which is required for the optimal 
operation of ATP synthase and binds to the enzyme in its place. Further studies 
are required to confirm this hypothesis and also to ascertain what, if any, 
downstream consequences result from an increase in ATP synthase activity.    
Following the proteomic study protein interactions with a number of proteins in 
the glycosphingolipid biosynthetic pathway, with particular interest on Gb3, were 
investigated using two complementary binding methodologies. This aspect of 
the study demonstrated that many of the proteins that interact with the 
glycosphingolipids are involved in a number of vital molecular functions, 
biological processes and biological pathways. In addition, a number of these 
proteins were found to have a role in energy production which consequently 
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may be affected by binding to a glycosphingolipid when an accumulation occurs 
such as in a lysosomal storage disorder.  
In addition to those proteins found to bind non-selectively to glycosphingolipids, 
some proteins were found to bind exclusively to a specific glycosphingolipid 
demonstrating an affinity for the sugar portion of the molecule, unique to each 
glycosphingolipid. One such protein was potassium-voltage gated channel 
subfamily H member 1, which was found to bind explicitly to Gb3. This prompted 
the investigation of touch thresholds in mice following exposure to Gb3 or lyso-
Gb3. Interestingly, this aspect of the study demonstrated that high levels of both 
Gb3 and lyso-Gb3 increase significantly the sensitivity to an applied mechanical 
stimulus. However, due to the concentration levels used in this study it is 
postulated that it is Gb3 and not lyso-Gb3 that is responsible for nociceptive pain 
in vivo in Fabry disease. However, ultimately before conclusions can be drawn 
this requires further investigation.     
In conclusion, this study has investigated the toxicity of Gb3 and lyso-Gb3 in a 
Fabry mouse model which has led to the identification of a number of potential 
mechanisms responsible for the underlying pathology associated with Fabry 
disease. Whilst further investigations are required to both confirm and expand 
aspects of this work, this study has highlighted a number of important avenues 
for investigation that have as yet received little or no attention in Fabry disease. 
It is only once all these avenues have been investigated that we will be able to 
fully understand this complex disease. 
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6.0 The investigation of mitochondrial respiratory chain enzyme 
activities in a Fabry mouse model 
 
6.1 Introduction 
 
In the study described in Chapter 5, a number of interactions between Gb3 and 
different mitochondrial proteins were detected. Of these proteins one, ATP 
synthase, was of particular interest and further targeted investigations found 
ATP synthase activity was increased in the presence of increasing 
concentrations of both Gb3 and lyso-Gb3. ATP synthase is part of the oxidative 
phosphorylation (OXPHOS) system, located in the mitochondrial inner 
membrane. In addition to ATP synthase, the OXPHOS system comprises four 
multi-subunit mitochondrial respiratory chain complexes, as well as the mobile 
electron carriers, cytochrome c and ubiquinone (Figure 6.1). Together these 
components of the mitochondrial respiratory chain are responsible for electron 
transport and contribute to the generation of the proton gradient in the 
mitochondrial intermembrane space that drives the synthesis of ATP by ATP 
synthase (Fernández-Vizarra, Tiranti and Zeviani 2009).   
The first and largest enzyme in the mitochondrial respiratory chain and 
OXPHOS system is complex I (nicotinamide adenine dinucleotide (NADH): 
ubiquinone oxidoreductase). The L-shaped structure of Complex I is composed 
of 45 subunits, 7 of which are encoded by the mitochondrial DNA (mtDNA) with 
the remaining 38 subunits encoded by the nuclear genome (Carroll et al., 2006). 
Complex I is responsible for the oxidation of NADH from the tricarboxylic acid 
cycle and beta oxidation, the two electrons produced during this reaction are 
transferred via flavin mononucleotide and iron-sulfur prosthetic groups and are 
subsequently used in the reduction of ubiquinone to ubiquinol (Baradaran et al., 
2013; Hirst 2009; Hirst 2013). The potential energy produced by the redox 
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reaction is coupled to the transfer of 4H+ across the mitochondrial inner 
membrane from the matrix to the intermembrane space. This contributes to the 
proton motive force that supports ATP synthesis and the mitochondrial import 
and export of metabolites and proteins (Hirst 2013). 
The second complex in the mitochondrial respiratory chain, complex II 
(succinate: ubiquinone oxidoreductase) is composed of 4 subunits and is the 
only complex in the mitochondrial respiratory chain encoded solely by the 
nuclear genome (Pearl 2013). Complex II is responsible for the oxidation of 
succinate to fumarate as part of the citric acid cycle, resulting in the transfer of 
electrons to covalently bound flavin adenine dinucleotide (FAD) to generate 
FADH2. FADH2 then transfers electrons via iron-sulphur clusters and 
cytochrome b to reduce ubiquinone to ubiquinol (Cecchini 2003; Pearl 2013).  
The penultimate subunit in the mitochondrial respiratory chain is complex III 
(ubiquinol: cytochrome c oxidoreductase). This complex is formed of 11 
subunits of which 3, cytochrome b, cytochrome c1 and the Rieske iron sulfur 
protein are encoded by mtDNA (Pearl 2013). Complex III functions to catalyse 
the oxidation of ubiquinol and the reduction of cytochrome c operating though a 
Q-cycle mechanism which couples electron transfer to the generation of the 
proton gradient (Schapira 2003). To achieve this first, two electrons are 
removed from reduced ubiquinol at the ubiquinone binding site (QO-site) of the 
complex and sequentially passed to two different chains. The first electron is 
transferred via the Rieske iron sulfur protein (ISP) and cytochrome c1 to reduce 
cytochrome c, enabling the small heme-containing protein to diffuse away from 
complex III. The second electron from ubiquinol is transferred via low- and high-
potential hemes of cytochrome b (cytochrome bL and cytochrome bH, 
respectively) to oxidised ubiquinone bound at a second quinone processing site, 
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the Qi-site, producing a ubisemiquinone. The process is then repeated, a 
second molecule of reduced ubiquinol binds at QO, transferring one electron to 
a cytochrome c molecule and a second electron to ubisemiquinone at Qi to give 
ubiquinol. Each reduction of a ubiquinol molecule results in the release of 2H+ 
into the intermembrane space. In addition, 2H+ from the mitochondrial matrix 
are utilised by the reduction of ubiquinone at Qi (De Vries et al., 1982; Crofts 
2004).       
Complex IV (cytochrome c oxidase) is the terminal enzyme in the mitochondrial 
respiratory chain and is made up of 13 subunits. The three subunits composed 
of copper redox centres, cytochrome and heme are endoed by mtDNA with 10 
smaller subunits which are nuclear encoded (Pearl 2013). The role of complex 
IV is to transfer four electrons, from four molecules of cytochrome c, in order to 
catalyse the reduction of oxygen to two water molecules (Brzezinski and Gennis 
2008). Cytochrome c oxidase has four redox centres two of which are copper 
centres, CuA and CuB, and two of which are heme centres, heme a and heme 
a3. An electron from the first molecule of oxidised cytochrome c is transferred 
via CuA, heme a and heme a3, to CuB reducing Cu
2+ to Cu+. An electron from a 
second molecule of cytochrome c is transferred via CuA, heme a and heme a3 
reducing Fe3+ to Fe2+. Subsequently oxygen binds to heme a3 followed by CuB 
resulting in a peroxide bridge forming between these two centres. Third and 
fourth electrons from two further oxidised cytochrome c molecules and 2H+ from 
the mitochondrial matrix sequentially break this bond, producing hydroxyl 
groups bound to the copper and iron in CuB and heme a3, respectively. Finally, 
the addition of 2H+ from the mitochondrial matrix produces 2H2O from the 
hydroxyl groups. Concurrently 4H+ are removed from the mitochondrial matrix 
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and translocated across the membrane to the intermembrane space, 
contributing to the proton gradient (Wikström 1977; Wikström 2004).  
Of the mitochondrial respiratory chain enzymes complexes I, III and IV all 
contribute during electron transport to the H+ gradient across the mitochondrial 
inner membrane. This H+ gradient is used to generate the proton motive force 
that supports ATP synthesis via ATP synthase (complex V or F0F1-ATP 
synthase). ATP synthase is a large protein complex composed of a membrane-
embedded domain (F0), central and side stalks and a large headpiece (F1). ATP 
synthase can be thought of as a complex of two motors, an ATP driven F1 
motor and a proton driven F0 motor which are connected by a common rotary 
shaft (von Ballmoos, Cook, and Dimroth 2008). In functional mitochondria the 
proton flow through F0 causes rotation of the F0 rotor which in turn changes the 
conformational state of subunits within the F1 domain resulting ultimately in the 
synthesis of ATP. However, the reaction is reversible and when the H+ gradient 
across the mitochondrial inner membrane decreases ATP synthase can utilise 
ATP hydrolysis in the F1 domain to induce the rotation of the F0 rotor in the 
reverse direction thereby driving proton pumping (Orriss et al., 1998; Stock, 
Leslie and Walker 1999). 
The mitochondrial respiratory chain has been recognised as a potential source 
of reactive oxygen species (ROS) which include superoxide (O2-), hydrogen 
peroxide (H2O2) and the hydroxyl free radical (∙OH). Within the respiratory 
chain, complex I and complex III are considered as the main producers of 
superoxide anions that are released into the mitochondrial matrix and the 
intermembrane space, respectively. Damage to the mitochondrial respiratory 
chain could alter ATP synthesis resulting in a perturbation of energy to the cell 
and mitochondrial ROS production has been associated with the aging process 
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and in the pathogenesis of neurodegenerative diseases such as Parkinson’s 
disease (Liu, Fiskum and Schubert 2002; Dröse and Brandt 2012). 
In the study described in the previous chapter an increase in ATP synthase 
activity was demonstrated when the enzyme was exposed to both Gb3 and lyso-
Gb3 at levels representative of those observed in Fabry disease. Therefore, in 
the present study the activities of the enzymes that precede ATP synthase, the 
mitochondrial respiratory chain enzymes, were investigated in the tissues of a 
Fabry mouse model.  
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Figure 6.1 Schematic representation of the mitochondrial respiratory chain. Electron (e-) flow, depicted by the dotted line, drives the 
translocation of 10 protons from the mitochondrial matrix to the intermembrane space. Q; ubiquinone; Cyt C; cytochrome c;   
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6.2  Results  
 
All investigations outlined in the following section were performed on tissues 
from a Fabry mouse model (see section 2.1.2.4) provided by Dr Raphael 
Schiffmann, Baylor University Medical Centre as part of a collaborative project. 
All tissues were homogenised prior to analysis as described in section 2.2.8.1.    
 
6.2.1  Gb3 and lyso-Gb3 analyses of Fabry mouse tissues 
 
Gb3 and lyso-Gb3 analyses (as described in section 2.2.1) were performed on 
liver, kidney, heart and brain tissue from Fabry mice (n = 8) and wild-type 
control mice (n = 8). Both Gb3 (Figure 6.2) and lyso-Gb3 (Figure 6.3) levels were 
found to be statistically and significantly elevated by Students t-test (p < 0.05) in 
each tissue type compared to the respective control tissue group. 
 
 
 
Figure 6.2  Globotriaosylceramide (Gb3) levels in liver, kidney, heart and 
brain tissues from a Fabry mouse model (n = 8 per group). Data expresses 
as mean ± standard deviation. **** p < 0.0001 
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Figure 6.3  Globotriaosylsphingosine levels in liver, kidney, heart and 
brain tissues from a Fabry mouse model (n = 8 per group). Data expressed 
as mean ± standard deviation. * p < 0.05, **** p < 0.0001 
 
6.2.2  Assessment of mitochondrial respiratory chain enzymes in 
the tissues of a Fabry mouse model 
 
Citrate synthase activity is frequently used as a mitochondrial marker and also 
as a measure of mitochondrial enrichment (Winder and Holloszy 1977; Fatania 
and Dalziel 1980; Hargreaves, Heales and Land 1999). Following 
homogenisation of Fabry mouse tissues citrate synthase assays were 
performed on all samples as described in section 2.2.8.5. All mitochondrial 
respiratory chain enzyme activities are subsequently shown expressed as a 
ratio to citrate synthase with transformation of data prior to statistical analyses 
as described in section 2.2.8.6.  
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6.2.3 Assessment of complex I activity in the tissues of a Fabry mouse 
model 
 
Assessment of complex I activity as described in section 2.2.8.2 was 
determined in tissues from Fabry mice (n = 8) and wild-type control mice (n = 
8). No statistically significant differences in complex I activity were observed by 
Students t-test in liver (p = 0.18), kidney (p = 0.18), heart (p = 0.56) or brain (p = 
0.97) tissue from Fabry mice compared to the respective wild-type control group 
(Figure 6.4). A summary of the data is shown in Table 6.1.    
 
 
 
Figure 6.4  Complex I activity in liver, kidney, heart and brain tissues 
from Fabry and wild-type control mice. Data shown as a ratio to citrate 
synthase with transformation (n = 8 per group). Data expressed as mean ± 
standard deviation.    
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6.2.3  Assessment of complex II/III activity in the tissues of a Fabry 
mouse model 
 
A combined complex II/III assay was used to assess enzyme activity in Fabry 
mouse tissues as described in section 2.2.8.3. A statistically significant 
decrease (p < 0.02) in complex II/III activity was observed by Students t-test in 
kidney tissues from Fabry mice (n = 8) compared to kidney tissues from wild-
type control mice (n = 8) (Figure 6.5). However, no statistically significant 
alterations were observed in liver (p = 0.57), heart (p = 0.06) or brain (p = 0.34) 
tissues from Fabry mice (n = 8) compared to the respective control group (n = 
8). The operation of the complex II/III assay is dependent on ubiquinone 
availability and therefore it should be noted that a low activity of complex II/III 
may also be related to ubiquinone status. A summary of the data is shown in 
Table 6.1.  
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Figure 6.5  Complex II/III activity in liver, kidney, heart and brain tissues 
from Fabry and wild-type control mice. Data shown as a ratio to citrate 
synthase with transformation (n = 8 per group). Data expressed as mean ± 
standard deviation. * p < 0.05   
 
6.2.4  Assessment of complex IV activity in the tissues of a Fabry 
mouse model 
 
Assessment of complex IV activity as described in section 2.2.8.4 was 
determined in tissues from Fabry mice (n = 8) and wild-type control mice (n = 8) 
(Figure 6.6). No statistically significant differences in complex IV activity were 
observed by Students t-test in liver (p = 0.12), kidney (p = 0.36), heart (p = 0.14) 
or brain (p = 0.25) tissues from Fabry mice compared to the respective wild-type 
control mouse tissue. A summary of the data is shown in Table 6.1.     
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Figure 6.6  Complex IV activity in liver, kidney, heart and brain tissues of 
Fabry and wild-type control mice. Data shown as a ratio to citrate 
synthase with transformation (n = 8 per group). Data expressed as mean ± 
standard deviation.  
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Table 6.1 Mitochondrial respiratory chain enzyme activities in liver, kidney, heart and brain tissues from Fabry mice (n = 8) and 
wild-type control mice (n = 8). CS = citrate synthase; SD = standard deviation   
 
Tissue type 
Complex  I  
(corrected for CS and transformed) 
Complex II/III 
(corrected for CS and transformed) 
Complex IV 
(corrected for CS and transformed) 
Fabry Control p value Fabry Control p value Fabry Control p value 
Liver  
Mean ± SD 
0.53 ± 0.25 0.40 ± 0.05 0.18 0.27 ± 0.08 0.25 ± 0.05 0.57 0.05 ± 0.02 0.04 ± 0.01 0.12 
Kidney 
Mean ± SD 
0.60 ± 0.14 0.74 ± 0.26 0.18 0.32 ± 0.05 0.40 ± 0.07 0.02 0.04 ± 0.01 0.04 ± 0.01 0.34 
Heart 
Mean ± SD 
0.38 ± 0.10 0.35 ± 0.07 0.56 0.04 ± 0.02 0.06 ± 0.01 0.06 0.005 ± 0.002 0.006 ± 0.001 0.14 
Brain 
Mean ± SD 
0.36 ± 0.34 0.35 ± 0.23 0.97 0.25 ± 0.05 0.23 ± 0.03 0.34 0.04 ± 0.02 0.03 ± 0.02 0.25 
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6.2.5 Relationship of Gb3 and lyso-Gb3 levels to mitochondrial respiratory 
chain activity in a Fabry mouse model 
 
Following the observation that complex II/III activity was reduced statistically 
and significantly in kidney tissues from a Fabry mouse model, the relationship 
between these mitchondrial respiratory chain complexes with Gb3 (Figure 6.7a) 
and lyso-Gb3 (Figure 6.7b) levels were assessed. However, no correlation 
between complex II/III and Gb3 level (r = 0.4) or lyso-Gb3 level (r = -0.1) in Fabry 
mouse kidney tissues was demonstrated.          
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Figure 6.7 Lack of correlation observed between complex II/III activity with a.) Gb3 levels and; b.) lyso-Gb3 levels in kidney 
tissues from Fabry mice (n = 3). 
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6.3 Discussion 
 
Mitochondria are the so-called “powerhouses” of the cell. They are referred to 
as such due to the energy they produce in the form of ATP which provides more 
than 90 % of the cellular energy required to maintain its physiological activities 
(Szewczyk and Wojtczak 2002; Bertram et al., 2006). However, mitochondria 
provide much more than just the provision of ATP and exert multiple roles within 
the cell. Mitochondria are an important source of reactive oxygen species 
(Murphy 2009), function to maintain Ca2+ homeostasis (Patergnani et al. 2011) 
and play a key role in activating cellular proliferation and apoptosis (Wang and 
Youle 2009). Therefore, it is not surprising that mitochondrial dysfunction has 
been described in a number of diseases including neurodegenerative diseases 
such as Alzheimer’s disease and Parkinson’s disease (Mandemakers, Morais 
and Strooper 2007), diabetes (Blake and Trounce 2013) and epilepsy 
(Folbergrová and Kunz 2012).     
In the present study, mitochondrial respiratory chain enzyme activity has been 
assessed in the tissues of a Fabry disease mouse model. However, due to the 
discreet phenotype displayed by the Fabry disease mouse model, initial 
investigations to determine Gb3 and lyso-Gb3 levels in the tissues of Fabry and 
control mice were performed. This showed that statistically significant increases 
of both of these toxic metabolites were present in the liver, kidney, heart and 
brain tissues of the Fabry mice confirming that the tissues were suitable for 
subsequent analyses of the mitochondrial respiratory chain enzymes. 
Following analysis of the mitochondrial respiratory chain enzymes using 
established spectrophotometric methodologies a statistically significant 
reduction in complex II/III activity was observed in kidney tissues from Fabry 
mice compared to that of control mice. The kidneys are known to possess a 
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high density of mitochondria which are required in the production of ATP (Hall et 
al., 2008). ATP is essential to drive the sodium-potassium ATPase pump which 
in turn generates the electrical gradient across the proximal tubular epithelium 
responsible for maintaining low intracellular sodium levels (Niaudet 1998). The 
gradient drives all the activities of the renal proximal tubular cell including 
transport activity responsible for the reabsorption of > 99 % of the daily 
glomerular filtrate, most of which occurs along the proximal tubule (Hall et al., 
2008). Renal disease due to mitochondrial dysfunction or cytopathy has been 
described with common clinical manifestations including tubular disorders, 
chronic tubulointerstitial nephritis and glomerular diseases (Niaudet and Rotig 
1997; Doleris et al., 2000). The most common biochemical findings in these 
disorders are defects in complex III and/or complex IV (Emma et al., 2011). In 
this study the spectrophotometric methodology used determines combined 
complex II and complex III activity and therefore further analyses would be 
required to conclude if the significant reduction observed in this study was 
attributable solely to a reduction in the activity of complex III. In addition, the 
complex II/III assay is dependent on ubiquinone availability and therefore the 
reduced activities observed during this study may be attributable to an alteration 
in ubiquinone status however, subsequent analyses would be required to 
investigate this hypothesis.    
Renal impairment is reported in approximately half of all patients with Fabry 
disease with the developing proteinuric kidney complications similar to those 
experienced by diabetic patients (Schiffmann et al., 2009; Branton et al., 2002; 
Mehta et al., 2004). Previous studies have suggested that diabetes induces 
alterations in mitochondrial respiratory chain complex activity as well as 
mitochondrial respiration in the kidney (Rosca et al., 2005; Katyare and Satav 
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2005) and renal complex III has been shown to be a target for glycation and 
inhibition during chronic diabetes (Rosca et al., 2005). More recently, complex 
III activity has also been shown to be reduced significantly in rats induced with 
diabetes (Munusamy et al., 2009).   
The collective term ROS is used to describe a number of reactive molecules, 
such as H2O2, and free radicals, such as O2 
–, derived from molecular oxygen. 
Most molecular oxygen is reduced to water by complex IV of the mitochondrial 
respiratory chain. However, 1 – 4 % of oxygen is incompletely reduced to O2
- 
which primarily occurs at complex I and complex III making these complexes 
susceptible to oxidative damage (Bolaños et al., 1994; Bolaños et al.,1996). The 
production of O2
- at complex III is due to autoxidation of ubisemiquinone formed 
during the Q cycle process. The QO site of the complex is located close to the 
intermembrane space and is thought to be the major site of O2
- production 
(Zhang and Gutterman 2007). Interestingly, excess intracellular Gb3 levels have 
been shown to induce oxidative stress in vascular endothelial cells from Fabry 
disease patients (Shen et al., 2008). In addition, a study performed in a Fabry 
mouse model demonstrated uncoupling of endothelial nitric oxide synthase 
(eNOS) within the endothelium resulting in the subsequent generation of ROS 
(Shayman 2010). Furthermore, uncoupling of NOS has been shown to result in 
the formation of peroxynitrite which in addition to directly inhibiting the 
mitochondrial respiratory chain enzymes (Szabó 2003) has also been shown to 
inhibit various ion pumps including calcium pumps (Klebl, Ayoub, and Pette 
1998), calcium-activated potassium channels and membrane Na+/K+ ATPase 
activity (Muriel and Sandoval 2000). The effect of the inhibition of an ion pump 
would invariably lead to the dysregulation of ion balance in peroxynitrite-
challenged cells (Szabó 2003) and unsurprisingly, imbalance of  ion 
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homeostasis has previously been described in lysosomal storage disorders 
(Miedel et al., 2008).  
Although a statistically significant reduction in complex II/III activity was 
observed in the kidney of the Fabry mouse model, this result was not replicated 
in the other organs analysed. The activity of complex II/III in Fabry mouse heart 
tissue was shown to be reduced compared to that of control tissue however,  
this reduction did not quite reach statistical significance (p = 0.057). A large 
proportion of patients with Fabry disease experience cardiac involvement (see 
section 1.3.6.1) with the predominant cardiac manifestation reported to be left 
ventricular hypertrophy (Weidemann et al., 2005; Linhart et al., 2000; 
Kampmann et al., 2002; Senechal and Germain 2003). A number of patients 
with mitochondrial cytopathies are also reported to develop left ventricular 
hypertrophy and this condition is often attributable to inherited mutations in 
genes encoding metabolic pathways and mitochondrial proteins (Bos, Towbin 
and Ackerman 2009). The similarities in cardiac symptoms experienced by 
those patients with Fabry disease and mitochondrial cytopathies suggests that a 
common mechanism perhaps even reduction of complex II/III activity, which has 
previously been reported in heart failure (Jarreta et al., 2000), may be a 
contributing factor in the development of hypertrophic cardiomyopathy in these 
patients.      
No statistically significant alterations were observed in the activity of complex I 
or complex IV of the mitochondrial respiratory chain in any tissue type analysed 
in this study (see Table 6.1). Contrastingly however, Lücke et al., (2004) have 
previously reported statistically significant reductions in complex I and complex 
IV in fibroblasts from three patients with Fabry disease. An explanation for the 
difference in mitochondrial respiratory chain enzyme activity observed in this 
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study with that of Lücke et al., (2004) first and foremost may be attributable to 
the differences in biological material used for the analyses. In this study liver, 
kidney, heart and brain tissues from Fabry mice was analysed and therefore a 
comparison to activities in human Fabry fibroblasts may not be appropriate. In 
addition, the methodology used for the measurement of mitochondrial 
respiratory chain activity by Lücke et al., (2004) used a combined complex I + III 
and complex II + III assay. This differs to the methodology used in this study 
where a specific complex I activity protocol was used. Therefore, a direct 
comparison of these methods may not be suitable and may go some way to 
explain the differences observed.  
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6.4 Conclusion 
In conclusion, in this study a clear statistical reduction in the activities of the 
mitochondrial respiratory chain complex, complex II/III, in the kidney tissues of a 
Fabry mouse model has been demonstrated. When considering the high 
density of mitochondria in the kidneys combined with the amount of renal 
impairment observed in Fabry disease this finding is somewhat unsuprising. 
Futhermore, the fact that complex III is a primary site of ROS production and 
that uncoupling of eNOS within the endothelium resulting in the subsequent 
generation of ROS has been demonstrated in Fabry disease, further supports a 
reduction in complex II/III activity and suggests that this finding is most likely 
due to a reduction in complex III activity. However, due to the combined 
complex II/III assay used during this study further investigations are required to 
establish if the reduction in complex II/III observed in this study is attributable 
solely to a reduction of complex III. In addition, the nature of the complex II/III 
assay relies on the availability of ubiquinone and investigations to establish 
ubiquinone status would be required to fully establish the origin of the reduction 
of complex II/III activity. Additional investigations would enable a full and 
complete understanding of complex II/III in the Fabry mouse model to be 
achieved.   
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General discussion  
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7.0 General discussion  
 
The aim of this study was to identify potential diagnostic biomarkers and 
disease mechanisms in the lysosomal storage disorder Fabry disease. To 
achieve this goal both proteomic and metabolomic mass spectrometry based 
methodologies, as well as a number of complementary techniques, have been 
used.  
The initial aspect of this study used a label-free quantitative proteomic 
methodology to analyse urine samples obtained from paediatric Fabry disease 
patients prior to the initiation of ERT and again following 12 months of 
treatment. This enabled a typical urinary proteomic profile from paediatric Fabry 
disease patients to be created and also identified alterations in protein levels 
pre- and 12 months post-treatment. One protein, the lysosomal protein 
prosaposin, was shown to have a statistically significant reduction in the urine of 
these patients. Prosaposin is the precursor protein for the mature saposins A, 
B, C and D which are necessary for the hydrolysis of glycolipids with short 
glycan chains by lysosomal luminal hydrolases (Sandhoff, Kolter and Harzer 
2001). Therefore it was unsurprising that prosaposin would be elevated in the 
urine of these patients prior to treatment and previous studies have indeed 
demonstrated accumulations of the mature saposins in plasma and tissue of 
various lysosomal storage disorders (Chang et al., 2000; Morimoto et al., 1990). 
However, the MRM-based UPLC MS/MS assay that was developed in this 
study has enabled the rapid and reliable quantitation of prosaposin, verifying the 
findings of the label-free study, and providing confirmation that prosaposin was 
reduced significantly following one-year of treatment in paediatric Fabry disease 
patients. In addition to the Fabry disease patient group, an age- and sex-
matched healthy control group and a paediatric type I diabetic patient group 
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were also analysed. The type I diabetic patient group were selected for 
inclusion, for use as a positive control group, due to the fact that the developing 
proteinuric kidney complications are similar to those that develop in Fabry 
disease. Following analysis of prosaposin in these additional patient groups this 
protein was found to be elevated in only the pre-treatment Fabry disease group 
suggesting that a reduction in this protein biomarker, as observed following one-
year of ERT, may be indicative of an improvement in lysosomal function. 
However, to fully investigate this hypothesis in order to draw conclusions 
regarding the validity of prosaposin as a biomarker of improved lysosomal 
function and therefore of lysosomal storage orders in general, requires 
additional analyses. Furthermore, whilst the mature saposins A-D were able to 
be detected using the MRM UPLC-MS/MS assay developed in this study only 
saposin A was detectable in all patients. Saposins B, C and D were detectable 
in approximately 50 % of patients and whilst there could be a number of 
reasons for this, further development of the assay is required to optimise the 
detection of these mature saposins. A complete saposin assay would provide 
further information on a patient’s lysosomal status and could be a diagnostic 
tool in those sphingolipidoses requiring mature saposins as cofactors. 
In addition to the mature saposins A-D, the known saposins include the 
genetically distinct GM2AP. A small reduction in this protein was detected during 
the proteomic profiling study and due to the relationship with the saposins this 
protein was selected for inclusion into the initial MRM UPLC-MS/MS assay. The 
increased sensitivity and specificity of the MRM UPLC-MS/MS assay enabled a 
statistically significant reduction in this protein to be observed following 12 
months of treatment in paediatric Fabry disease patients. However, in contrast 
to prosaposin which was only found to be increased in the pre-treatment Fabry 
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disease patient group, GM2AP was also found to be increased in the paediatric 
type I diabetic group. Renal involvement is a major contributor to morbidity in 
Fabry disease patients with the developing proteinuric kidney complications, the 
same as those experienced by diabetic patients. Therefore it was postulated 
that the elevation in GM2AP levels in both the paediatric Fabry disease and type 
I diabetic patients could be an indicator of pre-symptomatic kidney disease. To 
investigate this hypothesis further a second MRM UPLC-MS/MS assay was 
developed. This assay encompassed a number of known and potential 
biomarkers of established renal disease. However, to assess the ability of these 
biomarkers to detect pre-symptomatic kidney disease a number of ‘at-risk’ 
paediatric patient groups, with no signs of microalbuminuria using conventional 
methods, were investigated. In addition, samples obtained from an adult Fabry 
disease and an adult type II diabetic group with a degree of renal involvement, 
as well as an adult control group were also analysed.  
Albumin, which at present is the principle biomarker used to monitor kidney 
function, was included in the assay. However, whilst none of the paediatric 
patients displayed detectable levels of microalbuminuria using conventional 
methods, this assay was able to detect alterations in this protein in these 
paediatric patient groups. This demonstrated the sensitivity of the assay and the 
ability of the method to detect pre-symptomatic kidney disease in ‘at-risk’ patient 
groups. Eleven potential biomarkers, in addition to albumin, were analysed in 
the multiplex pre-symptomatic kidney disease assay. A number of alterations in 
these proteins were identified in both the paediatric and adult patient groups. 
Many of the differences observed between the adult Fabry disease, type II 
diabetic and control groups reached statistical significance. This was expected 
as these patients have a degree of impaired kidney function however, by 
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analysing these potential biomarkers in the adult patient groups and relating 
them with levels observed in paediatric cohorts provides essential information 
as to the biomarkers most likely to become increased in the respective 
paediatric groups as kidney impairment progresses.  
As expected few of the changes detected in the paediatric patient groups 
reached statistical significance. This is most likely due to the age of these 
patients and that there is not, as yet, any significant kidney damage. This assay 
has demonstrated the ability to detect changes in a number of known renal 
biomarkers as well as a number of potential new renal biomarkers at extremely 
low levels demonstrating its potential to detect pre-symptomatic kidney disease 
in these patients. With the continued analysis of those patients most ‘at risk’ this 
assay may not only have the ability to detect pre-symptomatic kidney disease 
but also to establish the most appropriate time for therapeutic intervention. In 
addition, differences in the levels of these biomarkers between each of the 
patient groups suggests that this assay is sensitive enough to detect the rate of 
progression of renal disease and may highlight different aspects of renal 
disease to which different patient groups may be susceptible. Using the renal 
assay the assessment of renal biomarkers in pre-treatment Fabry disease 
patients and their levels following one- two and three-years of ERT was also 
assessed. Alterations in these potential biomarkers were revealed and 
importantly this assay further highlighted differences between those patients 
with the most disease and least disease burden. However, in order to draw 
conclusions about the effectiveness of ERT on renal disease assessment of 
progression of renal disease in those patients not receiving treatment would be 
required. With the growth of diabetes and obesity in society those ‘at-risk’ of 
developing renal disease is also increasing. Therefore a panel of biomarkers 
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with the ability to detect renal disease, before conventional methods, and the 
onset of severe and irreversible complications is vital. However, further 
investigation and longitudinal observational studies are required in order to fully 
validate these biomarkers prior to their routine use.  
Following the proteomic study a metabolomic study to identify potential 
metabolite biomarkers in Fabry disease was carried out in Professor Christiane 
Auray-Blais laboratory at the Centre for Research, University of Sherbrooke, 
Quebec, Canada. The targeted metabolomic approach to biomarker discovery 
was used to identify potential Gb3-related biomarkers in the circulation of 
treatment naive adult male Fabry disease patients. This study revealed the 
presence of seven novel biomarkers which required subsequent structural 
elucidation and characterisation. Of the seven potential biomarkers five were 
shown to be Gb3-related analogs/isoforms three corresponded to Gb3 having an 
extra double bond on the sphingosine chain (d18:2) with C16:0, C18:0 and 
C22:1 fatty acids. The fourth biomarker was shown to correspond to a mixture 
of two structural isomers, the first with a d16:1 sphingosine and a C16:0 fatty 
acid and the second with a d18:1 sphingosine and a C14:0 fatty acid. This 
finding was of particular importance as it is the first time that a Gb3 analogue 
with a d16:1 sphingosine moiety has been reported. Furthermore, this Gb3 
analogue was also present in its methylated form. Two of the seven potential 
biomarkers did not show fragmentation profiles similar to Gb3 and were 
therefore not considered to be Gb3-related analogs/isoforms. Unfortunately the 
concentration of these two potential biomarkers was too low to permit the 
structural elucidation of these metabolites.  
In addition to the five novel Gb3-related analogs/isoforms detected in this aspect 
of the study a number of Gb3-related analogs/isoforms identified previously in 
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the urine of Fabry patients were also detected. All known and novel Gb3-related 
analogs/isoforms were analysed subsequently in the plasma of treatment naïve 
female Fabry disease patients. This analysis showed that as with conventional 
Gb3 and lyso-Gb3 measurements, these biomarkers, where present, were 
detectable at reduced levels in female patients. This finding further 
demonstrates that women are often less severely affected than their male 
counterparts.  
The final aspect of the metabolomic study compared the relative concentrations 
of all Gb3-related analogs/isoforms between plasma and urine. This exposed 
significant differences in the levels of excretion of the Gb3-related 
analogs/isoforms and suggests that specific analyses comprising certain 
analogs/isoforms may be beneficial depending on the biological matrix used for 
analysis. Unfortunately due to the low abundance of many of the Gb3-related 
analogs/isoforms detected in this study it is unlikely that all of the metabolites 
will be able to be incorporated into routine analyses. However, variations in the 
relative quantitation of Gb3-related analogs/isoforms between urine and plasma 
have been exposed. Furthermore, it has been demonstrated that the metabolic 
profile in these patients is much more complex than thought previously and 
cannot be elucidated fully by the analysis of Gb3 and lyso-Gb3 levels alone. In 
addition, this study has provided a metabolic profile of Gb3-related 
analogs/isoforms in Fabry patients however further studies are needed in order 
to better understand the underlying metabolic process occurring in Fabry 
disease. 
In addition to identifying potential biomarkers this study has aimed to elucidate 
the underlying molecular mechanisms associated with Fabry disease. In order 
to achieve this Gb3 and lyso-Gb3 toxicity in the Fabry mouse model, with 
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particular focus on protein: glycosphingolipid interactions, has been 
investigated. This aspect of the study first used label-free quantitative 
proteomics to create a proteomic profile of Fabry mouse tissues enabling 
differences between protein levels in Fabry disease and control mouse tissues 
to be identified. Data from the proteomic study were analysed using two 
software platforms, ProteinLynx and Progenesis LC-MS. Results obtained from 
each software were cross-referenced and those proteins found to be altered 
using both software platforms, were selected for further investigation. Using this 
workflow the proteins ATP synthase subunit beta (mitochondrial), ATP synthase 
subunit alpha (mitochondrial), ribonuclease UK114,  agmatinase 
(mitochondrial), alpha synuclein and ATP binding cassette sub-family B 
member 8 (mitochondrial) were all determined to be proteins of interest. These 
proteins were subsequently interrogated with the GO annotation system using 
the PANTHER website. By analysing the data in this way a large number of 
common molecular functions, biological processes and/or biological pathways 
were identified which link the proteins. Alterations in proteins contributing to any 
or all of the functions, processes or pathways identified would most likely result 
in their sub-optimal operation and costly downstream effects. However, the 
extent to which they contribute to disease pathology requires further 
investigation.  
Following the proteomic profiling aspect of this study, two complementary novel 
protein: glycosphingolipid interaction methodologies were used to identify 
proteins that interact solely with Gb3 as well as proteins that interact with both 
Gb3 and other glycosphingolipids in the glycosphingolipid biosynthetic pathway. 
The use of other glycosphingolipids as positive controls enabled the detection of 
potential common but also any unique molecular mechanisms associated with 
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the lysosomal storage disorders to be detected. Both methodologies used the 
same underlying principles to bind deacylated or ‘lyso’ versions of the 
glycosphingolipids through the primary amine group to either a RS100 
ProteinChip or Dynabeads® M-270 Epoxy and a C12 or C5 linker-arm, 
respectively. Both methodologies effectively restore the deacylated 
glycosphingolipids to their acylated forms and although binding the molecules in 
this way renders the fatty acid group unavailable for interactions importantly the 
sugar portion, unique to each of the molecules, is available for binding.  
Using the RS100 ProteinChip 157 proteins were detected interacting with Gb3 
and/or GM1 ganglioside in control mouse brain tissue. Although PBS was used 
to control for non-specific binding this could indicate that a more stringent wash 
procedure is required. Unfortunately, due to time constraints optimisation of 
binding conditions in order to minimise non-specific binding was not possible for 
the purpose of this thesis. However, before further experimentation using this 
methodology is performed optimum binding conditions should be established. 
Of the 157 proteins detected in this study 32 proteins were found to interact with 
both Gb3 and GM1 ganglioside. Interestingly three proteins, ATP synthase 
subunit alpha, ATP synthase subunit beta and alpha-synuclein were also 
detected in Fabry mouse tissues during the proteomic profiling study. All 
proteins that interact with Gb3 and/or GM1 ganglioside were classified 
subsequently according to the GO annotation system. This analysis revealed 
many molecular functions, biological processes and biological pathways linking 
the proteins but most importantly a large proportion of the proteins detected 
were found to be located in the mitochondria or to possess catalytic activity 
involving ATP. This suggests that those proteins that interact with Gb3 and/or 
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GM1 ganglioside may have a role in energy production which may be affected 
by binding to a glycosphingolipid.      
The second, complimentary protein: glycosphingolipid interaction study used 
Dynabeads® M-270 epoxy to identify proteins that interacted with Gb3, GM1 
ganglioside, galactosylceramide and ceramide in control mouse kidney tissues.  
When results for those proteins found to interact with Gb3 and/or GM1 
ganglioside using both protein: glycosphingolipid interaction methodologies 
were cross-referenced three common interactions were revealed. The proteins 
beta-actin-like protein 2 and tubulin alpha-1B chain were detected to bind only 
to GM1 ganglioside and aspartate aminotransferase (mitochondrial) was 
detected to bind to both Gb3 and GM1 ganglioside.  
As with the RS100 ProteinChip methodology a number of common connections 
with proteins that interact with glycosphingolipids and ATP and/or that have an 
association with the mitochondrial respiratory chain enzymes were also 
revealed using the Dynabead® methodology. Although no protein was found to 
bind to all four glycosphingolipids in the Dynabeads® study, voltage dependent 
anion selective channel protein 1 (VDAC1), was found to interact with Gb3, 
galactosylceramide and ceramide. Interestingly this protein binds a number of 
ATP-dependent enzymes and is also an important regulator of Ca2+ transport in 
and out of the mitochondria (Báthori et al., 2006). This is of particular 
importance as aberrant Ca2+ handling has been described in the lysosomal 
storage disorders (Kiselyov et al., 2010). Another ion channel, potassium-
voltage gated channel subfamily H member 1, was found to bind explicitly to 
Gb3. A role for voltage-gated potassium channels (KV) in neuropathic and 
nociceptive pain has been demonstrated (Klein et al., 2012). As neuropathic 
pain is one of the most frequent, early and debilitating clinical manifestations 
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experienced in patients with Fabry disease, the effect of Gb3 and also lyso-Gb3, 
on pain thresholds in mice was assessed using a von Frey assay. The results 
obtained from the von Frey assay demonstrated that, following exposure to high 
levels of either Gb3 or lyso-Gb3, a significant increase in sensitivity to 
mechanical stimuli was produced. No difference in the effect on sensitivity 
between injection with Gb3 or lyso-Gb3 was observed when each metabolite 
was injected at a high concentration level. The level of Gb3 used in this assay 
was based on the plasma Gb3 level of Fabry patients with a severe disease 
phenotype. The lyso-Gb3 concentration although significantly less concentrated, 
than the Gb3 levels used, remains much greater than lyso-Gb3 levels observed 
in vivo. This suggests that it is probably Gb3 that is causing the pain response in 
Fabry disease. However, this hypothesis requires further investigation with a 
wider array of glycosphingolipids and their deacylated counterparts at high, 
medium and low concentration levels.    
Of particular interest during this study was the observation that ATP synthase 
subunits alpha and beta (mitochondrial) were shown to be increased in Fabry 
mice during the proteomic profiling study. As a result the effect of high, medium 
and low level glycosphingolipids and their corresponding deacylated or ‘lyso’ 
counterparts, as well as the phospholipid cardiolipin were assessed regarding 
their effect on ATP synthase activity. As expected cardiolipin, which is essential 
for the catalytic and structural operation of ATP synthase demonstrated the 
greatest effect on the enzyme demonstrating significant increase in ATP 
synthase activity at the high, medium and low concentrations. In addition, the 
high concentration level of GM1 ganglioside, Gb3, sulfatide and lactosylceramide 
and their deacylated counterparts, as well as lyso-glucocerebroside were all 
shown to increase significantly ATP synthase activity. At the medium 
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concentration level GM1 ganglioside, lactosylceramide, lyso-GM1, lyso-Gb3 and 
lyso-glycosylceramide were shown to increase significantly ATP synthase 
activity. However, no significant increases in ATP synthase activity were 
demonstrated using any glycosphingolipid or lyso-glycosphingolipid at the 
lowest concentration level assessed. When high, medium and low level 
glycosphingolipids were compared with their deacylated counterparts the effect 
on ATP synthase activity was shown to be very similar.  
As with the von Frey assay the high level of glycosphingolipids used was based 
on the plasma Gb3 level of Fabry patients with a severe disease phenotype. 
With the medium level the equivalent to that of a mild disease phenotype and 
the low level equivalent to those levels observed in controls. In comparison the 
levels of lyso-glycosphingolipids, although considerably less concentrated, are 
still higher than those levels observed in a diseased state. The low 
concentration level of lyso-Gb3 used in this study is comparable to physiological 
levels observed in Fabry disease. However, at this level no lyso-
glycosphingolipids produced any effect on ATP synthase activity. Therefore as 
with those results observed in the von Frey assay it is most likely that it is the 
glycosphingolipids and not their deacylated counterparts that are affecting ATP 
synthase activity in vivo. 
A hypothesis to explain how glycosphingolipids alter ATP synthase activity 
could be that in cases where there are increased concentrations of certain 
glycosphingolipids, such as in lysosomal storage disorders, the 
glycosphingolipids are able to displace cardiolipin and bind to ATP synthase in 
its place. Further evidence to support this, is the finding demonstrated in this 
study, that ATP synthase subunits alpha and beta were shown to bind to the 
glycosphingolipids Gb3 and GM1 ganglioside when immobilised on an RS100 
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ProteinChip. However, it should be noted that the demonstration that 
glycosphingolipids affect ATP synthase activity does not necessarily mean that 
an increase in ATP production or indeed any noticeable disruption to this 
pathway will result in vivo. Therefore, further analyses are required to assess 
not only ATP synthase activity but also ATP production in vivo. Only once these 
investigations have been completed will the full relevance of the findings in this 
study become apparent.  
During the investigation of Gb3 and lyso-Gb3 toxicity in the Fabry mouse model 
a number of common connections with proteins that are located in the 
mitochondria or have an association with the mitochondrial respiratory chain 
enzymes were revealed. In addition, the finding that increased concentrations of 
glycosphingolipids and their deacylated counterparts increase ATP synthase 
activity (complex V) prompted the investigation of the enzymes preceding 
complex V in the OPHOS system. In this aspect of the study the mitochondrial 
respiratory chain enzymes, complex I, complex II/III and complex IV were 
assessed in the tissues (liver, kidney, heart and brain) of a Fabry mouse model.  
Following this analysis a significant reduction in complex II/III activity was 
observed in kidney tissues from Fabry mice compared to that of control mice. 
However, no other significant reductions were observed in complex II/III activity 
in heart, liver, or brain Fabry mouse tissues. In addition, no statistically 
significant alterations were observed in the activity of complex I or complex IV of 
the mitochondrial respiratory chain in any tissue type analysed in this study.   
The significant reduction observed in complex II/III activity in the kidney is of 
particular interest as complex III is susceptible to oxidative damage (Bolaños et 
al., 1994; Bolaños et al.,1996). The production of O2
- at complex III is due to 
autoxidation of ubisemiquinone formed during the Q cycle process. The QO site 
- 370 - 
 
of the complex is located close to the intermembrane space and is thought to be 
the major site of O2
- production (Zhang and Gutterman 2007). Interestingly, 
excess intracellular Gb3 levels have been shown to induce oxidative stress in 
vascular endothelial cells from Fabry disease patients (Shen et al., 2008). In 
addition, a study performed in a Fabry mouse model demonstrated uncoupling 
of endothelial nitric oxide synthase (eNOS) within the endothelium resulting in 
the subsequent generation of ROS (Shayman 2010). In this study a combined 
complex II/III assay was used and therefore further investigations are required 
to establish if the reduction in complex II/III observed in this study is attributable 
solely to a reduction of complex III. In addition, the nature of the complex II/III 
assay relies on the availability of ubiquinone and investigations to establish 
ubiquinone status would be required to fully establish the origin of the reduction 
in complex II/III activity. 
Furthermore, In contrast to the results obtained in this study, a study by Lücke 
et al., (2004) has reported statistically significant reductions in complex I and 
complex IV in fibroblasts from three patients with Fabry disease. Differences in 
the results obtained between these studies could be attributable to both 
differences in the biological starting materials and the methodologies used. 
However, further investigations are required to confirm these findings. Only 
once these studies have been completed will a full and complete understanding 
of complex II/III in the Fabry mouse model be achieved.   
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7.1 Conclusions 
 
In conclusion, this study has used both proteomic and metabolomic mass 
spectrometry based methodologies to identify and validate a number of 
potential biomarkers that can be used in conjunction with Gb3 and lyso-Gb3 to 
provide a more detailed understanding of Fabry disease progression and 
response to treatment. A novel and rapid multiplex assay for the detection of 
prosaposin and GM2AP, as well as a second multiplex assay with the potential 
to detect pre-symptomatic kidney disease in those patients most ‘at risk’ have 
been developed. Both assays have the potential to be translated for use in 
chemical pathology departments. Importantly proteomic and metabolomic 
aspects of the study have highlighted the fact that a panel of biomarkers is 
required in order to gain a greater understanding of this multisystemic disease.   
In addition to proteomic and metabolomic methodologies, a number of 
complementary techniques have been used in order to elucidate the underlying 
pathological disease mechanisms in Fabry disease. This has revealed a 
number of interesting avenues requiring further investigation but has 
demonstrated that there is much still to be learned about this complex disease.      
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7.2  Further work 
 
The work completed in this thesis has revealed a number of biomarkers that 
when used in conjunction with Gb3 and lyso-Gb3 may provide further information 
and understanding in not only Fabry disease but other lysosomal disorders. 
However, in order to complete this work to enable the most information to be 
gathered requires the further development of the prosaposin and GM2AP 
UPLC-MS/MS assay to optimise the detection of the mature saposins in order 
to analyse a larger cohort of Fabry patients as well as other lysosomal storage 
disorders which require saposins as cofactors. In addition, the continued 
analysis of renal biomarkers in those ‘at-risk’ patient groups is required in order 
to fully validate these biomarkers prior to their routine use.   
The  metabolomic  aspect  of  this study  revealed a  large  number  of  analogs/ 
isoforms  in  the  plasma  of  Fabry  patients.  In order  for  these  biomarkers to 
provide valuable information requires incorporation of the most abundant of the 
analogs/isoforms  into  routine Gb3 analyses. In addition, the low abundance of  
two  of  the  metabolite  biomarkers  revealed  during  the  study  prevented   the  
elucidation  of  their  structures.   Only  by  establishing  the   structure  of  these  
potential  biomarkers  can  we  gain  the fullest possible picture of the metabolic  
profile in Fabry disease.    
The study in chapter 5 to investigate the toxicity of Gb3 and lyso-Gb3 in a Fabry 
mouse model has revealed a number of avenues for exploration which have as 
yet have received little attention. Particularly, the use of immunohistochemistry 
to validate the proteins detected as altered in mouse tissues during the label-
free proteomic profiling study should be performed. In addition, further 
investigations into the finding that ATP synthase is increased by increasing 
levels of glycosphingolipids and their deacylated counterparts, using blue native 
- 373 - 
 
gel, should be performed in Fabry mice to confirm the increases observed in 
this study. In addition, an assessment of the levels of ATP production is 
required to ascertain to what, if any, the effect an increase in ATP synthase 
activity will have.  
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9.0 Appendices   
 
9.1 Appendix A 
 
9.1.1 Supplementary data 
 
The calibration curves shown in Figure 9.1 were generated during the analysis 
of prosaposin (Figure 9.1a) and GM2AP (Figure 9.1b) as described in section 
2.2.5.7. 
 
 
Figure 9.1 Calibration curve generated during the analysis a.) Prosaposin 
using a marker peptide from the saposin A region of the molecule (R2 = 
0.99); and b.) GM2 activator protein (R
2 = 0.98).  
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The calibration curves shown in Figures 9.2.1 and 9.2.2 were generated during 
the analysis of the pre-symptomatic kidney disease biomarkers as described in 
section 2.2.5.8. It should be noted that the concentrations of albumin, 
osteopontin and prostaglandin-H2 D-isomerase are displayed in nmol whilst all 
other peptides concentrations are displayed in pmol. 
 
 
 
Figure 9.2.1 Calibration curves generated during the analysis of a.) 
albumin; b.) cubilin; c.) endothelial protein C receptor; d.) Ig gamma-4 
chain C region; e.) lysosomal alpha glucosidase; and f.) megalin.  
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Figure 9.2.2  Calibration curve generated during the analysis of a.) 
neutrophil gelatinase associated lipocalin; b.) osteopontin c.) 
prostaglandin-H2 D-isomerase; d.) retinol binding protein; e.) sortilin; and 
f.) vitamin D binding protein. 
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